<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cards List 2007

<!-- PAGE=? -->
1

<!-- PAGE=? -->
CRISIS MANAGEMENT

<!-- PAGE=? -->
o ACLS

<!-- PAGE=? -->
o Airway (CVCI)

<!-- PAGE=? -->
o airway fire

<!-- PAGE=? -->
o airway pressure increase

<!-- PAGE=? -->
o air embolus

<!-- PAGE=? -->
o amniotic fluid embolus

<!-- PAGE=? -->
o anaphylaxis

<!-- PAGE=? -->
o aspiration

<!-- PAGE=? -->
o asthmatic crisis

<!-- PAGE=? -->
o ATLS

<!-- PAGE=? -->
o Crush

<!-- PAGE=? -->
o Hypothermia

<!-- PAGE=? -->
o autonomic hyperreflexia

<!-- PAGE=? -->
o blood components/transfusion

<!-- PAGE=? -->
o bradycardia

<!-- PAGE=? -->
o bronchospasm

<!-- PAGE=? -->
o bupivacaine toxicity

<!-- PAGE=? -->
o burns

<!-- PAGE=? -->
o cement embolus

<!-- PAGE=? -->
o diabetes insipidus

<!-- PAGE=? -->
o DIC

<!-- PAGE=? -->
o DKA

<!-- PAGE=? -->
o epidural hematoma

<!-- PAGE=? -->
o fat embolus

<!-- PAGE=? -->
o fever

<!-- PAGE=? -->
o high spinal

<!-- PAGE=? -->
o hypotension

<!-- PAGE=? -->
o hypertension

<!-- PAGE=? -->
o hypercarbia

<!-- PAGE=? -->
o hypocarbia

<!-- PAGE=? -->
o hypoxia

<!-- PAGE=? -->
o increased intracranial pressure

<!-- PAGE=? -->
o level of consciousness decrease

<!-- PAGE=? -->
o lidocaine toxicity

<!-- PAGE=? -->
o masseter muscle rigidity

<!-- PAGE=? -->
o malignant hyperthermia

<!-- PAGE=? -->
o mixed venous oxygen saturation decrease

<!-- PAGE=? -->
o NALS

<!-- PAGE=? -->
o neuroleptic malignant syndrome

<!-- PAGE=? -->
o oliguria

<!-- PAGE=? -->
o PALS

<!-- PAGE=? -->
o pulmonary embolus

<!-- PAGE=? -->
o seizure

<!-- PAGE=? -->
o ST changes

<!-- PAGE=? -->
o STP intra-arterial injection

<!-- PAGE=? -->
o tension pneumothorax

<!-- PAGE=? -->
o thyroid storm

<!-- PAGE=? -->
o tracheobronchial injury

<!-- PAGE=? -->
o transfusion reaction

<!-- PAGE=? -->
o transfusion associated lung injury

<!-- PAGE=? -->
o TURP syndrome

<!-- PAGE=? -->
Overdose

<!-- PAGE=? -->
o acetaminophen

<!-- PAGE=? -->
o anticholinergic

<!-- PAGE=? -->
o cholinergic

<!-- PAGE=? -->
o cocaine

<!-- PAGE=? -->
o acute

<!-- PAGE=? -->
o chronic

<!-- PAGE=? -->
o ethanol

<!-- PAGE=? -->
o acute

<!-- PAGE=? -->
o chronic

<!-- PAGE=? -->
o ethylene glycol

<!-- PAGE=? -->
o MAOIs

<!-- PAGE=? -->
o Methanol

<!-- PAGE=? -->
o phenylthiazines

<!-- PAGE=? -->
o salicylates

<!-- PAGE=? -->
o serotonergic

<!-- PAGE=? -->
o tricyclics

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cards List 2007

<!-- PAGE=? -->
2

<!-- PAGE=? -->
COEXISTING DISEASE

<!-- PAGE=? -->
Cardiac

<!-- PAGE=? -->
o AI

<!-- PAGE=? -->
o AS

<!-- PAGE=? -->
o Arterial line waveforms

<!-- PAGE=? -->
o ASD

<!-- PAGE=? -->
o CAD

<!-- PAGE=? -->
o cardiomyopathy

<!-- PAGE=? -->
o HOCM

<!-- PAGE=? -->
o restrictive

<!-- PAGE=? -->
o dilated

<!-- PAGE=? -->
o CHF

<!-- PAGE=? -->
o cor pulmonale

<!-- PAGE=? -->
o CVP monitoring

<!-- PAGE=? -->
o Eisenmenger's

<!-- PAGE=? -->
o ICD

<!-- PAGE=? -->
o MR

<!-- PAGE=? -->
o MS

<!-- PAGE=? -->
o MVP

<!-- PAGE=? -->
o PA catheter

<!-- PAGE=? -->
o pacemakers

<!-- PAGE=? -->
o pulmonary HTN

<!-- PAGE=? -->
o SBE

<!-- PAGE=? -->
o transplanted heart

<!-- PAGE=? -->
o VSD

<!-- PAGE=? -->
o WPW

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
o asthma

<!-- PAGE=? -->
o ARDS

<!-- PAGE=? -->
o bronchopleural fistula

<!-- PAGE=? -->
o COPD

<!-- PAGE=? -->
o cystic fibrosis

<!-- PAGE=? -->
o lung transplant

<!-- PAGE=? -->
o OSA

<!-- PAGE=? -->
o sarcoid

<!-- PAGE=? -->
o TB

<!-- PAGE=? -->
Renal

<!-- PAGE=? -->
o ARF

<!-- PAGE=? -->
o CRF

<!-- PAGE=? -->
o Bartter syndrome

<!-- PAGE=? -->
o pulmonary renal syndromes

<!-- PAGE=? -->
Neurologic

<!-- PAGE=? -->
o ALS

<!-- PAGE=? -->
o Guillain-Barré

<!-- PAGE=? -->
o Huntington's

<!-- PAGE=? -->
o MS

<!-- PAGE=? -->
o muscular dystrophy

<!-- PAGE=? -->
o myasthenia gravis

<!-- PAGE=? -->
o myasthenic syndrome

<!-- PAGE=? -->
o muscular dystrophy

<!-- PAGE=? -->
o Parkinson's

<!-- PAGE=? -->
o spinal cord injury

<!-- PAGE=? -->
o acute

<!-- PAGE=? -->
o chronic

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
o carcinoid

<!-- PAGE=? -->
o cirrhosis

<!-- PAGE=? -->
o inflammatory bowel disease

<!-- PAGE=? -->
o pancreatitis

<!-- PAGE=? -->
Hematology

<!-- PAGE=? -->
o carboxyhemoglobin

<!-- PAGE=? -->
o hemophilia a

<!-- PAGE=? -->
o hemophilia b

<!-- PAGE=? -->
o Jehovah's Witness

<!-- PAGE=? -->
o methemoglobinemia

<!-- PAGE=? -->
o sickle cell anemia

<!-- PAGE=? -->
o thalassemia

<!-- PAGE=? -->
o Von Willebrand's disease

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
o anorexia

<!-- PAGE=? -->
o hypo-/hypernatremia

<!-- PAGE=? -->
o hypo-/hyperkalemia

<!-- PAGE=? -->
o hypo-/hypercalcemia

<!-- PAGE=? -->
o hypo-/hypermagnesemia

<!-- PAGE=? -->
o obesity

<!-- PAGE=? -->
o porphyria

<!-- PAGE=? -->
o SIADH

<!-- PAGE=? -->
o rhabdomyolysis

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cards List 2007

<!-- PAGE=? -->
3

<!-- PAGE=? -->
Endocrine

<!-- PAGE=? -->
o Acromegaly

<!-- PAGE=? -->
o Addisonian crisis

<!-- PAGE=? -->
o Cushing's disease

<!-- PAGE=? -->
o diabetes

<!-- PAGE=? -->
o Hyper-ACTH

<!-- PAGE=? -->
o hyperaldosteronism

<!-- PAGE=? -->
o hypoaldosteronism

<!-- PAGE=? -->
o hyperthyroidism

<!-- PAGE=? -->
o hypothyroidism

<!-- PAGE=? -->
o MEN

<!-- PAGE=? -->
o pheochromocytoma

<!-- PAGE=? -->
Pain

<!-- PAGE=? -->
o cancer

<!-- PAGE=? -->
o celiac plexus block

<!-- PAGE=? -->
o chronic pain medications

<!-- PAGE=? -->
o complex regional pain syndrome

<!-- PAGE=? -->
o postherpetic neuralgia

<!-- PAGE=? -->
o phantom limb pain

<!-- PAGE=? -->
Pediatric

<!-- PAGE=? -->
o apnea/monitoring

<!-- PAGE=? -->
o BPD

<!-- PAGE=? -->
o cerebral palsy

<!-- PAGE=? -->
o croup

<!-- PAGE=? -->
o dehydration

<!-- PAGE=? -->
o diaphragmatic hernia

<!-- PAGE=? -->
o epiglottitis

<!-- PAGE=? -->
o Fontan physiology

<!-- PAGE=? -->
o gastroschisis

<!-- PAGE=? -->
o ICH

<!-- PAGE=? -->
o incarcerated hernia

<!-- PAGE=? -->
o omphalocele

<!-- PAGE=? -->
o PDA

<!-- PAGE=? -->
o prematurity

<!-- PAGE=? -->
o pyloric stenosis

<!-- PAGE=? -->
o RDS

<!-- PAGE=? -->
o ROP

<!-- PAGE=? -->
o scoliosis

<!-- PAGE=? -->
o stridor

<!-- PAGE=? -->
o TEF

<!-- PAGE=? -->
o tetralogy of Fallot

<!-- PAGE=? -->
o Treacher Collins

<!-- PAGE=? -->
o vital signs (normal)

<!-- PAGE=? -->
Immune

<!-- PAGE=? -->
o amyloidosis

<!-- PAGE=? -->
o ankylosing spondylitis

<!-- PAGE=? -->
o dermatomyositis

<!-- PAGE=? -->
o epidermolysis bullosa

<!-- PAGE=? -->
o HIV, post exposure prophylaxis

<!-- PAGE=? -->
o IgA deficiency

<!-- PAGE=? -->
o ITP

<!-- PAGE=? -->
o rhabdomyolysis

<!-- PAGE=? -->
o scleroderma/CREST

<!-- PAGE=? -->
o SIRS

<!-- PAGE=? -->
o Sjogren's

<!-- PAGE=? -->
o SLE

<!-- PAGE=? -->
o tumor lysis syndrome

<!-- PAGE=? -->
Obstetrical

<!-- PAGE=? -->
o abruption

<!-- PAGE=? -->
o cardiomyopathy

<!-- PAGE=? -->
o cardiac disease

<!-- PAGE=? -->
o DM

<!-- PAGE=? -->
o Grand multip

<!-- PAGE=? -->
o Multiple gestation

<!-- PAGE=? -->
o non-obstetric surgery

<!-- PAGE=? -->
o PDPH

<!-- PAGE=? -->
o PET

<!-- PAGE=? -->
o Physiologic changes

<!-- PAGE=? -->
o Neuro sequelae from regional/delivery

<!-- PAGE=? -->
o placenta accreta

<!-- PAGE=? -->
o placenta previa

<!-- PAGE=? -->
o preterm labour

<!-- PAGE=? -->
o prolapsed cord

<!-- PAGE=? -->
o retained placenta

<!-- PAGE=? -->
o trauma

<!-- PAGE=? -->
o uterine atony

<!-- PAGE=? -->
o uterine inversion

<!-- PAGE=? -->
o uterine rupture

<!-- PAGE=? -->
o valvular disease

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cards List 2007

<!-- PAGE=? -->
4

<!-- PAGE=? -->
Miscellaneous

<!-- PAGE=? -->
o achondroplasia

<!-- PAGE=? -->
o atypical pseudocholinesterase

<!-- PAGE=? -->
o bioterrorism

<!-- PAGE=? -->
o chemotherapy

<!-- PAGE=? -->
o Down syndrome

<!-- PAGE=? -->
o geriatric

<!-- PAGE=? -->
o Marfan's

<!-- PAGE=? -->
o necrotizing fasciitis

<!-- PAGE=? -->
o Pierre Robin

<!-- PAGE=? -->
o Prader-Willi

<!-- PAGE=? -->
Regional

<!-- PAGE=? -->
o airway

<!-- PAGE=? -->
o ankle

<!-- PAGE=? -->
o anticoagulation

<!-- PAGE=? -->
o axillary

<!-- PAGE=? -->
o Bier

<!-- PAGE=? -->
o cervical

<!-- PAGE=? -->
o digit

<!-- PAGE=? -->
o elbow

<!-- PAGE=? -->
o femoral

<!-- PAGE=? -->
o infraclavicular

<!-- PAGE=? -->
o interscalene

<!-- PAGE=? -->
o sciatic

<!-- PAGE=? -->
o stellate

<!-- PAGE=? -->
o supraclavicular

<!-- PAGE=? -->
o transtracheal

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cards List 2007

<!-- PAGE=? -->
5

<!-- PAGE=? -->
SURGICAL/OR

<!-- PAGE=? -->
Preoperative

<!-- PAGE=? -->
o NPO guidelines

<!-- PAGE=? -->
o drug prophylaxis

<!-- PAGE=? -->
Postoperative problems

<!-- PAGE=? -->
o delayed emergence

<!-- PAGE=? -->
o jaundice

<!-- PAGE=? -->
o delirium

<!-- PAGE=? -->
Neurosurgery

<!-- PAGE=? -->
o aneurysm

<!-- PAGE=? -->
o brain death

<!-- PAGE=? -->
o diskectomy

<!-- PAGE=? -->
o ECT

<!-- PAGE=? -->
o MRI

<!-- PAGE=? -->
o pituitary tumor

<!-- PAGE=? -->
o posterior fossa tumor

<!-- PAGE=? -->
o sitting position

<!-- PAGE=? -->
o spinal rods

<!-- PAGE=? -->
o supratentorial tumor

<!-- PAGE=? -->
o V-P shunt

<!-- PAGE=? -->
Eye

<!-- PAGE=? -->
o cataract

<!-- PAGE=? -->
o ruptured globe

<!-- PAGE=? -->
o strabismus

<!-- PAGE=? -->
Thoracic

<!-- PAGE=? -->
o bronchoscopy

<!-- PAGE=? -->
o bullectomy

<!-- PAGE=? -->
o lobectomy

<!-- PAGE=? -->
o lateral position

<!-- PAGE=? -->
o mediastinoscopy

<!-- PAGE=? -->
o one lung physiology

<!-- PAGE=? -->
o pneumonectomy

<!-- PAGE=? -->
o preop assessment

<!-- PAGE=? -->
o thoracoscopy

<!-- PAGE=? -->
o thymectomy

<!-- PAGE=? -->
o VATS

<!-- PAGE=? -->
ENT

<!-- PAGE=? -->
o airway abscess

<!-- PAGE=? -->
o cleft palate

<!-- PAGE=? -->
o foreign body

<!-- PAGE=? -->
o laser surgery

<!-- PAGE=? -->
o radical neck dissection

<!-- PAGE=? -->
o tonsillectomy/bleeding

<!-- PAGE=? -->
Vascular

<!-- PAGE=? -->
o AAA -- elective

<!-- PAGE=? -->
o AAA - ruptured

<!-- PAGE=? -->
o Aortic dissection

<!-- PAGE=? -->
o AV fistula

<!-- PAGE=? -->
o carotid endarterectomy

<!-- PAGE=? -->
o fem-pop

<!-- PAGE=? -->
o leg amputation

<!-- PAGE=? -->
Urology

<!-- PAGE=? -->
o cystectomy

<!-- PAGE=? -->
o lithiasis/extraction

<!-- PAGE=? -->
o prostatectomy

<!-- PAGE=? -->
o renal transplant

<!-- PAGE=? -->
o TURP

<!-- PAGE=? -->
o TURBT

<!-- PAGE=? -->
General surgery

<!-- PAGE=? -->
o Appendectomy

<!-- PAGE=? -->
o bowel resection

<!-- PAGE=? -->
o cholecystectomy

<!-- PAGE=? -->
o laparoscopy

<!-- PAGE=? -->
o parathyroidectomy

<!-- PAGE=? -->
o thyroidectomy

<!-- PAGE=? -->
Orthopedics

<!-- PAGE=? -->
o fractured hip

<!-- PAGE=? -->
o total hip

<!-- PAGE=? -->
o total knee

<!-- PAGE=? -->
Miscellaneous Procedures

<!-- PAGE=? -->
o ECT

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Format

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Intraoperative Events

<!-- PAGE=? -->
This is an emergent, potentially life-threatening, situation that demands my immediate attention to simultaneously diagnosis and treat.

<!-- PAGE=? -->
I will immediately examine the pt and pulse, recycling the BP while scanning the surgical field.  I will look at the ventilator and monitors for abnormal settings and alarms, specifically noting …(ECG for rate, ryhtym, and ST changes, BP, SpO2, capnograph trace, ET volatile concentration, FIO2, temperature and airway pressure)

<!-- PAGE=? -->
I will then immediately inform the surgeon of the situation, and call for assistance and (equipment) while I (put the pt on 100% O2 and) begin supportive resuscitation with a temporizing drug and look for a cause.

<!-- PAGE=? -->
While mentally reviewing the pt's history and intraoperative events, I would develop my broad differential which includes:

<!-- PAGE=? -->
In this particular pt, I am most concerned about … and will attempt to rule this in or out by …..

<!-- PAGE=? -->
I will confirm that the Airway is patent & protected (by verifying placement of my ETT)

<!-- PAGE=? -->
I will assess Breathing , confirming adequate oxygenation and ventilation by delivering 100% O2 by manual ventilation to assess pulmonary compliance.

<!-- PAGE=? -->
I will confirm adequacy of Circulation and perfusion by palpating the pt's pulse noting its rate, rhythm & contour.

<!-- PAGE=? -->
I will auscultate for abnormal heart sounds, bilateral breath sounds, check for tracheal deviation, subcutaneous emphysema, assess the JVP and examine the skin for temperature and color.

<!-- PAGE=? -->
(If the patient is conscious) I will assess neurologic status and pupils.

<!-- PAGE=? -->
I will ensure the IV is secure and confirm (or turn off) all drugs and infusions

<!-- PAGE=? -->
My specific diagnosis and treatment plan will depend on my findings.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Remote Location Assessment

<!-- PAGE=? -->
This is an emergent, potentially life-threatening, situation that demands my immediate attention to simultaneously diagnosis and treat. On my way to assess the patient, I will keep in mind the following considerations/DDx:

<!-- PAGE=? -->
On arrival in the ______, I will follow current (ATLS/BLS/ACLS) protocols and will obtain a new set of vital signs.  I will ensure that the pt is on 100% O2, has good IV access and is attached to the standard CAS monitors cycling every 2min.

<!-- PAGE=? -->
As I review the vitals and ABCs, I will concurrently obtain a brief Hx (AMPLE) from the pt, attending physician/TTL or brief review of the chart.

<!-- PAGE=? -->
I will immediately assess the pt's need for resuscitation by examining the pt's A/W for patency and ease of intubation, Breathing for adequacy of oxygenation and ventilation, and Circulation for adequacy of perfusion and signs of bleeding

<!-- PAGE=? -->
I will palpate the pt's pulse noting rate, rhythm & contour.

<!-- PAGE=? -->
I will auscultate for abnormal heart sounds, bilateral breath sounds, check for tracheal deviation, subcutaneous emphysema, assess the JVP and examine the skin for temperature and color.

<!-- PAGE=? -->
I will examine assess the pt's LOC, pupils and GCS.

<!-- PAGE=? -->
I will then base my investigations and treatment plan on my findings. OR

<!-- PAGE=? -->
I will ensure that blood has been sent for a CBC, glucose, electrolytes, coags, cross-match, ABG, and that CXR/EKG have done.

<!-- PAGE=? -->
I will continually reassess the pt's vital signs looking for response to my treatment

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Trauma:

<!-- PAGE=? -->
From the brief description provided, I am concerned this patient may be at risk of ….

<!-- PAGE=? -->
After ruling out immediately life threatening injuries and securing the C-spine in a collar with in-line stabalization, I will commence my secondary survey examining the pt from head to toe, looking for evidence of abnormal movement, bleeding or other injury. I will insert an NG/OG and Foley, splint obvious fractures and then arrange further investigation and consults as my history and exam dictate.

<!-- PAGE=? -->
This pt requires further investigation and possible surgical management. Before this can occur, I have several tasks to concurrently complete:

<!-- PAGE=? -->
o Secure the A/W

<!-- PAGE=? -->
o Control ventilation

<!-- PAGE=? -->
o Improve perfusion

<!-- PAGE=? -->
o Treat possible high ICP

<!-- PAGE=? -->
Airway:

<!-- PAGE=? -->
I will continue to administer a high inspired O2 and will attempt to improve the A/W by placement of oro- (and nasopharyngeal) A/Ws.  If inadequate, I will quickly change to 2 then 3 person BMV while I prepare to definitively secure the A/W.

<!-- PAGE=? -->
I will ensure that appropriate help is available. This will include another anesthetist and a General or ENT surgeon who is scrubbed and ready to provide a rapid surgical A/W if necessary.

<!-- PAGE=? -->
I will have the difficult A/W cart ready and from it I want: Plan A, B, and Rescue.  I will ensure that I have easy access to an array of small ETTs and the jet ventilator.   I will have the rigid bronch, tracheostomy and cricothyroidotomy sets are at hand.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Crisis:

<!-- PAGE=? -->
This situation is now more urgent and the pt is clearly unstable. The pt is at serious risk of deteriorating neurologic status, A/W compromise and hemodynamic collapse. I will immediately take steps to optimize the A/W, Breathing and Circulation.

<!-- PAGE=? -->
I will continually reassess the pt's vital signs looking for response to my treatment

<!-- PAGE=? -->
This is a very difficult, life threatening situation and the pt is not responding to my initial management.  I would reassess the pt's vital signs and ABCs.

<!-- PAGE=? -->
Statements:

<!-- PAGE=? -->
Pre-op

<!-- PAGE=? -->
In addition to my usual anesthetic hx of Allergies, Medications, PMHx and ROS, in this particular patient I will focus on the HPI ….

<!-- PAGE=? -->
I will pay close attention to …  looking for…..

<!-- PAGE=? -->
I would ask for an …. (test), looking for …(result >) ….

<!-- PAGE=? -->
Complete a meticulous airway exam looking for patency and ease of intubation

<!-- PAGE=? -->
Setup

<!-- PAGE=? -->
Although this can be done by either and regional or general technique, for this particular patient in my hands I'm more comfortable doing....

<!-- PAGE=? -->
Having checked my machine and preparing my routine and emergency drugs, I would attach the pt to the standard CAS monitors.  In addition, I would also secure …. (5 lead EKG with ST monitoring, PNS, Lines)

<!-- PAGE=? -->
Induction

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
With a free-flowing IV secured and the pt in the sniffing position, I will pre-oxygenate the pt for 3 minutes/4 VC breaths.

<!-- PAGE=? -->
I will give x ug/kg Narcotic, then proceed with Induction Agent titrated to effect, keeping in mind that I want to maintain BP

<!-- PAGE=? -->
After confirming and securing ETT placement, I will ventilate the lungs with 100% oxygen and maintain the pt on….

<!-- PAGE=? -->
Other

<!-- PAGE=? -->
I am not familiar with that drug/disease, it sounds like a …… . I will immediately confer with a colleague and consult a reference book for that information.

<!-- PAGE=? -->
From the information given to me I understand …..

<!-- PAGE=? -->
In this situation, the my primary concern is …..

<!-- PAGE=? -->
Because I have been told …..  I believe there is strong evidence to suggest this pt is …..

<!-- PAGE=? -->
I have two considerations which are in conflict ….

<!-- PAGE=? -->
I forgot that this patient ….., therefore I would change my plan to……

<!-- PAGE=? -->
While on one hand I would like to…,  on the other hand …. in this particular case I will opt for .... because

<!-- PAGE=? -->
I will transfuse to a Hgb of 90 to a maximum of x volume, realizing that surgery may be the only way to stop bleeding

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Achondroplasia

<!-- PAGE=? -->
Airway/C-spine precautions

<!-- PAGE=? -->
Difficult neuroaxial anesthesia

<!-- PAGE=? -->
Pulmonary disease

<!-- PAGE=? -->
RLD

<!-- PAGE=? -->
Central/obstructive sleep apnea

<!-- PAGE=? -->
Pulm HTN

<!-- PAGE=? -->
General:

<!-- PAGE=? -->
Autosomal dominant (80% new mutations)

<!-- PAGE=? -->
Short extremities

<!-- PAGE=? -->
Normal trunk length, intelligence, and life span

<!-- PAGE=? -->
Flat chest

<!-- PAGE=? -->
Kyphoscoliosis

<!-- PAGE=? -->
Lumbar lordosis

<!-- PAGE=? -->
Foramen magnum stenosis

<!-- PAGE=? -->
Investigation:

<!-- PAGE=? -->
Obesity/Gerd/IV

<!-- PAGE=? -->
o Echo, CXR, EKG, Flex/Ext films

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
 Difficult mask ventilation

<!-- PAGE=? -->
 Difficult direct laryngoscopy

<!-- PAGE=? -->
 Choanal Stenosis

<!-- PAGE=? -->
C-Spine

<!-- PAGE=? -->
 Foramen magnum stenosis

<!-- PAGE=? -->
 Cervical stenosis

<!-- PAGE=? -->
 Odontoid hypoplasia

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
 Kyphoscoliosis (restrictive lung disease)

<!-- PAGE=? -->
 Central and obstructive sleep apnea

<!-- PAGE=? -->
 Pulmonary hypertension

<!-- PAGE=? -->
 Cor pulmonale

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
 Pulm HTN.hyperplasia

<!-- PAGE=? -->
 RV Strain

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
 Spinal cord compression

<!-- PAGE=? -->
 Nerve Root compression

<!-- PAGE=? -->
 Hydrocephalus

<!-- PAGE=? -->
Regional

<!-- PAGE=? -->
 Narrow epidural space

<!-- PAGE=? -->
 Difficult subarachnoid anesthesia

<!-- PAGE=? -->
 Epidural preferable secondary to titratability

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ACLS - ACS

<!-- PAGE=? -->
ABC

<!-- PAGE=? -->
Monitors, EKG, CXR

<!-- PAGE=? -->
MONA

<!-- PAGE=? -->
Optimize DO2 - incr supply, decr demand

<!-- PAGE=? -->
EKG:

<!-- PAGE=? -->
STEMI: ST-segment elevation >1 mm (0.1 mV) in 2 or more contiguous precordial leads or 2 or more adjacent limb leads BACHS

<!-- PAGE=? -->
 UA/ NSTEMI: Ischemic ST-segment depression >0.5 mm (0.05 mV) or dynamic T-wave inversion (even if transient) with pain or discomfort NG-BACHS

<!-- PAGE=? -->
Normal or nondiagnostic changes in ST segment

<!-- PAGE=? -->
-PCI better:

<!-- PAGE=? -->
 symptom duration of >3 and <12 hours

<!-- PAGE=? -->
 contraindications to fibrinolysis

<!-- PAGE=? -->
 cardiogenic shock or heart failure

<!-- PAGE=? -->
- NO nitrates

<!-- PAGE=? -->
 hypotension (SBP <90 mm Hg or >30 mm Hg below baseline)

<!-- PAGE=? -->
 extreme bradycardia (<50 bpm) or tachycardia (>100 bpm)

<!-- PAGE=? -->
 caution  with suspected inferior wall MI or (RV) involvement

<!-- PAGE=? -->
 phosphodiesterase inhibitor for erectile dysfunction within the last 24 hours

<!-- PAGE=? -->
Clopidogrel : irreversibly inhibits the platelet adenosine diphosphate receptor, reduction in platelet aggregation through a different mechanism than aspirin.

<!-- PAGE=? -->
B-blockers reduces the size of the infarct, incidence of cardiac rupture, and mortality, reduce the incidence of ventricular ectopy and fibrillation -The integrin GP IIb/IIIa receptor is considered the final common pathway to platelet aggregation.

<!-- PAGE=? -->
-ACEI in first 24H, Statin in first few days

<!-- PAGE=? -->
-GIK no benefit

<!-- PAGE=? -->
-lidocaine increased all-cause mortality rates.

<!-- PAGE=? -->
-prudent to maintain serum potassium >4 mEq/L and magnesium >2 mEq/L

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->
Absolute Contraindications :

<!-- PAGE=? -->
C(HAMS)ABThree T

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Any prior intracranial hemorrhage

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Known structural cerebral vascular lesion (eg, AVM)

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Known malignant intracranial neoplasm (primary or metastatic)

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 hours

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Suspected aortic dissection

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Active bleeding or bleeding diathesis (excluding menses)

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Significant closed head trauma or facial trauma within 3 months

<!-- PAGE=? -->
Relative Contraindications

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
History of chronic, severe, poorly controlled hypertension

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Severe uncontrolled hypertension on presentation (SBP >180 mm Hg or DBP >110 mm Hg)†

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
History of prior ischemic stroke >3 months, dementia, or known intracranial pathology not covered in contraindications

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Traumatic or prolonged (>10 minutes) CPR or major surgery (<3 weeks)

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Recent (within 2 to 4 weeks) internal bleeding

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Noncompressible vascular punctures

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
For streptokinase/anistreplase: prior exposure (_5 days ago) or prior allergic reaction to these agents

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Pregnancy

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Active peptic ulcer

<!-- PAGE=? -->
GLYPH<31>

<!-- PAGE=? -->
Current use of anticoagulants: the higher the INR, the higher the risk of bleeding

<!-- PAGE=? -->
Chest discomfort suggestive

<!-- PAGE=? -->
of ischemia

<!-- PAGE=? -->
EMS assessment and care and hospital preparation:

<!-- PAGE=? -->
Monitor; support ABCs. Be prepared to provide CPR

<!-- PAGE=? -->
defibnllation

<!-- PAGE=? -->
Administer oxygen; aspirin, nitroglycerin; and morphine if needed

<!-- PAGE=? -->
If available

<!-- PAGE=? -->
obtain 12-lead ECG; If ST-elevation:

<!-- PAGE=? -->
Notity receiving hospital with transmission or interpretation

<!-- PAGE=? -->
Begin fibrinolytic checklist (Figure 2)

<!-- PAGE=? -->
Notified hospita

<!-- PAGE=? -->
should mobilize hospltal resources t0 respond to STEMI

<!-- PAGE=? -->
Immediate ED assessment (<10 min)

<!-- PAGE=? -->
Immediate ED general treatment

<!-- PAGE=? -->
Check vital signs; evaluate oxygen saturation

<!-- PAGE=? -->
Start oxygen at

<!-- PAGE=? -->
Umin; maintain 0sat >909

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
Aspirin 160 to 325 mg

<!-- PAGE=? -->
not given by EMS)

<!-- PAGE=? -->
Obtain review 12-lead ECG

<!-- PAGE=? -->
Pertorm brief, targeted history; physica

<!-- PAGE=? -->
exam

<!-- PAGE=? -->
Morphine IV if pain not relieved by nitroglycerin

<!-- PAGE=? -->
Review/complete fibrinolytic checklist (Figure 2);

<!-- PAGE=? -->
Obtain initial cardiac marker levels;

<!-- PAGE=? -->
initial electrolyte and coagulation studies

<!-- PAGE=? -->
Obtain portable chest x-ray (<30 min)

<!-- PAGE=? -->
Review initial 12-lead ECG

<!-- PAGE=? -->
13

<!-- PAGE=? -->
ST elevation or new or

<!-- PAGE=? -->
ST depression or dynamic

<!-- PAGE=? -->
Normal or nondiagnostic changes

<!-- PAGE=? -->
presumably new LBBB;

<!-- PAGE=? -->
T-wave inversion; strongly

<!-- PAGE=? -->
in ST segment or

<!-- PAGE=? -->
wave

<!-- PAGE=? -->
strongly suspicious for injury

<!-- PAGE=? -->
suspicious for ischemia

<!-- PAGE=? -->
Iul

<!-- PAGE=? -->
10

<!-- PAGE=? -->
14

<!-- PAGE=? -->
Start adjunctive treatments as

<!-- PAGE=? -->
Start adjunctive treatments as

<!-- PAGE=? -->
Develops high or intermedi -

<!-- PAGE=? -->
indicated (see text tor contraindications)

<!-- PAGE=? -->
indicated (see text for contraindications)

<!-- PAGE=? -->
ate risk criteria (Tables 3, 4)

<!-- PAGE=? -->
Do not delay repertusion

<!-- PAGE=? -->
Nitroglycerin

<!-- PAGE=? -->
ß-Adrenergic receptor blockers

<!-- PAGE=? -->
ß-Adrenergic receptor blockers

<!-- PAGE=? -->
troponin-positive?

<!-- PAGE=? -->
Clopidogrel

<!-- PAGE=? -->
Clopidogrel

<!-- PAGE=? -->
Heparin (UFH or LMWH)

<!-- PAGE=? -->
Heparin (UFH or LMWH)

<!-- PAGE=? -->
15

<!-- PAGE=? -->
Glycoprotein Ilblllla inhibitor

<!-- PAGE=? -->
Consider admission to

<!-- PAGE=? -->
ED chest pain unit or to

<!-- PAGE=? -->
Time from onset of

<!-- PAGE=? -->
Admit to monitored bed

<!-- PAGE=? -->
monitored bed in ED

<!-- PAGE=? -->
symptoms <12 hours?

<!-- PAGE=? -->
Assess risk status (Tables 3,4)

<!-- PAGE=? -->
Follow:

<!-- PAGE=? -->
Serial cardiac markers

<!-- PAGE=? -->
lincluding troponin)

<!-- PAGE=? -->
12

<!-- PAGE=? -->
Repeat ECGIcontinuous

<!-- PAGE=? -->
ST segment monitoning

<!-- PAGE=? -->
High-risk patient (Tables 3, 4 for

<!-- PAGE=? -->
Consider stress test

<!-- PAGE=? -->
risk stratification):

<!-- PAGE=? -->
Reperlusion strategy:

<!-- PAGE=? -->
Aetractory ischemic chest pain

<!-- PAGE=? -->
Therapy defined by patient and center

<!-- PAGE=? -->
Recurrent persistent ST deviation

<!-- PAGE=? -->
cnteria (Table 2

<!-- PAGE=? -->
Ventricular tachycardia

<!-- PAGE=? -->
16

<!-- PAGE=? -->
Be aware of reperfusion goals:

<!-- PAGE=? -->
Hemodynamic instability

<!-- PAGE=? -->
Develops high or intermedi -

<!-- PAGE=? -->
Door-to-balloon inflation (PCI)

<!-- PAGE=? -->
Signs of pump tailure

<!-- PAGE=? -->
ate risk criteria (Tables 3,

<!-- PAGE=? -->
goal of 90 min

<!-- PAGE=? -->
Early invasive strategy; including

<!-- PAGE=? -->
OR

<!-- PAGE=? -->
Door-to-needle (fibrinolysis)

<!-- PAGE=? -->
catheterization and revascularization

<!-- PAGE=? -->
troponin-positive?

<!-- PAGE=? -->
goal of 30 min

<!-- PAGE=? -->
for shock within 48 hours of an AMI

<!-- PAGE=? -->
Continue adjunctive therapies and:

<!-- PAGE=? -->
ACE inhibitorslangiotensin

<!-- PAGE=? -->
therapies as indicated.

<!-- PAGE=? -->
receptor blocker (ARB) within

<!-- PAGE=? -->
ACE inhibitor/ARB

<!-- PAGE=? -->
24 hours of symptom onset

<!-- PAGE=? -->
HMG CoA reductase inhibitor

<!-- PAGE=? -->
If no evidence of ischemia

<!-- PAGE=? -->
HMG CoA reductase inhibitor

<!-- PAGE=? -->
(statin therapy)

<!-- PAGE=? -->
or infarction; can discharge

<!-- PAGE=? -->
Istatin therapy)

<!-- PAGE=? -->
Not at high risk: cardiology t0 risk-stratily

<!-- PAGE=? -->
with follow-up

<!-- PAGE=? -->
and

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ACLS - Arrest

<!-- PAGE=? -->
PULSELESS Arrest

<!-- PAGE=? -->
BLS Algorithm: Call for help. give CPR

<!-- PAGE=? -->
Give oxygen when available

<!-- PAGE=? -->
Attach monitorldefibrillator when available

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
VFNT

<!-- PAGE=? -->
Asystole/PEA

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Manual biphasic: device specific

<!-- PAGE=? -->
10

<!-- PAGE=? -->
(typically 120 to 200 J)

<!-- PAGE=? -->
Note;

<!-- PAGE=? -->
Resume CPR immediately for 5 cycles

<!-- PAGE=? -->
AED: device speclfic

<!-- PAGE=? -->
When IVIIO avallable  give vasopressor

<!-- PAGE=? -->
Monophasic: 360

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
mg IVIO

<!-- PAGE=? -->
Resume CPR immediately

<!-- PAGE=? -->
Repeat every 3 to 5 min

<!-- PAGE=? -->
May give

<!-- PAGE=? -->
dose of vasopressin 40 U IVIIO to

<!-- PAGE=? -->
replace first or second dose ol epinephrine

<!-- PAGE=? -->
4

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Consider atropine

<!-- PAGE=? -->
mg IVIIO

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
for asystole or slow PEA rate

<!-- PAGE=? -->
Repeat every 3to 5 min (up t0 3 doses)

<!-- PAGE=? -->
Continue CPR while defibrillator is charging

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Manual biphasic: device

<!-- PAGE=? -->
(same as first shock or higher dose)

<!-- PAGE=? -->
Note

<!-- PAGE=? -->
200

<!-- PAGE=? -->
AED: device specitic

<!-- PAGE=? -->
Monophasic: 360

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Resume CPR Immediately after the shock

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
When IVIIO available , give vasopressor during CPR

<!-- PAGE=? -->
(betore oratter the shock)

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
mg IVIIO

<!-- PAGE=? -->
Repeat every 3t0 5 min

<!-- PAGE=? -->
give 1 dose of vasopressin 40 U IVIIO to

<!-- PAGE=? -->
replace first or second dose of epinephrine

<!-- PAGE=? -->
13

<!-- PAGE=? -->
If asystole, 90 to Box 10

<!-- PAGE=? -->
Nol

<!-- PAGE=? -->
If electrical activity, check

<!-- PAGE=? -->
Go t0

<!-- PAGE=? -->
pulse. If no pulse, go to

<!-- PAGE=? -->
Box

<!-- PAGE=? -->
Box 10

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
pulse present, begin

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
postresuscitation care

<!-- PAGE=? -->
During CPR

<!-- PAGE=? -->
Continue

<!-- PAGE=? -->
while detibrillator is charging

<!-- PAGE=? -->
Push hard and fast (1OO/min)

<!-- PAGE=? -->
Rotate compressors every

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Ensure lull chest recoll

<!-- PAGE=? -->
2 minutes with rhythm checks

<!-- PAGE=? -->
Manua

<!-- PAGE=? -->
biphasic: device

<!-- PAGE=? -->
Search for and treat possible

<!-- PAGE=? -->
(samne as lirst shock or higher dose)

<!-- PAGE=? -->
Minimize interruptions in chest

<!-- PAGE=? -->
contributing tactors:

<!-- PAGE=? -->
Note

<!-- PAGE=? -->
compressions

<!-- PAGE=? -->
Hypovolemla

<!-- PAGE=? -->
AED: device specitic

<!-- PAGE=? -->
One cycle of CPR: 30 compressions

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Monophasic: 360

<!-- PAGE=? -->
then 2 breatns; 5 cycles

<!-- PAGE=? -->
min

<!-- PAGE=? -->
Hydrogen ion (acidosts)

<!-- PAGE=? -->
Resume CPR Immediately after the shock

<!-- PAGE=? -->
Avoid hyperventilation

<!-- PAGE=? -->
Hypo-thyperkalemia

<!-- PAGE=? -->
Consider antianhythmics;

<!-- PAGE=? -->
during CPa

<!-- PAGE=? -->
Hypoglycemia

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
amiodarone (300 mg IVIIO once, then

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
consider aoditional

<!-- PAGE=? -->
Tamponade, cardiac

<!-- PAGE=? -->
lidocaine (1 to

<!-- PAGE=? -->
5 makg first dose, then 05 to

<!-- PAGE=? -->
rescuers no longer deliver "cycles"

<!-- PAGE=? -->
Tension pneumothorax

<!-- PAGE=? -->
of CPR. Give continous chest com-

<!-- PAGE=? -->
Thrombosis (coronary or

<!-- PAGE=? -->
Consider magnesium, loading dose

<!-- PAGE=? -->
pressions without pauses for breaths.

<!-- PAGE=? -->
pulmonary)

<!-- PAGE=? -->
to 2g IVIO for torsades de pointes

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
Atter 5 cycles of CPR;

<!-- PAGE=? -->
got to Box 5 above

<!-- PAGE=? -->
specific

<!-- PAGE=? -->
specilic

<!-- PAGE=? -->
150

<!-- PAGE=? -->
I would immediately institute ACLS protocols by asking the surgeon to begin fast, hard chest compressions at 100/min while I ventilate a 8-10 breaths/min, being careful to minimize intrathoracic pressure.

<!-- PAGE=? -->
Shock, Shock, EVerybody SHOCK - And Lets Make it Better EVA

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Brady -All Trained Dogs Eat Gum

<!-- PAGE=? -->
-Pacing is also recommended for severely symptomatic patients, especially when the block is at or below the His-Purkinje level (ie, type II second-degree or third-degree AV block

<!-- PAGE=? -->
-Atropine is useful for treating symptomatic sinus bradycardia and may be beneficial for any type of AV block at the nodal level.

<!-- PAGE=? -->
-Avoid relying on atropine in type II second-degree or third-degree AV block or in patients with third-degree AV block, or post-transplant (reports of slowing)

<!-- PAGE=? -->
-epi/dopamine 2-10ug/min second line

<!-- PAGE=? -->
-IV glucagon (3 mg initially, followed by infusion at 3 mg/h if necessary) for CCB or BB OD

<!-- PAGE=? -->
Tachy (3 QUESTIONS)

<!-- PAGE=? -->
-Stable?

<!-- PAGE=? -->
-Wide? (VT, SVT with abberancy)

<!-- PAGE=? -->
-Regular? (NSR if <160, PSVT/AVNR if > 160, flutter) vs Irreg (Afib, MAT, flutter with variable block)

<!-- PAGE=? -->
-wide: amio, cardiovert, lytes, overdrive, consider SVT

<!-- PAGE=? -->
-any SVT - vagal + adenosine, anything else - Amio

<!-- PAGE=? -->
-Afib : rate control with diltiazem, B-blockers, or magnesium, rhythm control <48 hours duration: Amiodarone, ibutilide, propafenone, flecainide, digoxin, clonidine, or magnesium

<!-- PAGE=? -->
-WPW :  Procaineaminde Ibutilide Sotalol Amiodarone

<!-- PAGE=? -->
-Long QT - stop offending drug, fix lytes.  Overdrive pace (isoproterenol or electrical)

<!-- PAGE=? -->
-Polymorphic VT : treat long QT, (if no long QT - amio)

<!-- PAGE=? -->
Adenosine : briefly depresses AV and sinus node activity. 6mg then 12mg x 2. safe in pregnancy . Larger doses may be required for patients with a significant blood level of theophylline, caffeine, or theobromine. The initial dose should be reduced to 3 mg in patients taking dipyridamole or carbamazepine, those with transplanted hearts, or if given by central venous access.

<!-- PAGE=? -->
Amio: effects on sodium, potassium, and calcium channels as well as a- and B-adrenergic blocking properties. 150 mg of IV amiodarone over 10 minutes, then 1 mg/min x 6 hours ,  then a 0.5mg/min x 18 hours . Supplementary infusions of 150 mg can be repeated every 10 minutes max total daily IV dose of 2.2 g .

<!-- PAGE=? -->
Verapamil and diltiazem: nondihydropyridine CCB, slow conduction and increase refractoriness in the AV node. Verapamil and, to a lesser extent, diltiazem may decrease myocardial contractility and critically reduce cardiac output in patients with severe left ventricular dysfunction.

<!-- PAGE=? -->
-Verapamil: 2.5-5mg IV over 2 min q 15min to max 20mg

<!-- PAGE=? -->
-Diltiazem: 0.25mg/kg over 2 min q 15min, infusion of 5-15mg/h

<!-- PAGE=? -->
Ibutilide is a short-acting,  acts by prolonging the action potential duration and increasing the refractory period of cardiac tissue. 0.01mg/kg over 10 mintues, q10min x 2

<!-- PAGE=? -->
Lidocaine - not the drug of choice. 1.5mg/kg

<!-- PAGE=? -->
Procainamide - suppresses both atrial and ventricular arrhythmias by slowing conduction in myocardial tissue. infusion of 2050 mg/min until the arrhythmia is suppressed, hypotension ensues, the QRS complex is prolonged by 50% from its original duration, or a total of 17 mg/kg (1.2 g for a 70-kg patient ).

<!-- PAGE=? -->
ACLS - Brady/Tachy

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Sotalol: prolongs action potential duration and increases cardiac tissue refractoriness. It also has nonselective B-blocking properties. 1 to 1.5 mg/kg , then infused at a rate of 10 mg/min. Bicarb 1meq/kg

<!-- PAGE=? -->
Dig

<!-- PAGE=? -->
0.5mg IV (works by incr vagal - poor effect in pt's c hiqh sympathetic

<!-- PAGE=? -->
BRADYCARDIA

<!-- PAGE=? -->
Heart rate <60 bpm and

<!-- PAGE=? -->
inadequate for clinical condition

<!-- PAGE=? -->
Maintain patent airway; assist breathing as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Monitor ECG (identify rhythm) , blood pressure, oximetry

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
Signs or symptoms of poor perfusion caused by the bradycardia?

<!-- PAGE=? -->
(eg, acute altered mental status, ongoing chest pain, hypotension or other signs of shock)

<!-- PAGE=? -->
Pour

<!-- PAGE=? -->
ObservelMonitor

<!-- PAGE=? -->
Prepare for transcutaneous pacing;

<!-- PAGE=? -->
use without delay for high-degree block

<!-- PAGE=? -->
(type Il second-degree block or

<!-- PAGE=? -->
third-degree AV block)

<!-- PAGE=? -->
Consider atropine 0.5 mg IV while

<!-- PAGE=? -->
awaiting pacer. May repeat to a

<!-- PAGE=? -->
total dose of 3 mg. If ineffective;

<!-- PAGE=? -->
begin pacing

<!-- PAGE=? -->
Consider epinephrine (2 to 10 ug/min)

<!-- PAGE=? -->
Reminders

<!-- PAGE=? -->
or dopamine (2 to 10 pgkg per minute)

<!-- PAGE=? -->
If pulseless arrest develops; g0 to Pulseless Arrest Algorithm

<!-- PAGE=? -->
infusion while awaiting pacer or if

<!-- PAGE=? -->
Search tor and treat possible contributing factors:

<!-- PAGE=? -->
pacing ineffective

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Tamponade; cardiac

<!-- PAGE=? -->
Hydrogen ion (acidosis)

<!-- PAGE=? -->
Tension pneumothorax

<!-- PAGE=? -->
Hypo-/hyperkalemia

<!-- PAGE=? -->
Thrombosis (coronary or pulmonary)

<!-- PAGE=? -->
Prepare for transvenous pacing

<!-- PAGE=? -->
Hypoglycemia

<!-- PAGE=? -->
Trauma (hypovolemia, increased ICP)

<!-- PAGE=? -->
Treat contributing causes

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
TACHYCARDIA

<!-- PAGE=? -->
Wlth Pulses

<!-- PAGE=? -->
Assess and support ABCs as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Monitor

<!-- PAGE=? -->
ECG (identity rhythm) , blood pressure, oximetry

<!-- PAGE=? -->
Identily and treat reversible causes

<!-- PAGE=? -->
Perform immediate

<!-- PAGE=? -->
synchronized cardioversion

<!-- PAGE=? -->
Establlsh IV access

<!-- PAGE=? -->
Is patient stable?

<!-- PAGE=? -->
Establish IV access and give

<!-- PAGE=? -->
Obtain 12-lead ECG

<!-- PAGE=? -->
Slubie

<!-- PAGE=? -->
Unstable signs include altered

<!-- PAGE=? -->
sedation if patient

<!-- PAGE=? -->
(when available)

<!-- PAGE=? -->
mental status; ongoing chest pain;

<!-- PAGE=? -->
is conscious; do not delay

<!-- PAGE=? -->
or rhythm strio

<!-- PAGE=? -->
hypotension or other signs of shock

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Is ORS narrow (<0.12 sec)?

<!-- PAGE=? -->
Note: rate-related symptoms

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
uncommon if heart rate <1SO/min

<!-- PAGE=? -->
It pulseless arrest develops

<!-- PAGE=? -->
see Pulseless Arrest Algorithm

<!-- PAGE=? -->
Narru

<!-- PAGE=? -->
Is Rhythm Regular?

<!-- PAGE=? -->
Rhythm Regular?

<!-- PAGE=? -->
Export consultation

<!-- PAGE=? -->
advised

<!-- PAGE=? -->
Attempt vagal maneuvers

<!-- PAGE=? -->
Irregular Narrow-Complex

<!-- PAGE=? -->
Give adenosine 6 mg rapid

<!-- PAGE=? -->
IV pushIf no coversion;

<!-- PAGE=? -->
give 12 mg rapid IV push;

<!-- PAGE=? -->
ventncular

<!-- PAGE=? -->
may repeat 12 mg dose once

<!-- PAGE=? -->
atnaltachycardia)

<!-- PAGE=? -->
aberrancy

<!-- PAGE=? -->
uncertaln rhythm

<!-- PAGE=? -->
Control rate (eg

<!-- PAGE=? -->
diltiazem

<!-- PAGE=? -->
Amlodarone

<!-- PAGE=? -->
Complex Tachycardia

<!-- PAGE=? -->
150 mg IV Over 10 min

<!-- PAGE=? -->
(Box 11)

<!-- PAGE=? -->
Does rhythm

<!-- PAGE=? -->
convert?

<!-- PAGE=? -->
lo maximum dose 0i

<!-- PAGE=? -->
pro exclted otrial

<!-- PAGE=? -->
Note: Consider

<!-- PAGE=? -->
expert consultation

<!-- PAGE=? -->
synchronized

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Avoid AVnodal

<!-- PAGE=? -->
rhythm converle,

<!-- PAGE=? -->
probable reentry SVT

<!-- PAGE=? -->
ectopic atnaltachycardia

<!-- PAGE=? -->
mics (09. omlodarone

<!-- PAGE=? -->
150 mg IV over 10 min)

<!-- PAGE=? -->
Treal recurrence wilh

<!-- PAGE=? -->
consultation

<!-- PAGE=? -->
torsades de pointes,

<!-- PAGE=? -->
agents (09diltlazem,

<!-- PAGE=? -->
give magneslum

<!-- PAGE=? -->
pblockers)

<!-- PAGE=? -->
Consider exoert consultation

<!-- PAGE=? -->
2g over

<!-- PAGE=? -->
During Evaluation

<!-- PAGE=? -->
Trcat contrbuting lactors:

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
Note: It patient becomes

<!-- PAGE=? -->
and vascular access

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Tamponade, cardiac

<!-- PAGE=? -->
unstable; 90 10 Box

<!-- PAGE=? -->
when possible

<!-- PAGE=? -->
Hydrogen ion (acidosis)

<!-- PAGE=? -->
Tension pneumothorax

<!-- PAGE=? -->
Consider

<!-- PAGE=? -->
expert

<!-- PAGE=? -->
Hypo-Ihyperkalemia

<!-- PAGE=? -->
Thrombosis (coronary Or

<!-- PAGE=? -->
consultation

<!-- PAGE=? -->
Hypoglycemia

<!-- PAGE=? -->
pulmonary

<!-- PAGE=? -->
Prepare tor

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Trauma (hipovolemia)

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Ventricular Tachycardia

<!-- PAGE=? -->
Monomorphic

<!-- PAGE=? -->
Usually ischemic

<!-- PAGE=? -->
Treat: amiodarone, cardioversion

<!-- PAGE=? -->
Polymorphic

<!-- PAGE=? -->
Long QT (think torsades)

<!-- PAGE=? -->
o Congenital or acquired (toxin/trauma)

<!-- PAGE=? -->
o Electrolyte abnormalities or high adrenergic state

<!-- PAGE=? -->
o Fix lytes, cardiovert, overdrive pacing

<!-- PAGE=? -->
Normal QT

<!-- PAGE=? -->
o Most likely ischemia

<!-- PAGE=? -->
o Amiodarone, beta blockers, cardioversion

<!-- PAGE=? -->
Cardioversion in Full Stomach: modified RSI, hemodynamic priority Cardioversion in Full Stomach + Diff A/W :  Topicalize + midaz vs midaz and 'awake shock'

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ACLS - CVA

<!-- PAGE=? -->
The Cincinnati Prehospital Stroke Scale ( SAD- Smile Altered speech Drift )

<!-- PAGE=? -->
1.Facial Droop (have patient show teeth or smile):

<!-- PAGE=? -->
2.Arm Drift (patient closes eyes and holds both arms straight out for 10seconds):

<!-- PAGE=? -->
3.Abnormal Speech (have the patient say 'you can't teach an old dog new tricks'):

<!-- PAGE=? -->
If any 1 of these 3 signs is abnormal, the probability of a stroke is 72%.

<!-- PAGE=? -->
-A 12-lead ECG does not take priority over the CT scan, but it may identify a recent acute myocardial infarction or arrhythmias (eg, atrial fibrillation) as the cause of an embolic stroke.

<!-- PAGE=? -->
-lower blood glucose in patients with acute ischemic stroke when the serum glucose level is >10 mmol/L

<!-- PAGE=? -->
-Hyper thermia in the setting of acute cerebral ischemia is associated with increased morbidity and mortality

<!-- PAGE=? -->
-no prophylactic seizure prevention

<!-- PAGE=? -->
-major complication of IV tPA for stroke is symptomatic intracranial hemorrhage. 4-6%,  angioedema (occurs in about 1.5% of patients), acute hypotension, and systemic bleeding.

<!-- PAGE=? -->
CVA: rule out hypoglycemia, initial assessment is performed within 10 minutes, a CTscan is performed and interpreted within 25 minutes, and fibrinolytics are administered to selected patients within 60 minutes of arrival at the ED and within 3 hours of the onset of symptoms.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Identity signs of possible stroke

<!-- PAGE=? -->
Critical EMS assessments and actions

<!-- PAGE=? -->
Support ABCs; give oxygen if needed

<!-- PAGE=? -->
Perform prehospital stroke assessment (Tables

<!-- PAGE=? -->
and 2)

<!-- PAGE=? -->
Establish time when patient last known normal (Note:

<!-- PAGE=? -->
therapies may be available beyond 3 hours from onset)

<!-- PAGE=? -->
NINDS

<!-- PAGE=? -->
Transport; consider triage to a center with a stroke unit

<!-- PAGE=? -->
TIME

<!-- PAGE=? -->
if appropriate; consider bringing a witness, tamily

<!-- PAGE=? -->
GOALS

<!-- PAGE=? -->
member, or caregiver

<!-- PAGE=? -->
Alert hospital

<!-- PAGE=? -->
Check glucose if possible

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
Immediate general assessment and stabllization

<!-- PAGE=? -->
Assess ABCs, vital signs

<!-- PAGE=? -->
Provide oxygen if hypoxemic

<!-- PAGE=? -->
Obtain IV access and blood samples

<!-- PAGE=? -->
Check glucose; treat if indicated

<!-- PAGE=? -->
Pertorm neurologic screening assessment

<!-- PAGE=? -->
Activate stroke team

<!-- PAGE=? -->
Order emergent CT scan of brain

<!-- PAGE=? -->
Obtain 12-lead ECG

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arriva

<!-- PAGE=? -->
Immediate neurologic assessment by stroke team or designee

<!-- PAGE=? -->
Review patient history

<!-- PAGE=? -->
Establish symptom onset

<!-- PAGE=? -->
Perform neurologic examination (NIH Stroke Scale or Canadian Neurologic Scale)

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arriva

<!-- PAGE=? -->
Does CT scan show any hemorrhage?

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Probable acute ischemic stroke; consider fibrinolytic therapy

<!-- PAGE=? -->
Consult neurologist or neurosurgeon;

<!-- PAGE=? -->
Check for fibrinolytic exclusions (Table 3)

<!-- PAGE=? -->
consider transfer if not available

<!-- PAGE=? -->
Repeat neurologic exam: are deficits rapidly improving to normal?

<!-- PAGE=? -->
Patient remains candidate for

<!-- PAGE=? -->
Not

<!-- PAGE=? -->
fibrinolytic therapy?

<!-- PAGE=? -->
Administer

<!-- PAGE=? -->
aspirin

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Candidatc

<!-- PAGE=? -->
Review riskslbenefits with patient and family:

<!-- PAGE=? -->
Begin stroke pathway

<!-- PAGE=? -->
If acceptable

<!-- PAGE=? -->
Admit to stroke unit if available

<!-- PAGE=? -->
Give tPA

<!-- PAGE=? -->
Monitor BP; treat if indicated (Table 4)

<!-- PAGE=? -->
No anticoagulants or antiplatelet treatment for

<!-- PAGE=? -->
Monitor neurologic status; emergent CT

<!-- PAGE=? -->
24 hours

<!-- PAGE=? -->
if deterioration

<!-- PAGE=? -->
Monitor blood glucose; treat if needed

<!-- PAGE=? -->
Initiate supportive therapy; treat

<!-- PAGE=? -->
comorbidities

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ACLS http://www.americanheart.org/presenter.jhtml?identifier=3035517

<!-- PAGE=? -->
Ethics:

<!-- PAGE=? -->
-DNR, signs of death, futile (no quality or length of life), extreme prematurity (gestational age <23 weeks or birth weight 400 g) and anencephaly.

<!-- PAGE=? -->
-For the newborn infant, discontinuation of resuscitation can be justified after 10 minutes without signs of life

<!-- PAGE=? -->
-Prolonged efforts should be made for infants and children with recurring or refractory VF or VT, drug toxicity, or a primary hypothermic insult.

<!-- PAGE=? -->
3. CPR

<!-- PAGE=? -->
-30:2 for everything, except 2 rescuer child which is 15:2

<!-- PAGE=? -->
-SCA: should telephone the emergency response number and get an AED

<!-- PAGE=? -->
-A sphyxial arrest (eg, drowning) should deliver about 5 cycles (about 2 minutes) of CPR before leaving

<!-- PAGE=? -->
-After delivery of 2 rescue breaths, healthcare providers should attempt to feel a pulse

<!-- PAGE=? -->
-Rescue breaths without chest compressions should be delivered at a rate of about 10 to 12 breaths per minute for the adult and a rate of about 12 to 20 breaths per minute for the infant and child.

<!-- PAGE=? -->
-100 compressions per minute fast, hard, continuously, allow complete chest recoil between compressions, without pauses for ventilation. should give 8 to 10 breaths per minute. change compressor and ventilator roles approximately every 2 minutes

<!-- PAGE=? -->
-newborn: until the newborn leaves the hospital,  Infant: <1yo, Child: < adolescence or puberty

<!-- PAGE=? -->
-Each rescue breath should be delivered in 1 second and should produce visible chest rise.

<!-- PAGE=? -->
-depress the chest of the infant and child by one third to one half the depth of the chest.

<!-- PAGE=? -->
-1½  to 2 inches, using the heel of both hands.

<!-- PAGE=? -->
-rescue breathing rate for the newborn infant with pulses is approximately 40 to 60 breaths per minute.

<!-- PAGE=? -->
-newborn infant should deliver 90 compressions and 30 ventilations (about 120 events) per minute.

<!-- PAGE=? -->
4. Adult BLS

<!-- PAGE=? -->
-hypothermia: assess breathing to confirm respiratory arrest and assess the pulse to confirm cardiac arrest or profound bradycardia for 30 to 45 seconds

<!-- PAGE=? -->
-Choking: do not interfere with the patient's spontaneous coughing

<!-- PAGE=? -->
-The likelihood of success was increased when combinations of back blows or slaps, abdominal thrusts, and chest thrusts were used.

<!-- PAGE=? -->
-abdominal thrusts are not recommended for infants <1 year of age because thrusts may cause injuries.

<!-- PAGE=? -->
-Chest thrusts should be used for obese patients, in the late stages of pregnancy

<!-- PAGE=? -->
5. Electric Therapy

<!-- PAGE=? -->
-afib: 100J (mono or biphasic), other rentry (50J)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
-reasonable to use selected energies of 150 J to 200 J with a biphasic truncated exponential waveform or 120 J with a rectilinear biphasic waveform for the initial shock. -If a monophasic defibrillator is used, select a dose of 360 J for all shocks.

<!-- PAGE=? -->
-This synchronization avoids shock delivery during the relative refractory portion of the cardiac cycle, when a shock could produce VF. The energy (shock dose) used for a synchronized shock is lower than that used for unsynchronized shocks (defibrillation).

<!-- PAGE=? -->
-If cardioversion is needed and it is impossible to synchronize a shock (eg, the patient's rhythm is irregular), use high-energy unsynchronized shocks. -delivery of low energy unsynchronized shocks is likely to induce VF.

<!-- PAGE=? -->
-Cardioversion will not be effective for treatment of junctional tachycardia or ectopic or multifocal atrial tachycardia because these rhythms have an automatic focus. may increase the rate of the tachyarrhythmia

<!-- PAGE=? -->
-Synchronized cardioversion is not used for treatment of VF, pulseless VT, or unstable polymorphic (irregular) VT.

<!-- PAGE=? -->
-Monomorphic VT (regular form and rate) with a pulse responds well to monophasic waveform cardioversion (synchronized) shocks at initial energies of 100 J.

<!-- PAGE=? -->
-Pacing is not recommended for patients in asystolic cardiac arrest

<!-- PAGE=? -->
7: Airway:

<!-- PAGE=? -->
-should deliver a tidal volume sufficient to produce chest rise (approximately 6 to 7 mL/kg or 500 to 600 mL) over 1 second.

<!-- PAGE=? -->
-8-10 breaths with airway, 10-12 with perfusing rhythm

<!-- PAGE=? -->
-adjust for those with autopeep

<!-- PAGE=? -->
-defer insertion of an advanced airway until the patient fails to respond to initial CPR and defibrillation attempts, limit compression interruptions -reconfirm after each movement of patient

<!-- PAGE=? -->
7.4 Monitoring and Meds

<!-- PAGE=? -->
-Carotid pulsations during CPR do not indicate the efficacy of coronary blood flow or myocardial or cerebral perfusion during CPR.

<!-- PAGE=? -->
-ABG not accurate

<!-- PAGE=? -->
-SpO2 does not ensure adequate CO

<!-- PAGE=? -->
-End-tidal CO2 monitoring is a safe and effective noninvasive indicator of cardiac output during CPR -reflects changes in CO

<!-- PAGE=? -->
-milrinone IV loading dose (50 u g/kg over 10 minutes) is followed by an IV infusion at a rate of 0.375 to 0.75 u

<!-- PAGE=? -->
g/kg per minute

<!-- PAGE=? -->
-Ca: no benefit, possible harm. necessary. (The 10% solution contains 1.36 mEq of calcium or 27.2 mg elemental calcium per milliliter.)

<!-- PAGE=? -->
-Nipride: The recommended dosing range for sodium nitroprusside is 0.1 to 5ug/kg/minute

<!-- PAGE=? -->
-HCO3-:. Dose 1meq/kg

<!-- PAGE=? -->
-K (Ca, insulin, ventolin, Bicarb, hypervent)

<!-- PAGE=? -->
7.5 Post ressuc.

<!-- PAGE=? -->
-should not actively rewarm hemodynamically stable patients who spontaneously develop a mild degree of hypothermia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
-unconscious adult patients with ROSC after out-ofhospital cardiac arrest should be cooled to 32°C to 34°C

<!-- PAGE=? -->
(89.6°F to 93.2°F) for 12 to 24 hours when the initial rhythm was VF

<!-- PAGE=? -->
-Although not significantly higher, cases of pneumonia and sepsis increased in the hypothermia-induction group.3,4 Cooling may also increase hyperglycemia -maintain strict glucose control during the postresuscitation period. -optimize cerebral perfusion pressure

<!-- PAGE=? -->
-Therefore, median nerve somatosensory-evoked potentials measured 72 hours after cardiac arrest can be used to predict neurologic outcome in patients with hypoxicanoxic coma.  An electroencephalogram performed _24 to 48 hours after resuscitation has also been shown to provide useful predictive

<!-- PAGE=? -->
-In most cases the prognosis for adults who remain deeply comatose (GCS <5) after cardiac arrest can be predicted with accuracy after 2 to 3 days. -predict death or poor neurologic outcome:

<!-- PAGE=? -->
_ Absent corneal reflex at 24 hours

<!-- PAGE=? -->
_ Absent pupillary response at 24 hours

<!-- PAGE=? -->
_ Absent withdrawal response to pain at 24 hours

<!-- PAGE=? -->
_ No motor response at 24 hours

<!-- PAGE=? -->
_ No motor response at 72 hours

<!-- PAGE=? -->
Arrest:

<!-- PAGE=? -->
-IO is safe in all ages

<!-- PAGE=? -->
-Note that central venous catheterization is a relative (not absolute) contraindication for fibrinolytic therapy

<!-- PAGE=? -->
-Naloxine, Atropine, Vasopressin, Epi, Lidocaine are absorbed via the trachea. (2-2.5x dose dilute the recommended dose in 5 to 10 mL of water)

<!-- PAGE=? -->
-Defib dose: Biphasic: recommended or 200, Mono: 360

<!-- PAGE=? -->
-Vasopressor after 1 or 2 shocks plus CPR

<!-- PAGE=? -->
-drug doses should be prepared before the rhythm check so they can be administered as soon as possible after the rhythm check, so that it circulates with CPR

<!-- PAGE=? -->
-for recurrent VF/VTthe patient may be a candidate for early treatment with antiarrhythmic medications

<!-- PAGE=? -->
-max atropine 3mg

<!-- PAGE=? -->
-lower rates of ROSC and a higher incidence of asystole with use of lidocaine.

<!-- PAGE=? -->
-Magnesium is not likely to be effective in terminating irregular/polymorphic VT in patients with a normal QT interval

<!-- PAGE=? -->
-There is insufficient evidence to recommend for or against the routine use of fibrinolysis for cardiac arrest.

<!-- PAGE=? -->
-Ongoing CPR is not a contraindication to fibrinolysis

<!-- PAGE=? -->
-no evidence for pacing asystole

<!-- PAGE=? -->
-no recommendation for precordial thump for VF/VT

<!-- PAGE=? -->
-Torsades de Pointes

<!-- PAGE=? -->
This polymorphic VT is seen in patients with a long QT interval, which may be congenital or may result from toxicity with type IA antiarrhythmics (eg, procainamide, quinidine, and disopyramide) or type III antiarrhythmics (eg, sotalol and amiodarone), tricyclic antidepressants, digitalis, or electrolytes: low Mg, Ca, K.

<!-- PAGE=? -->
-Regardless of the cause, treat torsades de pointes with a rapid (over several minutes) IV infusion of magnesium sulfate.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
- Electrical overdrive or pharmacologic overdrive pacing with isoproterenol pacing at rates of 100 to 120 beats per minute may terminate torsades de pointes.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Adult BLS

<!-- PAGE=? -->
No movement or response

<!-- PAGE=? -->
PHONE 911 or emergency number

<!-- PAGE=? -->
Get AED

<!-- PAGE=? -->
or send second rescuer (if available) to do this

<!-- PAGE=? -->
Open AIRWAY; check BREATHING

<!-- PAGE=? -->
If not breathing; give 2 BREATHS that make chest rise

<!-- PAGE=? -->
5A

<!-- PAGE=? -->
If no response; check pulse:

<!-- PAGE=? -->
Give 1 brealh every

<!-- PAGE=? -->
Do you DEFINITELY feel

<!-- PAGE=? -->
5 to 6 seconds

<!-- PAGE=? -->
pulse withln 10 seconds?

<!-- PAGE=? -->
Recheck pulse every

<!-- PAGE=? -->
2 minutes

<!-- PAGE=? -->
No Pulac

<!-- PAGE=? -->
Give cycles of 30 COMPRESSIONS and 2 BREATHS

<!-- PAGE=? -->
until AEDIdefibrillator arrives; ALS providers take over; or

<!-- PAGE=? -->
victim starts t0 move

<!-- PAGE=? -->
Push hard and fast (1OO/min) and release completely

<!-- PAGE=? -->
Minimize interruplions in compressions

<!-- PAGE=? -->
AED/defibrillator ARRIVES

<!-- PAGE=? -->
Check Rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Arrest

<!-- PAGE=? -->
PULSELESS ArrEST

<!-- PAGE=? -->
BLS Algorithm: Call for help, give CPR

<!-- PAGE=? -->
Give oxygen when avallable

<!-- PAGE=? -->
Attach monitorldefibrillator when available

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
VFNT

<!-- PAGE=? -->
Asystole/PEA

<!-- PAGE=? -->
Give 1 shock

<!-- PAGE=? -->
Manual biphasic: device specific

<!-- PAGE=? -->
10

<!-- PAGE=? -->
(typically 120 to 200 J)

<!-- PAGE=? -->
Note:

<!-- PAGE=? -->
Resume CPR immediately for 5 cycles

<!-- PAGE=? -->
AED: device specific

<!-- PAGE=? -->
When IVIIO available; give vasopressor

<!-- PAGE=? -->
Monophasic: 360 J

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
Resume CPR immediately

<!-- PAGE=? -->
May give 1 dose of vasopressin 40 U IVIIO to

<!-- PAGE=? -->
replace first or second dose ol epinephrine

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Consider atropine

<!-- PAGE=? -->
mg IVIIO

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
tor asystole or slow PEA rate

<!-- PAGE=? -->
Repeat every 3 to 5 min (up t0 3 doses)

<!-- PAGE=? -->
Continue CPR while defibrillator is charging

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Manual biphasic: device specific

<!-- PAGE=? -->
(same as first shock or higher dose)

<!-- PAGE=? -->
Note

<!-- PAGE=? -->
use

<!-- PAGE=? -->
200 J

<!-- PAGE=? -->
AED: device specitic

<!-- PAGE=? -->
Monophasic: 360 J

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Resume CPR Immediately after the shock

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
When IVIIO available, give vasopressor during CPR

<!-- PAGE=? -->
(betore or after the shock)

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
mg IVIIO

<!-- PAGE=? -->
Repeat every 3to 5 min

<!-- PAGE=? -->
or

<!-- PAGE=? -->
give

<!-- PAGE=? -->
dose of vasopressin 40 U IVilO to

<!-- PAGE=? -->
12

<!-- PAGE=? -->
replace first or second dose of epinephrine

<!-- PAGE=? -->
13

<!-- PAGE=? -->
Nol

<!-- PAGE=? -->
If electrical activity; check

<!-- PAGE=? -->
Go to

<!-- PAGE=? -->
pulse. If no pulse, g0 to

<!-- PAGE=? -->
Box 4

<!-- PAGE=? -->
Box 10

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
If pulse present, begin

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
postresuscitatlon care

<!-- PAGE=? -->
Shockahlr

<!-- PAGE=? -->
During CPR

<!-- PAGE=? -->
Continue CPR while defibrillator is charging

<!-- PAGE=? -->
Push hard and fast (1OO/min)

<!-- PAGE=? -->
Rotate compressors every

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Ensure (ull chest recoll

<!-- PAGE=? -->
2 minutes with rhythm checks

<!-- PAGE=? -->
Manual biphasic: device specific

<!-- PAGE=? -->
Search for and treat possible

<!-- PAGE=? -->
Minimlze interruptions In chest

<!-- PAGE=? -->
contributing tactors:

<!-- PAGE=? -->
Note

<!-- PAGE=? -->
compressions

<!-- PAGE=? -->
Hypovolemla

<!-- PAGE=? -->
AED: device specitic

<!-- PAGE=? -->
One cycle of CPR: 30 compressions

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Monophasic: 360 J

<!-- PAGE=? -->
then 2 breaths; 5 cycles =2 min

<!-- PAGE=? -->
Hydrogen ion (acidosis)

<!-- PAGE=? -->
Resume CPR Immediately after the shock

<!-- PAGE=? -->
Avoid hyperventilalion

<!-- PAGE=? -->
Hypo-/hyperkalemia

<!-- PAGE=? -->
mg

<!-- PAGE=? -->
May

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Brady

<!-- PAGE=? -->
Brady

<!-- PAGE=? -->
BRADYCARDIA

<!-- PAGE=? -->
Heart rate <60 bpm and

<!-- PAGE=? -->
inadequate for clinical condition

<!-- PAGE=? -->
2

<!-- PAGE=? -->
Maintain patent airway; assist breathing as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Monitor ECG (identify rhythm), blood pressure, oximetry

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
3

<!-- PAGE=? -->
Signs or symptoms of poor perfusion caused by the bradycardia?

<!-- PAGE=? -->
(eg, acute altered mental status, ongoing chest pain; hypotension or other signs of shock)

<!-- PAGE=? -->
4A

<!-- PAGE=? -->
Adoquato

<!-- PAGE=? -->
Poor

<!-- PAGE=? -->
Perlusion

<!-- PAGE=? -->
Perlusion

<!-- PAGE=? -->
Observe/Monitor

<!-- PAGE=? -->
Prepare for transcutaneous pacing;

<!-- PAGE=? -->
use without

<!-- PAGE=? -->
for high-degree block

<!-- PAGE=? -->
(type Il second-degree block or

<!-- PAGE=? -->
third-degree AV block)

<!-- PAGE=? -->
Consider atropine 0.5 mg IV while

<!-- PAGE=? -->
awaiting pacer.

<!-- PAGE=? -->
total dose of 3 mg. If ineffective,

<!-- PAGE=? -->
begin pacing

<!-- PAGE=? -->
Consider epinephrine (2 to 10 pg/min)

<!-- PAGE=? -->
Reminders

<!-- PAGE=? -->
dopamine (2 to 10 pg/kg per minute)

<!-- PAGE=? -->
If pulseless arrest develops; g0 to Pulseless Arrest Algorithm

<!-- PAGE=? -->
infusion while awaiting pacer or if

<!-- PAGE=? -->
Search for and treat possible contributing factors:

<!-- PAGE=? -->
pacing ineffective

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
delay

<!-- PAGE=? -->
May

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Tachy

<!-- PAGE=? -->
TACHYCARDIA

<!-- PAGE=? -->
WIth Pulses

<!-- PAGE=? -->
Assess and support ABCs as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Monitor ECG (identity rhythm) , blood pressure, oximetry

<!-- PAGE=? -->
Identity and treat reversible causes

<!-- PAGE=? -->
Perform immediate

<!-- PAGE=? -->
synchronized cardioversion

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
Is patient stable?

<!-- PAGE=? -->
Establish IV access and give

<!-- PAGE=? -->
Obtain 12-lead ECG

<!-- PAGE=? -->
Unstable signs include altered

<!-- PAGE=? -->
sedation if patient

<!-- PAGE=? -->
(when available)

<!-- PAGE=? -->
mental status, ongoing chest pain,

<!-- PAGE=? -->
is conscious; do not delay

<!-- PAGE=? -->
rhythm strip

<!-- PAGE=? -->
hypotension or other signs of shock

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Is ORS narrow (<0.12 sec)?

<!-- PAGE=? -->
Note: rate-related symptoms

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
uncommon If heart rate <15O/min

<!-- PAGE=? -->
If pulseless arrest develops;

<!-- PAGE=? -->
see Pulseless Arrest Algorithm

<!-- PAGE=? -->
Marruv

<!-- PAGE=? -->
12

<!-- PAGE=? -->
WIDE QRS'=

<!-- PAGE=? -->
Is Rhythm Regular?

<!-- PAGE=? -->
Is Rhythm Regular?

<!-- PAGE=? -->
Export consultation

<!-- PAGE=? -->
advised

<!-- PAGE=? -->
Attempt vagal maneuvers

<!-- PAGE=? -->
Irregular Narrow-Complex

<!-- PAGE=? -->
Give adenosine 6 mg rapid

<!-- PAGE=? -->
Tachycaruia

<!-- PAGE=? -->
13

<!-- PAGE=? -->
14

<!-- PAGE=? -->
IV push. If no conversion,

<!-- PAGE=? -->
give 12 mg rapid IV push;

<!-- PAGE=? -->
It ventncular

<!-- PAGE=? -->
may repeat 12 mg dose once

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
uncertaln rhythm

<!-- PAGE=? -->
See Irregular Narrow-

<!-- PAGE=? -->
Amlodarone

<!-- PAGE=? -->
Complex Tachycardia

<!-- PAGE=? -->
Does rhythm

<!-- PAGE=? -->
cautionin pulmonary disease

<!-- PAGE=? -->
convert?

<!-- PAGE=? -->
Note: Consider

<!-- PAGE=? -->
expert consultation

<!-- PAGE=? -->
synchronized

<!-- PAGE=? -->
advised

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Avoid AV nodal

<!-- PAGE=? -->
blocking agents

<!-- PAGE=? -->
10

<!-- PAGE=? -->
adenosine, dlgoxin

<!-- PAGE=? -->
Give adenosine

<!-- PAGE=? -->
prohable reentry SVT

<!-- PAGE=? -->
Consider antiarhyith-

<!-- PAGE=? -->
amlodarone

<!-- PAGE=? -->
Ireentry supravenlriculor

<!-- PAGE=? -->
Control rate (eg diltiazein,

<!-- PAGE=? -->
Il recurrent polymnor-

<!-- PAGE=? -->
consultation

<!-- PAGE=? -->
adenosine or longer-

<!-- PAGE=? -->
acting AV nodal blocking

<!-- PAGE=? -->
agents

<!-- PAGE=? -->
diltlazem

<!-- PAGE=? -->
Treal

<!-- PAGE=? -->
undarlying causo

<!-- PAGE=? -->
pblockers)

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
(load with 1 2gover

<!-- PAGE=? -->
eo

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ACS

<!-- PAGE=? -->
Chest discomfort suggestive

<!-- PAGE=? -->
of ischemia

<!-- PAGE=? -->
EMS assessment and care and hospital preparation:

<!-- PAGE=? -->
Monitor; support ABCs. Be prepared t0 provide CPR and defibrillation

<!-- PAGE=? -->
Administer oxygen; aspirin; nitroglycerin, and morphine if needed

<!-- PAGE=? -->
If available; obtain 12-lead ECG; if ST-elevation:

<!-- PAGE=? -->
Notity receiving hospital with transmission or interpretation

<!-- PAGE=? -->
Begin fibrinolytic checklist (Figure 2)

<!-- PAGE=? -->
Notified hospital should mobilize hospital resources to respond to STEMI

<!-- PAGE=? -->
Immediate ED assessment (<10 min)

<!-- PAGE=? -->
Immediate ED general treatment

<!-- PAGE=? -->
Check vital signs; evaluate oxygen saturation

<!-- PAGE=? -->
Start oxygen at 4 Umin; maintain 0, sat >909

<!-- PAGE=? -->
Establish IV access

<!-- PAGE=? -->
Aspirin 160 t0 325 mg (if not given by EMS)

<!-- PAGE=? -->
Obtain review 12-lead ECG

<!-- PAGE=? -->
Nitroglycerin sublingual, spray or IV

<!-- PAGE=? -->
Perform brief, targeted history; physical exam

<!-- PAGE=? -->
Morphine IV it pain not relieved by nitroglycerin

<!-- PAGE=? -->
Review/complete fibrinolytic checklist (Figure 2);

<!-- PAGE=? -->
check contraindications (Table 1)

<!-- PAGE=? -->
Obtain initial cardiac marker levels;

<!-- PAGE=? -->
initial electrolyte and coagulation studies

<!-- PAGE=? -->
Obtain portable chest x-ray (<30 min)

<!-- PAGE=? -->
Review initial 12-lead ECG

<!-- PAGE=? -->
13

<!-- PAGE=? -->
ST elevation or new or

<!-- PAGE=? -->
ST depression or dynamic

<!-- PAGE=? -->
Normal or nondiagnostic changes

<!-- PAGE=? -->
presumably new LBBB;

<!-- PAGE=? -->
T-wave inversion; strongly

<!-- PAGE=? -->
in ST segment or T wave

<!-- PAGE=? -->
strongly suspicious for Injury

<!-- PAGE=? -->
suspicious for ischemia

<!-- PAGE=? -->
Han

<!-- PAGE=? -->
10

<!-- PAGE=? -->
14

<!-- PAGE=? -->
Start adjunctive treatments as

<!-- PAGE=? -->
Start adjunctive treatments as

<!-- PAGE=? -->
Develops high or intermedi -

<!-- PAGE=? -->
indicated (see text tor contraindications)

<!-- PAGE=? -->
indicated (see text for contraindications)

<!-- PAGE=? -->
ate risk criteria (Tables 3, 4)

<!-- PAGE=? -->
Do not delay repertusion

<!-- PAGE=? -->
Nitroglycerin

<!-- PAGE=? -->
OR

<!-- PAGE=? -->
ß-Adrenergic receptor blockers

<!-- PAGE=? -->
B-Adrenergic receptor blockers

<!-- PAGE=? -->
troponin-positive?

<!-- PAGE=? -->
Clopidogrel

<!-- PAGE=? -->
Clopidogrel

<!-- PAGE=? -->
Heparin (UFH or LMWH)

<!-- PAGE=? -->
Heparin (UFH or LMWH)

<!-- PAGE=? -->
Glycoprotein Ilblllla inhibitor

<!-- PAGE=? -->
15

<!-- PAGE=? -->
Consider admisslon to

<!-- PAGE=? -->
ED chest pain unit or to

<!-- PAGE=? -->
Time from onset of

<!-- PAGE=? -->
Admit to monitored bed

<!-- PAGE=? -->
monitored bed in ED

<!-- PAGE=? -->
symptoms <12 hours?

<!-- PAGE=? -->
Assess risk status (Tables 3,4)

<!-- PAGE=? -->
Follow:

<!-- PAGE=? -->
Serial cardiac markers

<!-- PAGE=? -->
(including troponin)

<!-- PAGE=? -->
12

<!-- PAGE=? -->
Repeat ECGicontinuous

<!-- PAGE=? -->
ST segment monitoring

<!-- PAGE=? -->
High-risk patient (Tables 3, 4 for

<!-- PAGE=? -->
Consider stress test

<!-- PAGE=? -->
risk stratification):

<!-- PAGE=? -->
Reperlusion strategy:

<!-- PAGE=? -->
Retractory ischemic chest pain

<!-- PAGE=? -->
Therapy defined by patient and center

<!-- PAGE=? -->
Recurrentpersistent ST deviation

<!-- PAGE=? -->
criteria (Table 2)

<!-- PAGE=? -->
Ventricular tachycardia

<!-- PAGE=? -->
16

<!-- PAGE=? -->
Be aware of

<!-- PAGE=? -->
reperfusion goals:

<!-- PAGE=? -->
Hemodynamic instability

<!-- PAGE=? -->
Develops high or intermedi -

<!-- PAGE=? -->
Door-to-balloon inflation (PCI)

<!-- PAGE=? -->
Signs of pump tailure

<!-- PAGE=? -->
ate rsk criteria (Tables 3

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
CVA

<!-- PAGE=? -->
Identlfy signs of possible stroke

<!-- PAGE=? -->
Critical EMS assessments and actions

<!-- PAGE=? -->
Support ABCs; give oxygen if needed

<!-- PAGE=? -->
Perform prehospital stroke assessment (Tables

<!-- PAGE=? -->
and 2)

<!-- PAGE=? -->
Establish time when patient last known normal (Note:

<!-- PAGE=? -->
therapies may be available beyond 3 hours from onset)

<!-- PAGE=? -->
NINDS

<!-- PAGE=? -->
Transport; consider triage to a center with a stroke unit

<!-- PAGE=? -->
TIME

<!-- PAGE=? -->
appropriate; consider bringing a witness; tamily

<!-- PAGE=? -->
GOALS

<!-- PAGE=? -->
member; or caregiver

<!-- PAGE=? -->
Alert hospital

<!-- PAGE=? -->
Check glucose if possible

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
Immediate general assessment and stabllization

<!-- PAGE=? -->
Assess ABCs, vital signs

<!-- PAGE=? -->
Provide oxygen if hypoxemic

<!-- PAGE=? -->
Obtain IV access and blood samples

<!-- PAGE=? -->
Check glucose; treat if indicated

<!-- PAGE=? -->
Perform neurologic screening assessment

<!-- PAGE=? -->
Activate stroke team

<!-- PAGE=? -->
Order emergent CT scan of brain

<!-- PAGE=? -->
Obtain 12-lead ECG

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
Immediate neurologic assessment by stroke team or designee

<!-- PAGE=? -->
Review patient history

<!-- PAGE=? -->
Establish symptom onset

<!-- PAGE=? -->
2

<!-- PAGE=? -->
Perform neurologic examination (NIH Stroke Scale or Canadian Neurologic Scale)

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
Does CT scan show any hemorrhage?

<!-- PAGE=? -->
Min

<!-- PAGE=? -->
Mo Hemorrhagc

<!-- PAGE=? -->
Probable acute Ischemic stroke; consider fibrinolytic therapy

<!-- PAGE=? -->
Consult neurologist or neurosurgeon;

<!-- PAGE=? -->
Check for fibrinolytic exclusions (Table 3)

<!-- PAGE=? -->
consider transfer if not available

<!-- PAGE=? -->
Repeat neurologic exam: are deficits rapidly improving to normal?

<!-- PAGE=? -->
Patient remains candidate for

<!-- PAGE=? -->
fibrinolytic therapy?

<!-- PAGE=? -->
Administer aspirin

<!-- PAGE=? -->
ED

<!-- PAGE=? -->
Arrival

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Candidate

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Acromegaly

<!-- PAGE=? -->
'a endocrinopathy caused by excess GH that has multi-system effects'

<!-- PAGE=? -->
Difficult airway

<!-- PAGE=? -->
Macroglossia

<!-- PAGE=? -->
TMJ arthritis

<!-- PAGE=? -->
Subglottic narrowing

<!-- PAGE=? -->
OSA

<!-- PAGE=? -->
Cardiovascular dysfunction

<!-- PAGE=? -->
HTN

<!-- PAGE=? -->
Cardiomegaly

<!-- PAGE=? -->
Endocrine dysfunction

<!-- PAGE=? -->
DM (insulin resistance)

<!-- PAGE=? -->
Pituitary mass effect

<!-- PAGE=? -->
Systems Review (Assessment H&P)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cushing's Disease

<!-- PAGE=? -->
'an endocrinopathy caused by excess adrenal hormone affect with multiple system involvement'

<!-- PAGE=? -->
CVS - HTN

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
Hyperglycemia

<!-- PAGE=? -->
¾ K

<!-- PAGE=? -->
¾ H+

<!-- PAGE=? -->
Cushing's Syndrome:

<!-- PAGE=? -->
Central obesity and thin extremities

<!-- PAGE=? -->
Proximal muscle weakness

<!-- PAGE=? -->
Osteopenia at a young age and back pain

<!-- PAGE=? -->
Hypertension and fluid retention

<!-- PAGE=? -->
Glucose intolerance and hyperglycemia

<!-- PAGE=? -->
Psychiatric disorders

<!-- PAGE=? -->
Purple stria

<!-- PAGE=? -->
Plethoric facies

<!-- PAGE=? -->
Spontaneous ecchymoses

<!-- PAGE=? -->
Hyperpigmentation

<!-- PAGE=? -->
Hirsutism

<!-- PAGE=? -->
Polyuria

<!-- PAGE=? -->
Acne

<!-- PAGE=? -->
A/W

<!-- PAGE=? -->
Difficult due to moon facies and delicate mucosa CNS

<!-- PAGE=? -->
Personality changes / psychosis

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
Muscle weakness

<!-- PAGE=? -->
Prolonged intubation, decrease dose of muscle relaxant CV

<!-- PAGE=? -->
HTN

<!-- PAGE=? -->
Increased fluid volume

<!-- PAGE=? -->
LVH

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
Gastric ulceration

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
Adrenal suppression

<!-- PAGE=? -->
Electrolytes( ¾ K + , metabolic alkalosis)

<!-- PAGE=? -->
Hyperglycemia

<!-- PAGE=? -->
Misc

<!-- PAGE=? -->
Osteopenia

<!-- PAGE=? -->
Immunosuppression

<!-- PAGE=? -->
Muscle wasting

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
CVS instability

<!-- PAGE=? -->
o decrease response to pressors

<!-- PAGE=? -->
o decr SVR, CO

<!-- PAGE=? -->
o inappropriate bradycardia

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Metabolic/Electrolytes

<!-- PAGE=? -->
o hyponatremia

<!-- PAGE=? -->
o ¾ glycemia

<!-- PAGE=? -->
o ↑ H+

<!-- PAGE=? -->
Addison's/Adrenal Insuff.

<!-- PAGE=? -->
'an endocrinopathy caused by lack of adrenal hormone with multiple system involvement'

<!-- PAGE=? -->
Etiology:

<!-- PAGE=? -->
-iatrogenic: prednisone >20mg/day, >1week, in last 1 year

<!-- PAGE=? -->
-autoimmune

<!-- PAGE=? -->
-associated with hashimoto's, sepsis, adrenal hemorrhage

<!-- PAGE=? -->
-Normal production = 100mg hydrocortisone/day

<!-- PAGE=? -->
Other:

<!-- PAGE=? -->
-orthostatic symptoms

<!-- PAGE=? -->
-hyperpigmentation (excess corticotrophin)

<!-- PAGE=? -->
-anemia

<!-- PAGE=? -->
-hypercalcemia

<!-- PAGE=? -->
Dx:

<!-- PAGE=? -->
-ACTH stimulation test: Adrenal insufficient if unable to ↑ cortisol 9 ug/dL in response to 250 ug cosyntropin

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
-300mg hydrocortisone/day

<!-- PAGE=? -->
-50ug fludrocortisone/day PO

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Decr CO

<!-- PAGE=? -->
Potential for Rapid HR (with SNS)

<!-- PAGE=? -->
Anticoagulation

<!-- PAGE=? -->
Embolism Risk

<!-- PAGE=? -->
P neumo/pneumonia I schemia/Infiltrative R heumatic valve/ A trial Myxoma/Alcohol T hyroid/Thoracic surgery E lectrolytes/Endocrine S ystemic - CRF/Sepsis

<!-- PAGE=? -->
Causes:

<!-- PAGE=? -->
IHD (acute, chronic)

<!-- PAGE=? -->
Infiltrative: Rheumatic, Sarcoid, amyloid

<!-- PAGE=? -->
Sepsis

<!-- PAGE=? -->
Endocrine: Thyroid disease, Pheochromocytoma

<!-- PAGE=? -->
Valves: MS

<!-- PAGE=? -->
Toxicity (cocaine, digoxin, TCA), Alcohol

<!-- PAGE=? -->
Pericarditis

<!-- PAGE=? -->
SAH

<!-- PAGE=? -->
CHF

<!-- PAGE=? -->
Electrolytes, Hypoxia, Acid/Base

<!-- PAGE=? -->
Post op: CV, thoracic surgery

<!-- PAGE=? -->
Afib

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
-EKG

<!-- PAGE=? -->
-look for cause

<!-- PAGE=? -->
-avoid sympathetic stimulation

<!-- PAGE=? -->
Unstable:

<!-- PAGE=? -->
Synchronized cardioversion 100 J

<!-- PAGE=? -->
Correct underlying abnormalities

<!-- PAGE=? -->
Stable:

<!-- PAGE=? -->
Vagal maneuvers

<!-- PAGE=? -->
Adenosine 6 mg iv push (SE bronchospasm)

<!-- PAGE=? -->
Adenosine 12 mg iv push

<!-- PAGE=? -->
Verapamil 2.5-5 mg iv

<!-- PAGE=? -->
Digoxin 0.25-0.75 mg iv

<!-- PAGE=? -->
Beta blockade

<!-- PAGE=? -->
Synchronized cardioversion if <48h

<!-- PAGE=? -->
Pacing prn

<!-- PAGE=? -->
rhythm control <48 hours duration: Amiodarone, ibutilide, propafenone, flecainide, digoxin, clonidine, or magnesium

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Clinical Predictors

<!-- PAGE=? -->
High (Unstable) -

<!-- PAGE=? -->
Valve

<!-- PAGE=? -->
Muscle

<!-- PAGE=? -->
Ryhtym

<!-- PAGE=? -->
Vessels

<!-- PAGE=? -->
Interm:

<!-- PAGE=? -->
Renal

<!-- PAGE=? -->
Angina

<!-- PAGE=? -->
DM

<!-- PAGE=? -->
Failure

<!-- PAGE=? -->
MI

<!-- PAGE=? -->
Low:

<!-- PAGE=? -->
Stroke

<!-- PAGE=? -->
Htn

<!-- PAGE=? -->
Age>80

<!-- PAGE=? -->
Mets <4

<!-- PAGE=? -->
EKG - abnormal

<!-- PAGE=? -->
Sinus - not 6.

<!-- PAGE=? -->
AHA Guidelines

<!-- PAGE=? -->
TABLE 1. Clinical Predictors of Increased Perioperative Cardiovascular Risk (Myocardial Infarction, Heart Failure, Death)

<!-- PAGE=? -->
Major

<!-- PAGE=? -->
Unstable coronary syndromes

<!-- PAGE=? -->
Acute or recent myocardial infarction with evidence of important ischemic risk by clinical symptoms or noninvasive study

<!-- PAGE=? -->
Unstable or severe angina (Canadian class Ill or IV

<!-- PAGE=? -->
Decompensated heart failure

<!-- PAGE=? -->
Significant arrhythmias

<!-- PAGE=? -->
High-grade atrioventricular block

<!-- PAGE=? -->
Symptomatic ventricular arrhythmias in the presence of underlying heart disease

<!-- PAGE=? -->
Supraventricular arrhythmias with uncontrolled ventricular rate Severe valular disease

<!-- PAGE=? -->
Intermediate

<!-- PAGE=? -->
Mild angina pectoris (Canadian class

<!-- PAGE=? -->
Previous myocardial infarction by history or pathological 0 waves

<!-- PAGE=? -->
Compensated or prior heart failure

<!-- PAGE=? -->
Diabetes mellitus (particularly insulin-dependent)

<!-- PAGE=? -->
Renal insufficiency

<!-- PAGE=? -->
Minor

<!-- PAGE=? -->
Advanced age

<!-- PAGE=? -->
Abnormal ECG (left ventricular hypertrophy , left bundle-branch block ST-T abnormalities)

<!-- PAGE=? -->
Rhythm other than sinus (e.9., atrial fibrillation)

<!-- PAGE=? -->
Low functional capacity (e.9, inability to climb one flight of stairs with bag of groceries)

<!-- PAGE=? -->
History of stroke

<!-- PAGE=? -->
Uncontrolled systemic hypertension

<!-- PAGE=? -->
ECG indicates electrocardiogram.

<!-- PAGE=? -->
tMay include stable angina in patients who are unusually sedentary. tCampeau L Grading of angina pectoris. Circulatian. 1976,54.522-523

<!-- PAGE=? -->
The American   College of   Cardiology National recent Ml as greater than days but less than or equal to month (30 days); acute Ml is within 7 days.

<!-- PAGE=? -->
Surgery

<!-- PAGE=? -->
High:

<!-- PAGE=? -->
Big/Fluid shifts

<!-- PAGE=? -->
Emerg

<!-- PAGE=? -->
Vascular Interm: 5%

<!-- PAGE=? -->
CEA

<!-- PAGE=? -->
H&N

<!-- PAGE=? -->
Ortho

<!-- PAGE=? -->
Prostate

<!-- PAGE=? -->
Peritoneal

<!-- PAGE=? -->
Thoracic

<!-- PAGE=? -->
Low: (1%)

<!-- PAGE=? -->
Breast

<!-- PAGE=? -->
Endoscopic

<!-- PAGE=? -->
Superficial

<!-- PAGE=? -->
TABLE 3 Cardiac Risk' Stratification for Noncardiac Surgical Procedures

<!-- PAGE=? -->
High (Reported cardiac risk often greater than 5%)

<!-- PAGE=? -->
Emergent major operations, particularly in the elderly

<!-- PAGE=? -->
Aortic and other major vascular surgery

<!-- PAGE=? -->
Peripheral vascular surgery

<!-- PAGE=? -->
Anticipated prolonged surgical procedures associated with large fluid shifts andlor blood loss

<!-- PAGE=? -->
Intermediate (Reported cardiac rsk generally less than 5%)

<!-- PAGE=? -->
Carotid endarterectomy

<!-- PAGE=? -->
Head and neck surgery

<!-- PAGE=? -->
Intraperitoneal intrathoracic surgery and

<!-- PAGE=? -->
Orthopedic surgery

<!-- PAGE=? -->
Prostate surgery

<!-- PAGE=? -->
Low (Reported cardiac risk generally less than 196)

<!-- PAGE=? -->
Endoscopic procedures

<!-- PAGE=? -->
Superficial procedure

<!-- PAGE=? -->
Cataract surgery

<!-- PAGE=? -->
Breast surgery

<!-- PAGE=? -->
'Combined incidence of cardiac death and nonfatal myocardial infarction. tDo not generally require further preoperative cardiac testing

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Clinical Intermediate:

<!-- PAGE=? -->
OR high: NIT

<!-- PAGE=? -->
OR low - OR

<!-- PAGE=? -->
OR Int - depends on FC

<!-- PAGE=? -->
Clinical Low: only test if

<!-- PAGE=? -->
OR risk high AND

<!-- PAGE=? -->
Low FC

<!-- PAGE=? -->
room

<!-- PAGE=? -->
Oooratng

<!-- PAGE=? -->
Siep

<!-- PAGE=? -->
Goto

<!-- PAGE=? -->
an

<!-- PAGE=? -->
Hioh

<!-- PAGE=? -->
procoduro

<!-- PAGE=? -->
Poo:

<!-- PAGE=? -->
(0o

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
1. Airway Surgery

<!-- PAGE=? -->
Shared airway

<!-- PAGE=? -->
Potential difficult

<!-- PAGE=? -->
Post-op swelling/laryngospasm

<!-- PAGE=? -->
2. Laser  Airway Precautions

<!-- PAGE=? -->
Support : Limit FiO2 < 0.4, Avoid N2O

<!-- PAGE=? -->
Source : micro Laser ETT with 2 cuffs, dyed saline

<!-- PAGE=? -->
Ignition : Limit laser pulse

<!-- PAGE=? -->
Saline, bucket &clamp readily available

<!-- PAGE=? -->
Fire extinguisher (type A-H2O or  C-CO2)

<!-- PAGE=? -->
3.    Laser Protection

<!-- PAGE=? -->
Eye protection (pt/staff)

<!-- PAGE=? -->
Laser mask

<!-- PAGE=? -->
Door Sign

<!-- PAGE=? -->
Airway - Laser Surgery

<!-- PAGE=? -->
Airway Fire Management

<!-- PAGE=? -->
Stop ventilation

<!-- PAGE=? -->
Clamp/Disconnect oxygen

<!-- PAGE=? -->
Remove ETT

<!-- PAGE=? -->
Flood with saline

<!-- PAGE=? -->
Intubate

<!-- PAGE=? -->
Bronchoscopy

<!-- PAGE=? -->
Dexamethasone 0.5 mg/kg (max 20 mg)

<!-- PAGE=? -->
CXR

<!-- PAGE=? -->
ABG - carbon monoxide

<!-- PAGE=? -->
Postop ventilation & monitoring

<!-- PAGE=? -->
? tracheostomy

<!-- PAGE=? -->
Options:

<!-- PAGE=? -->
-Awake + Topical

<!-- PAGE=? -->
GA + MLT, PPV

<!-- PAGE=? -->
-GA + Saunders injector (50psi x 0.5-1sec insp) - need high O2

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Airway - Foreign Body Aspiration

<!-- PAGE=? -->
Pediatric patient

<!-- PAGE=? -->
Airway emergency, potential for complete obstruction

<!-- PAGE=? -->
Full Stomach

<!-- PAGE=? -->
Rigid Bronch:

<!-- PAGE=? -->
Shared and Unprotected A/W

<!-- PAGE=? -->
Stimulating

<!-- PAGE=? -->
Risk of Tracheobronchial injury

<!-- PAGE=? -->
Difficult Volatile Delivery

<!-- PAGE=? -->
Difficult oxygenation/ventilation

<!-- PAGE=? -->
5. FB

<!-- PAGE=? -->
Risk of pneumo, avoid N2O

<!-- PAGE=? -->
Hypoxia, hypercarbia

<!-- PAGE=? -->
Potential pneumonia/sepsis

<!-- PAGE=? -->
Potential tracheobronchial injury

<!-- PAGE=? -->
Conflicts:

<!-- PAGE=? -->
-full stomach vs urgent

<!-- PAGE=? -->
-full stomach vs unprotected a/w

<!-- PAGE=? -->
-SV vs adequate depth of anesthesia

<!-- PAGE=? -->
-PPV vs ball-valve/dislodging

<!-- PAGE=? -->
-simulating vs anesthetic delivery

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
General / Manifestations

<!-- PAGE=? -->
Coughing, choking, cyanosis

<!-- PAGE=? -->
Tachypnea, wheezing

<!-- PAGE=? -->
Hoarseness, stridor

<!-- PAGE=? -->
CXR (insp/exp) - atelectasis, pneumonia, hyperinflation , R > L

<!-- PAGE=? -->
90% radiolucent

<!-- PAGE=? -->
vegetable - expansion

<!-- PAGE=? -->
peanut oil - chemical bronchitis

<!-- PAGE=? -->
hemoptysis

<!-- PAGE=? -->
pneumo

<!-- PAGE=? -->
pneumonia

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
EMERGENCY SITUATION

<!-- PAGE=? -->
Elevate HOB, O2, Monitors

<!-- PAGE=? -->
IV

<!-- PAGE=? -->
Antibiotics for pneumonia

<!-- PAGE=? -->
Gastric Prophylaxis

<!-- PAGE=? -->
Antisialogogue

<!-- PAGE=? -->
Topicalize A/W

<!-- PAGE=? -->
Bronchodilators, Racemic Epi, Steroid

<!-- PAGE=? -->
Surgeon preped with rigid bronchoscope

<!-- PAGE=? -->
Inhalational induction ( +/- CP) with Sevo (no N2O) and then change to Halothane

<!-- PAGE=? -->
Ketamine Bolus PRN

<!-- PAGE=? -->
Ventilation via side port of rigid bronchoscope

<!-- PAGE=? -->
Permissive hypercapnia and SpO2 >85%

<!-- PAGE=? -->
If unable to keep SV, slowly titrate Propofol and Remi infusion + Apneic Oxygenation + PPV PRN

<!-- PAGE=? -->
Following removal of FB examine the entire tracheobronchial tree

<!-- PAGE=? -->
± ETT and emergence

<!-- PAGE=? -->
'In light of my previously stated conflicts, I am going to attempt to maintain spontaneous ventilation.  However, I realize that it may be hard to maintain adequate depth of anesthesia and ventilation with inadequately delivered volatile agents, therefore I will have at hand Ketamine boluses and Propofol/Remi infusion ready to go'

<!-- PAGE=? -->
High Aspiration Risk or Difficult A/W: RSI or Awake intubation with PPV then switch to rigid bronch with direct vision + AEC

<!-- PAGE=? -->
DISASTER SCENARIO - ETT/Rigid Bronch force FB distal or ETT distal to obstruction, emergency thorocotomy & bronchotomy

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
Laryngeal/subglottic edema

<!-- PAGE=? -->
PTX

<!-- PAGE=? -->
Tracheobronchial trauma (subglottic edema)

<!-- PAGE=? -->
BPF

<!-- PAGE=? -->
Pulmonary hemorrhage

<!-- PAGE=? -->
Pneumonia

<!-- PAGE=? -->
aspiration

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Emergency

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Hemodynamic Compromise

<!-- PAGE=? -->
Full Stomach

<!-- PAGE=? -->
Lung Isolation

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
Lung Isolation

<!-- PAGE=? -->
Position bleeding lung ↓

<!-- PAGE=? -->
SLT endobronch vs Blocker vs DLT

<!-- PAGE=? -->
Intubation

<!-- PAGE=? -->
Is bleeding manageable with 2 suctions + Tburg

<!-- PAGE=? -->
} Yes: RSI with CP

<!-- PAGE=? -->
} No: diff a/w - ketamine (topical with blocks, inhaled)

<!-- PAGE=? -->
Volume/Coag correction

<!-- PAGE=? -->
Fluid / PRBC / Plasma

<!-- PAGE=? -->
large IV, art line

<!-- PAGE=? -->
Treat Etiology

<!-- PAGE=? -->
Consult Int Rad/Thoracics/Resp

<!-- PAGE=? -->
Epi (2 mg / 1L ICED NS)

<!-- PAGE=? -->
Airway - Massive hemoptysis (= 600 ml/24H)

<!-- PAGE=? -->
DDx

<!-- PAGE=? -->
Bronchitis (pneumonia)

<!-- PAGE=? -->
Bronchiectasis

<!-- PAGE=? -->
Neoplasm

<!-- PAGE=? -->
Lung abscess

<!-- PAGE=? -->
PE/Infarct

<!-- PAGE=? -->
AV malformation

<!-- PAGE=? -->
Pulm HTN

<!-- PAGE=? -->
PAC trauma

<!-- PAGE=? -->
Other sites: epistaxisis, oral, vomit

<!-- PAGE=? -->
-death usually from asphyxia, not blood loss

<!-- PAGE=? -->
-avoid high Paw (VAE)

<!-- PAGE=? -->
-SLT into L by insert concave down, turn head to R shoulder -if SLT fills with blood, put blocker down first, then remove tube -surgeon may need to do Rigid bronch for treatment, but must do lung isolation first - then stabilize, AEC + rigid bronch

<!-- PAGE=? -->
-for epistaxis - foley in nose to divert blood away from oropharynx

<!-- PAGE=? -->
PAC

<!-- PAGE=? -->
Pull back 5 cm

<!-- PAGE=? -->
Last resort → inflate until dampened PA tracing

<!-- PAGE=? -->
Tracheostomy Bleeding

<!-- PAGE=? -->
Bleeding 1 month post-tracheostomy is assumed to be inominate artery (Right inominate artery, Left common carotid, Sup/Inf thyroid vein)

<!-- PAGE=? -->
 Tamponade

<!-- PAGE=? -->
intubate from above and elevate trachea with finger

<!-- PAGE=? -->
20cc in tracheal cuff

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
A/W Obstruction

<!-- PAGE=? -->
Tongue

<!-- PAGE=? -->
Soft Tissue

<!-- PAGE=? -->
-OSA

<!-- PAGE=? -->
Orophayrnx

<!-- PAGE=? -->
-Vomit, blood, FB

<!-- PAGE=? -->
Cords

<!-- PAGE=? -->
-Laryngospasm

<!-- PAGE=? -->
Jaw thrust + CPAP

<!-- PAGE=? -->
Sux 10-20mg

<!-- PAGE=? -->
-Edema

<!-- PAGE=? -->
Dexamethasone 0.5mg/kg

<!-- PAGE=? -->
Racemic Epi 0.5ml of 2.25% in 3cc NS

<!-- PAGE=? -->
Trachea

<!-- PAGE=? -->
-Compression (Carotid, thyroid, para-thyroid surgery)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ABNORMAL AIRWAY

<!-- PAGE=? -->
Pompe's disease

<!-- PAGE=? -->
(glycogen storage II)

<!-- PAGE=? -->
Muscle deposits, macroglossia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Airway - Topicalize

<!-- PAGE=? -->
-I will attach the pt to the standard CAS monitors and O2 via NP.  I will premedicate the pt with an antisialogogue such as glycopyrolate 0.3mg IV/IM.  Then, I will judiciously give short acting, easily reversible and titratable anxiolysis medications such as midazolam 25ug/kg and fentanyl 0.5ug/kg boluses.  I will then proceed to topicalize the pt's airway keeping in mind the maximum dose of each local anesthetic.

<!-- PAGE=? -->
Needle

<!-- PAGE=? -->
Bloody

<!-- PAGE=? -->
Soiled

<!-- PAGE=? -->
Near toxic dose

<!-- PAGE=? -->
Spray

<!-- PAGE=? -->
Infection

<!-- PAGE=? -->
Tumor

<!-- PAGE=? -->
Distorted

<!-- PAGE=? -->
NEEDLE

<!-- PAGE=? -->
(Ant Ethmoid: 4% Cocaine soaked pledgets parallel to surface of nose until cribriform plate)

<!-- PAGE=? -->
(Sphenopalatine: 4% Lido soaked pledgets, 45 deg to palate, above middle turb until sphenoid x 5 min)

<!-- PAGE=? -->
Glossopharyngeal: 25g spinal needle, base of tonsillar pillar, 0.5cm deep (air-too deep, blood too lateral), 2cc 2% lidocaine with epi

<!-- PAGE=? -->
SLN: 25g 1.5' needle, 1-2cm deep,  ant/caudad to hyoid cornu,  2cc 2% lido with epi

<!-- PAGE=? -->
RLN: 20g angiocath through cricothryoid membrane directed 45 deg caudad, 4cc 2% lido at end insp

<!-- PAGE=? -->
SPRAY

<!-- PAGE=? -->
(Pledgets soaked in Cocaine 4% x 2cc to topicalize nasal passage)

<!-- PAGE=? -->
Gargle with 4 cc of viscous 2% Lidocaine to block the tongue and oropharynx

<!-- PAGE=? -->
Directable Atomizer with 4cc of 4% Lidocaine  to topicalize

<!-- PAGE=? -->
the glossopharyngeal nerve at the base of the tonsillar pillars,

<!-- PAGE=? -->
the SLN in the piriform fossa and

<!-- PAGE=? -->
the trachea by timing nebulization with deep inspiration

<!-- PAGE=? -->
Have supplental 1% Lidocaine in slip-tip syringes to administer through FOB

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Airway Trauma

<!-- PAGE=? -->
Trauma - associated HI, C-spine injury

<!-- PAGE=? -->
Airway Emergency - risk of complete Obstruction

<!-- PAGE=? -->
Difficult Oxygenation/Ventilation

<!-- PAGE=? -->
Potential Bronch-pleural/subcu/mediastinal fistula

<!-- PAGE=? -->
Upper A/W:

<!-- PAGE=? -->
 Bilateral (but not unilateral) mandibular condyle fractures may prevent adequate mouth opening

<!-- PAGE=? -->
BPF:

<!-- PAGE=? -->
Difficult Ventilation (CO2 retention)

<!-- PAGE=? -->
Need to isolate lung/BPF

<!-- PAGE=? -->
Tension Pneumo

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
 Chest Tube - high suction vs. PEEP

<!-- PAGE=? -->
 Single (Good) Lung Ventilation - Endobronch or BPF side dependant

<!-- PAGE=? -->
 Differential Lung Ventilation - HFV with Pinsp just below opening pressure of BPF

<!-- PAGE=? -->
 Pleurodesis - Bronch, Thoroscopic, Chest Tube

<!-- PAGE=? -->
Tracheal-Bronchial Injury

<!-- PAGE=? -->
 Dx: dyspnea, hypoxia, subcutaneous air without pneumo, mediastinal air, 'fallen lung sign', persistent air leak after chest tube

<!-- PAGE=? -->
o ? where is the lesion

<!-- PAGE=? -->
o ? where is the RUL orifice

<!-- PAGE=? -->
o ? is there room for a proximal blocker

<!-- PAGE=? -->
o ? is the airway soiled

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
-keep pt SV (like all BPF) -no CP

<!-- PAGE=? -->
Nasopharyngeal

<!-- PAGE=? -->
Do not remove misplaced tube prior to intubation (hemorrhage)

<!-- PAGE=? -->
Mid-trachea

<!-- PAGE=? -->
Awake FOB

<!-- PAGE=? -->
Inhalational + FOB/rigid

<!-- PAGE=? -->
RSI + rigid

<!-- PAGE=? -->
RSI + tube just subglottic + FOB

<!-- PAGE=? -->
Lower trachea

<!-- PAGE=? -->
difficult

<!-- PAGE=? -->
Left main bronchus

<!-- PAGE=? -->
Awake FOB

<!-- PAGE=? -->
Inhalational

<!-- PAGE=? -->
⋅ DLT (L if room, otherwise  R)

<!-- PAGE=? -->
⋅ Bronchial blocker

<!-- PAGE=? -->
⋅ R SLT

<!-- PAGE=? -->
⋅ ETT + Jet ventilation

<!-- PAGE=? -->
Right main bronchus

<!-- PAGE=? -->
Awake FOB

<!-- PAGE=? -->
Inhalational

<!-- PAGE=? -->
⋅ L-DLT

<!-- PAGE=? -->
⋅ Bronchial blocker

<!-- PAGE=? -->
⋅ L-SLT

<!-- PAGE=? -->
⋅ ETT + Jet ventilation

<!-- PAGE=? -->
High Freq. Ventilation

<!-- PAGE=? -->
HFPPV

<!-- PAGE=? -->
o 1-2Hz

<!-- PAGE=? -->
o Vt=Vd

<!-- PAGE=? -->
o Open - no established outflow pathway, not protected

<!-- PAGE=? -->
o Closed - airway  protected, established (cath in ett)

<!-- PAGE=? -->
HFJV (Saunders)

<!-- PAGE=? -->
o 2-6Hz

<!-- PAGE=? -->
o 50psi

<!-- PAGE=? -->
HFO

<!-- PAGE=? -->
o 6-40Hz

<!-- PAGE=? -->
o Vt 50-80cc

<!-- PAGE=? -->
Lung Bullae:

<!-- PAGE=? -->
-Pre-op chest tube or prep chest for easy insertion

<!-- PAGE=? -->
-DLT

<!-- PAGE=? -->
-minimize Paw

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
4A, 4T, 4P

<!-- PAGE=? -->
-asthma, anaphylaxis, aspiration, awake -tube kinked/occluded, esophageal, endobronchial, trouble with circuit -pneumo, pulm edema, pe, procedure (position/pneumoperitonium)

<!-- PAGE=? -->
Machine/monitors Circuit /Ventilator Settings ETT/Pt

<!-- PAGE=? -->
100% O2 manually ventilate to assess compliance disconnect - listen for rush of air escaping, attempt to bag check ETT position Listen for A/E = bilat, adventious sounds Suction cath/fob

<!-- PAGE=? -->
Watch out: Barotrauma, venous return/hypotension

<!-- PAGE=? -->
Airway Pressure

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
Diff bmv

<!-- PAGE=? -->
o Beard-seal- lube

<!-- PAGE=? -->
o Obese-chest wall

<!-- PAGE=? -->
o Older-neck mobility

<!-- PAGE=? -->
o Toothless-chipmunk stuffing

<!-- PAGE=? -->
o Snoring

<!-- PAGE=? -->
Diff surgical

<!-- PAGE=? -->
o Surgery

<!-- PAGE=? -->
o Hematoma/infection

<!-- PAGE=? -->
o Obese/Cervical flexion

<!-- PAGE=? -->
o Radiation

<!-- PAGE=? -->
o Tumor

<!-- PAGE=? -->
Anticiated

<!-- PAGE=? -->
Temporize: Heliox, Dex, Racemic, CPAP

<!-- PAGE=? -->
Cooperative

<!-- PAGE=? -->
o Awake (FOB, Bullard, DL, TL)

<!-- PAGE=? -->
o Regional (only if surgery can be stopped, access to airway)

<!-- PAGE=? -->
Uncooper

<!-- PAGE=? -->
o Inhalational

<!-- PAGE=? -->
o Haldol

<!-- PAGE=? -->
o Ketamine

<!-- PAGE=? -->
Un-anticipated

<!-- PAGE=? -->
-BMV+

<!-- PAGE=? -->
o wake up

<!-- PAGE=? -->
o any adjunct

<!-- PAGE=? -->
-BMV-

<!-- PAGE=? -->
o Rescue (LMA, Combi, surg)

<!-- PAGE=? -->
5BARS

<!-- PAGE=? -->
o Best position/bring up head

<!-- PAGE=? -->
o BURP

<!-- PAGE=? -->
o Blade

<!-- PAGE=? -->
o Bougie

<!-- PAGE=? -->
o Back off/BMV

<!-- PAGE=? -->
o Alterate - lightwand, ILMA, Bullard

<!-- PAGE=? -->
o Rescue - LMA, Combitube

<!-- PAGE=? -->
o Surgical - ct jet, ct tube, retro

<!-- PAGE=? -->
Indirect

<!-- PAGE=? -->
- not good for soiled airway

<!-- PAGE=? -->
-FOB, bullard, glidescope, Shikani

<!-- PAGE=? -->
Blind

<!-- PAGE=? -->
- not good for distorted anatomy

<!-- PAGE=? -->
-lightwand, bougie, digital, combi

<!-- PAGE=? -->
Direct Vision

<!-- PAGE=? -->
- good for soiled airway, distorted

<!-- PAGE=? -->
-larygoscope

<!-- PAGE=? -->
ER:

<!-- PAGE=? -->
Soiled? -no indirect

<!-- PAGE=? -->
Airway anatomy change/injury? -no blind

<!-- PAGE=? -->
14g + 3.5ett connector OR  3ml syringe + 8ett connector

<!-- PAGE=? -->
-use MLT. Nasal Raw, AEC, Bougie, Cut LMA

<!-- PAGE=? -->
-Fastrac takes normal size tubes (upside down for angle)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Amyloidosis CCAARS

<!-- PAGE=? -->
'a hereditary or acquired disease with multi-system involvement secondary to accumulation of protein fibrils in tissues'

<!-- PAGE=? -->
Difficult airway

<!-- PAGE=? -->
Macroglossia

<!-- PAGE=? -->
Tracheal Stenosis

<!-- PAGE=? -->
Autonomic dysfunction

<!-- PAGE=? -->
Cardiomyopathy - Restrictive

<!-- PAGE=? -->
Conduction defects

<!-- PAGE=? -->
CHF

<!-- PAGE=? -->
Coagulopathy

<!-- PAGE=? -->
Factor X def

<!-- PAGE=? -->
Friable capillaries

<!-- PAGE=? -->
Renal Periop Failure/Nephrotic syndrome

<!-- PAGE=? -->
Steroids

<!-- PAGE=? -->
O/E:

<!-- PAGE=? -->
-Othostatic Vitals

<!-- PAGE=? -->
-S3

<!-- PAGE=? -->
-CT Chest, FV Loop

<!-- PAGE=? -->
-Echo, EKG

<!-- PAGE=? -->
-Factor X assay

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
-PA Cath/TEE

<!-- PAGE=? -->
Heriditary or Acquired (with cancer, infection or inflammation - RA)

<!-- PAGE=? -->
Accumulation of insoluble protein fibrils in various tissues

<!-- PAGE=? -->
Congo Red stain - green birefringence

<!-- PAGE=? -->
Sudden death occurs > 30% of patients

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Anaphylaxis

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Anaphylaxis

<!-- PAGE=? -->
Idiopathic

<!-- PAGE=? -->
Hereditary Angioedema

<!-- PAGE=? -->
Autosomal dominant

<!-- PAGE=? -->
Hereditary forms Type I and II - 50% present by age 7 and 100% present by age 30

<!-- PAGE=? -->
↓ functional activity C1 esterase inhibitor

<!-- PAGE=? -->
Lower GI complaints

<!-- PAGE=? -->
triggered by surgical manipulation of aerodigestive tract and stress

<!-- PAGE=? -->
prophylaxis

<!-- PAGE=? -->
danazol 600 mg PO OD x 5 days (C1 esterase inhibitor production)

<!-- PAGE=? -->
ii) day of OR:

<!-- PAGE=? -->
antifibrinolytics (inhibit plasmin)

<!-- PAGE=? -->
C1 esterase inhibitor concentrate

<!-- PAGE=? -->
plasma 10 ml/kg  (contains inhibitor, but can potentially worsen because has substrate)

<!-- PAGE=? -->
acute attack

<!-- PAGE=? -->
ETT

<!-- PAGE=? -->
ii) C1esterase inhibitor concentrate 25 mcg/kg IV

<!-- PAGE=? -->
iii) FFP

<!-- PAGE=? -->
iv) steroids don't work acutely

<!-- PAGE=? -->
Aquired Angioedema - C1 esterase deficiency

<!-- PAGE=? -->
Lupus

<!-- PAGE=? -->
malignancy

<!-- PAGE=? -->
Lymphoproliferative disease

<!-- PAGE=? -->
ACE-I

<!-- PAGE=? -->
Histamine release

<!-- PAGE=? -->
Angioedema

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
C-spine kyphosis, fusion and instability

<!-- PAGE=? -->
Respiratory Compromise

<!-- PAGE=? -->
•

<!-- PAGE=? -->
RLD

<!-- PAGE=? -->
PHTN

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
AI

<!-- PAGE=? -->
Conduction defects

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
Spinal stenosis

<!-- PAGE=? -->
Difficult and Unpredictable neuroaxial regional

<!-- PAGE=? -->
Other

<!-- PAGE=? -->
Positioning Difficulty

<!-- PAGE=? -->
Immune suppressants

<!-- PAGE=? -->
Ankylosing Spondylitis

<!-- PAGE=? -->
'Progressive inflammatory arthritis involving the ligaments and articulations of the spine causing: '

<!-- PAGE=? -->
General

<!-- PAGE=? -->
Lower back pain, sacroiliitis, uveitits

<!-- PAGE=? -->
Autosomal dominant, Male:female - 10:1

<!-- PAGE=? -->
90% HLA-B27

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
C-spine kyphosis, spine fusion with risk of fracture

<!-- PAGE=? -->
TMJ and arytenoids arthritis

<!-- PAGE=? -->
Atlantoaxial instability

<!-- PAGE=? -->
CV

<!-- PAGE=? -->
Aortic insufficiency

<!-- PAGE=? -->
Cardiomyopathy

<!-- PAGE=? -->
Conduction defects

<!-- PAGE=? -->
Myocarditis

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
RLD due to Pulm Fibrosis and Chest Wall Rigidity

<!-- PAGE=? -->
Difficult Ventilation, high Paw

<!-- PAGE=? -->
PHTN

<!-- PAGE=? -->
Pleuritic inflammation

<!-- PAGE=? -->
Chostochondral rigidity

<!-- PAGE=? -->
Flexion deformity of thoracic spine (restrictive)

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
Spinal stenosis

<!-- PAGE=? -->
Radiculopathies

<!-- PAGE=? -->
Vertebrobasilar insufficiency

<!-- PAGE=? -->
Misc.

<!-- PAGE=? -->
Anemia

<!-- PAGE=? -->
Inflammatory bowel disease

<!-- PAGE=? -->
Increased blood loss (high Paw)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Malnutrition & Metabolic derangements

<!-- PAGE=? -->
Lytes: ¾ K, ¾ Mg, ¾ Ca,

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
acid/base

<!-- PAGE=? -->
Cardiac Dysfunction

<!-- PAGE=? -->
Arryhthmias - LQT, Brady

<!-- PAGE=? -->
Autonomic dysfunction

<!-- PAGE=? -->
LV dysfunction

<!-- PAGE=? -->
Aspiration Risk - decr emptying, vomit

<!-- PAGE=? -->
Anorexia nervosa:

<!-- PAGE=? -->
High mortality if  weight loss exceeds 35% normal body weight

<!-- PAGE=? -->
Mortality 7-10%, starvation, suicide

<!-- PAGE=? -->
Bulimia nervosa:

<!-- PAGE=? -->
Binge-eating, self-induced vomiting

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
Elevated amylase

<!-- PAGE=? -->
Co-existing alcohol, drug abuse

<!-- PAGE=? -->
Benign parotid enlargement

<!-- PAGE=? -->
Anorexia & Bulimia

<!-- PAGE=? -->
Common anesthetic considerations:

<!-- PAGE=? -->
ECG/ECHO

<!-- PAGE=? -->
Electrolytes, RFTs, Glu, ABG

<!-- PAGE=? -->
Gastric Prophylaxis

<!-- PAGE=? -->
CBC

<!-- PAGE=? -->
Expect exaggerated hemodynamic responses intraoperatively

<!-- PAGE=? -->
Cautious NMB (decr mass)

<!-- PAGE=? -->
CNS:

<!-- PAGE=? -->
Altered autonomic activity (decr SNS)

<!-- PAGE=? -->
CV:

<!-- PAGE=? -->
Orthostatic hypotension

<!-- PAGE=? -->
Conduction Abn - Bradycardia, Long QT

<!-- PAGE=? -->
Decreased myocardial muscle mass, contractility

<!-- PAGE=? -->
MVP

<!-- PAGE=? -->
CHF

<!-- PAGE=? -->
ECG changes: T inversion, ST ↓ , prolonged QT

<!-- PAGE=? -->
Sudden death attributed to arrhythmias

<!-- PAGE=? -->
Heme:

<!-- PAGE=? -->
Pancytopenia

<!-- PAGE=? -->
Decr Fibrinogen

<!-- PAGE=? -->
Metabolic:

<!-- PAGE=? -->
Electrolyte abnormalities (rare), ↓ K  in self-induced vomiting, laxative

<!-- PAGE=? -->
Bone density ↓

<!-- PAGE=? -->
Hypothermia /decr BMR

<!-- PAGE=? -->
Decreased gastric emptying

<!-- PAGE=? -->
Occasionally: fatty liver, altered LFTs

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Antiarhythmics

<!-- PAGE=? -->
Class 1A Quinidine, Procainamide, Disopyramide ↓ Phase 0, ↑ Phase 3

<!-- PAGE=? -->
Clas 1B Lidocaine, Tocainide, Mexilitine, Dophyenylhydrantoin ↑ Phase 3

<!-- PAGE=? -->
Class 1C Fleicanide, Propafenone ↓ Phase 0

<!-- PAGE=? -->
Class II β -blockers

<!-- PAGE=? -->
Class III Amiodarone, Sotalol, Bretylium K channel (prolong reoplarization

<!-- PAGE=? -->
Class IV Verapamil, Diltiazem Calcium channel blockers

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hemodynamic goals

<!-- PAGE=? -->
Sinus rythym (for diastolic dysfunction)

<!-- PAGE=? -->
Maintain High filling pressures

<!-- PAGE=? -->
HR 50-70

<!-- PAGE=? -->
Maintain High afterload/CPP

<!-- PAGE=? -->
Minimize cardiac depressants

<!-- PAGE=? -->
High Ischemia Risk

<!-- PAGE=? -->
SBE prophylaxis

<!-- PAGE=? -->
Regional anesthesia

<!-- PAGE=? -->
SAB Relative contraindicated

<!-- PAGE=? -->
Good Pain Relief to avoid Tachy

<!-- PAGE=? -->
Aortic Stenosis

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
} Idiopathic degeneration (>60yo)

<!-- PAGE=? -->
} Congenital bicuspid valve (<60yo)

<!-- PAGE=? -->
} Rheumatic heart disease

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
} Diastolic Dysfx, Systolic preserved until late

<!-- PAGE=? -->
} Concentric hypertrophy

<!-- PAGE=? -->
} ↑ myocardial work load and oxygen requirements

<!-- PAGE=? -->
} ↓ Supply: Low DBP, High LVEDP

<!-- PAGE=? -->
} NSR: to fill low compliance LV

<!-- PAGE=? -->
} Symptoms correlate with 50% mortality

<!-- PAGE=? -->
 A ngina - 5 years

<!-- PAGE=? -->
 S yncope - 3 years

<!-- PAGE=? -->
 D yspnea - 2 years

<!-- PAGE=? -->
Evaluation

<!-- PAGE=? -->
} SEM Right 2 nd ICS, delayed upstroke

<!-- PAGE=? -->
 Radiation above right clavicle suspicious for mod/severe disease

<!-- PAGE=? -->
 S3 and S4, decr P2

<!-- PAGE=? -->
} ECG: LVH

<!-- PAGE=? -->
} Echo

<!-- PAGE=? -->
 Calcified valve

<!-- PAGE=? -->
 LVH

<!-- PAGE=? -->
 ↑ AV gradient

<!-- PAGE=? -->
 post-stenotic aneurysm

<!-- PAGE=? -->
 associated mitral valve disease

<!-- PAGE=? -->
} CVP:  Large 'a' wave

<!-- PAGE=? -->
Mx:

<!-- PAGE=? -->
o Symptomatic + Ugent: IABP, Valvuloplasty

<!-- PAGE=? -->
o Symptomatic + Non-urgent: AVR

<!-- PAGE=? -->
o 5lead, Aline, DEFIB PADS, PAC, TEE, Opioid Induction

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hemodynamic goals

<!-- PAGE=? -->
Avoid bradycardia, HR > 80

<!-- PAGE=? -->
Decrease afterload

<!-- PAGE=? -->
Maintain, Avoid rapid incr preload

<!-- PAGE=? -->
Minimize cardiac depressants

<!-- PAGE=? -->
AFib

<!-- PAGE=? -->
SBE prophylaxis

<!-- PAGE=? -->
LV ischemia, failure, CHF

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
} Acute

<!-- PAGE=? -->
 SBE

<!-- PAGE=? -->
 Trauma/Disection

<!-- PAGE=? -->
} Chronic

<!-- PAGE=? -->
 Rheumatic HD

<!-- PAGE=? -->
 SBE

<!-- PAGE=? -->
 HTN

<!-- PAGE=? -->
 Root Dilatation

<!-- PAGE=? -->
 CVD (Marfans)

<!-- PAGE=? -->
Aortic Regurgitation

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
} ↓ LV forward flow

<!-- PAGE=? -->
} Eccentric LV hypertrophy & dliation

<!-- PAGE=? -->
} LVH + ↓ DBP → angina

<!-- PAGE=? -->
} ↑ LVEDV → pulmonary edema

<!-- PAGE=? -->
Evaluation

<!-- PAGE=? -->
} symptoms of CHF

<!-- PAGE=? -->
 Dyspnea

<!-- PAGE=? -->
 Orthopnea

<!-- PAGE=? -->
 Fatigue

<!-- PAGE=? -->
} Early Diastolic decrescendo murmur @ LLSB

<!-- PAGE=? -->
} Diastolic rumble @ apex

<!-- PAGE=? -->
} S3, rales

<!-- PAGE=? -->
} ↑ pulse pressure / waterhammer pulses

<!-- PAGE=? -->
} de Musset's: head bob

<!-- PAGE=? -->
} Quinke's: nailbed

<!-- PAGE=? -->
} ECG

<!-- PAGE=? -->
 LVH, LAD

<!-- PAGE=? -->
 LBBB

<!-- PAGE=? -->
} CXR

<!-- PAGE=? -->
} Echo

<!-- PAGE=? -->
 LV dilation

<!-- PAGE=? -->
 Regurgitant Fraction

<!-- PAGE=? -->
Mx:

<!-- PAGE=? -->
} Vasodilator - ACEI, Nitrates

<!-- PAGE=? -->
} Ionotrope - dig, dobutamine, milrinone, ketamine

<!-- PAGE=? -->
} Diuretic

<!-- PAGE=? -->
} IABP Contraidicate

<!-- PAGE=? -->
} PAOP underestimates LVEDP

<!-- PAGE=? -->
} Retrograde cardioplegia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Prevention:

<!-- PAGE=? -->
NPO:

<!-- PAGE=? -->
} Solids 6H

<!-- PAGE=? -->
} Peds - Breast Mild 4H

<!-- PAGE=? -->
} Clr fluids 2H

<!-- PAGE=? -->
Rx:

<!-- PAGE=? -->
} Antacids (non-particulate)

<!-- PAGE=? -->
 Goal = pH > 2.5

<!-- PAGE=? -->
 Sodium citrate 30cc

<!-- PAGE=? -->
} Dopamine antagonist: Metoclopramide

<!-- PAGE=? -->
 Reduces gastric volume (gastrokinetic)

<!-- PAGE=? -->
 0.1 mg/kg IV

<!-- PAGE=? -->
 S/E:

<!-- PAGE=? -->
EPS

<!-- PAGE=? -->
Dysphoria

<!-- PAGE=? -->
Sedation

<!-- PAGE=? -->
} H2 blockers: Ranitidine

<!-- PAGE=? -->
 ↑ gastric pH / ↓ gastric volume

<!-- PAGE=? -->
 0.5 mg/kg IV

<!-- PAGE=? -->
 S/E

<!-- PAGE=? -->
Agitation

<!-- PAGE=? -->
Confusion

<!-- PAGE=? -->
NG

<!-- PAGE=? -->
Regional

<!-- PAGE=? -->
RSI

<!-- PAGE=? -->
Aspiration

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
Trendelenberg position

<!-- PAGE=? -->
Suction airway

<!-- PAGE=? -->
Cuffed ETT

<!-- PAGE=? -->
Bronchoscopy if particulate matter suspected

<!-- PAGE=? -->
O2

<!-- PAGE=? -->
PEEP

<!-- PAGE=? -->
Antibiotics not routinely used unless:

<!-- PAGE=? -->
} Worsening hypoxia

<!-- PAGE=? -->
} Pulmonary infiltrate

<!-- PAGE=? -->
} Pulmonary effusion

<!-- PAGE=? -->
} High risk patient

<!-- PAGE=? -->
 Malnourished

<!-- PAGE=? -->
 EtOH abuse

<!-- PAGE=? -->
 Poor dentition

<!-- PAGE=? -->
Aspiration more severe if pH<2.5 and >25ml

<!-- PAGE=? -->
If no S/S in 2H - unlikely to worsen

<!-- PAGE=? -->
CXR not predictive

<!-- PAGE=? -->
Aspiration of blood does not cause chemical burns to the tracheobronchial tree

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ASRA Guidelines

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Table 6. Neuraxial Anesthesia in the Patient Receiving Thromboprophylaxis

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hx/Px:

<!-- PAGE=? -->
Course, Triggers, PPV, Steroid

<!-- PAGE=? -->
Wheeze, SpO2, I:E, acc. Muscle, pulsus paradox

<!-- PAGE=? -->
Invest:

<!-- PAGE=? -->
CXR, ABG, PFTs (pre/post), PEFR

<!-- PAGE=? -->
Echo: pulm htn, RVH

<!-- PAGE=? -->
Glu, Lytes

<!-- PAGE=? -->
Resp Consult

<!-- PAGE=? -->
Mx:

<!-- PAGE=? -->
-alternative to GA/ETT (may be difficult - subglottic stenosis) -monitor Pplat as measure of Paw (<30)

<!-- PAGE=? -->
-bronchodilators, Ketamine, Inhaled Induction, deep extubation -keep the patient deep, topical / IV lidocaine with intbtn/extbatn -avoid histamine/ach-releasing drugs

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
'Reversible Reactive Airway disease characterized by bronchoconstriction and airflow obstruction'

<!-- PAGE=? -->
Exaccerbation/Bronchospasm with Airway Instrumentation

<!-- PAGE=? -->
Difficult Ventilation

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
PPV

<!-- PAGE=? -->
} Barotrauma

<!-- PAGE=? -->
} Hyperinflation

<!-- PAGE=? -->
Medication S/E:

<!-- PAGE=? -->
} Tachydysrythmias

<!-- PAGE=? -->
} Hypokalemia

<!-- PAGE=? -->
} Steroid

<!-- PAGE=? -->
Hyperglycemia

<!-- PAGE=? -->
Adrenal suppression

<!-- PAGE=? -->
Myopathy

<!-- PAGE=? -->
Exaccerbation Tx:

<!-- PAGE=? -->
Salbutamol (may initially worsen V/Q since vasodilation

<!-- PAGE=? -->
Nebules - 0.15 mg/kg

<!-- PAGE=? -->
Continuous aerosol - 15 mg/hour

<!-- PAGE=? -->
IV - 1.0-10 mcg/kg/min

<!-- PAGE=? -->
Atrovent (Peak effect 60-90min)

<!-- PAGE=? -->
Nebules 0.5mg

<!-- PAGE=? -->
Methylprednisolone

<!-- PAGE=? -->
2 mg/kg IV (max 125 mg)

<!-- PAGE=? -->
Magnesium Sulfate

<!-- PAGE=? -->
50 mg/kg IV (1.2-2g)

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
0.01 mcg/kg SC (max 0.3 mg) q20mins

<!-- PAGE=? -->
0.01-0.1 mcg/kg/min IV

<!-- PAGE=? -->
Cromolyn

<!-- PAGE=? -->
Theophylline

<!-- PAGE=? -->
5 mg/kg IV loading dose

<!-- PAGE=? -->
consult respirology to calculate maintenance

<!-- PAGE=? -->
Heliox (min 70%)

<!-- PAGE=? -->
BiPAP/PPV

<!-- PAGE=? -->
For hypercarbia, hypoxia, exhaustion

<!-- PAGE=? -->
Min Paw, PCV, long I:E, low RR, permissive hypercarbia

<!-- PAGE=? -->
Volatile

<!-- PAGE=? -->
Muscle Relaxants

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
TRAUMA

<!-- PAGE=? -->
Potential for multiple hidden injuries and hemorrhage sites

<!-- PAGE=? -->
Potential Head injury / incr ICP

<!-- PAGE=? -->
Difficult airway with Cervical spine precautions

<!-- PAGE=? -->
Full stomach

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Unknown medications or substance use

<!-- PAGE=? -->
Emerg Script, ATLS Protocol

<!-- PAGE=? -->
Alert Trauma team

<!-- PAGE=? -->
Primary Survey (immediately life threatening injuries)

<!-- PAGE=? -->
Airway and cervical spine protection/stabilization

<!-- PAGE=? -->
 Ascertain patency & ease of intubation

<!-- PAGE=? -->
 Rapidly assess for airway obstruction and injury

<!-- PAGE=? -->
Breathing

<!-- PAGE=? -->
 Ensure adequate oxygenation and ventilation

<!-- PAGE=? -->
 Inspect neck, chest, and trachea

<!-- PAGE=? -->
 Palpate, Percuss and ausculate bilaterally

<!-- PAGE=? -->
Circulation with hemorrhage control

<!-- PAGE=? -->
 Identify external bleeding, potential for internal bleeding

<!-- PAGE=? -->
 Assess for adequacy of perfusion: LOC, Skin, Pulse & blood pressure, HR, HS, JVP

<!-- PAGE=? -->
Disability

<!-- PAGE=? -->
 LOC: GCS & pupils

<!-- PAGE=? -->
Exposure/Environment

<!-- PAGE=? -->
 Expose & prevent hypothermia

<!-- PAGE=? -->
Adjuncts

<!-- PAGE=? -->
 CXR, pelvis,(lateral C-spine), FAST, EKG

<!-- PAGE=? -->
 foley/OG

<!-- PAGE=? -->
 ABG, other bloodwork

<!-- PAGE=? -->
 crossmatch, tox screen, amylase, routine, BHCG

<!-- PAGE=? -->
Secondary Survey

<!-- PAGE=? -->
Head-Toe

<!-- PAGE=? -->
Adjuncts: CT, consults

<!-- PAGE=? -->
Conflicts:

<!-- PAGE=? -->
RSI vs HD

<!-- PAGE=? -->
Cspine vs Cricoid

<!-- PAGE=? -->
SPECIAL:

<!-- PAGE=? -->
Pregnancy:

<!-- PAGE=? -->
DDx PV Bleed:

<!-- PAGE=? -->
 uterine rupture,

<!-- PAGE=? -->
 abruption,

<!-- PAGE=? -->
 placenta previa,

<!-- PAGE=? -->
 ruptured vasa previa,

<!-- PAGE=? -->
 vaginal trauma,

<!-- PAGE=? -->
 open pelvic fracture,

<!-- PAGE=? -->
 bladder/urethral injury,

<!-- PAGE=? -->
U/S, Kleihauer-Betke acid elution technique (adult cells remain colorless while fetal red cells turn bright purple-pink)

<!-- PAGE=? -->
Rhogam

<!-- PAGE=? -->
tilt backboard, chest tubes 2 levels higher, FHR, higher chest compressions

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Major Vessel Injury

<!-- PAGE=? -->
 Ideally, deep anesthesia and profound muscle relaxation required before airway manipulation - prevent HTN, coughing, bucking, gagging to prevent dislodgement of hemostatic clot from injured vessel

<!-- PAGE=? -->
Closed Head/Open Globe

<!-- PAGE=? -->
 Ideally, deep anesthesia and profound muscle relaxation before airway manipulation

<!-- PAGE=? -->
 Prevent coughing, gagging, bucking with consequent ½ ICP and ½ IOP

<!-- PAGE=? -->
 Prevent brain ischemia ( ¾ CPP)

<!-- PAGE=? -->
 Head Injured

<!-- PAGE=? -->
 Opioids omitted or administered after preoxygenation and IV anesthetic administration (avoid hypoxia)

<!-- PAGE=? -->
 Avoid ketamine

<!-- PAGE=? -->
 Lidocaine useful in suppressing response to a airway manipulation

<!-- PAGE=? -->
 Esmolol useful to maintain HTN (may worsen ICH)

<!-- PAGE=? -->
 Modify RSI to keep CPP, MR in mind

<!-- PAGE=? -->
 Open Globe

<!-- PAGE=? -->
 Ketamine OK

<!-- PAGE=? -->
 Sux OK if defasciculating NDMR given

<!-- PAGE=? -->
 RSI

<!-- PAGE=? -->
 Difficult airway

<!-- PAGE=? -->
 Conflict: ICP vs Airway

<!-- PAGE=? -->
 Hypoxia/Hypercarbia worse, therefore awake intubation with meticulous topicalization, minimal sedation

<!-- PAGE=? -->
 Avoid anesthetics and NMB's

<!-- PAGE=? -->
 Hypotensive along with above injuries

<!-- PAGE=? -->
 Goal: maintain CPP, avoid strain

<!-- PAGE=? -->
 Little or no IV anesthetic given

<!-- PAGE=? -->
 Just large dose of NMB

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ATLS

<!-- PAGE=? -->
General:

<!-- PAGE=? -->
-assume hypoxia and hypovolemia until proven otherwise

<!-- PAGE=? -->
-Disabilty : -any change: revaluate ventilation/perfusion, then assess for traumatic neural injury

<!-- PAGE=? -->
-Foley contraindicated with urethral injury suspected: blood at meatus, perineal ecchymosis ,blood in scrotum, high riding, non-palpable prostate, pelvic #.  Need urethragram, urology.

<!-- PAGE=? -->
-OG: reduces risk of aspiration.  Gasrtric Dilatation can produce vagal induced hypotension/bradycardia.

<!-- PAGE=? -->
-Tetanus immunization

<!-- PAGE=? -->
HX:

<!-- PAGE=? -->
-blunt: belted, steering wheel deformation, direction of impact, intrusion, ejection, extrication time, windscreen, airbag, position in vehicle, other passengers -penetrating: type of weapon, number, velocity, caliber, distance from weapon.

<!-- PAGE=? -->
-burn: open or closed space, substances consumed by fire,

<!-- PAGE=? -->
-always consider etiology of trauma: hypoglycemia, CVA, MI etc…

<!-- PAGE=? -->
-with alcohol, more likely to become hypothermic (vasodilation)

<!-- PAGE=? -->
2 nd Survey

<!-- PAGE=? -->
-immobilzation of the entire patient until spinal injury can be excluded

<!-- PAGE=? -->
-consider vascular injury: bruit, nearby blunt injury - angio

<!-- PAGE=? -->
-should not explore wounds deep to platysma.

<!-- PAGE=? -->
-check all motor/sensory/vascular in extremities

<!-- PAGE=? -->
-rule our compartment syndrome

<!-- PAGE=? -->
Airway:

<!-- PAGE=? -->
-talk to patient, look for signs of hypoxia/hypercarbia, listen for noisy breathing/obstruction, feel for deviated trachea, #, sub-q

<!-- PAGE=? -->
-Remove helmet - 2 people or cast cutter

<!-- PAGE=? -->
Laryngeal Trauma:

<!-- PAGE=? -->
-hoarse, sub-q emphysema, palpable fracture

<!-- PAGE=? -->
-FOB/cricothyroidotomy/trach

<!-- PAGE=? -->
-Jet insuflation :

<!-- PAGE=? -->
14g (18g in peds). 45deg caudally. Y-connector  (or hole in tube) to O2 tubing. 15L/min (5L/min if glottic obstruction).  Only adequate ventilation for about 30min.

<!-- PAGE=? -->
-Surgical Cricothyroidotomy: stabilize thyroid cartilage throughout, transverse incision, enlarged with curved hemostat/scalpel handle, 5-7mm ETT, not for age <12yo

<!-- PAGE=? -->
Breathing:

<!-- PAGE=? -->
ETCO2: wait for 6 breaths before reading

<!-- PAGE=? -->
ABG: pO2 measured, Sat is calculated

<!-- PAGE=? -->
Circulation

<!-- PAGE=? -->
-Move quickly to PRBC if little response to crystalloid bolus: Crosssed (1hr) , Type Specific (10min), O-neg, O

<!-- PAGE=? -->
-Consider OR to stop bleeding early - part of resuccitation

<!-- PAGE=? -->
-ringers preferred solution , warmed to 37-40deg

<!-- PAGE=? -->
-peds: try to maintain 1cc/kg/hr UO, 2 if <1yo

<!-- PAGE=? -->
-consider autotransfusion of Chest Tube blood (NaCitrate as anticoagulant)

<!-- PAGE=? -->
-CHI/DAI patient prone to development of coag abnormailiters because of reslease of tissue thromboplastin (from damaged neural tissue)

<!-- PAGE=? -->
-blunt cardiac trauma maybe an indication for CVP

<!-- PAGE=? -->
-incr CVP: overtransfusion, cardiac dysfunction, tamponbade, pneumo

<!-- PAGE=? -->
-any cardiac arrhythmia - hypoxia/hypoperfusion should be suspected.

<!-- PAGE=? -->
-humerus/tibia 750ml, femur 1.5L, pelvic x'ple L

<!-- PAGE=? -->
-IO before Central Line, usually <6yo:

<!-- PAGE=? -->
-flex knee with padding to 30deg.

<!-- PAGE=? -->
-Ant/Med, 1-3cm below the tibial tuberecle

<!-- PAGE=? -->
-Initial 90deg angle, needle bevel toward foot (away from epiphyseal plate), then angle 45-60degrees.

<!-- PAGE=? -->
-sometimes can't aspirate

<!-- PAGE=? -->
Venous cut down: transverse incision, ligate distal, tie proximal

<!-- PAGE=? -->
Shock:

<!-- PAGE=? -->
-assumed to be hypovolemic (most other causes also respond to fluid)

<!-- PAGE=? -->
-usually requires surgeon.

<!-- PAGE=? -->
-can calculate the amount of fluid needed to give based on % blood loss.  If VS do not normalize, other cause of shock or ongoing bleeding.

<!-- PAGE=? -->
-must assess pt's response to initial fluid bolus - stabilize, transient or min response (need to rule out other causes, likely emergent OR)

<!-- PAGE=? -->
-neurogenic: hypotension without tachycardia or vasoconstriction, wide pulse pressure.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Page 98. ADVANCED TRAUMA LIFE SUPPORT CLASSIFICATION OF HEMORRHAGIC SHOCK*

<!-- PAGE=? -->
Thoracic:

<!-- PAGE=? -->
-sucking chest wound: if opening is 2/3s the diameter of trachea, are preferentially enters wound.  Tape occlusive dressing on 3 sides, then chest tube

<!-- PAGE=? -->
-flail chest: lung contusion, paradoxical movement, pain

<!-- PAGE=? -->
-Lung Contusion: consider early intubation

<!-- PAGE=? -->
-tracheobronchial tree injury: usual 1 inch from carina, hemoptysis, sub-q emphesema, pneumo, large air leak after chest tube, FOB.  Tx: lung isolation

<!-- PAGE=? -->
-massive hemothorax: 1500cc or >200cc/hr for 2 hours

<!-- PAGE=? -->
-penetrating injuries medial to nipples or scapula are dangerous

<!-- PAGE=? -->
-tamponade: distended neck veins can be absent if hypovolemic, pulsus paradox, Kussmauls, Becks

<!-- PAGE=? -->
-14G angiocath, 1-2cm inferior to xiphisternum, aim for tip of scapula

<!-- PAGE=? -->
when needle contacts epicardiu: incr T wave voltage, dysrythmia

<!-- PAGE=? -->
if positive, need to open inspection of heart

<!-- PAGE=? -->
can be false negative (clot)

<!-- PAGE=? -->
-ED Thoracotomy: 1) penetrating injury with Initial signs of life enroute 2) blunt with PEA in ED for: release of tamponade, control of bleeding, open cardiac massage, x-clamp descending Ao.

<!-- PAGE=? -->
-myocardial contusion: chest pain, hypotension, dysrythmia, wall motion abnormaility, infarction.  At risk for sudden syrhtmias - monitored for 24H. No enzymes needed… just EKG

<!-- PAGE=? -->
-Aortic Disruption: must be contained hematoma.  Decel injury.  CT angio is standard

<!-- PAGE=? -->
-Diaphragm rupture/hernia: upper GI study, thoracoscopy.  Mainly post/lat L hemidiaphram (right hidden by liver)

<!-- PAGE=? -->
-Traversing Mediastinum: Mortality 20%.  bilat chest tubes,  CXR for mediastinal air (esoph or TBT rupture).

<!-- PAGE=? -->
-Chest Crush:  occlusion of SVC can cause massive swelling, cerebral edema.

<!-- PAGE=? -->
-Rib# - if 1-3 broken . significant force.  Higher force required to break ribs in young.  10-12: hepatosplenic injury

<!-- PAGE=? -->
-Esophageal Rupture: suspect in L pneumo/hemo with no rib#, lower chet.upper abdo trauma, pain out of proportion

<!-- PAGE=? -->
-Thoracocentesis :2 nd ICS MCL, ChestTube: 5ICS, AAL

<!-- PAGE=? -->
Abdo:

<!-- PAGE=? -->
-organs most frequent injured:

<!-- PAGE=? -->
-Blunt: spleen, liver and retroperitoneal hemorrhage

<!-- PAGE=? -->
-Penetrating: liver, bowel, diaphragm, colon.

<!-- PAGE=? -->
-30% of stab wounds to ant abdo do not penetrate the peritoneum

<!-- PAGE=? -->
-DPL: 100k RBC/mm3, >500 WBC, GS: bacteria present

<!-- PAGE=? -->
-FAST: pericardial sac, hepatorenal fossa, splenorenal fossa, pelvis. Poor in obese, excess gas/sub-q emph.

<!-- PAGE=? -->
-CT may miss GI, diaphragm or pancreatic injury

<!-- PAGE=? -->
-a normal amylase doesn't exclude pancreatic injury

<!-- PAGE=? -->
-consider laproscopic surgery

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Head Injury

<!-- PAGE=? -->
-2x the mortality with severe HI if hypotensive/hypoxic -hypotension rarely secondary to HI itself - if hypotensive, look for and fix cause of bleeding before imaging head -ICP> 20 is detrimental -aim for perfusion pressure >60-70 -CBF: Normal 50cc/100g tissue/min, 20-25: EEG decrease, 5: infarct -bilat dilated pupils usually due to inadequate perfusion, metabolic -GCS 8 accepted difinition of coma (9-13 mod head injury) -Basal skull - commonly CN7 palsy -CN3: runs along edge of tentorium, with parasympathetic fibers along the outside.  With compression (from uncus/med temporal lobe), it first dilates and then inf and lat gaze. -Uncal herniation also compresses corticospinal (pyramidal) tract in midbrain - contralat weakness -Kernohan's notch synd: uncal herniation may push midbrain over and affect contralat CN3 -Subdural brain damage and prognosis is much worse than epidural -CT head for all HI Medical Tx: Isotonic fluid (avoid pverload), PCO2 35, Mannitol 1g/kg, Lasix 0.5mg/kg, barbiturates, -Dilatin prophylaxis for seizure in 1 st week, ICH, Depressed skull# Brain Death: GCS=3, pupils non-reactive, absent brainstem relexes, no spontaneous breathing Spine: -Approximately 2% of victims with blunt trauma have a spinal injury, tripled if the victim has a craniofacial injury or GCS< 8 -Corticospinal: postlat, ipsilat voluntary movment -Spinothalamic - anterolat, pain and temp from contralat -Posterior Column - proprioception, vibration, light touch from ipsilat -Neurogenic Shock: impaired descending sympathetics -Spinal Shock is loss of spinal reflexes seen after injury…  recovers -May not have signs of acute abdomen Syndromes: -Central Cord: greater motor loss in upper than lower with hyper-extension injury and OA- anterior spinal artery injury -Anterior Cord: posterior column sparing - infarction in ant spinal artier -Brown-Sequard - ipspilat motor loss, ipsilat position loss, contralat sensory - hemisection -though contreverisal: Solumedrol 30mg/kg then 5.4mg/kg for total 24H (48H is started 3-8H), must start withing 8hours. Injuries: -injury above clacicle: assume unstable C-spine -55% of spine injuries are C spine, 15% in each other area -Atlanto-occipital Dislocation - usually fatal -Atlas/C1 - 5% of c-spine #, -Jefferson (burst), axial loading, usually no cord injury, unstable -Rotary - mainly kids, RA -Axis/C2 - 18% of c-spine # -Odontoid: Type 1) tip 2) through base, most common, 3) base extending into body -Hangman's: pars interarticularis, extension injury, unstable -at C3 and below, spinal canal narrows and therefore more likely to cause cord injury -most movement is at C5 and C6 -most common # C5, most common subluxation is C5/6 -neurologic injury is common in facet dislocation -most thoracic # are stable, but burst, chance and subluxations can cause nerve injury because canal is narrow-always unstable -lumbar spine - usually unstable, usually damage to cauda equine with bowel/bladder -Chance: spilting of vertebrae with flexion, commonly retroperitoneal or abdo injury Clearing: -do not need lat C-spine Xray …  doesn't change management in ED - of no neuro signs, or altered LOC, or neck pain or tenderness (doesn't mention distracting injury - palpate, active rotate, flex/extend (no need for xrays) -if tenderness: X-rays, flex/ext views -neuro signs or unconscious: MRI, CT myelogram -if Xrays and 3mm cut CT are normal (no soft tissue swelling) - unlikely to have significant unstability -Lat, AP and open mouth has sensitivity of 92% .  Ct maybe better for C1/2 -If one # in spine, 10% chance of another -X-ray: Alingment, Bones, Cartilage (disc space), Soft Tissue (prevertebral >5mm at C3) -thoracolumbar: if neuro def, tender OR altered: full spine xray -normal spine xrays do not rule out cord injury

<!-- PAGE=? -->
-remove backboard even if unsable spine # (for transport only)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
MSK:

<!-- PAGE=? -->
Crush:

<!-- PAGE=? -->
-hypovolemia, metabolic acidosis, hyperK, hypoCa, DIC

<!-- PAGE=? -->
-Tx: fluid, osmotic diuresis, alkalization of urine (reduces intratubular precipitation)

<!-- PAGE=? -->
-muscle can only tolerate ischemia for 6H

<!-- PAGE=? -->
-amputated part washed in Ringers, wrapped with gauze soaked in Penicillin, towel, bag and transported on ice

<!-- PAGE=? -->
Compartment Syndrome

<!-- PAGE=? -->
tibial, forarm, crush

<!-- PAGE=? -->
-changes in distal pulse are not reliable, late sign.  Tissue pressure> 35-45 suggests damage.  Pain is first sign

<!-- PAGE=? -->
-if arterial injury, consider 1 attempt at reduction

<!-- PAGE=? -->
Pelvic#

<!-- PAGE=? -->
-injuries to T aorta are higher in those with pelvic #

<!-- PAGE=? -->
-first sign leg length discrepancy/rotational deformity

<!-- PAGE=? -->
-call blood bank ASAP

<!-- PAGE=? -->
-key: Are they bleeding intraperitoneal? FAST

<!-- PAGE=? -->
-if positive: laparotomy, if negative: diagnostic/therapeutic angio

<!-- PAGE=? -->
-if hemodynamically unstable: if open go to or, if closed rule out abdo injury first

<!-- PAGE=? -->
-Pelvic - if increased volume #, more blood loss

<!-- PAGE=? -->
-pneumatic antishock garment fir control of hemorrahage with pelvic #

<!-- PAGE=? -->
Pediatrics:

<!-- PAGE=? -->
-Peds/athletic: lots of researve… run out fast

<!-- PAGE=? -->
-higher energy per unit body area, often internal damage with no broken bones, when bones break - very high energy

<!-- PAGE=? -->
-Broselow Pediatric Measuring Tape

<!-- PAGE=? -->
-Nasotracheal in peds is not advised

<!-- PAGE=? -->
-cricothyroidotomy is safe >9yo, if less use needle + jet

<!-- PAGE=? -->
-hypotension represent sever blood loss of >45% - followed quickly by bradycardia.

<!-- PAGE=? -->
-lower limit SBP=70+2xage(y), DBP = 2/3 x SBP

<!-- PAGE=? -->
-after 2nd 20cc/kg bolus, consider blood

<!-- PAGE=? -->
-move quickly to IO (proximal tibia or distal femur), venous cutdown

<!-- PAGE=? -->
-mobility of mediatinal structures makes them more seisitive to tension pneumo and flail segments

<!-- PAGE=? -->
-commonly swallow a lot of air

<!-- PAGE=? -->
-intra-abdominal injuries common secondary to thin abdo wall and large organs. Chance#

<!-- PAGE=? -->
-kids can hide a lot of blood in head because of open sutures/frontelles

<!-- PAGE=? -->
-incr ICP maybe hidden because of open sutures

<!-- PAGE=? -->
-persistent or incr vomiting, recurrent seizures warrants CT

<!-- PAGE=? -->
-spinal cord injury is rare

<!-- PAGE=? -->
Pg 297

<!-- PAGE=? -->
Page 304: Pediatric GCS verbal scale

<!-- PAGE=? -->
5: social smile, fixes and follows, 4 cries but consolable, 3 persistent irratble, 2 agitated

<!-- PAGE=? -->
-C2/3, or C3/4 ant subluxation is okay, can be  >3mm

<!-- PAGE=? -->
Pregnancy:

<!-- PAGE=? -->
-treat mother first

<!-- PAGE=? -->
-consult obs/neonates, FHR monitor

<!-- PAGE=? -->
-may lose 1.5L before any signs, hidden fetal compromise

<!-- PAGE=? -->
-15mmHg decree BP in 2 nd trimester

<!-- PAGE=? -->
-uterus protects other organs from injury

<!-- PAGE=? -->
-consider AFE, or DIC secondary to AFE - order fibrinogen level routinely

<!-- PAGE=? -->
-placenta sensitive to catecholamines… combined with hypotension/hypovolemia: hidden fetal hypoxia

<!-- PAGE=? -->
-abruptio (PV bleed irratble uterus), PROM, uterine rupture ( tender, peritoneal signs, hard to feel, abnormal lie)

<!-- PAGE=? -->
-abruption is most common cause of fetal mortality in blunt trauma. 30% no bleeding.  Frequent uterine contraction most sensitive.

<!-- PAGE=? -->
-all Rh- should ge Rh IG therapy within 72H, even with -'ve Kleinhauer-Betke test, unless injury is remote from uterus

<!-- PAGE=? -->
-consider Emergency C/S if can be done in 4-5min in hypovolemic arrest (though likely fetal hypoxia already done)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Elderly:

<!-- PAGE=? -->
-men do worse than women in low-mod ISS.

<!-- PAGE=? -->
-may not increase HR, (decrease sysmp activity/Rx) .

<!-- PAGE=? -->
-BP doesn't correlate with CO, sensitive to decrease blood flow, decr cardiac compliance, preexisting volume depletion (htn/diuretic) - consider early intubation/CVP

<!-- PAGE=? -->
10.7 ACLS Trauma

<!-- PAGE=? -->
-A high rate of volume infusion with the therapeutic goal of a systolic blood pressure >100 mm Hg is now recommended only for patients with isolated head or extremity trauma, either blunt or penetrating. In the urban setting, aggressive prehospital volume resuscitation for penetrating trauma is no longer recommended because it is likely to increase blood pressure and consequently accelerate the rate of blood loss, delay arrival at the trauma center, -In rural settings, transport times to trauma centers will be longer, so volume resuscitation for blunt or penetrating trauma is provided during transport to maintain a systolic blood pressure of 90 mm Hg

<!-- PAGE=? -->
TABLE. Suggested Indlcatlons for Resuscitatlve Thoracotomy: Patlents WIth Traumatlc Cardlac Arrest

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Awareness:

<!-- PAGE=? -->
 0.1% incidence

<!-- PAGE=? -->
 Develop PTSD

<!-- PAGE=? -->
Risk Factors:

<!-- PAGE=? -->
 CPB

<!-- PAGE=? -->
 OB

<!-- PAGE=? -->
 Trauma

<!-- PAGE=? -->
 Diff Intubation

<!-- PAGE=? -->
 NMB

<!-- PAGE=? -->
 TIVA

<!-- PAGE=? -->
 Opiod Based

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
 check old chart for risk factors

<!-- PAGE=? -->
 Psychologist referral

<!-- PAGE=? -->
 BIS

<!-- PAGE=? -->
 Benzos

<!-- PAGE=? -->
 Avoid NMB

<!-- PAGE=? -->
 Regional

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Approach:

<!-- PAGE=? -->
Vessel

<!-- PAGE=? -->
Pressure (htn, venous congestion)

<!-- PAGE=? -->
Cut (surgical)

<!-- PAGE=? -->
Coagulation

<!-- PAGE=? -->
Primary (plt plug)

<!-- PAGE=? -->
Plt disorder/#

<!-- PAGE=? -->
production

<!-- PAGE=? -->
sequest

<!-- PAGE=? -->
consumption

<!-- PAGE=? -->
Anti-platlet drug

<!-- PAGE=? -->
Secondary (thrombin)

<!-- PAGE=? -->
Coagulation Factors

<!-- PAGE=? -->
production

<!-- PAGE=? -->
consumption

<!-- PAGE=? -->
Ca

<!-- PAGE=? -->
temp

<!-- PAGE=? -->
-correct coagulopathy

<!-- PAGE=? -->
-ABCs, ACT, ABG

<!-- PAGE=? -->
-CBC, INR, PTT, TT, Fibrinogen, FDP, DAT, Haptoglobin, Smear

<!-- PAGE=? -->
art line

<!-- PAGE=? -->
-IVs (surgeon can canulate large vien)

<!-- PAGE=? -->
-Vascular Surgeon: clamp aorta

<!-- PAGE=? -->
Bleeding

<!-- PAGE=? -->
-cell saver

<!-- PAGE=? -->
-decrease anesthetic

<!-- PAGE=? -->
-watch for side effects of transfusion

<!-- PAGE=? -->
-consider: endoscopy, laparotomy, embolization, blackemore

<!-- PAGE=? -->
Undiagnosed inherited coagulopathy

<!-- PAGE=? -->
vWD

<!-- PAGE=? -->
AT III deficiency

<!-- PAGE=? -->
HHT

<!-- PAGE=? -->
Hemophilia

<!-- PAGE=? -->
AFE

<!-- PAGE=? -->
FE

<!-- PAGE=? -->
Sepsis

<!-- PAGE=? -->
Trauma (brain, uterus)

<!-- PAGE=? -->
Complication of transfusion

<!-- PAGE=? -->
Dilutional thrombocytopenia

<!-- PAGE=? -->
Hypocalcemia

<!-- PAGE=? -->
tPA

<!-- PAGE=? -->
Hemolytic transfusion reaction

<!-- PAGE=? -->
Sepsis

<!-- PAGE=? -->
Drug-induced platelet dysfunction

<!-- PAGE=? -->
DIC

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Pre-op

<!-- PAGE=? -->
B12/Folate

<!-- PAGE=? -->
Iron

<!-- PAGE=? -->
o 300 mg PO TID x 6 wks

<!-- PAGE=? -->
o 200 mg IV 3/wk (hypotension)

<!-- PAGE=? -->
EPO - 600 U/kg SC/week x 3 wks

<!-- PAGE=? -->
Autologous donation

<!-- PAGE=? -->
Intra-op

<!-- PAGE=? -->
Surgical hemostasis

<!-- PAGE=? -->
Tourniquets

<!-- PAGE=? -->
Proper positioning

<!-- PAGE=? -->
ANVH

<!-- PAGE=? -->
Cell-saver

<!-- PAGE=? -->
Induced/Controlled hypotension

<!-- PAGE=? -->
Prevent hypothermia/acidosis/hypocalcemia

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
Post-op

<!-- PAGE=? -->
Autologus Transfusion Service (Chest Tube with NaCitrate)

<!-- PAGE=? -->
Limit blood sampling

<!-- PAGE=? -->
Blood Conservation/Transfusion

<!-- PAGE=? -->
Autologous Blood Donation

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
o patient refusal

<!-- PAGE=? -->
o Age < 16 years or > 71 years old

<!-- PAGE=? -->
o Weight < 40 Kg

<!-- PAGE=? -->
o uncontrolled HTN  (volume deplete)

<!-- PAGE=? -->
o Hgb < 120

<!-- PAGE=? -->
o Unstable CAD

<!-- PAGE=? -->
o Severe AS

<!-- PAGE=? -->
o Recent MI/CVA

<!-- PAGE=? -->
o Cyanotic Heart Sz.

<!-- PAGE=? -->
o Seizures

<!-- PAGE=? -->
o Bacteremia:

<!-- PAGE=? -->
 T > 38 o C on the day of donation

<!-- PAGE=? -->
 bacterial infection < 1 week prior

<!-- PAGE=? -->
 dental surgery within 72 hours

<!-- PAGE=? -->
Indicated Procedures

<!-- PAGE=? -->
o AAA

<!-- PAGE=? -->
o Major orthopedic

<!-- PAGE=? -->
o Cardiac (i.e. valve, ∅ CABG)

<!-- PAGE=? -->
Procedure

<!-- PAGE=? -->
o Donated weekly x 4u max

<!-- PAGE=? -->
o discarded after 35 days

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
DDAVP

<!-- PAGE=? -->
0.3 mcg/kg IV/SC (max 20 mcg)

<!-- PAGE=? -->
Onset - 30 min

<!-- PAGE=? -->
Peak - 2-4 hours

<!-- PAGE=? -->
Duration - 6-8 hours

<!-- PAGE=? -->
SE - hypotension, hyponatremia

<!-- PAGE=? -->
Conjugated Estrogen

<!-- PAGE=? -->
0.6 mg/kg/day IV x 5 days

<!-- PAGE=? -->
Onset - 6 hours

<!-- PAGE=? -->
Peak - 5 days

<!-- PAGE=? -->
Duration - 14 days

<!-- PAGE=? -->
TXA

<!-- PAGE=? -->
10 mg/kg IV bolus then 2 mg/kg/hr infusion

<!-- PAGE=? -->
25 mg/kg QID PO x 2-8 days

<!-- PAGE=? -->
Aprotinin

<!-- PAGE=? -->
1 ml test dose (10,000 KIU)

<!-- PAGE=? -->
200 ml bolus over 30 min (2,000,000 KIU)

<!-- PAGE=? -->
50 ml/hour (500,000 KIU)

<!-- PAGE=? -->
Kogenate / rFVIII - Hemophilia

<!-- PAGE=? -->
Major OR (100%) ~ 50 U/kg then 25 U/kg Q8H

<!-- PAGE=? -->
Minor OR (50%) ~ 25 U/kg then 15 U/kg Q8H

<!-- PAGE=? -->
1 U/kg increases plasma FVIII 2%

<!-- PAGE=? -->
Dosage required (IU) = body weight (kg) × desired % factor VIII increase /  2%/IU/kg

<!-- PAGE=? -->
Humate-P - vWD

<!-- PAGE=? -->
pooled from FFP

<!-- PAGE=? -->
75 IU/kg Q8H then 50 IU/kg

<!-- PAGE=? -->
goal - nadir vWF:RCo > 50%

<!-- PAGE=? -->
1.5 IU/kg elevation of vWF:RCo activity per 1 IU/kg Humate-P

<!-- PAGE=? -->
Recombinant FVII

<!-- PAGE=? -->
50 - 100 mcg/kg IV Q4H

<!-- PAGE=? -->
thrombin burst on plts

<!-- PAGE=? -->
Transfusion

<!-- PAGE=? -->
PRBC - 1u incr Hg 10

<!-- PAGE=? -->
Plt - 0.1u/kg = 1u/10kg (apharesis = 6u)

<!-- PAGE=? -->
o 1u increase plts by 7

<!-- PAGE=? -->
FFP - 10ml/kg (5ml/kg to reverse warfarin)

<!-- PAGE=? -->
Cryo - 0.1u/kg = 1u/10kg

<!-- PAGE=? -->
o If fibrinogem <100

<!-- PAGE=? -->
Massive Transfusion

<!-- PAGE=? -->
Definition - ½ blood volume in 3 hours

<!-- PAGE=? -->
Protocol

<!-- PAGE=? -->
5 units PRBC's + 1 litre plasma

<!-- PAGE=? -->
5 units PRBC's + 5 units platelets + 10 units cryoprecipitate

<!-- PAGE=? -->
5 units PRBC's + 1 litre plasma + FVII

<!-- PAGE=? -->
5 units PRBC's + 5 units platelets

<!-- PAGE=? -->
Calcium

<!-- PAGE=? -->
Normothermia

<!-- PAGE=? -->
MgSO4

<!-- PAGE=? -->
Complications:

<!-- PAGE=? -->
} Citrate toxicity

<!-- PAGE=? -->
} Hyperkalemia

<!-- PAGE=? -->
} Volume overload

<!-- PAGE=? -->
} Hypothermia

<!-- PAGE=? -->
} Dilutional Coagulopathy

<!-- PAGE=? -->
 Fibrinogen, II, V, VIII, platelets

<!-- PAGE=? -->
} Metabolic alkalosis/acidosis

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
} Citrate toxicity

<!-- PAGE=? -->
} Hyperkalemia

<!-- PAGE=? -->
} Volume overload

<!-- PAGE=? -->
} Hypothermia

<!-- PAGE=? -->
} Dilutional Coagulopathy

<!-- PAGE=? -->
 Fibrinogen, II, V, VIII, platelets

<!-- PAGE=? -->
Immunological

<!-- PAGE=? -->
} Hemolytic

<!-- PAGE=? -->
 Immediate hemolytic transfusion reaction (1:20,000)

<!-- PAGE=? -->
A, B, Kell, Kidd, Lewis, Duffy

<!-- PAGE=? -->
 Delayed hemolytic transfusion reaction (1:5,000)

<!-- PAGE=? -->
Rh, Kidd

<!-- PAGE=? -->
} Non-Hemolytic

<!-- PAGE=? -->
 Febrile reactions (1:30)

<!-- PAGE=? -->
 GVHD

<!-- PAGE=? -->
 TRALI (1:5000)

<!-- PAGE=? -->
 Anaphylactic

<!-- PAGE=? -->
Anti-IgA

<!-- PAGE=? -->
} Immunomodulation

<!-- PAGE=? -->
Infectious

<!-- PAGE=? -->
} Viral

<!-- PAGE=? -->
 CMV

<!-- PAGE=? -->
 HBV (1:300,000)

<!-- PAGE=? -->
 HCV (1:1M)

<!-- PAGE=? -->
 HIV (1:4M)

<!-- PAGE=? -->
} Bacterial

<!-- PAGE=? -->
 RBC's (1:200,000) Yersinia Enterocoliticia

<!-- PAGE=? -->
 Platelet's (1:2500) - Staph Aureus

<!-- PAGE=? -->
Transfusion Risks

<!-- PAGE=? -->
Risk of Transfusion Reaction

<!-- PAGE=? -->
1. ABO + Rh → 99.8% safe

<!-- PAGE=? -->
3. Full X-match → 99.95% safe

<!-- PAGE=? -->
2. ABO + Rh + Ab screen → 99.94% safe

<!-- PAGE=? -->
** If no previous transfusion nor pregnancy the risk of incompatible blood ~ 1:1000 otherwise ~ 1:100

<!-- PAGE=? -->
Management of Hemolytic Transfusion Reaction

<!-- PAGE=? -->
STOP the transfusion

<!-- PAGE=? -->
Maintain urine output > 100 ml/hour

<!-- PAGE=? -->
IV fluids / mannitol 0.25 -0.5 g/kg

<!-- PAGE=? -->
Lasix 20 mg

<!-- PAGE=? -->
Alkalinize the urine

<!-- PAGE=? -->
pH > 7

<!-- PAGE=? -->
40 - 70 mEq / 70 kg

<!-- PAGE=? -->
Urine & plasma Hgb

<!-- PAGE=? -->
CBC, INR, PTT, fibrinogen, Smear

<!-- PAGE=? -->
DAT (Coomb's)

<!-- PAGE=? -->
Return unused blood and discarded sample to blood bank

<!-- PAGE=? -->
Recross-match patient

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Brain Death Criteria

<!-- PAGE=? -->
DEF N  - irreversible loss of all brain function demonstrated by coma, apnea, and absence of brainstem reflexes

<!-- PAGE=? -->
Single physician (2 if transplant candidate), two examinations

<!-- PAGE=? -->
Known cause of death

<!-- PAGE=? -->
All reversible causes fixed - lytes, glucose, drugs (relaxants, sedatives)

<!-- PAGE=? -->
absence of brainstem reflexes

<!-- PAGE=? -->
T ≥ 34

<!-- PAGE=? -->
o pupillary

<!-- PAGE=? -->
o oculocephalic (doll's eye)

<!-- PAGE=? -->
o oculovestbular (cold calorics)

<!-- PAGE=? -->
o corneal

<!-- PAGE=? -->
o gag

<!-- PAGE=? -->
o cough

<!-- PAGE=? -->
o respirations

<!-- PAGE=? -->
o Note:  seizures or decorticate positioning rule out brain death

<!-- PAGE=? -->
Apnea Test

<!-- PAGE=? -->
o Hyperventilate on 100% O2

<!-- PAGE=? -->
o Apnea until pH<7.28 or pCO2 > 60 (pCO2 increased by 20 from baseline)

<!-- PAGE=? -->
Ancillary Testing

<!-- PAGE=? -->
o Cerebral angiography (4-vessels) to r/o intracranial flow

<!-- PAGE=? -->
o Radionuclide angiography (perfusion scintography)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Early:

<!-- PAGE=? -->
Emergency

<!-- PAGE=? -->
Etiology and Result (Trauma)

<!-- PAGE=? -->
Potential Difficult A/W

<!-- PAGE=? -->
Edema

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Myocardial depressant

<!-- PAGE=? -->
Resp/Inhalation Injury

<!-- PAGE=? -->
CO poisoning

<!-- PAGE=? -->
pulm edema

<!-- PAGE=? -->
Potential Rhabdomyalsis

<!-- PAGE=? -->
Difficult IV, Temperature Maintenance

<!-- PAGE=? -->
Later:

<!-- PAGE=? -->
Potential Difficult A/W

<!-- PAGE=? -->
Airway, head, neck scarring

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
Burns

<!-- PAGE=? -->
Distributive shock

<!-- PAGE=? -->
Incr CO

<!-- PAGE=? -->
Potential Resp insufficiency

<!-- PAGE=? -->
Eschar

<!-- PAGE=? -->
Hypermetabolic

<!-- PAGE=? -->
Altered Pharmocology

<!-- PAGE=? -->
Resistant to NDMR, avoid Sux

<!-- PAGE=? -->
Opioid tolerant

<!-- PAGE=? -->
STP - tolerant

<!-- PAGE=? -->
Infection, Sepsis

<!-- PAGE=? -->
Temperature Instability

<!-- PAGE=? -->
Multisystem Morbidity:

<!-- PAGE=? -->
Airway -

<!-- PAGE=? -->
potentially difficult

<!-- PAGE=? -->
need to secure early,

<!-- PAGE=? -->
Cardiovascular -

<!-- PAGE=? -->
then septic/distributive shock

<!-- PAGE=? -->
hypovolemia, myocardial depression,

<!-- PAGE=? -->
difficult IV, monitor access

<!-- PAGE=? -->
inhalation injury, CO

<!-- PAGE=? -->
Respiratory -

<!-- PAGE=? -->
ARDS,

<!-- PAGE=? -->
Renal-

<!-- PAGE=? -->
BOOP, chest wall restriction

<!-- PAGE=? -->
pre-renal failure,

<!-- PAGE=? -->
Endo -

<!-- PAGE=? -->
rhabdo

<!-- PAGE=? -->
hypermetabolic state (VCO2, VO2),

<!-- PAGE=? -->
impaired thermoregulation

<!-- PAGE=? -->
hyperglycemia,

<!-- PAGE=? -->
Heme -

<!-- PAGE=? -->
anemia

<!-- PAGE=? -->
DIC, thrombocytopenia,

<!-- PAGE=? -->
ID - Sepsis/MOF

<!-- PAGE=? -->
ulceration,

<!-- PAGE=? -->
GI -

<!-- PAGE=? -->
ileus, bacterial translocation

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Burn Resuscitation

<!-- PAGE=? -->
Estimate %BSA involved - rule of nines (adults), pt's palm = 1%BSA

<!-- PAGE=? -->
Major burn - >10% full thickness, > 25% partial thickness, face/hands/perineum, inhalational/chemical/electrical, serious co-morbid disease, <10, >50

<!-- PAGE=? -->
Parkland formula - crystalloid 4 mL/kg/%BSA burned, 1/2 in first 8 hours post-burn, 1/2 over next 16 hours (based on time of injury, not time of presentation)

<!-- PAGE=? -->
do not apply cold water/compress: causes hypothermia

<!-- PAGE=? -->
antibiotics are not indicated

<!-- PAGE=? -->
-CO poisoning.: <20% min symptoms, 20-30: headache.nausea, 30-40: confusion, 40-60 coma, >60- death

<!-- PAGE=? -->
-elevate HOB to decrease swelling

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
¾ Hb, Ht, Lytes, Crea

<!-- PAGE=? -->
¾ ABG, CXR, COHb level

<!-- PAGE=? -->
¾ ECG

<!-- PAGE=? -->
¾ Myoglobinuria, Myoglobinemia

<!-- PAGE=? -->
Electrical:

<!-- PAGE=? -->
-immediately: temporary paralysis, unconsciousness, arterial spasm

<!-- PAGE=? -->
-minimal external signs, but destruction of internal tissues, coagulation abnormalities (hemolysis, thrombosis) -commonly associated with fractures (muscles contraction or fall)

<!-- PAGE=? -->
poor conductors of electricity (bone) generate heat - damage to muscle

<!-- PAGE=? -->
-Vfib or other arrhythmias common

<!-- PAGE=? -->
-cerebral hemorrhage, neuropathy

<!-- PAGE=? -->
-rhabdomyalasis, compartment syndrome

<!-- PAGE=? -->
Chemical:

<!-- PAGE=? -->
-30min decontamination

<!-- PAGE=? -->
-digestive tract perforation

<!-- PAGE=? -->
-lyte abnormalities

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
-change 0.8 mg/dL for every 1 g/dL in albumin

<!-- PAGE=? -->
Hyper:

<!-- PAGE=? -->
>10.5 mEq/L (Cai  >4.8 mg/dL)

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Arrythmia

<!-- PAGE=? -->
DDx: (

<!-- PAGE=? -->
C-H-I-M-P-S)

<!-- PAGE=? -->
Cancer

<!-- PAGE=? -->
-bone invasion (breast)

<!-- PAGE=? -->
-pth like (ss lung),

<!-- PAGE=? -->
Hyperthyroidism

<!-- PAGE=? -->
Iatrogenic

<!-- PAGE=? -->
Multiple myeloma

<!-- PAGE=? -->
hyperParathyroidism (prim & tert)

<!-- PAGE=? -->
Sarcoid

<!-- PAGE=? -->
-depression, weakness, fatigue, confusion, hallucinations, disorientation, hypotonicity, seizures, and coma -dysphagia, constipation, peptic ulcers, and pancreatitis -diuresis can cause dehydration, loss of sodium, potassium, magnesium

<!-- PAGE=? -->
-Contractility increase until the calcium level reaches 15 mg/dL, then decreases

<!-- PAGE=? -->
-Automaticity is decreased and ventricular systole is shortened.

<!-- PAGE=? -->
-QT interval typically shortens,  PR and QRS intervals are prolonged

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
Saline hydration 100-300 cc/hr

<!-- PAGE=? -->
o May be 5-10L dehydrated

<!-- PAGE=? -->
o Need hydration in order to expel calcium from PCT

<!-- PAGE=? -->
Lasix 0.5 - 1.0 mg/kg Q4H

<!-- PAGE=? -->
Calcium

<!-- PAGE=? -->
Bisphosphonates: Pamidronate 50 mg IV over 24 hours

<!-- PAGE=? -->
Glucocorticoids: Hydrocortisone 100 mg IV Q8H

<!-- PAGE=? -->
Mitromycin

<!-- PAGE=? -->
Calcitonin 100-200 U IV/SC Q6H

<!-- PAGE=? -->
o 25 mcg/kg in 1 litre NS over 3 hours

<!-- PAGE=? -->
o Peak effect in 24hrs

<!-- PAGE=? -->
Chelator: Phosphate - IV K/Na PO4

<!-- PAGE=? -->
Dialysis

<!-- PAGE=? -->
Hypo:

<!-- PAGE=? -->
-<8.5 mg/dL (Cai <4.2 mg/dL)

<!-- PAGE=? -->
-toxic shock syndrome, abnormalities in Mg, after thyroid surgery, tumor lysis syndrome

<!-- PAGE=? -->
-paresthesias, muscle cramps, carpopedal spasm, stridor, tetany, and seizures, hyperreflexia and positive Chvostek and Trousseau signs -decreased myocardial contractility and heart failure

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
-10cc x 10%calcium gluconate, = 93mg of elemental calcium IV over 10 minutes, then infusion

<!-- PAGE=? -->
-5cc x 10% calcium chloride = 136.5 mg of elemental calcium over 10 minutes, then infusion

<!-- PAGE=? -->
-Measure serum calcium every 4 to 6 hours. Correct abnormalities in magnesium, potassium, and pH simultaneously

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Mass

<!-- PAGE=? -->
Obstructive pneumonia

<!-- PAGE=? -->
Compression of vessel

<!-- PAGE=? -->
Compressions of nerve

<!-- PAGE=? -->
Compression of airway/duct/organ

<!-- PAGE=? -->
Metabolic - paraneoplastic

<!-- PAGE=? -->
Mets

<!-- PAGE=? -->
Malnutrition - anemia

<!-- PAGE=? -->
Meds - chemo

<!-- PAGE=? -->
Tumor Lysis Syndrome

<!-- PAGE=? -->
Hyperuricemia → ARF

<!-- PAGE=? -->
Hyperkalemia

<!-- PAGE=? -->
Hyperphosphotemia → hypocalcemia

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
Fluids

<!-- PAGE=? -->
2-3 x maintenance requirements → U/O 2-3 ml/kg/hr

<!-- PAGE=? -->
NaHCO3 (urine pH > 7.0) if ↑ uric acid level

<!-- PAGE=? -->
Allopurinol

<!-- PAGE=? -->
600 mg/day PO or IV

<!-- PAGE=? -->
Rasburicase (urate oxidase)

<!-- PAGE=? -->
0.2 mg/kg

<!-- PAGE=? -->
Calcium

<!-- PAGE=? -->
CaCl (13.5 mEq / gram) → 10-30 mg/kg

<!-- PAGE=? -->
Ca Gluc (4.5 mEq / gram) → 50 mg/kg

<!-- PAGE=? -->
Cancer

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Carbon Monoxide Poisoning

<!-- PAGE=? -->
Normal CO = 1-3% (Smoker CO < 10%)

<!-- PAGE=? -->
Carboxyhemoglobin has 200 x affinity for O2 as normal Hgb

<!-- PAGE=? -->
<20% min symptoms, 20-30: headache.nausea, 30-40: confusion, 40-60 coma, >60- death

<!-- PAGE=? -->
t½ =  4 hours (FiO2 = 21%)

<!-- PAGE=? -->
t½ =  40 minutes (FiO2 = 100%)

<!-- PAGE=? -->
t½ =  15 minutes (FiO2 = hyperbaric)

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Supportive, hyperventilate 100% O2, +/- hyperbaric oxygen

<!-- PAGE=? -->
Contraindications to Hyperbaric Therapy

<!-- PAGE=? -->
Ongoing resuscitation

<!-- PAGE=? -->
Emphysematous people with blebs

<!-- PAGE=? -->
Hemodynamically unstable

<!-- PAGE=? -->
Indications for hyperbaric therapy

<!-- PAGE=? -->
CO > 40%

<!-- PAGE=? -->
CO > 20% & IHD or > 50 years old

<!-- PAGE=? -->
CO > 15% & pregnant

<!-- PAGE=? -->
Coma

<!-- PAGE=? -->
Signs of ischemia or arrhythmia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Endocrine active GI tumor

<!-- PAGE=? -->
Histamine (hypotension)

<!-- PAGE=? -->
Serotonin (hypertension & bronchospasm)

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
Valvular heart disease (TR/PS)

<!-- PAGE=? -->
Unpredictable Hemodynamics ( ↓ / ↑ BP)

<!-- PAGE=? -->
Pharmacology:

<!-- PAGE=? -->
Avoid histamine release

<!-- PAGE=? -->
Avoid catecholamines

<!-- PAGE=? -->
Optimization → Octreotide, Benedryl, steroids

<!-- PAGE=? -->
General

<!-- PAGE=? -->
Tumors arise from enterochromaffin tissue

<!-- PAGE=? -->
o 75% GI (appendix, ileum, rectum, gastric)

<!-- PAGE=? -->
o 20% Lung/bronchial

<!-- PAGE=? -->
secrete serotonin (5-HIAA), histamine, prostoglandin, kallikrien, corticotropin

<!-- PAGE=? -->
carcinoid syndrome ⇒ lung tumor or liver metastases

<!-- PAGE=? -->
Carcinoid Syndrome

<!-- PAGE=? -->
5-35% patients

<!-- PAGE=? -->
flushing

<!-- PAGE=? -->
diarrhea, abdominal pain

<!-- PAGE=? -->
hypo/hypertension

<!-- PAGE=? -->
bronchspasm

<!-- PAGE=? -->
Carcinoid Tumors

<!-- PAGE=? -->
hyperglycemia

<!-- PAGE=? -->
40% cardiac involvement

<!-- PAGE=? -->
Right heart failure

<!-- PAGE=? -->
o TR ± PS

<!-- PAGE=? -->
Treatment & Anesthetic management

<!-- PAGE=? -->
Octreotide

<!-- PAGE=? -->
o 50-500 mcg SC Q8H

<!-- PAGE=? -->
o 100 mcg/hr IV

<!-- PAGE=? -->
o 100-200 mcg IV bolus

<!-- PAGE=? -->
Histamine (H1)antagonists

<!-- PAGE=? -->
o 0.5 mg/kg IV diphenhydramine

<!-- PAGE=? -->
Steroids

<!-- PAGE=? -->
o 100 mg hydrocortisone IV

<!-- PAGE=? -->
Avoid histamine releasing drugs

<!-- PAGE=? -->
o Morphine, meperidine

<!-- PAGE=? -->
o Atracuriumn, mivacurium, pancuronium

<!-- PAGE=? -->
o STP

<!-- PAGE=? -->
Catecholamines may increase the release of vasoactive substances

<!-- PAGE=? -->
o Epi, norepi, dopamine, isoprot have all been reported to cause carcinoid crisis

<!-- PAGE=? -->
o Use minimal doses & titrate slowly

<!-- PAGE=? -->
Histamine Receptors H1

<!-- PAGE=? -->
coronary vasoconstriction

<!-- PAGE=? -->
bronchoconstriction

<!-- PAGE=? -->
vasodilation

<!-- PAGE=? -->
inotropism

<!-- PAGE=? -->
chronotropism

<!-- PAGE=? -->
dromotropism

<!-- PAGE=? -->
H2

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Supply

<!-- PAGE=? -->
O2 Content

<!-- PAGE=? -->
o pO2 K FIO2, Ve

<!-- PAGE=? -->
o SpO2 K V/Q

<!-- PAGE=? -->
o Hg K

<!-- PAGE=? -->
Blood Delivery

<!-- PAGE=? -->
o CPP

<!-- PAGE=? -->
DBP K

<!-- PAGE=? -->
Diastole L HR

<!-- PAGE=? -->
LVEDP - optimize

<!-- PAGE=? -->
o Coronary VR - NTG

<!-- PAGE=? -->
ST change DDx:

<!-- PAGE=? -->
 Heart:

<!-- PAGE=? -->
-chronic changes

<!-- PAGE=? -->
-normal variant

<!-- PAGE=? -->
-contusion

<!-- PAGE=? -->
-pericarditis

<!-- PAGE=? -->
 Others:

<!-- PAGE=? -->
-artifact

<!-- PAGE=? -->
-electrolyte (K, Ca)

<!-- PAGE=? -->
-ICP, head injury

<!-- PAGE=? -->
-hypothermia

<!-- PAGE=? -->
-drugs - dig

<!-- PAGE=? -->
Cardiac Ischemia

<!-- PAGE=? -->
'need to assess peri-operative ischemia risk, and optimize cardiac O2 supply/demand'

<!-- PAGE=? -->
Demand (CO)

<!-- PAGE=? -->
HR

<!-- PAGE=? -->
SV

<!-- PAGE=? -->
o Preload - optimize

<!-- PAGE=? -->
o Contract - BBlock

<!-- PAGE=? -->
o After L

<!-- PAGE=? -->
Intra-op Mx:

<!-- PAGE=? -->
-Verify

<!-- PAGE=? -->
-MONA, NBAH

<!-- PAGE=? -->
-CPP more important than A/L reduction

<!-- PAGE=? -->
-if failing heart: fluid,  ionotropes, phenylephrine

<!-- PAGE=? -->
-TEE/PAC/Art

<!-- PAGE=? -->
-termination of surgery

<!-- PAGE=? -->
-ICU post op

<!-- PAGE=? -->
-ABG/lactate for perfusion

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cardiac Goals

<!-- PAGE=? -->
IHD - keep heart small to decr wall tension and incr perfusion pressure

<!-- PAGE=? -->
-SBE -minimize abrupt changes

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
CardioMyopathy

<!-- PAGE=? -->
Hypertrophic

<!-- PAGE=? -->
 HTN

<!-- PAGE=? -->
 chronic outflow obstruction

<!-- PAGE=? -->
Dilated

<!-- PAGE=? -->
 Ischemia

<!-- PAGE=? -->
 EtOH

<!-- PAGE=? -->
 Viral

<!-- PAGE=? -->
 valvular (vol overload with AR, MR)

<!-- PAGE=? -->
 Risks

<!-- PAGE=? -->
 Arrhythmias

<!-- PAGE=? -->
 CHF

<!-- PAGE=? -->
 pulmonary edema

<!-- PAGE=? -->
 MI

<!-- PAGE=? -->
 Hypotension

<!-- PAGE=? -->
 organ failure

<!-- PAGE=? -->
 CVA (embolic or ischemic)

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
 Tx underlying cause

<!-- PAGE=? -->
 CHF tx with ACEi's, digoxin, diuresis

<!-- PAGE=? -->
 Prevent cardiac thrombus with warfarin

<!-- PAGE=? -->
 Tx arrhythmias (medical, AICD)

<!-- PAGE=? -->
 May require cardiac transplantation

<!-- PAGE=? -->
 avoid volatiles and other cardiac depressants

<!-- PAGE=? -->
 careful fluid mangement guided by PA catheter

<!-- PAGE=? -->
HOCM

<!-- PAGE=? -->
-autosomal dominant - defect into mitochondrial metabolsim -septal hypertrophy, tachydysrythmias, VT, sudden death -LVOT obstruction, MR, ischemia -afib poorly tolerated: defib on -SBE

<!-- PAGE=? -->
Cardiac Transplant

<!-- PAGE=? -->
Denervated Heart

<!-- PAGE=? -->
Preload dependent

<!-- PAGE=? -->
Silent ischemia

<!-- PAGE=? -->
Direct acting vasopressors (glucagons, dopamine, isopreteronol)

<!-- PAGE=? -->
Immunosupressed

<!-- PAGE=? -->
Infection risk

<!-- PAGE=? -->
Anti-rejection medications

<!-- PAGE=? -->
heme / hepatic / renal

<!-- PAGE=? -->
Early CAD

<!-- PAGE=? -->
10% @ 1-year

<!-- PAGE=? -->
50% @ 5-years

<!-- PAGE=? -->
Rejection

<!-- PAGE=? -->
Acute vs chronic

<!-- PAGE=? -->
Fatigue, SOB, and dysrhthymias

<!-- PAGE=? -->
Conduction delays

<!-- PAGE=? -->
10% RBBB

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Carotid Endarterectomy

<!-- PAGE=? -->
CVA patient

<!-- PAGE=? -->
Frequent Coexisting disease

<!-- PAGE=? -->
DM

<!-- PAGE=? -->
CAD

<!-- PAGE=? -->
CRF

<!-- PAGE=? -->
Anti-plt agent

<!-- PAGE=? -->
Goal:

<!-- PAGE=? -->
Cerebral perfusion - Maintain/Monitor

<!-- PAGE=? -->
Hemodynamics - Control of Lability/Stress

<!-- PAGE=? -->
Cerebral Protection

<!-- PAGE=? -->
Poor Airway Access

<!-- PAGE=? -->
Post-operative concerns / Disposition

<!-- PAGE=? -->
Allow for rapid recovery and assessment

<!-- PAGE=? -->
Monitored Bed: IHD, HTN, Brady

<!-- PAGE=? -->
Greatest benefit > 70% stenosis, Marginal benefit > 60% stenosis

<!-- PAGE=? -->
Stroke risk

<!-- PAGE=? -->
o 1/4 intraoperative, 1/3 hemodynamic consequence

<!-- PAGE=? -->
o symptomatic pt - 6.5% stroke & death, asymptomatic pt - 2.3%

<!-- PAGE=? -->
o High risk patients

<!-- PAGE=? -->
 Urgent surgery

<!-- PAGE=? -->
 Left disease

<!-- PAGE=? -->
 Bilateral disease

<!-- PAGE=? -->
 CEA & CABG

<!-- PAGE=? -->
 Postoperative HTN (> 110 mmHg)

<!-- PAGE=? -->
Anesthetic management

<!-- PAGE=? -->
o Optimize brain perfusion, ↓ CMRO2

<!-- PAGE=? -->
o Minimize myocardial stress

<!-- PAGE=? -->
o Allow for rapid recovery and assessment

<!-- PAGE=? -->
o Avoid N20 because of air emboli

<!-- PAGE=? -->
o Cervical plexus block (C2-4) vs GA

<!-- PAGE=? -->
Monitoring (none have been shown to change stroke rates)

<!-- PAGE=? -->
o Arterial catheter

<!-- PAGE=? -->
o Awake patient

<!-- PAGE=? -->
o 16-lead EEG (gold standard)

<!-- PAGE=? -->
o SSEP: > 50% reduction of amplitude is significant for ischemia

<!-- PAGE=? -->
o Stump pressures

<!-- PAGE=? -->
 < 25 mmHg or > 50 mmHg are useful indicators of cerebral perfusion

<!-- PAGE=? -->
o TCD (MCA): Goal > 40% mean velocity compared to preclamp

<!-- PAGE=? -->
o None have been shown to change stroke rates

<!-- PAGE=? -->
Cerebral protection

<!-- PAGE=? -->
o Shunt (Embolization / Dissection)

<!-- PAGE=? -->
o Hypothermia: Not recommended, avoid hyperthermia

<!-- PAGE=? -->
o HTN - maintain normal/ ↑ BP

<!-- PAGE=? -->
o Glycemic control

<!-- PAGE=? -->
o Normocarbia - prevent 'steal'

<!-- PAGE=? -->
o Consider barbituate - (risks of ↓ BP and delayed emergence)

<!-- PAGE=? -->
Post-operative concerns

<!-- PAGE=? -->
o Bradycardia

<!-- PAGE=? -->
o HTN

<!-- PAGE=? -->
 20% incidence

<!-- PAGE=? -->
 orthostatic hypotension

<!-- PAGE=? -->
 2 o damaged baroreceptors

<!-- PAGE=? -->
o Hyperperfusion syndrome

<!-- PAGE=? -->
 > 100% ↑ CBF

<!-- PAGE=? -->
 cerebral edema

<!-- PAGE=? -->
 management → BP control

<!-- PAGE=? -->
o RLN injury - 2%

<!-- PAGE=? -->
o Hypoglossal nerve injury

<!-- PAGE=? -->
o Wound hematoma - 2%

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cyclosporin

<!-- PAGE=? -->
Nephrotoxicity

<!-- PAGE=? -->
Hypertension

<!-- PAGE=? -->
Hepatotoxicity

<!-- PAGE=? -->
Neurotoxicity - headaches, paresthesiaes, seizures

<!-- PAGE=? -->
Take 4-7 hrs preop for best absorption

<!-- PAGE=? -->
Hyperkalemia, Mg wasting

<!-- PAGE=? -->
Prednisone

<!-- PAGE=? -->
Hyperglycemia

<!-- PAGE=? -->
Infection, immunosuppression

<!-- PAGE=? -->
GI bleeding

<!-- PAGE=? -->
Bleomycin Toxicity

<!-- PAGE=? -->
High risk → exposure in last 2 months, DLCO decreases > 15% pre and post treatment, or concomitant radiation, CRF

<!-- PAGE=? -->
Steroids (15% hypersensitivity pneumonitis)

<!-- PAGE=? -->
Higher transfusion trigger

<!-- PAGE=? -->
FiO2 < 30 % (SpO2 90-92%)

<!-- PAGE=? -->
FK506

<!-- PAGE=? -->
Diabetes

<!-- PAGE=? -->
Renal failure

<!-- PAGE=? -->
Hypertension

<!-- PAGE=? -->
Chemotherapeutic Agents

<!-- PAGE=? -->
Azathioprine

<!-- PAGE=? -->
Bone marrow suppression

<!-- PAGE=? -->
Pancreatitis

<!-- PAGE=? -->
Cisplatinum

<!-- PAGE=? -->
Nephrotoxicity

<!-- PAGE=? -->
Peripheral neuropathy

<!-- PAGE=? -->
Hypomagnesemia

<!-- PAGE=? -->
Auditory complications

<!-- PAGE=? -->
Methotrexate

<!-- PAGE=? -->
Hepatotoxicity

<!-- PAGE=? -->
Pulmonary toxicity

<!-- PAGE=? -->
Immunouppression

<!-- PAGE=? -->
Cyclophosphomide

<!-- PAGE=? -->
Pulmonary toxicity - fibrosis

<!-- PAGE=? -->
Pericardial toxicity

<!-- PAGE=? -->
Hepatotoxicity

<!-- PAGE=? -->
Daunorubicin

<!-- PAGE=? -->
Cardiotoxicity

<!-- PAGE=? -->
o CHF < 3% if < 400 mg/m 2

<!-- PAGE=? -->
o CHF 18% if > 700 mg/m 2

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
HyperCapnia

<!-- PAGE=? -->
Incr Production

<!-- PAGE=? -->
-Intrinsic

<!-- PAGE=? -->
Shivering

<!-- PAGE=? -->
Hyperthermia

<!-- PAGE=? -->
Seizure

<!-- PAGE=? -->
Hyperthyroid

<!-- PAGE=? -->
MH

<!-- PAGE=? -->
Sepsis

<!-- PAGE=? -->
Pheo

<!-- PAGE=? -->
NMS

<!-- PAGE=? -->
-Extrinsic

<!-- PAGE=? -->
TPN

<!-- PAGE=? -->
Laparoscopy

<!-- PAGE=? -->
NaHCO2

<!-- PAGE=? -->
Tourniquet release

<!-- PAGE=? -->
Decr Elimination

<!-- PAGE=? -->
-Won't Breath (Central)

<!-- PAGE=? -->
Obese (OSA/Pickwikian)

<!-- PAGE=? -->
Hypothermic

<!-- PAGE=? -->
Sedation

<!-- PAGE=? -->
Residual anesthetic

<!-- PAGE=? -->
Systemic Opioids/Sedation

<!-- PAGE=? -->
Central Opioids

<!-- PAGE=? -->
-Can't Breath (Peripheral)

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
ALS, Post-polio, Cord injury

<!-- PAGE=? -->
NMBA

<!-- PAGE=? -->
Overdose

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Interaction (Abx, Mg)

<!-- PAGE=? -->
Altered pharmocodynamics

<!-- PAGE=? -->
Chest Wall

<!-- PAGE=? -->
Myesthenia, muscular dystrophy

<!-- PAGE=? -->
Pleura

<!-- PAGE=? -->
Airways

<!-- PAGE=? -->
bronchospasm

<!-- PAGE=? -->
External

<!-- PAGE=? -->
Splinting/Pain

<!-- PAGE=? -->
Distended abdo

<!-- PAGE=? -->
Tight dressing

<!-- PAGE=? -->
Rebreathing Circuit

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hypocapnia

<!-- PAGE=? -->
Decreased production

<!-- PAGE=? -->
-Hypothyroid

<!-- PAGE=? -->
-Hypothermia

<!-- PAGE=? -->
-Muscle relaxants

<!-- PAGE=? -->
-Tourniquet

<!-- PAGE=? -->
Decreased Delivery = Increased Dead Space

<!-- PAGE=? -->
-Decreased CO/BP

<!-- PAGE=? -->
-PE/FE

<!-- PAGE=? -->
-AFE

<!-- PAGE=? -->
-VAE

<!-- PAGE=? -->
Increased CO2 elimination

<!-- PAGE=? -->
-Hyperventilation

<!-- PAGE=? -->
Miscellaneous

<!-- PAGE=? -->
-High sampling rate

<!-- PAGE=? -->
-Circuit leakage

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Potential for other Substances

<!-- PAGE=? -->
Drug interaction

<!-- PAGE=? -->
Increased MAC

<!-- PAGE=? -->
Avoid sympathomemetics

<!-- PAGE=? -->
Avoid unopposed B-blockade

<!-- PAGE=? -->
Enhanced sympathetic activity

<!-- PAGE=? -->
↑ HR/BP/Temp

<!-- PAGE=? -->
Risk of vasospasm and ischemia

<!-- PAGE=? -->
(OB - increased risk of abruption and fetal malformations)

<!-- PAGE=? -->
General

<!-- PAGE=? -->
Blocks reuptake of presynsaptic of norepinephrine and dopamine

<!-- PAGE=? -->
Cocaine prolongs the action potential and QRS duration and impairs myocardial contractility.

<!-- PAGE=? -->
Cocaine

<!-- PAGE=? -->
Side Effects

<!-- PAGE=? -->
Vasospasm - ischemia

<!-- PAGE=? -->
Cardiac dysrhythmias

<!-- PAGE=? -->
o Prolonged WRS duration

<!-- PAGE=? -->
↑ HR/ BP/ Temp

<!-- PAGE=? -->
Platelet aggregation

<!-- PAGE=? -->
Seizures, CVA

<!-- PAGE=? -->
OB - abruptio placentae & fetal malformations

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Benzodiazepines

<!-- PAGE=? -->
Phentolamine

<!-- PAGE=? -->
Nitroglycerine

<!-- PAGE=? -->
Labetolol: not good : blocks the peripheral signs of druginduced sympathetic excess without affecting central nervous system effects such as seizures.

<!-- PAGE=? -->
Esmolol

<!-- PAGE=? -->
Sodium bicarbonate 1 to 2 mEq/kg

<!-- PAGE=? -->
Active cooling

<!-- PAGE=? -->
For ventricular arrhythmia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Congenital Heart Dz

<!-- PAGE=? -->
?Obstructive

<!-- PAGE=? -->
?Shunting

<!-- PAGE=? -->
Bubble-free technique

<!-- PAGE=? -->
Control PVR and SVR ratio

<!-- PAGE=? -->
Chronic Cyanosis vs RV Overload

<!-- PAGE=? -->
SBE Prophylaxis

<!-- PAGE=? -->
KETAMINE - GOOD for shunts, keeps contract, svr/PVR the same

<!-- PAGE=? -->
Fontan:

<!-- PAGE=? -->
Connects venous directly to PA for single ventricle

<!-- PAGE=? -->
ToF

<!-- PAGE=? -->
RVOT obstruction (Dynamic infindibular spasm)

<!-- PAGE=? -->
Overriding aorta

<!-- PAGE=? -->
VSD (membranous)

<!-- PAGE=? -->
RVH

<!-- PAGE=? -->
'Tet spells' - R to L shunt

<!-- PAGE=? -->
Incr SVR/Avoid hypotension

<!-- PAGE=? -->
} Fluid bolus

<!-- PAGE=? -->
} Abdominal compression

<!-- PAGE=? -->
} Phenylephrine (5 mcg/kg)/Ketamine

<!-- PAGE=? -->
Decr PVR

<!-- PAGE=? -->
} NaHCO3

<!-- PAGE=? -->
} O2

<!-- PAGE=? -->
Decr RVOT spasm

<!-- PAGE=? -->
} Avoid SNS/Propranolol (10 mcg/kg)

<!-- PAGE=? -->
} Deepen anesthetic

<!-- PAGE=? -->
} Opioids

<!-- PAGE=? -->
CXR - 'boot-shaped' heart

<!-- PAGE=? -->
ECG - RAD, RVH

<!-- PAGE=? -->
ABG - PaO2 < 50, normal pH & PaCO2

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Palliative (increase PA flow)

<!-- PAGE=? -->
o Blalock-Taussig - sublcavian to PA shunt

<!-- PAGE=? -->
o Long-term: Pulmonary HTN, LV volume overload

<!-- PAGE=? -->
Corrective treatment involves

<!-- PAGE=? -->
o Patch closure of VSD

<!-- PAGE=? -->
o Pulmonary valvulotomy

<!-- PAGE=? -->
o Enlargement of RVOT

<!-- PAGE=? -->
o Shunting through foramen ovale post-repair functions as a 'pop-off' valve, if RV can't function at the same efficiency as the LV.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
PDA:

<!-- PAGE=? -->
 45% in preterm

<!-- PAGE=? -->
 incr pulm blood flow, CHF

<!-- PAGE=? -->
 failure to thrice, poor feeding, CHF

<!-- PAGE=? -->
 bounding/palmar pulses, low DBP, continous machinery murmur

<!-- PAGE=? -->
 check preductal and post ductal sat

<!-- PAGE=? -->
 ECHO - severity of shunt

<!-- PAGE=? -->
 Fluid restrict, diuretics

<!-- PAGE=? -->
 Indomethacin 0.1mg/kg IV Q12H x 3

<!-- PAGE=? -->
 Surgical correction

<!-- PAGE=? -->
ASD:

<!-- PAGE=? -->
75% ostium secundum septal defect

<!-- PAGE=? -->
Ostium primum: altitude, Down's, AV Canal

<!-- PAGE=? -->
< 0.5 cm: no hemodynamic sequelae

<!-- PAGE=? -->
> 2.0 cm: L → R shunt

<!-- PAGE=? -->
Closure if Qp:Qs 1.5:1, >25mm

<!-- PAGE=? -->
Signs / symptoms

<!-- PAGE=? -->
} CHF - dyspnea

<!-- PAGE=? -->
} SVT / AFIB

<!-- PAGE=? -->
} Paradox Air Emb / CVA

<!-- PAGE=? -->
} Fixed split S2, Loud S1

<!-- PAGE=? -->
} Crescendo-Decrescendo murmur

<!-- PAGE=? -->
} RHF -HSM, edema, JVP

<!-- PAGE=? -->
LFTs, RFT

<!-- PAGE=? -->
ECG: RAD, RBBB, AF

<!-- PAGE=? -->
Echo/Bubble Test

<!-- PAGE=? -->
CXR: Prominent PA's

<!-- PAGE=? -->
Mx:

<!-- PAGE=? -->
} Digoxin

<!-- PAGE=? -->
} PPV

<!-- PAGE=? -->
} Diuretic

<!-- PAGE=? -->
} Antiarrythmics

<!-- PAGE=? -->
} Epidural: LRTS

<!-- PAGE=? -->
} Avoid N20

<!-- PAGE=? -->
Eisenmenger:

<!-- PAGE=? -->
Reversal of L → right shunt as a result of ↑ PVR ≥ SVR

<!-- PAGE=? -->
50% related to untreated VSD, 10% related to untreated ASD

<!-- PAGE=? -->
Signs and Symptoms

<!-- PAGE=? -->
} Cyanosis

<!-- PAGE=? -->
} ↓ functional capacity

<!-- PAGE=? -->
} palpitations / AF

<!-- PAGE=? -->
} erythrocytosis / hyperviscosity syndrome

<!-- PAGE=? -->
} PAE / brain abscess

<!-- PAGE=? -->
ECG :PHTN & RHF

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
} Phlebotomy (Hct > 65%)

<!-- PAGE=? -->
} Discourage pregnancy (30% mortality)

<!-- PAGE=? -->
} Heart-lung transplant

<!-- PAGE=? -->
Hemodynamic goals

<!-- PAGE=? -->
} Aggressive treatment of hypovolemia: prevention of PAE

<!-- PAGE=? -->
} Laparoscopy contraindicated

<!-- PAGE=? -->
} PPV is deleterious: early extubation

<!-- PAGE=? -->
} Avoid neuroaxial analgesia/anesthesia: ↓ SVR

<!-- PAGE=? -->
} OB

<!-- PAGE=? -->
 Epidural > GA

<!-- PAGE=? -->
 LOR → saline

<!-- PAGE=? -->
 Coagulopathy of congenital heart disease

<!-- PAGE=? -->
DIC / fibrinolysis / platelet dysfunction

<!-- PAGE=? -->
CBC, INR/PTT, fibrinogen, D-Dimer, TEG

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
COPD

<!-- PAGE=? -->
'COPD is a chronic lung disease characterized by airflow obstruction and V/Q mismatch due to chronic bronchitis or tissue destruction'

<!-- PAGE=? -->
Airway reactivity

<!-- PAGE=? -->
Bullous disease

<!-- PAGE=? -->
PHTN / cor pulmonale

<!-- PAGE=? -->
Meds: Steroid

<!-- PAGE=? -->
Need for

<!-- PAGE=? -->
Pulmonary assessment

<!-- PAGE=? -->
CXR

<!-- PAGE=? -->
PFT's

<!-- PAGE=? -->
ABG

<!-- PAGE=? -->
FEV1 >50%

<!-- PAGE=? -->
DLCO >50%

<!-- PAGE=? -->
Pulmonary optimization

<!-- PAGE=? -->
Post-op

<!-- PAGE=? -->
Analgesia

<!-- PAGE=? -->
Ventilation

<!-- PAGE=? -->
Bronchial Hygeine

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Chronic bronchitis

<!-- PAGE=? -->
{ Productive cough for > 3months over 2 consecutive years

<!-- PAGE=? -->
Emphysema

<!-- PAGE=? -->
{ ↑ air space destruction of lung parenchyma, loss of elastic tissue

<!-- PAGE=? -->
Epidemiology

<!-- PAGE=? -->
{ Smoking

<!-- PAGE=? -->
{ Alpha1 - antitrypsin deficiency

<!-- PAGE=? -->
Clinical

<!-- PAGE=? -->
{ Cough

<!-- PAGE=? -->
{ Wheezing

<!-- PAGE=? -->
{ Dyspnea

<!-- PAGE=? -->
{ Fatigue

<!-- PAGE=? -->
{ Sputum

<!-- PAGE=? -->
PFT's

<!-- PAGE=? -->
{ ↓ FEV1

<!-- PAGE=? -->
{ ↓ FEV1/FVC

<!-- PAGE=? -->
{ ↑ RV & FRC/TLC

<!-- PAGE=? -->
CXR

<!-- PAGE=? -->
{ Hyperlucency

<!-- PAGE=? -->
{ Flat diaphragms

<!-- PAGE=? -->
{ bulla

<!-- PAGE=? -->
Risk-reduction

<!-- PAGE=? -->
{ Smoking cessation > 8 weeks

<!-- PAGE=? -->
{ Optimized reversible airflow obstruction

<!-- PAGE=? -->
{ Minimally invasive surgery

<!-- PAGE=? -->
{ Consider regional / neuroaxial analgesia

<!-- PAGE=? -->
{ Pysitherapy/Inentive Spirometry

<!-- PAGE=? -->
{ Resp consult

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
{ Pre-op

<!-- PAGE=? -->
⇒ Smoking cessation

<!-- PAGE=? -->
⇒ Supplemental O2 (PaO2 < 55)

<!-- PAGE=? -->
⇒ Beta-agonists

<!-- PAGE=? -->
⇒ Anticholinergics

<!-- PAGE=? -->
⇒ Inhaled/PO corticosteroids

<!-- PAGE=? -->
⇒ Antibiotics

<!-- PAGE=? -->
⇒ Vaccinations (pneumovax)

<!-- PAGE=? -->
{ Intrao-op

<!-- PAGE=? -->
⇒ Avoid GA/ETT

<!-- PAGE=? -->
⇒ Avoid high Paw

<!-- PAGE=? -->
{ Disposition

<!-- PAGE=? -->
⇒ FEV1 < 30% = post-op ventilation (ICU)

<!-- PAGE=? -->
⇒ Chest physiotherapy

<!-- PAGE=? -->
⇒ Tracheal Toilet

<!-- PAGE=? -->
⇒ Lung expansion maneuvers

<!-- PAGE=? -->
⇒ Maximize analgesia

<!-- PAGE=? -->
Laparoscopy Conflict

<!-- PAGE=? -->
{ Requires GA/ETT + Incr Ventilation

<!-- PAGE=? -->
⇒ Risk of Autopeep

<!-- PAGE=? -->
⇒ Incr Paw

<!-- PAGE=? -->
⇒ Incr pCO2

<!-- PAGE=? -->
⇒ Incr Pulm HTN - worsens RHF

<!-- PAGE=? -->
{ Better Post-op Pain Control

<!-- PAGE=? -->
 Plan for Laparoscope with low pressure, ready to abandon

<!-- PAGE=? -->
 Post-op epidural

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Varying Degrees of mental handicap

<!-- PAGE=? -->
Uncooperative

<!-- PAGE=? -->
Slow emergence

<!-- PAGE=? -->
GERD

<!-- PAGE=? -->
Respiratory complications from chronic aspiration

<!-- PAGE=? -->
asthma

<!-- PAGE=? -->
Muscle spasticity & contractures

<!-- PAGE=? -->
Seizure disorder

<!-- PAGE=? -->
Cerebral Palsy

<!-- PAGE=? -->
'A non-progressive disorder associated with motor abnormalities resulting from neurologic insult in early development.'

<!-- PAGE=? -->
most commonly spastic quadraplegia

<!-- PAGE=? -->
1/3 of patients have a seizure disorder

<!-- PAGE=? -->
Ö phenytoin

<!-- PAGE=? -->
 gingival hyperplasia

<!-- PAGE=? -->
 megaloblastic anemia

<!-- PAGE=? -->
Ö Phenobarbital

<!-- PAGE=? -->
 C-P450 induction

<!-- PAGE=? -->
cognitive impairment & speech defects

<!-- PAGE=? -->
skeletal muscle spasticity contractures and fixed deformities of numerous joints

<!-- PAGE=? -->
1-3 / 1000 live births

<!-- PAGE=? -->
common procedures: orthopedic osteotomies, tendon release

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Crush Injury

<!-- PAGE=? -->
Trauma patient

<!-- PAGE=? -->
Rhabdomyolysis (myoglobinuria) and acute renal failure

<!-- PAGE=? -->
Hyperkalemia and hypocalcemia

<!-- PAGE=? -->
Compartment syndrome and neurovascular injury to involved limb

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Acidosis

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
Aggressive fluid resuscitation, foley catheter, urine for myoglobin

<!-- PAGE=? -->
Electrolytes, BUN and Cr to r/o renal failure and hyperkalemia

<!-- PAGE=? -->
Avoid Sux

<!-- PAGE=? -->
Measures to reduce incidence renal failure include

<!-- PAGE=? -->
Good Renal Perfusion

<!-- PAGE=? -->
Mannitol (controversial if patient is hemodynamically unstable but good because free radical scavenger as well as osmotic diuretic)

<!-- PAGE=? -->
Alkalinazation urine (1 amp HCO3 in 1L ½NS)-reduces ppt of myoglobin in the renal tubules (goal urine with pH>6.5)

<!-- PAGE=? -->
Treat hypocalcemia (due to calcium deposition in injured muscle)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
FACTORS INVOLVED IN MYOCARDIAL OXYGEN SUPPLY AND DEMAND

<!-- PAGE=? -->
MYOCARDIAL OXYGEN CONSUMPTION

<!-- PAGE=? -->
Heart rate

<!-- PAGE=? -->
Contractile state

<!-- PAGE=? -->
Myocardial wall tension

<!-- PAGE=? -->
Arterial oxygen content

<!-- PAGE=? -->
Basal oxygen requirements

<!-- PAGE=? -->
Oxygen cost of muscle fiber shortening

<!-- PAGE=? -->
Oxygen cost of electrical activation

<!-- PAGE=? -->
MYOCARDIAL OXYGEN SUPPLY  (DO2) = Q x Content = (Diastolic Time x DBP-LVEDP) x (Hg x SpO2 x 1.38)

<!-- PAGE=? -->
Aortic diastolic pressure at coronary ostea Left ventricular end-diastolic pressure Coronary artery diameter and tone Arterial oxygen content Heart Rate - (diastolic time)

<!-- PAGE=? -->
HEMODYNAMIC VARIABLES: CALCULATIONS AND NORMAL VALUES

<!-- PAGE=? -->
Variable

<!-- PAGE=? -->
Calculation

<!-- PAGE=? -->
Normal Values

<!-- PAGE=? -->
Cardiac index (CI)

<!-- PAGE=? -->
CO/BSA

<!-- PAGE=? -->
2.5-4.0 l•min-1•m-2

<!-- PAGE=? -->
Stroke volume (SV)

<!-- PAGE=? -->
CO/HR

<!-- PAGE=? -->
60-90 ml•beat-1

<!-- PAGE=? -->
Stroke index (SI)

<!-- PAGE=? -->
SV/BSA

<!-- PAGE=? -->
40-60 ml•beat-1•m-2

<!-- PAGE=? -->
Mean arterial pressure

<!-- PAGE=? -->
Diastolic blood pressure

<!-- PAGE=? -->
80-120 mm Hg

<!-- PAGE=? -->
(MAP)

<!-- PAGE=? -->
+ one third pulse pressure

<!-- PAGE=? -->
Systemic vascular

<!-- PAGE=? -->
MAP - CVP/CO ´ 79.9

<!-- PAGE=? -->
1200-1500 dyne•cm•s-5

<!-- PAGE=? -->
resistance (SVR)

<!-- PAGE=? -->
Pulmonary vascular

<!-- PAGE=? -->
PAP - PWP/CO ´ 79.9

<!-- PAGE=? -->
100-300 dyne•cm•s-5

<!-- PAGE=? -->
resistance (PVR)

<!-- PAGE=? -->
Right ventricular stroke

<!-- PAGE=? -->
0.0136 (PAP - CVP)SI

<!-- PAGE=? -->
5-9 g•m•beat-1•m-2

<!-- PAGE=? -->
work index (RVSWI)

<!-- PAGE=? -->
Left ventricular stroke

<!-- PAGE=? -->
0.136 (MAP - PWP)SI

<!-- PAGE=? -->
45-60 g•m•beat-1•m-2

<!-- PAGE=? -->
work index (LVSWI)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
NORMAL CATHETERIZATION DATA

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cyanide Toxicity

<!-- PAGE=? -->
Cyanide binds to ferric containing cytochrome oxidase found in mitochondria

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
Produces tissue anoxia and anaerobic metabolism

<!-- PAGE=? -->
Lactic acidosis

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
} Headache

<!-- PAGE=? -->
} Disorientation

<!-- PAGE=? -->
} Lethargy

<!-- PAGE=? -->
} Seizure

<!-- PAGE=? -->
} Coma

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
} HTN → hypotension/tachycardia → bradycardia

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
} 'Burnt almond' breath

<!-- PAGE=? -->
} Tachypnea → apnea

<!-- PAGE=? -->
} ↑ secretions

<!-- PAGE=? -->
} ↑ SvO2

<!-- PAGE=? -->
} ↓ VO2

<!-- PAGE=? -->
Metabolic acidosis

<!-- PAGE=? -->
Sodium Nitrite

<!-- PAGE=? -->
300 mg (10 ml of 3% solution)

<!-- PAGE=? -->
converts ferrous to ferric form (i.e. creates a methemoglobinemia)

<!-- PAGE=? -->
goal 30% MetHgb

<!-- PAGE=? -->
Sodium Thiosulfate

<!-- PAGE=? -->
12.5 grams (50 ml of 25% solution)

<!-- PAGE=? -->
sulfur donor → converts cyanide to thiosulfate which is excreted by the kidney

<!-- PAGE=? -->
sodium cyanate

<!-- PAGE=? -->
Hydroxocobalamin (B12a)

<!-- PAGE=? -->
4 grams

<!-- PAGE=? -->
exchange hydroxy- group for cyanide to form Cyanocobalamin (B12)

<!-- PAGE=? -->
*** In the event of life threatening methemoglobinemia consider exchange transfusion or methylene blue ***

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cystic Fibrosis/Bronchiectasis

<!-- PAGE=? -->
'A disease of the exocrine glands affecting the lungs and pancreas, leading to severe Respiratory, Cardiac and Pancreatic complications' 'A chronic respiratory disease characterized by irreversible dilation of bronchi with inflammation, purulent secretion, hemoptysis'

<!-- PAGE=? -->
1. Respiratory:

<!-- PAGE=? -->
Chronic sinusitis, Bronchiectasis, & Recurrent Infection

<!-- PAGE=? -->
Airflow obstruction & Bronchospasm

<!-- PAGE=? -->
Pulm Fibrosis, RLD

<!-- PAGE=? -->
V/Q mismatch - hypoxia/atelectasis

<!-- PAGE=? -->
CV

<!-- PAGE=? -->
PHTN/Co pulmonale

<!-- PAGE=? -->
(GI)

<!-- PAGE=? -->
Pancreatic insufficiency

<!-- PAGE=? -->
o DM

<!-- PAGE=? -->
o Malabsorption of Vit K dependent vitamins ( ½ INR)

<!-- PAGE=? -->
Malnutrition

<!-- PAGE=? -->
Hepatobiliary disease: obstructive, fibrotic

<!-- PAGE=? -->
Medications

<!-- PAGE=? -->
Steroids

<!-- PAGE=? -->
Immunomodulators

<!-- PAGE=? -->
Anesthetic Implications / Goals

<!-- PAGE=? -->
Optimize pre-op

<!-- PAGE=? -->
Avoid GA if possible, avoid high block

<!-- PAGE=? -->
High FiO2, no N2O, humidified gases, bronchodilators

<!-- PAGE=? -->
Minimize Paw, optimize PEEP, long I:E

<!-- PAGE=? -->
Extubation following toilet, reinflation of lungs (sustained breaths)

<!-- PAGE=? -->
Postop bronchodilators, chest physio, O2

<!-- PAGE=? -->
Autosomal recessive disorder

<!-- PAGE=? -->
Decreased chloride transport leads to dehydrated viscous secretions

<!-- PAGE=? -->
Hx:

<!-- PAGE=? -->
o Last exacerbation

<!-- PAGE=? -->
o Increased freq/duration of cough

<!-- PAGE=? -->
o Increased sputum or change in color

<!-- PAGE=? -->
o Increased dyspnea, decreased exercise tolerance

<!-- PAGE=? -->
O/E:

<!-- PAGE=? -->
o Wt, fever, SpO2, RR

<!-- PAGE=? -->
o clubbing, accessory muscle use, intercostals retractions, wheeze

<!-- PAGE=? -->
o Right heart

<!-- PAGE=? -->
Preop

<!-- PAGE=? -->
o CBC, Coags, LFTs, glucose, RFTs (abx)

<!-- PAGE=? -->
o EKG

<!-- PAGE=? -->
o PFTs, ABG

<!-- PAGE=? -->
o Echo(PHTN, RVH, RVF)

<!-- PAGE=? -->
o CXR, CT - ?subglottic stenosis (long intubation)

<!-- PAGE=? -->
Plan

<!-- PAGE=? -->
o Optimize pulmonary function -chest physio, rhDNase (pulmozyme)

<!-- PAGE=? -->
o Delay if in exacerbation

<!-- PAGE=? -->
o Resp consult

<!-- PAGE=? -->
o Control infection - antibiotics

<!-- PAGE=? -->
o Vit K prn

<!-- PAGE=? -->
o Treat bronchospasm - bronchodilators, steroids

<!-- PAGE=? -->
o Humidified air

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Structural:

<!-- PAGE=? -->
CVA

<!-- PAGE=? -->
o Embolic, Ischemic, Hemorrhagic

<!-- PAGE=? -->
Meettaboliiic D:

<!-- PAGE=? -->
Multi-organ failure - hepatic, renal, sepsis

<!-- PAGE=? -->
Electrolytes - Incr Ca/Mg, Decr Na/Ca

<!-- PAGE=? -->
Endocrine - thyroid, adrenal

<!-- PAGE=? -->
Toxins

<!-- PAGE=? -->
Temperature

<!-- PAGE=? -->
Acid/Base

<!-- PAGE=? -->
Bolus needed- dehydration

<!-- PAGE=? -->
O2/CO2

<!-- PAGE=? -->
Lactate

<!-- PAGE=? -->
Insulin - hyper/hypo

<!-- PAGE=? -->
Ischemia/ICP

<!-- PAGE=? -->
Infection - sepsis, intracranial

<!-- PAGE=? -->
Convulsions

<!-- PAGE=? -->
Drug Effect

<!-- PAGE=? -->
-anesthetic: volatile, benzo, opioid, induction, NMB -non-anesthetic: anti-depressant, clonidine, anti-cholin/H2, EtOH -overdose, residual, potentiation, withdrawl

<!-- PAGE=? -->
Resp Lytes

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
<33° has anesthetic effect, potentiates depressants

<!-- PAGE=? -->
<30° induces coma, fixed pupils, areflexia

<!-- PAGE=? -->
Delayed Emergence

<!-- PAGE=? -->
Mx:

<!-- PAGE=? -->
 Vital signs incl SpO2 and temp

<!-- PAGE=? -->
 ABC's

<!-- PAGE=? -->
 Neuro Exam (pupils, pain, corneal, gag, cough, reflexes, clonus, Babinski)

<!-- PAGE=? -->
 Test pt's degree of muscle relaxation

<!-- PAGE=? -->
 Ensure discontinuation of all anesthetic

<!-- PAGE=? -->
 DON'T:

<!-- PAGE=? -->
D50W IV at 1cc/kg (1 amp)

<!-- PAGE=? -->
Naloxone 0.04mg increments

<!-- PAGE=? -->
Flumazenil 0.2mg increments

<!-- PAGE=? -->
Neostigmine 0.07ug/kg

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
 Glucometer

<!-- PAGE=? -->
 ABGs

<!-- PAGE=? -->
 Lytes (Na, K), Ca, Mg, BUN, Crea, LFTs, Serum Osmolality, (TSH, steroid level)

<!-- PAGE=? -->
 Blood and urine toxicology

<!-- PAGE=? -->
 CT Head, EEG, Angiogram

<!-- PAGE=? -->
 ECG, ECHO

<!-- PAGE=? -->
 Neurology, neurosurgery, ICU

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Dental Surgery

<!-- PAGE=? -->
Pediatric/Non-coperative patient

<!-- PAGE=? -->
Nasal ETT

<!-- PAGE=? -->
Bloody airway

<!-- PAGE=? -->
Shared Airway

<!-- PAGE=? -->
SBE prophylaxis

<!-- PAGE=? -->
Potential difficult airway post-operatively

<!-- PAGE=? -->
Jaw wiring

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Diabetes Insipidus

<!-- PAGE=? -->
DDx Polyuria

<!-- PAGE=? -->
DI

<!-- PAGE=? -->
Hyperglycemia

<!-- PAGE=? -->
Fluid overload

<!-- PAGE=? -->
Mannitol / lasix

<!-- PAGE=? -->
High output ATN

<!-- PAGE=? -->
DDx Hypernatremia

<!-- PAGE=? -->
½ Na intake

<!-- PAGE=? -->
DI

<!-- PAGE=? -->
Cushing's

<!-- PAGE=? -->
Lithium toxicity

<!-- PAGE=? -->
Renal failure

<!-- PAGE=? -->
GI fluid loss

<!-- PAGE=? -->
Central DI (CDI)

<!-- PAGE=? -->
} Deficiency of ADH

<!-- PAGE=? -->
 Trauma

<!-- PAGE=? -->
 Hypoxia

<!-- PAGE=? -->
 Tumor

<!-- PAGE=? -->
 Anorexia

<!-- PAGE=? -->
 Sarcoidosis

<!-- PAGE=? -->
Nephrogenic DI (NDI)

<!-- PAGE=? -->
} Resistance to ADH

<!-- PAGE=? -->
 ↑ Ca

<!-- PAGE=? -->
 ↓ K

<!-- PAGE=? -->
 lithium, flouride

<!-- PAGE=? -->
 gentamycin, ampho B

<!-- PAGE=? -->
 SCD

<!-- PAGE=? -->
 Amyloidosis

<!-- PAGE=? -->
 Pregnancy

<!-- PAGE=? -->
 Obstructive uropathy

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
} Na > 155

<!-- PAGE=? -->
} Urine output > 300 ml/hr

<!-- PAGE=? -->
} Urine Osm < 300 mOsm/L

<!-- PAGE=? -->
} Urine SG < 1.010

<!-- PAGE=? -->
} Response to ADH → CDI otherwise NDI

<!-- PAGE=? -->
Water Deficit

<!-- PAGE=? -->
0.5 x weight (kg) x (Na-140)/140

<!-- PAGE=? -->
estimation → 1.5 litre for every 5 mEq > 140 mEq/L

<!-- PAGE=? -->
correct < 0.5 mEq/L/hour

<!-- PAGE=? -->
correct hypovolemia with NS

<!-- PAGE=? -->
correct Na with D5W or D5-0.45NSif ongoing losses

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Volume/Na correction

<!-- PAGE=? -->
NDI

<!-- PAGE=? -->
} Chloropropramide

<!-- PAGE=? -->
} Reversal of cause

<!-- PAGE=? -->
CDI

<!-- PAGE=? -->
} Thiazides

<!-- PAGE=? -->
} Vasopression

<!-- PAGE=? -->
 5 U SC Q6H

<!-- PAGE=? -->
 0.02 U/min

<!-- PAGE=? -->
} DDAVP 1-2 mcg SC BID

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Diabetes Mellitus

<!-- PAGE=? -->
'an endocrine disease of insulin insufficiency causing hyperglycemia and potentially associated with….'

<!-- PAGE=? -->
Co-existing diseases from macro/microvas.

<!-- PAGE=? -->
ASHD/PVD

<!-- PAGE=? -->
CRF

<!-- PAGE=? -->
Obesity

<!-- PAGE=? -->
Autonomic & peripheral neuropathy

<!-- PAGE=? -->
Difficult airway

<!-- PAGE=? -->
Perioperative glycemic control

<!-- PAGE=? -->
 Preop

<!-- PAGE=? -->
 Metaclopramide

<!-- PAGE=? -->
 Glucometer

<!-- PAGE=? -->
 ½ am insulin as N and hold PO hypoglycemics

<!-- PAGE=? -->
 Schedule surgery early in the day

<!-- PAGE=? -->
 Intraop

<!-- PAGE=? -->
 Good hemodynamic control

<!-- PAGE=? -->
 Hourly assays of blood glucose

<!-- PAGE=? -->
 Sliding scale or insulin infusion intraop

<!-- PAGE=? -->
 Postop

<!-- PAGE=? -->
 Glucometer Q1H-Q3H with insulin sliding scale or infusion

<!-- PAGE=? -->
Systems Review

<!-- PAGE=? -->
Hypoglycemia: IV dextrose (D5W 1cc/kg/hr) Insulin in 250cc NS)

<!-- PAGE=? -->
Hyperglycemia: Insulin sliding scale or infusion (50units

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
-HONK  - main feature dehydration glucose > 30, pH > 7.30, HCO3 > 18, AG < 12, Osm > 320, volume deficit 150 ml/kg

<!-- PAGE=? -->
-DKA  - main feature ket-acidosis

<!-- PAGE=? -->
⋅ pH < 7.3, AG > 12, HCO3 < 14, + Ketones, Osm 295-320, volume deficit 100 ml/kg

<!-- PAGE=? -->
⋅ Hepatic oxidation of FFA to ketones (beta-hydroxybutyrate, acetoacetate)

<!-- PAGE=? -->
⋅ Insulin deficiency in the context of glucagons excess

<!-- PAGE=? -->
⋅ Triggers i nsulin deficiency, i nfection, i nfarction

<!-- PAGE=? -->
⋅ Manifestations -↑ HR, ↑ RR, ↓ BP, ↓ LOC, hypothermia, abdominal pain

<!-- PAGE=? -->
⋅ Management

<!-- PAGE=? -->
o Volume replacement - 10 ml/kg/hr NS till glucose < 20 then add D5W, decr to 4cc/kg/hr after 4 hrs

<!-- PAGE=? -->
o Insulin - 0.1 U/kg bolus followed by 0.1 U/kg/hr (goal -↓ glucose 10% / hr), ↓ to 0.05 U/kg/hr when HCO3 > 20

<!-- PAGE=? -->
o KCL replacement - 0.3-0.5 mEq/kg/hr (once urine output established)

<!-- PAGE=? -->
o Mg, PO4 replacement

<!-- PAGE=? -->
Emergency OR & DKA

<!-- PAGE=? -->
⋅ pH > 7.20

<!-- PAGE=? -->
⋅ U/O > 0.5 ml/kg/hr

<!-- PAGE=? -->
⋅ K < 5.0

<!-- PAGE=? -->
⋅ ¾ Glucose

<!-- PAGE=? -->
⋅ x 2 (3-4 mmol/L)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Transplant - Donor

<!-- PAGE=? -->
o Rule of 100s:  Hg 100, U/O >100, SBP> 100

<!-- PAGE=? -->
o Electrolytes - DI/SIADH

<!-- PAGE=? -->
o Minimizing fluid for lungs

<!-- PAGE=? -->
o Must give some anesthetic to avoid hypertensive/tachy response

<!-- PAGE=? -->
Crash cart/pads on pts o

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Down's Syndrome (docc)

<!-- PAGE=? -->
Developmental Delay/Co-operation

<!-- PAGE=? -->
Obesity/OSA

<!-- PAGE=? -->
Cspine instability & Airway difficulty

<!-- PAGE=? -->
Subglottic stenosis

<!-- PAGE=? -->
Atlanto-Axial Subluxation

<!-- PAGE=? -->
Cervical spinal stenosis

<!-- PAGE=? -->
Congenital heart disease/Shunt (bubble free)

<!-- PAGE=? -->
Anesthetic Implications

<!-- PAGE=? -->
Preop cardic evaluation required

<!-- PAGE=? -->
Caregiver present until asleep

<!-- PAGE=? -->
Avoid heavy or unsupervised sedation; caution with opioids due to OSA

<!-- PAGE=? -->
Have variety of alternative airway management devices

<!-- PAGE=? -->
C-spine instability may warrant awake intubation or laryngoscopy with head neutral position

<!-- PAGE=? -->
May require smaller ETT if subglottic narrowing

<!-- PAGE=? -->
May require antibiotic prophylaxis

<!-- PAGE=? -->
Caution not to inject air bubbles (Rt → Lt shunt)

<!-- PAGE=? -->
Tracheal extubation awake

<!-- PAGE=? -->
Careful postop monitoring for airway obstruction

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
} upper airway obstruction

<!-- PAGE=? -->
 macroglossia

<!-- PAGE=? -->
 small mandible

<!-- PAGE=? -->
 short neck

<!-- PAGE=? -->
 tonsil & adenoid hypertrophy

<!-- PAGE=? -->
} subglottic stenosis

<!-- PAGE=? -->
} cervical spinal stenosis (10%)

<!-- PAGE=? -->
} TMJ subluxation

<!-- PAGE=? -->
} C1-C2 subluxation (30%)

<!-- PAGE=? -->
 1-2% symptomatic (pain, torticolis)

<!-- PAGE=? -->
 Worse with ext

<!-- PAGE=? -->
 flexion/extension xray's @ 4, 8, 12, and 16 years old

<!-- PAGE=? -->
 Xrays - if altered head position for OR or patient displays hyperreflexia or clonus

<!-- PAGE=? -->
 Atlanto-Dens Interval > 5mm is unstable

<!-- PAGE=? -->
CVS (in 50%, 8%cyanotic)

<!-- PAGE=? -->
} ECD (50%), VSD (25%), ASD, ToF (4%), PDA

<!-- PAGE=? -->
} SBE prophylaxis

<!-- PAGE=? -->
} Diligent avoidance of bubbles with IV's

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
} obstructive & central sleep apnea

<!-- PAGE=? -->
} pulmonary HTN

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
} mental retardation, ¾ cooperation

<!-- PAGE=? -->
Endocrinology

<!-- PAGE=? -->
} hypothyroidism, obesity, prone to hypothermia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Drowning

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
ARDS

<!-- PAGE=? -->
Pulmonary edema

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Ischemic encephalopathy

<!-- PAGE=? -->
C-spine stabilization if:

<!-- PAGE=? -->
o history of diving

<!-- PAGE=? -->
o use of a water slide

<!-- PAGE=? -->
o signs of injury

<!-- PAGE=? -->
o signs of alcohol intoxication.

<!-- PAGE=? -->
early CPR, intubation

<!-- PAGE=? -->
no need to clear the airway of aspirated water, only a modest amount of water is aspirated and is rapidly absorbed into the central circulation, so it does not act as an obstruction in the trachea.

<!-- PAGE=? -->
two thirds of victims who received rescue breathing and 86% of victims who required compressions and ventilations vomited.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Rule of 6's Dopamine / Dobutamine

<!-- PAGE=? -->
(6 x wt) mg in 100 ml's @ 1 ml/hr = 10 mcg/min ~ 1 mcg/kg/min

<!-- PAGE=? -->
Norepinephrine / Epinephrine (0.6 x wt) mg in 100 ml's @ 1 ml/hr = 1 mcg/min ~ 0.1 mcg/kg/min

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
AOOR

<!-- PAGE=? -->
Repeated, brief but stimulating procedure

<!-- PAGE=? -->
Triphasic Physiological response

<!-- PAGE=? -->
PNS: Rythym, Bradycardia

<!-- PAGE=? -->
SNS: HTN/Tachy

<!-- PAGE=? -->
Recovery: post-ictal

<!-- PAGE=? -->
Requires muscle relaxation

<!-- PAGE=? -->
Medications - i.e. Antipsychotics, MAOI

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
Treatment modality for severe depression, mania, schizophrenia

<!-- PAGE=? -->
Contraindication PIMP ARDS

<!-- PAGE=? -->
Goal: 25-120s

<!-- PAGE=? -->
Pregnancy

<!-- PAGE=? -->
MI ( < 1 months)

<!-- PAGE=? -->
↑ ICP

<!-- PAGE=? -->
Pheochromocytoma

<!-- PAGE=? -->
Retinal Detach/Glaucoma

<!-- PAGE=? -->
Aneurysm (cerebral/AAA)

<!-- PAGE=? -->
DVT

<!-- PAGE=? -->
Stroke <3months)

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
Methohexital 0.5-1 mg/kg

<!-- PAGE=? -->
Succinylcholine 0.5 mg/kg

<!-- PAGE=? -->
STP: 1-2mg/kg

<!-- PAGE=? -->
Adjuncts

<!-- PAGE=? -->
Esmolol 0.5-1 mg/kg (may ↓ seizure duration)

<!-- PAGE=? -->
Glycopyrolate

<!-- PAGE=? -->
Remi 1ug/kg

<!-- PAGE=? -->
Ketorolac

<!-- PAGE=? -->
ECT

<!-- PAGE=? -->
Special Patient Populations - post op monitoring!

<!-- PAGE=? -->
Cerebral Aneurysm

<!-- PAGE=? -->
Intracranial Mass

<!-- PAGE=? -->
o NTG/nitroprusside & beta-blockers to attenuate ↑ CBF

<!-- PAGE=? -->
o Dose titration of ECT

<!-- PAGE=? -->
o Unilateral electrode opposite lesion

<!-- PAGE=? -->
o Hyperventilation, diuretics, steroids

<!-- PAGE=? -->
Pacemaker / ICD

<!-- PAGE=? -->
o Convert to fixed rate pacing

<!-- PAGE=? -->
o Deactivate defibrillator (over sense)

<!-- PAGE=? -->
o Roc 0.05mg.kg, PNS, plan for post-PPV

<!-- PAGE=? -->
o Avoid tachy, hypertensive - optimize supply demand

<!-- PAGE=? -->
o Esmolol, Labetolol, Remi, NTG, Aline/ETT

<!-- PAGE=? -->
Pregnancy

<!-- PAGE=? -->
o Tocolysis/Gastric prophalaxis

<!-- PAGE=? -->
o Secure airway - Remi, esmolol

<!-- PAGE=? -->
Atrial Fib

<!-- PAGE=? -->
o Potential conversion to NSR

<!-- PAGE=? -->
o r/o thrombus with TEE

<!-- PAGE=? -->
o anticoagulation x 3 weeks

<!-- PAGE=? -->
TCA:

<!-- PAGE=? -->
o SNRI, Anti-chol - Unpredictable response

<!-- PAGE=? -->
MAOI:

<!-- PAGE=? -->
o Preventing breakdown of dope, NE, serotonin

<!-- PAGE=? -->
o Exaggerated response

<!-- PAGE=? -->
o Prolonged sux response

<!-- PAGE=? -->
MH

<!-- PAGE=? -->
CAD

<!-- PAGE=? -->
Li

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Physiologic and Pharmacologic Changes

<!-- PAGE=? -->
Coexisitng Dz

<!-- PAGE=? -->
Dementia

<!-- PAGE=? -->
 Loss of reserve

<!-- PAGE=? -->
 Loss of elastance - HTN, diastolic dysfunction, emphysema

<!-- PAGE=? -->
 Loss of H2O, muscle mass - BMR

<!-- PAGE=? -->
 Incr Lipid

<!-- PAGE=? -->
AIRWAY: difficult BMV

<!-- PAGE=? -->
CNS: incr pain threshold, sensitivity to depressant, decr MAC CVS: decr CI, endogenous B-blockade, HTN, CAD

<!-- PAGE=? -->
RESP: incr closing capacity, V/Q mismatch, RLD

<!-- PAGE=? -->
GU: decr GFR

<!-- PAGE=? -->
-risk of hypothermia

<!-- PAGE=? -->
-decr metabolism of drugs - decr Hepatic BF

<!-- PAGE=? -->
Elderly

<!-- PAGE=? -->
Dementia

<!-- PAGE=? -->
 Etiology

<!-- PAGE=? -->
 Coexisiting Dz

<!-- PAGE=? -->
 Cooperation

<!-- PAGE=? -->
 Pharmacology:

<!-- PAGE=? -->
o Avoid Anticholinergics, long-acting

<!-- PAGE=? -->
o Aricept (donepezil), Tacrine (Cognex) - NMBA interaction

<!-- PAGE=? -->
 Post-op

<!-- PAGE=? -->
o Risk of Delerium

<!-- PAGE=? -->
o Poor use of PCA

<!-- PAGE=? -->
Etiology: Alzheimer, Parkinson's, ETOH, Multiinfarct, HIV

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Emergency Drill

<!-- PAGE=? -->
Oxygen - 100%

<!-- PAGE=? -->
Halothane - minimize anesthetic, supplement amnestic agents

<!-- PAGE=? -->
Surgeon - alert OR staff

<!-- PAGE=? -->
Help

<!-- PAGE=? -->
IV - give 100 ml/kg bolus NS

<!-- PAGE=? -->
Tube - bag patient to assess compliance

<!-- PAGE=? -->
Scan monitors (ECG,  ETCO2,  NIBP,  Paw,  SpO2)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Follow-up

<!-- PAGE=? -->
Hand bag patient to check for compliance

<!-- PAGE=? -->
Scan machine, ventilator and circuit for abnormal alarms settings or function

<!-- PAGE=? -->
Check ETT position

<!-- PAGE=? -->
Pass suction catheter through ETT

<!-- PAGE=? -->
Listen for adventitious sounds, =A/E and HS

<!-- PAGE=? -->
Expose patient

<!-- PAGE=? -->
 JVP

<!-- PAGE=? -->
 Tracheal position

<!-- PAGE=? -->
 SC emphysema

<!-- PAGE=? -->
 urticaria

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
DCM

<!-- PAGE=? -->
Alcoholic cirrhosis/hepatitis/ liver failure

<!-- PAGE=? -->
↓ SVR

<!-- PAGE=? -->
hypoglycemia

<!-- PAGE=? -->
encephalopathy

<!-- PAGE=? -->
coagulopathy

<!-- PAGE=? -->
Malnutrition:

<!-- PAGE=? -->
Magnesium

<!-- PAGE=? -->
Vitamins/Folate

<!-- PAGE=? -->
Thiamine

<!-- PAGE=? -->
Potential withdrawl (DT's)

<!-- PAGE=? -->
 CNS

<!-- PAGE=? -->
 CVS

<!-- PAGE=? -->
 GI

<!-- PAGE=? -->
o Potential other substances

<!-- PAGE=? -->
o Incr/decr MAC

<!-- PAGE=? -->
o SDH

<!-- PAGE=? -->
o Wernicke-Korsakoff, cerebellar degeneration, ataxia

<!-- PAGE=? -->
o DCM

<!-- PAGE=? -->
o Arrythmia

<!-- PAGE=? -->
 RESP

<!-- PAGE=? -->
o Aspiration pneumonia

<!-- PAGE=? -->
o Smoking

<!-- PAGE=? -->
o Liver Failure/cirrhosis, Varices

<!-- PAGE=? -->
o Pancreatitis

<!-- PAGE=? -->
 MET

<!-- PAGE=? -->
o Hypoglycemia

<!-- PAGE=? -->
o ketoacidosis

<!-- PAGE=? -->
ETOH Abuse

<!-- PAGE=? -->
Delerium Tremens

<!-- PAGE=? -->
life threatening

<!-- PAGE=? -->
48-72 hours post withdrawl

<!-- PAGE=? -->
tremor , delerium , hallucinations

<!-- PAGE=? -->
autonomic instability

<!-- PAGE=? -->
seizures

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
} Dextrose & thiamine

<!-- PAGE=? -->
} Benzodiazepine

<!-- PAGE=? -->
 Lorazempam 1 mg PO/IV Q4-6H

<!-- PAGE=? -->
} Magnesium

<!-- PAGE=? -->
} B-blockade

<!-- PAGE=? -->
Serum EtOH > 50 mg/dL -↓ judgement / mental activity

<!-- PAGE=? -->
Serum EtOH > 150 mg/dL - ataxia, slurred speech

<!-- PAGE=? -->
Serum EtOH > 350 mg/dL - lethargy, coma

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Risk factors

<!-- PAGE=? -->
} Multiple trauma

<!-- PAGE=? -->
} Long bone #

<!-- PAGE=? -->
} Hypovolemic shock

<!-- PAGE=? -->
} Intramedullary instrumentation

<!-- PAGE=? -->
} RA

<!-- PAGE=? -->
} THA + cement

<!-- PAGE=? -->
} Bilateral TKR

<!-- PAGE=? -->
Incidence with isolated femur # → 4% (mortality 10%)

<!-- PAGE=? -->
Mechanism theories

<!-- PAGE=? -->
} Mechanical

<!-- PAGE=? -->
 Microemboli

<!-- PAGE=? -->
} Biochemical

<!-- PAGE=? -->
 Toxic and mechanical obstruction

<!-- PAGE=? -->
 FFA interact with pneumocytes → ARDS

<!-- PAGE=? -->
 FFA are either released during trauma or an unspecified chemical event at the site of injury releases mediators that result in coalesence of intravascular lipids with consequencial embolization

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
} Reversal of aggravating factors

<!-- PAGE=? -->
 Hypovolemia

<!-- PAGE=? -->
 Surgical stabilization

<!-- PAGE=? -->
} Respiratory management

<!-- PAGE=? -->
} +/- Corticosteroids

<!-- PAGE=? -->
Fat Embolism Syndrome

<!-- PAGE=? -->
the Confused POP.E: CRITERIA FOR DIAGNOSIS OF FAT EMBOLUS SYNDROME

<!-- PAGE=? -->
MAJOR

<!-- PAGE=? -->
Axillary/subconjunctival petechiae

<!-- PAGE=? -->
Hypoxemia (PaO2 < 60 mm Hg; FIO2 < 0.4)

<!-- PAGE=? -->
Central nervous system depression (disproportionate to hypoxemia) Pulmonary edema

<!-- PAGE=? -->
MINOR

<!-- PAGE=? -->
Tachycardia (>110 beats·min -1 )

<!-- PAGE=? -->
Hyperthermia

<!-- PAGE=? -->
Retinal fat emboli

<!-- PAGE=? -->
Urinary fat globules

<!-- PAGE=? -->
Decreased platelets/hematocrit (unexplained)

<!-- PAGE=? -->
Increased erythrocyte sedimentation rate

<!-- PAGE=? -->
Fat globules in sputum

<!-- PAGE=? -->
Diagnosis of fat embolus syndrome requires at least one sign from the major and four signs from the minor criteria categories.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hemophilia

<!-- PAGE=? -->
Potential airway bleeding

<!-- PAGE=? -->
Regional anesthesia 'contraindicated'

<!-- PAGE=? -->
Complications of recurrent transfusions

<!-- PAGE=? -->
Antibodies

<!-- PAGE=? -->
HIV

<!-- PAGE=? -->
Hepatitis / liver disease

<!-- PAGE=? -->
Factor VIII deficiency

<!-- PAGE=? -->
DDAVP

<!-- PAGE=? -->
FVIII concentrate

<!-- PAGE=? -->
rFVIII

<!-- PAGE=? -->
rFVII

<!-- PAGE=? -->
Factor IX deficiency

<!-- PAGE=? -->
FIX concentrate

<!-- PAGE=? -->
Hemophilia B

<!-- PAGE=? -->
Factor IX deficiency

<!-- PAGE=? -->
X-linked

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
Ö Prolonged PTT

<!-- PAGE=? -->
Ö Normal INR & platelets

<!-- PAGE=? -->
Ö Factor IX deficiency

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Ö Factor IX concentrates (t1/2 = 24 hours)

<!-- PAGE=? -->
Ö Goal: Factor IX > 30%

<!-- PAGE=? -->
Ö 1 U/kg → 1% ↑

<!-- PAGE=? -->
Hemophilia A

<!-- PAGE=? -->
Factor VIII deficiency

<!-- PAGE=? -->
2 / 10,000 male births

<!-- PAGE=? -->
X-linked recessive, 1/3 have no family history

<!-- PAGE=? -->
Severe < 1% factor VIII

<!-- PAGE=? -->
Mild 5-25%

<!-- PAGE=? -->
Moderate 1-4%

<!-- PAGE=? -->
Ö rare unprovoked bleeding

<!-- PAGE=? -->
Clinical manifestations

<!-- PAGE=? -->
Ö Hemarthrosis

<!-- PAGE=? -->
Ö Muscle hemorrhage

<!-- PAGE=? -->
Ö Abdominal bruising

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
Ö Prolonged PTT

<!-- PAGE=? -->
Ö Normal INR & platelets

<!-- PAGE=? -->
Ö Factor VIII deficiency

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Ö DDAVP

<!-- PAGE=? -->
 0.3 mcg/kg IV/SC (max 20 mcg)

<!-- PAGE=? -->
 onset 30 min, peak 60 min

<!-- PAGE=? -->
 3-4 x ½ FVIII level

<!-- PAGE=? -->
Ö Factor VIII concentrate (t1/2 = 8 hours)

<!-- PAGE=? -->
 1 U/kg → ↑ factor VIII 0.02 U/ml

<!-- PAGE=? -->
 minimum required for  surgery = 0.5 U/ml

<!-- PAGE=? -->
Ö rFVIII (Kogenate)

<!-- PAGE=? -->
 Major OR (100%) ~ 50 U/kg then 25 U/kg Q8H

<!-- PAGE=? -->
 Minor OR (50%) ~ 25 U/kg then 15 U/kg Q8H

<!-- PAGE=? -->
 1 U/kg increases plasma FVIII 2%

<!-- PAGE=? -->
 Dosage required (IU) = body weight (kg) × desired % factor VIII increase / 2%/IU/kg

<!-- PAGE=? -->
Ö Factor VII

<!-- PAGE=? -->
 50 - 100 mcg/kg IV Q4H

<!-- PAGE=? -->
 factor VIII inhibitors necessitate its use

<!-- PAGE=? -->
 10-20% hemophiliacs

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
HIV

<!-- PAGE=? -->
'a retroviral infection of CD4 T-cells that causes'

<!-- PAGE=? -->
1. CNS

<!-- PAGE=? -->
Neuropathy

<!-- PAGE=? -->
AIDS dementia/encephalopathy

<!-- PAGE=? -->
↑ ICP

<!-- PAGE=? -->
2. CVS

<!-- PAGE=? -->
Pericardial disease

<!-- PAGE=? -->
DCM

<!-- PAGE=? -->
PHTN

<!-- PAGE=? -->
Accelerated CAD

<!-- PAGE=? -->
Immunosuppression

<!-- PAGE=? -->
Opportunistic infections

<!-- PAGE=? -->
Bone marrow suppression

<!-- PAGE=? -->
Drug interaction

<!-- PAGE=? -->
Protease Inhibitors

<!-- PAGE=? -->
eg. Ritonavir, Saquinavir, idinavir, nelfinavir

<!-- PAGE=? -->
Inhibits p450

<!-- PAGE=? -->
o significant inhibition of fentanyl metabolism

<!-- PAGE=? -->
o caution with benzos and opioids

<!-- PAGE=? -->
GI symptoms

<!-- PAGE=? -->
Hyperlipidemia

<!-- PAGE=? -->
Peripheral neuropathy

<!-- PAGE=? -->
Glucose intolerance

<!-- PAGE=? -->
Increased liver enzymes

<!-- PAGE=? -->
Ritonavir

<!-- PAGE=? -->
increases effects of amiodarone,  diazepam, digoxin, fentanyl, meperidine, midazolam, quinidine

<!-- PAGE=? -->
decreases methadone effects (withdrawal)

<!-- PAGE=? -->
decreased warfarin effects

<!-- PAGE=? -->
Nucleoside analog reverse transcriptase inhibitors

<!-- PAGE=? -->
eg. Zidovudine (AZT)

<!-- PAGE=? -->
neuropathy, malaise, myalgias, myopathy

<!-- PAGE=? -->
headache, insomnia, nausea/vomiting

<!-- PAGE=? -->
increased CK

<!-- PAGE=? -->
Non-nucleoside reverse transcriptase inhibitors

<!-- PAGE=? -->
Stevens-Johnsons syndrome

<!-- PAGE=? -->
P450 induction (decreases serum levels of midazolam, fentanyl)

<!-- PAGE=? -->
Fusion Inhibitors

<!-- PAGE=? -->
insomnia, headaches, dizziness, nausea, eosinophilia bacterial pneumonia

<!-- PAGE=? -->
Systems:

<!-- PAGE=? -->
CNS and PNS

<!-- PAGE=? -->
Sensory neuropathy (distal, symmetrical)

<!-- PAGE=? -->
Meningitis (aseptic or opportunistic infections)

<!-- PAGE=? -->
AIDS encephalopathy or AIDS dementia complex

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
P. carinii, bacterial pneumonia, TB, aspergillosis

<!-- PAGE=? -->
Oral/pharyngeal candidiasis and herpetic lesions

<!-- PAGE=? -->
Cardiac

<!-- PAGE=? -->
Pericarditis, pericardial effusion, myocarditis

<!-- PAGE=? -->
Pulmonary hypertension

<!-- PAGE=? -->
Dilated cardiomyopathy

<!-- PAGE=? -->
MI (accelerated CAD)

<!-- PAGE=? -->
Decreased LV contractility

<!-- PAGE=? -->
Gastrointestinal

<!-- PAGE=? -->
Esophagitis, dysphagia, odynophagia

<!-- PAGE=? -->
Vomiting, loss of appetite, cachexia

<!-- PAGE=? -->
Hematology

<!-- PAGE=? -->
Bone marrow suppression

<!-- PAGE=? -->
•

<!-- PAGE=? -->
AIDS related lymphoma

<!-- PAGE=? -->
Obstetrical Anesthesia

<!-- PAGE=? -->
Treat with HAART (highly active antiretroviral therapy)

<!-- PAGE=? -->
Epidural blood patch OK

<!-- PAGE=? -->
Elective c -section decreases transmission to fetus

<!-- PAGE=? -->
Ergot contraindicated with anti-retrovirals

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
PARADISE

<!-- PAGE=? -->
Pre-existing HTN

<!-- PAGE=? -->
o Essential

<!-- PAGE=? -->
o Renovascular

<!-- PAGE=? -->
o Preeclamsia

<!-- PAGE=? -->
Awake/analgesia

<!-- PAGE=? -->
Autonomic Dysreflexia/ Bladder distension

<!-- PAGE=? -->
Resp (hypoxia/hypercarbia)

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
o Inotropes

<!-- PAGE=? -->
o Cocaine

<!-- PAGE=? -->
o MAOI

<!-- PAGE=? -->
o Withdrawl

<!-- PAGE=? -->
ICP/CNS

<!-- PAGE=? -->
Surgical

<!-- PAGE=? -->
 Tourniquet

<!-- PAGE=? -->
 CEA

<!-- PAGE=? -->
Endocrine

<!-- PAGE=? -->
o Pheochromocytoma

<!-- PAGE=? -->
o Carcinoid

<!-- PAGE=? -->
o Thyrotoxicosis

<!-- PAGE=? -->
o Conn's syndrome

<!-- PAGE=? -->
o MH

<!-- PAGE=? -->
Hypertension

<!-- PAGE=? -->
Verify

<!-- PAGE=? -->
Check drug administration - anesthetic depth, vasoactive drugs

<!-- PAGE=? -->
Check adequate oxygenation and ventilation

<!-- PAGE=? -->
Check depth of anesthesia, surgical stimulus

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
o BBlock - Esmolol, Labetolol

<!-- PAGE=? -->
o CCB - Verapamil, Hydalazine

<!-- PAGE=? -->
o ACE - Enalipril 0.625mg IV

<!-- PAGE=? -->
o ABlock - Phentoloamine 0.5-1mg

<!-- PAGE=? -->
o NTG - 0.1-2ug/kg/min

<!-- PAGE=? -->
o SNP -same

<!-- PAGE=? -->
Considerations:

<!-- PAGE=? -->
End organ-damage (cardiac, cerebral, renal, vascular), atherosclerosis

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
Altered cerebral autoregulation

<!-- PAGE=? -->
Hemodynamically Labile (induction, intubation, extubation)

<!-- PAGE=? -->
Exam:

<!-- PAGE=? -->
LVH/LVF (dyspnea, orthopnea, displaced apex, S3, S4, basal creps, rales), peripheral pulses

<!-- PAGE=? -->
-Delay if diastolic >110

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hyperthermia

<!-- PAGE=? -->
Iatrogenic

<!-- PAGE=? -->
o B-hugger

<!-- PAGE=? -->
o Hotline

<!-- PAGE=? -->
o Ambient temperature

<!-- PAGE=? -->
Hypermetabolic

<!-- PAGE=? -->
o MH

<!-- PAGE=? -->
o Carcinoid

<!-- PAGE=? -->
o Thyrotoxicosis

<!-- PAGE=? -->
o Pheo

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
o Hypothalamic dysregulation

<!-- PAGE=? -->
o ICH

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
o NMS

<!-- PAGE=? -->
o MAOI

<!-- PAGE=? -->
o Cocaine

<!-- PAGE=? -->
o SSRI

<!-- PAGE=? -->
o Transfusion Rxn

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Preload

<!-- PAGE=? -->
o Hypovolemia

<!-- PAGE=? -->
o Position

<!-- PAGE=? -->
o Obstructive

<!-- PAGE=? -->
 Surgical comp.

<!-- PAGE=? -->
 PEEP

<!-- PAGE=? -->
 Emboli (PTE, VAE, Fat, AFE)

<!-- PAGE=? -->
 PTX

<!-- PAGE=? -->
 Tamponade

<!-- PAGE=? -->
 Valve

<!-- PAGE=? -->
Contractility

<!-- PAGE=? -->
o Ischemia

<!-- PAGE=? -->
o Cardiomyopathy

<!-- PAGE=? -->
o Rate

<!-- PAGE=? -->
o Rhythm

<!-- PAGE=? -->
Afterload/SVR

<!-- PAGE=? -->
o SShocKED

<!-- PAGE=? -->
Hypovolemic

<!-- PAGE=? -->
Distributive - sepsis, anaphylactic, addisons, neurogenic Cardiogenic - ischemic, valvular, CM Obstructive - tamponade, AFE/PE/FE/VAE

<!-- PAGE=? -->
Hypotension

<!-- PAGE=? -->
Endocrine

<!-- PAGE=? -->
o Hypothyroid

<!-- PAGE=? -->
o Carcinoid

<!-- PAGE=? -->
o Post-Pheo

<!-- PAGE=? -->
o Hypothyroid

<!-- PAGE=? -->
o Adrenal insufficiency

<!-- PAGE=? -->
-pressor/ionotrope

<!-- PAGE=? -->
-art line

<!-- PAGE=? -->
-?PAC

<!-- PAGE=? -->
-check ABG

<!-- PAGE=? -->
Meds (ug/kg/min)

<!-- PAGE=? -->
-Ionotropes

<!-- PAGE=? -->
Dobutamine 5

<!-- PAGE=? -->
Milrinone 0.5

<!-- PAGE=? -->
-Vasopressors

<!-- PAGE=? -->
Phenylephrine 0.5

<!-- PAGE=? -->
Norepi 0.05

<!-- PAGE=? -->
-Both

<!-- PAGE=? -->
Epi 0.05

<!-- PAGE=? -->
Dopamine 5

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Emergency

<!-- PAGE=? -->
Cardiac

<!-- PAGE=? -->
Brady

<!-- PAGE=? -->
Ischemia risk (shivering, vasoconstrict)

<!-- PAGE=? -->
Vfib prone

<!-- PAGE=? -->
Altered Drug Kinetics

<!-- PAGE=? -->
Decr MAC

<!-- PAGE=? -->
Decr metabolism

<!-- PAGE=? -->
Delay in effect

<!-- PAGE=? -->
Coagulopathy

<!-- PAGE=? -->
Invasive Warming

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Etiology:

<!-- PAGE=? -->
Iatrogenic (Ambient temperature, Cold fluids)

<!-- PAGE=? -->
CNS (Hypothalamic dysregulation)

<!-- PAGE=? -->
Hypometabolic (Hypothyroidism)

<!-- PAGE=? -->
Drugs (Opioid overdose)

<!-- PAGE=? -->
Severity/Treatment:

<!-- PAGE=? -->
Mild hypothermia 34 - 36 o C

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Passive warming

<!-- PAGE=? -->
Moderate hypothermia 30 - 34 o C

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Active external warming (forced air, warm infusion)

<!-- PAGE=? -->
Severe hypothermia < 30 o C

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Active internal warming

<!-- PAGE=? -->
 Warm IV fluids (43 o C)

<!-- PAGE=? -->
 Warm, humidified O 2 (42-46 o C)

<!-- PAGE=? -->
 Pleural/Peritoneal/Bladder lavage (KCl free fluid)

<!-- PAGE=? -->
 Extracorporeal rewarming

<!-- PAGE=? -->
Autonomic defense mechanism

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Vasoconstriction

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Non-shivering thermeogenesis

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Shivering thermeogenesis

<!-- PAGE=? -->
GA& Regional inhibit thermoregualtion in a dose-dependent manner

<!-- PAGE=? -->
Elderly and children more prone

<!-- PAGE=? -->
Methods of heat loss: Radiation 60%, Evap. 20%, Convect. 15%, Conduct5%

<!-- PAGE=? -->
ACLS

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Remove wet garmets

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Protect from further heat loss

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Maintain horizontal and avoid rough movement

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Assess pulse/breathing over 30s

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> After initial ABC's and three shocks-assess temperature

<!-- PAGE=? -->
 < 30 o C: continue CPR / rewarm / no further shocks/drugs

<!-- PAGE=? -->
 > 30 o C: standard therapy, increase drug interval, sinus brady OK: don't pace

<!-- PAGE=? -->
ATLS:

<!-- PAGE=? -->
intracellular ice crystals, microvascular occlusion, infarct, reperfusion injury

<!-- PAGE=? -->
cardiac monitoring during rewarming

<!-- PAGE=? -->
extremely painful

<!-- PAGE=? -->
hold tobacco, other vasocontrictors

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hypoxemia (blood- PaO2 < 60mmHg):

<!-- PAGE=? -->
↓ FiO2

<!-- PAGE=? -->
Relative vs Absolute

<!-- PAGE=? -->
Hypoventilation

<!-- PAGE=? -->
V/Q mismatch

<!-- PAGE=? -->
Dead space ventilation

<!-- PAGE=? -->
PE, Emphysema

<!-- PAGE=? -->
Shunt

<!-- PAGE=? -->
Water (Pumonary edema)

<!-- PAGE=? -->
ii) Pus (pneumonia, aspiration)

<!-- PAGE=? -->
iii) Blood (4: VAE, PE, FE, AFE)

<!-- PAGE=? -->
iv) Nothing (Atelectasis, Pneumo)

<!-- PAGE=? -->
Low SVO2 - CO, Hgb, VO2

<!-- PAGE=? -->
Diffusion Gradient

<!-- PAGE=? -->
Hypoxia (tissues- insufficient O2 for requirements):

<!-- PAGE=? -->
Hypoxic

<!-- PAGE=? -->
Anemic

<!-- PAGE=? -->
Low O2 carrying capacity

<!-- PAGE=? -->
Circulatory

<!-- PAGE=? -->
Low CO

<!-- PAGE=? -->
Histotoxic

<!-- PAGE=? -->
Increased need

<!-- PAGE=? -->
Impaired utilization

<!-- PAGE=? -->
Hypoxemia/Hypoxia

<!-- PAGE=? -->
PAO2 = FIO2(PB-47) - 1.2(PaCO2)

<!-- PAGE=? -->
Cyanosis: SpO2 85%, requires 5g of deoxyHg

<!-- PAGE=? -->
Hypoxia Drill

<!-- PAGE=? -->
Verify SpO2 (temperature, circulation, motion)

<!-- PAGE=? -->
Emergency, lifethreatening, simultaneously Dx/Tx

<!-- PAGE=? -->
FIO2 100%, high flow, verify delivery

<!-- PAGE=? -->
Vitals/Monitors/Machine/Ventilator/Circuit/ETT

<!-- PAGE=? -->
Hand ventilate to assess compliance

<!-- PAGE=? -->
Confirm ETT placement

<!-- PAGE=? -->
A/E equal

<!-- PAGE=? -->
Suction/FOB

<!-- PAGE=? -->
ABG / CXR

<!-- PAGE=? -->
R/O massive shunt

<!-- PAGE=? -->
Recruitment maneuvers: PEEP, Prone

<!-- PAGE=? -->
NO

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Sepsis:

<!-- PAGE=? -->
Steroids

<!-- PAGE=? -->
>50% of septic shock patients have relative adrenal insufficiency and peripheral resistance to corticosteroids

<!-- PAGE=? -->
In non responders to ACTH stimulation,mortality decreased from 63% to 53% in those treated with hydrocortisone 50 mg q6h fludrocortisone 50ug od X 7 days

<!-- PAGE=? -->
Adrenal insufficient if unable to ↑ cortisol 9 ug/dL in response to 250 ug cosyntropin

<!-- PAGE=? -->
no benefit to steroids if not shown to be adrenal insufficient

<!-- PAGE=? -->
Glycemic Control

<!-- PAGE=? -->
critically ill patients are frequently hyperglycemic

<!-- PAGE=? -->
prospective, randomized trial of intensive insulin therapy in critically ill patients, most of whom had undergone cardiac surgery → mortality decreased from 8% to 4.6% in the group with sugars 4.4-6.1 mmol/L compared to the group with sugars 10.011.1mmol/L

<!-- PAGE=? -->
the patients with an insulin infusion had fewer infections, decreased transfusion requirements, and a shorter duration of mechanical ventilation

<!-- PAGE=? -->
another study suggested that keeping blood glucose less than 140 mg/dL (7.8 mmol/L) provided a survival benefit similar to that with the 'tighter' range of 80-110 mg/dL

<!-- PAGE=? -->
ICU Issues

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Mechanical Ventilation (ARDSnet)

<!-- PAGE=? -->
ARDS (PaO2/FIO2 < 300, Bilateral Infiltrates, PCWP <18)

<!-- PAGE=? -->
plateau pressures<30, permissive hypercapnea, PEEP, steroids in late phase

<!-- PAGE=? -->
Vt =  6 ml/kg IBW (compared to 12 ml/kg IBW reduced mortality  from 39.8% to 31%)

<!-- PAGE=? -->
NO difference in mortality: Prone, NO

<!-- PAGE=? -->
Activated Protein C

<!-- PAGE=? -->
decreased protein C in sepsis

<!-- PAGE=? -->
inactivates Va and VIIIa, inhibits thrombin formation, promotes fibrinolysis

<!-- PAGE=? -->
reduced mortality from 30.8%-24.7%

<!-- PAGE=? -->
most effective in patients with APACHEII score>25, but reasonable life expectancy

<!-- PAGE=? -->
major side effect is bleeding

<!-- PAGE=? -->
Early Goal Directed Resuscitation

<!-- PAGE=? -->
goal-directed resuscitation guided by central venous oxygen saturation decreased in-hospital mortality from 46.5% in the standard treatment group to 30.5% in the early goal-directed therapy group

<!-- PAGE=? -->
Alphabetical: CVP - MAP - SVO2

<!-- PAGE=? -->
consider early antibiotics

<!-- PAGE=? -->
Supplemental oxygen +

<!-- PAGE=? -->
endotracheal intubation and

<!-- PAGE=? -->
mechanical ventilation

<!-- PAGE=? -->
Central venous and

<!-- PAGE=? -->
arterial catheterization

<!-- PAGE=? -->
Sedation; paralysis

<!-- PAGE=? -->
(if intubated)

<!-- PAGE=? -->
or both

<!-- PAGE=? -->
Crystalloid

<!-- PAGE=? -->
28 mm Hg

<!-- PAGE=? -->
CVP

<!-- PAGE=? -->
Colloid

<!-- PAGE=? -->
8-12 mm

<!-- PAGE=? -->
Hg

<!-- PAGE=? -->
<65 mm Hg

<!-- PAGE=? -->
MAP

<!-- PAGE=? -->
Vasoactive agents

<!-- PAGE=? -->
>90 mm Hg

<!-- PAGE=? -->
765 and =90 mm Hg

<!-- PAGE=? -->
70%

<!-- PAGE=? -->
<70%

<!-- PAGE=? -->
Transfusion of red cells

<!-- PAGE=? -->
ScvOz

<!-- PAGE=? -->
until hematocrit = 30%

<!-- PAGE=? -->
Inotropic agents

<!-- PAGE=? -->
Goals

<!-- PAGE=? -->
achieved

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Hospital admission

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Laparoscopic Surgery

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Trochar Injury

<!-- PAGE=? -->
 Vessels

<!-- PAGE=? -->
 Viscus

<!-- PAGE=? -->
 Pneumoperitoneum

<!-- PAGE=? -->
 CVS:

<!-- PAGE=? -->
o ½ HR

<!-- PAGE=? -->
o ½ SVR / PVR

<!-- PAGE=? -->
o ½ CVP / PCWP - P incr but volume decr

<!-- PAGE=? -->
o ½ then ¾ venous return

<!-- PAGE=? -->
o ¾ CO / CI

<!-- PAGE=? -->
 RESP:

<!-- PAGE=? -->
o Paw incr

<!-- PAGE=? -->
o decr FRC

<!-- PAGE=? -->
o Endobronchial

<!-- PAGE=? -->
o Subq emphesema

<!-- PAGE=? -->
o pneumo

<!-- PAGE=? -->
 OTHER:

<!-- PAGE=? -->
o Incr intragastric P

<!-- PAGE=? -->
o Vagal: PONV

<!-- PAGE=? -->
o Decr U/O

<!-- PAGE=? -->
 CO2

<!-- PAGE=? -->
 CVS:

<!-- PAGE=? -->
o Intial incr sympathetic (BP/HR), then depression

<!-- PAGE=? -->
o CO2 embolism

<!-- PAGE=? -->
o increased PVR, decrease SVR

<!-- PAGE=? -->
o Dysrythmia

<!-- PAGE=? -->
 CNS:

<!-- PAGE=? -->
o Cerebral vasodilation - Incr ICP

<!-- PAGE=? -->
o 'Narcosis'

<!-- PAGE=? -->
Max IAP 15 mmHg (20 cmH2O)

<!-- PAGE=? -->
Minimal effects < 12 mmHg

<!-- PAGE=? -->
 1.36mmHg = 1cmH20

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Fluid management

<!-- PAGE=? -->
Bowel prep

<!-- PAGE=? -->
Post-operative analgesia

<!-- PAGE=? -->
TEA

<!-- PAGE=? -->
PCA

<!-- PAGE=? -->
Special scenarios

<!-- PAGE=? -->
COPD

<!-- PAGE=? -->
Asthma

<!-- PAGE=? -->
OSA

<!-- PAGE=? -->
ICP

<!-- PAGE=? -->
GA, ETT, PPV

<!-- PAGE=? -->
Cancer

<!-- PAGE=? -->
4 M's

<!-- PAGE=? -->
Laparotomy

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Liver Failure

<!-- PAGE=? -->
Decr Hepatic Function

<!-- PAGE=? -->
encephalopathy

<!-- PAGE=? -->
coagulopathy/thrombocytopenia

<!-- PAGE=? -->
hypoglycemia

<!-- PAGE=? -->
Altered Pharmacology

<!-- PAGE=? -->
} Metabolism

<!-- PAGE=? -->
} hypoalbuminemia

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
DCM

<!-- PAGE=? -->
Hyperdynamic shunt

<!-- PAGE=? -->
↓ SVR

<!-- PAGE=? -->
Pulm HTN

<!-- PAGE=? -->
Hepatorenal Syndrome

<!-- PAGE=? -->
Modified Child-Pugh

<!-- PAGE=? -->
Points

<!-- PAGE=? -->
1

<!-- PAGE=? -->
2

<!-- PAGE=? -->
3

<!-- PAGE=? -->
Alb

<!-- PAGE=? -->
U

<!-- PAGE=? -->
min

<!-- PAGE=? -->
>35

<!-- PAGE=? -->
28-35

<!-- PAGE=? -->
<28

<!-- PAGE=? -->
I

<!-- PAGE=? -->
NR

<!-- PAGE=? -->
<1.7

<!-- PAGE=? -->
1.7-2.3

<!-- PAGE=? -->
>2.3

<!-- PAGE=? -->
Bilirubin

<!-- PAGE=? -->
Y

<!-- PAGE=? -->
<34

<!-- PAGE=? -->
34-51

<!-- PAGE=? -->
>51

<!-- PAGE=? -->
A

<!-- PAGE=? -->
scites

<!-- PAGE=? -->
None

<!-- PAGE=? -->
Mod

<!-- PAGE=? -->
Tense

<!-- PAGE=? -->
E

<!-- PAGE=? -->
ncephalopathy

<!-- PAGE=? -->
None

<!-- PAGE=? -->
Grade 1-2

<!-- PAGE=? -->
Grade 3-4

<!-- PAGE=? -->
For intaabdominal surgery, perioperative mortality:

<!-- PAGE=? -->
Class A (5-6 points) → 10% mortality

<!-- PAGE=? -->
Class C (10-15 points) → 75% mortality

<!-- PAGE=? -->
Class B (7-9 points) → 35% mortality

<!-- PAGE=? -->
-Pre (vascular, shock, compression) -Hepatic : Infectious (viral, sepsis), Toxic (acetaminophen, halothane, isoniazid), Metabolic (Wilson's, Reye's, NASH)

<!-- PAGE=? -->
-Post (vascular, biliary)

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
Cerebral edema → ↑ ICP

<!-- PAGE=? -->
Encephalopathy (decr protein digestion)

<!-- PAGE=? -->
o Grade 1- decreased attention, mood change, tremor

<!-- PAGE=? -->
o Grade 2 - lethargy, ataxia, dysarthria, asterixis

<!-- PAGE=? -->
o Grade 3 confusion, delirium, disoriented, rigidity, seizures, nystagmus,

<!-- PAGE=? -->
o Grade 4 coma, oculocephalic, decorticate, decerebrate, dilated pupils

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
Hyperdynamic circulation ( ↑ CO, ↓ SVR, normal HR and BP)

<!-- PAGE=? -->
Dilated Cardiomyopathy

<!-- PAGE=? -->
Increased circulating volume, but relatively hypovolemic

<!-- PAGE=? -->
Afib

<!-- PAGE=? -->
Pulmonary hypertension

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
Hypoxemia

<!-- PAGE=? -->
Intrapulmonary shunting (hepatopulmonary  syndrome) - V/Q mismatch

<!-- PAGE=? -->
hypoventilation due to ascites

<!-- PAGE=? -->
pleural effusions

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
Gastroesophageal bleeding, varices

<!-- PAGE=? -->
Portal vein hypertension, splenomegaly

<!-- PAGE=? -->
Ascites

<!-- PAGE=? -->
Hypoalbuminemia, malnutrition

<!-- PAGE=? -->
GU

<!-- PAGE=? -->
Hepatorenal syndrome (= prerenal)

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
Hyponatremia

<!-- PAGE=? -->
Heme

<!-- PAGE=? -->
Anemia

<!-- PAGE=? -->
Coagulopathy (all factors except factor VIII)

<!-- PAGE=? -->
Thrombocytopenia (sequestration)

<!-- PAGE=? -->
Other

<!-- PAGE=? -->
Immunocompromised (TB, cancer, SBP - mortality 50%)

<!-- PAGE=? -->
↓ albumin -↑ free fraction of drugs (eg. STP)

<!-- PAGE=? -->
Hypoglycemia

<!-- PAGE=? -->
Do Not metabolize citrate

<!-- PAGE=? -->
cutaneous telangectasias, caput medusa, palmar erythema

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Jaundice:

<!-- PAGE=? -->
Pre-hepatic

<!-- PAGE=? -->
 Bili unconjugate

<!-- PAGE=? -->
 LFTs N

<!-- PAGE=? -->
 Transufusion txn

<!-- PAGE=? -->
 Hematoma

<!-- PAGE=? -->
 Hemolysis

<!-- PAGE=? -->
 Prosthetic valve

<!-- PAGE=? -->
Intrahepatic

<!-- PAGE=? -->
 Bili conjugated

<!-- PAGE=? -->
 LFTs  - transaminases increased

<!-- PAGE=? -->
 Hepatitis

<!-- PAGE=? -->
 Liver Dz worsening

<!-- PAGE=? -->
 Shock Liver

<!-- PAGE=? -->
 Drug induced - halothane

<!-- PAGE=? -->
Post-Hepatic

<!-- PAGE=? -->
 Bili conjugated

<!-- PAGE=? -->
 LFTs  - ALP/GGT increased

<!-- PAGE=? -->
 Infection

<!-- PAGE=? -->
 Bile Duct injury

<!-- PAGE=? -->
 Pancreatitis

<!-- PAGE=? -->
 Gallstones

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ABC's

<!-- PAGE=? -->
Midazolam/STP

<!-- PAGE=? -->
Hyperventilation / NaHCO3

<!-- PAGE=? -->
Hemodynamic support → vasopressin > epinephrine

<!-- PAGE=? -->
CPB

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
NaHCO3

<!-- PAGE=? -->
Hypertonic Saline

<!-- PAGE=? -->
Intralipid (20%) - 1 ml/kg

<!-- PAGE=? -->
ACLS:

<!-- PAGE=? -->
Na Channel Blockers (local anesthetics, TCA)

<!-- PAGE=? -->
-Sodium bicarbonate

<!-- PAGE=? -->
 provides hypertonic saline and induces systemic alkalinization

<!-- PAGE=? -->
 repeated boluses of 1 to 2 mEq/kg

<!-- PAGE=? -->
 maintenance infusion of 150 mEq/L of sodium bicarbonate plus 30 mEq KCl/L in D5W

<!-- PAGE=? -->
 Goal: pH of 7.45 to 7.55

<!-- PAGE=? -->
-hypertonic saline alone may be effective in treating the impaired conduction

<!-- PAGE=? -->
Local Anesthesia Toxicity

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Long QT Syndrome

<!-- PAGE=? -->
'Long QT is a congenital or acquired syndrome that predisposes to significant cardiac morbidity that requires:'

<!-- PAGE=? -->
Preop β -blocker therapy

<!-- PAGE=? -->
Avoidance of drugs or electrolytes changes that may incr QT

<!-- PAGE=? -->
Anticipation of potential ACLS/pacing intra and post -op

<!-- PAGE=? -->
Pacemaker / ICD

<!-- PAGE=? -->
QTc = QT / RR 1/2

<!-- PAGE=? -->
LQTS = QTc > 440 (lead II)

<!-- PAGE=? -->
Presents: syncope, sudden death, VT

<!-- PAGE=? -->
EKG: bifid/sinusoidal T wave, U wave

<!-- PAGE=? -->
Congenital LQTS

<!-- PAGE=? -->
o 30% congenital have normal phenotype (i.e. normal QT interval)

<!-- PAGE=? -->
o Associated with congenital deafness

<!-- PAGE=? -->
o Mutation in Na/K channels

<!-- PAGE=? -->
o Abnormally prolonged repolarization: regions of increased relative refractoriness, favouring EADs

<!-- PAGE=? -->
Aquired LQTS

<!-- PAGE=? -->
o SAH

<!-- PAGE=? -->
o R neck dissection

<!-- PAGE=? -->
o Hypo K, Mg, Ca

<!-- PAGE=? -->
o Drugs

<!-- PAGE=? -->
 Quinidine, Procainamide, Amiodarone, Sotalol, Lidocaine

<!-- PAGE=? -->
 Haldol, Droperidol, Quetiapine

<!-- PAGE=? -->
 Li

<!-- PAGE=? -->
 TCA, SSRI's

<!-- PAGE=? -->
 Macrolide antibiotics

<!-- PAGE=? -->
 Cisapride

<!-- PAGE=? -->
 Volatile anesthetics (except halothane)

<!-- PAGE=? -->
 Atropine / glycopyrolate

<!-- PAGE=? -->
Long-term treatment

<!-- PAGE=? -->
o β -blockade

<!-- PAGE=? -->
 goal - exercise HR < 130

<!-- PAGE=? -->
o antibradycardia pacing

<!-- PAGE=? -->
o ICD

<!-- PAGE=? -->
o Left cervicothoracic sympathectomy

<!-- PAGE=? -->
o Phenytoin - shortens QT

<!-- PAGE=? -->
Anesthetic Concerns

<!-- PAGE=? -->
o Continue β -blockade

<!-- PAGE=? -->
o Avoid SNS: anxiety, pain

<!-- PAGE=? -->
o Avoid ↓ K (hypervent) / Mg / Ca

<!-- PAGE=? -->
o Avoid drugs that prolong QT

<!-- PAGE=? -->
o Avoid hypovolemia

<!-- PAGE=? -->
o Avoid hypothermia

<!-- PAGE=? -->
o Assess pacemaker / ICD function

<!-- PAGE=? -->
o Pacing pads on, Defibrillator in OR

<!-- PAGE=? -->
o Avoid reversal of NDMR

<!-- PAGE=? -->
TORSADES DE POINTES

<!-- PAGE=? -->
DC cardioversion

<!-- PAGE=? -->
MgSO4 30 mg/kg IV bolus over 2min, followed by infusion of 2-4 grams/h

<!-- PAGE=? -->
Trans-venous pacing at 90-110 beats/min

<!-- PAGE=? -->
Isopreterenol infusion: 2-10ug/min

<!-- PAGE=? -->
IF NORMAL QT: can use amio

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Lung Isolation

<!-- PAGE=? -->
INDICATIONS FOR ONE-LUNG VENTILATION

<!-- PAGE=? -->
ABSOLUTE

<!-- PAGE=? -->
Isolation of each lung to prevent contamination of a healthy lung

<!-- PAGE=? -->
Infection (abscess, infected cyst)

<!-- PAGE=? -->
Massive hemorrhage

<!-- PAGE=? -->
Control of distribution of ventilation to only one lung

<!-- PAGE=? -->
Bronchopleural fistula

<!-- PAGE=? -->
Bronchopleural cutaneous fistula

<!-- PAGE=? -->
Unilateral cyst or bullae

<!-- PAGE=? -->
Major bronchial disruption or trauma

<!-- PAGE=? -->
Unilateral lung lavage

<!-- PAGE=? -->
Video-assisted thoracoscopic surgery

<!-- PAGE=? -->
RELATIVE

<!-- PAGE=? -->
Surgical exposure-high priority

<!-- PAGE=? -->
 Pneumonectomy

<!-- PAGE=? -->
 Upper lobectomy

<!-- PAGE=? -->
 Thoracic aortic aneurysm

<!-- PAGE=? -->
Surgical exposure-low priority

<!-- PAGE=? -->
Esophageal surgery

<!-- PAGE=? -->
Middle and lower lobectomy

<!-- PAGE=? -->
Thoracoscopy under general anesthesia

<!-- PAGE=? -->
Hypoxia on One-Lung

<!-- PAGE=? -->
Confirm ETT placement, patency & ventilation parameters

<!-- PAGE=? -->
Optimize PEEP to ventilated lung

<!-- PAGE=? -->
CPAP to non-ventilated lung

<!-- PAGE=? -->
Intermittant two-lung ventilation

<!-- PAGE=? -->
Selective bronchial blockade (bronchus intermedius)

<!-- PAGE=? -->
Clamp pulmonary artery (pneumonectomy)

<!-- PAGE=? -->
CPB

<!-- PAGE=? -->
Pridictors:

<!-- PAGE=? -->
-Right Lung surgery

<!-- PAGE=? -->
-Good FEV1 - (if not, 1. autopeep, 2. chronic HPV)

<!-- PAGE=? -->
-Poor 2 lung PaO2

<!-- PAGE=? -->
-usually see it by 20 mins if it is going to happen

<!-- PAGE=? -->
Bullae:

<!-- PAGE=? -->
-if bilat: prophylactic CT

<!-- PAGE=? -->
-if unilat:

<!-- PAGE=? -->
 prep chest for CT acess

<!-- PAGE=? -->
 DLT - isolate PRN

<!-- PAGE=? -->
 low Paw

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Bronchopulmonary Lavage

<!-- PAGE=? -->
Underlying Lung Disease

<!-- PAGE=? -->
 alveolar proteinosis

<!-- PAGE=? -->
 radioactive dust inhalation

<!-- PAGE=? -->
 cystic fibrosis

<!-- PAGE=? -->
 bronchiectasis

<!-- PAGE=? -->
Lung Isolation

<!-- PAGE=? -->
-100% FIO2 throughout (denitrogenate - no bubbles in alveoli - better lavage)

<!-- PAGE=? -->
-DLT: cuff seal should be checked to maintain perfect separation at a pressure of 50 cm H2O

<!-- PAGE=? -->
-Aline

<!-- PAGE=? -->
-Stethoscope over ventilated lung dx leakage of lavage fluid

<!-- PAGE=? -->
-Start with most severely affected ventilation side on V/Q or Left (gas exchange should be better through the larger, right lung) -side to be lavaged is down, head-up

<!-- PAGE=? -->
-warmed heparinized isotonic saline, 700-1000cc

<!-- PAGE=? -->
-head-down position and fluid is allowed to drain out

<!-- PAGE=? -->
-repeated until the effluent is clear

<!-- PAGE=? -->
-At least 90% of the saline volume should be recovered with each lavage.

<!-- PAGE=? -->
-ventilation is re-established with large VT (and pressures), compliance is decreased owing to loss of surfactant.

<!-- PAGE=? -->
-air-oxygen mixture may be introduced to help maintain alveolar patency

<!-- PAGE=? -->
-most patients' can be extubated in the operating room

<!-- PAGE=? -->
-return for other lung  days to 1 week after lavage of the first lung

<!-- PAGE=? -->
-Hypoxia risk on draining: risk has been reduced by passing a balloon-tipped catheter into the right main pulmonary artery (checked by radiography) and inflating the balloon during periods of right lung drainage.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Preoperative pulmonary evaluation

<!-- PAGE=? -->
Always assume pneumonectomy

<!-- PAGE=? -->
Whole-lung test with spirometry and ABG

<!-- PAGE=? -->
Split Lung function (V/Q) or post-op simulation testing if :

<!-- PAGE=? -->
o PaCO2 > 40 mm Hg,

<!-- PAGE=? -->
o FEV1 < 50%, FVC < 2 l, RV/TLC > 50%

<!-- PAGE=? -->
o maximal breathing capacity < 50%

<!-- PAGE=? -->
o predicted post resection FEV1 < 800 ml.

<!-- PAGE=? -->
Post-op simulation (block bronchus or PA) fails:

<!-- PAGE=? -->
 severe breathlessness

<!-- PAGE=? -->
 PA mean >40 mm Hg

<!-- PAGE=? -->
 PaCO2 >60 mm Hg

<!-- PAGE=? -->
 PaO2 <45 mm Hg

<!-- PAGE=? -->
#Most valid test; see text.

<!-- PAGE=? -->
Table 1. The "Three-Legged" Stool of Prethoracotomy

<!-- PAGE=? -->
Respiratory Assessment

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
Cardiopulmonary

<!-- PAGE=? -->
Lung Parenchymal

<!-- PAGE=? -->
Mechanics

<!-- PAGE=? -->
Reserve

<!-- PAGE=? -->
Function

<!-- PAGE=? -->
FEV 1* {ppo > 40%}

<!-- PAGE=? -->
VOz max,

<!-- PAGE=? -->
(>15

<!-- PAGE=? -->
DLCO* (ppo > 409)

<!-- PAGE=? -->
mUkglmin)

<!-- PAGE=? -->
MVV, RVITLC, FVC

<!-- PAGE=? -->
Stair climb >2 flights,

<!-- PAGE=? -->
PaOz>60

<!-- PAGE=? -->
6 min walk, exercise

<!-- PAGE=? -->
SpOz <4%

<!-- PAGE=? -->
PaCOz <45

<!-- PAGE=? -->
PpoFEV, % preopcrative FEV 19

<!-- PAGE=? -->
X (I

<!-- PAGE=? -->
Onc mcthod of cstimating the pcrccnt of functional lung tissuc is bascd on a calculation of the numbcr of functioning subscg- patients with PPoFEV, than 4096 had no or minor greater

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
Left

<!-- PAGE=? -->
10

<!-- PAGE=? -->
4

<!-- PAGE=? -->
10

<!-- PAGE=? -->
12

<!-- PAGE=? -->
Predicted Postoperative FEV 1 (ppoFEV

<!-- PAGE=? -->
409

<!-- PAGE=? -->
30- 40 %

<!-- PAGE=? -->
Extubate in Operating

<!-- PAGE=? -->
Consider extubation

<!-- PAGE=? -->
Staged weaning from

<!-- PAGE=? -->
Room if:

<!-- PAGE=? -->
based on:

<!-- PAGE=? -->
mech . ventilation

<!-- PAGE=? -->
Patient AWaC (alert,

<!-- PAGE=? -->
Exercise tolerance

<!-- PAGE=? -->
Consider extubation if

<!-- PAGE=? -->
warm and

<!-- PAGE=? -->
comfortable)

<!-- PAGE=? -->
DLCO

<!-- PAGE=? -->
20% plus:

<!-- PAGE=? -->
VIQ scan

<!-- PAGE=? -->
Thoracic Epidural

<!-- PAGE=? -->
Associated diseases

<!-- PAGE=? -->
Analgesia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Minimal pre/post-operative measurements for various sized pulmonary resections

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Magnesium

<!-- PAGE=? -->
 magnesium levels do not reliably reflect total body magnesium stores

<!-- PAGE=? -->
 necessary for the movement of sodium, potassium, and calcium into and out of cells

<!-- PAGE=? -->
 Alters presynaptic release Ach & ↓ motor end plate sensitivity to Ach

<!-- PAGE=? -->
 plays an important role in stabilizing excitable membranes

<!-- PAGE=? -->
Hyper

<!-- PAGE=? -->
 most common cause: renal failure

<!-- PAGE=? -->
 CNS: muscular weakness, paralysis, ataxia, drowsiness, and confusion

<!-- PAGE=? -->
 CVS: vasodilation/hypotension, bradycardia, cardiac arrhythmias

<!-- PAGE=? -->
 RESP: hypoventilation, and cardiorespiratory arrest.

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
 minimize intake

<!-- PAGE=? -->
 Ca to temporarily antagonize

<!-- PAGE=? -->
 Saline Diuresis (loop diuretic + NS)

<!-- PAGE=? -->
 dialysis

<!-- PAGE=? -->
Hypo

<!-- PAGE=? -->
 decreased absorption vs increased loss (kidneys or intestines)

<!-- PAGE=? -->
 altered thyroid hormone function

<!-- PAGE=? -->
 pentamidine, diuretics, alcohol

<!-- PAGE=? -->
 LYTES: hypocalcemia, hypokalemia

<!-- PAGE=? -->
 CNS: muscular tremors/fasciculations, nystagmus, tetany, altered mental state, ataxia, vertigo, seizures, and dysphagia

<!-- PAGE=? -->
 CVS: torsades de pointes

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
 1 to 2 g of MgSO4 IV push over 5 (Arrest, Torsade, seizure), 60 minutes (intermittent) IV

<!-- PAGE=? -->
 Calcium

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Monamine Oxidase Inhibitors

<!-- PAGE=? -->
Avoid drug interaction

<!-- PAGE=? -->
Opioids (meperidine, fentanyl, talwin)

<!-- PAGE=? -->
Anticholinergics

<!-- PAGE=? -->
Vasopressors

<!-- PAGE=? -->
Sympathomemetic: Cocaine, Ketamine

<!-- PAGE=? -->
Monitoring:

<!-- PAGE=? -->
Invasive hemodynamic

<!-- PAGE=? -->
Temperature

<!-- PAGE=? -->
 Inhibition of monoamine oxidase

<!-- PAGE=? -->
 Increase concentrations of norepinephrine

<!-- PAGE=? -->
Serotonin and dopamine to lesser extents

<!-- PAGE=? -->
MAOI-A (irreversible)

<!-- PAGE=? -->
} ↑ 5HT, Dopamine, and NE

<!-- PAGE=? -->
 Phenelzine (Nardil)

<!-- PAGE=? -->
 Isocarboxazid (Marplan)

<!-- PAGE=? -->
 Tranylcypromine (Parnate)

<!-- PAGE=? -->
MAOI-B (reversible)

<!-- PAGE=? -->
} ↑ 5HT only

<!-- PAGE=? -->
 Selegiline

<!-- PAGE=? -->
Combination of MAOI's and tyramine or sympathomimetics may result in malignant hypertension

<!-- PAGE=? -->
Possible triggers

<!-- PAGE=? -->
 Ephedrine

<!-- PAGE=? -->
 Opioids (meperidine, talwin, fentanyl)

<!-- PAGE=? -->
 Anticholinergics

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
 Vasopressors (indirect >> direct)

<!-- PAGE=? -->
 Cocaine

<!-- PAGE=? -->
Hypertensive Crisis

<!-- PAGE=? -->
} ↓ / ↑ BP

<!-- PAGE=? -->
} ↑ temperature

<!-- PAGE=? -->
} apnea

<!-- PAGE=? -->
} seizures

<!-- PAGE=? -->
Elective surgery during the first 21 days of treatment initiation should be postponed as this is the most dangerous time - with chronic therapy downregulation of receptors ↓ risk

<!-- PAGE=? -->
Regional anesthesia

<!-- PAGE=? -->
} Caution - hypotension → vasopressors → crisis

<!-- PAGE=? -->
} Minmize dosages of vasopressors (direct only)

<!-- PAGE=? -->
} Avoid epinephrine containing local anesthesia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Marfans

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
TMJ laxity

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
Scoliosis - RLD

<!-- PAGE=? -->
Pectus

<!-- PAGE=? -->
Spontaneous PTX

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
Aortic aneurysm/dissection

<!-- PAGE=? -->
CAD

<!-- PAGE=? -->
MVP / MR/ AI - SBE

<!-- PAGE=? -->
Positioning

<!-- PAGE=? -->
Features

<!-- PAGE=? -->
autosomal dominant

<!-- PAGE=? -->
defect in collagen synthesis resulting in ¾ tensile strength and elasticity of CT

<!-- PAGE=? -->
½ long bone length

<!-- PAGE=? -->
arachnodactily, joint laxity, ¾ muscle tone, scant SQ fat, high arched palate, pectus carinatum or excavatum and pes palnus

<!-- PAGE=? -->
arm span > height

<!-- PAGE=? -->
95% of deaths due to CVS complications

<!-- PAGE=? -->
Ehlers-Danlos : same + bleeding, vessel fragility, perf GI

<!-- PAGE=? -->
Systems Review (Assessment)

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
} TMJ dislocation with laryngoscopy

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
} RLD due to scoliosis, pectus carinatum or excavatum

<!-- PAGE=? -->
} Bronchogenic cysts; spont pneumothorax

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
} Aortic dz (cystic medial necrosis leading to dissection)

<!-- PAGE=? -->
} Aortic aneurysms

<!-- PAGE=? -->
} PA dilatation

<!-- PAGE=? -->
} Coronary artery abnormalities (medial necrosis of arterioles)

<!-- PAGE=? -->
} MVP, MR, AI

<!-- PAGE=? -->
} Arrhythmias and conduction disturbances

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
} Lens dislocation, myopia, retinal detachment

<!-- PAGE=? -->
MSK

<!-- PAGE=? -->
} Tall stature, joint hypermobility, recurrent dislocation, hernias

<!-- PAGE=? -->
Anesthetic Implications

<!-- PAGE=? -->
Avoid HTN; prevent sudden ½ in contractility or LV ejection velocity

<!-- PAGE=? -->
Routine monitors along with 5-lead ECG, TEE, and invasive monitors as indicated (care with probes and catheters)

<!-- PAGE=? -->
Carefully monitor for myocardial ischemia

<!-- PAGE=? -->
Careful laryngoscopy to avoid TMJ dislocation

<!-- PAGE=? -->
Careful positioning to avoid dislocations

<!-- PAGE=? -->
Ensure pt has deep anesthetic as to avoid ½ CO or significant HTN

<!-- PAGE=? -->
Gentle PPV as pts prone to pneumothorax

<!-- PAGE=? -->
Postop observation for CVS complications, fast Afib, pneumothorax, retinal detachment

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Mediastinal Mass

<!-- PAGE=? -->
Cancer - 5 M's

<!-- PAGE=? -->
Major vessel / airway occlusion

<!-- PAGE=? -->
Preoperative radiation

<!-- PAGE=? -->
Concomitant illness

<!-- PAGE=? -->
MG, Thyroid, Lymphoma

<!-- PAGE=? -->
4 T's

<!-- PAGE=? -->
} Thymoma

<!-- PAGE=? -->
} Thyroid goiter

<!-- PAGE=? -->
} Teratoma

<!-- PAGE=? -->
} 'terrible' lymphoma

<!-- PAGE=? -->
M ass Effect

<!-- PAGE=? -->
} Trachea

<!-- PAGE=? -->
} RLN/Sympathetic Chain

<!-- PAGE=? -->
} Cardiac

<!-- PAGE=? -->
} Major vessels

<!-- PAGE=? -->
 Syncope with valsalva

<!-- PAGE=? -->
} SVC syndrome

<!-- PAGE=? -->
 Dilation of collateral veins

<!-- PAGE=? -->
 Airway edema

<!-- PAGE=? -->
 ↑ ICP (headache, ↓ LOC)

<!-- PAGE=? -->
M etastatic disease

<!-- PAGE=? -->
M etabolic derangements

<!-- PAGE=? -->
} MG / LE syndrome

<!-- PAGE=? -->
} Hyper / hypothyroidism

<!-- PAGE=? -->
M edications

<!-- PAGE=? -->
} Chemotherapeutic

<!-- PAGE=? -->
} Antimyesthenic drugs

<!-- PAGE=? -->
} Corticosteroids

<!-- PAGE=? -->
} Mediastinal radiation

<!-- PAGE=? -->
Pre-operative assessment

<!-- PAGE=? -->
} S/S of a/w, vessel or nerve involvement - orthostatic change

<!-- PAGE=? -->
 Dyspnea, cyanosis, orthopnea, midline trachea, wheeze

<!-- PAGE=? -->
 Fatigue, headache, incr. JVP, pulsus paradoxsus hypotension

<!-- PAGE=? -->
 stridor, change in voice, Horner's

<!-- PAGE=? -->
} ABG

<!-- PAGE=? -->
} CXR / CT

<!-- PAGE=? -->
} PFT's & flow volume loops (positional)

<!-- PAGE=? -->
} Orthostatic Echo

<!-- PAGE=? -->
} +/- awake bronchoscopy

<!-- PAGE=? -->
} always consider preoperative radiation

<!-- PAGE=? -->
Anesthetic Management

<!-- PAGE=? -->
} Surgeon, second bed, CPB on standby

<!-- PAGE=? -->
} Lower extremity IV access

<!-- PAGE=? -->
} A line

<!-- PAGE=? -->
} If symptomatic attempt under local anesthesia

<!-- PAGE=? -->
} Awake FOB intubation

<!-- PAGE=? -->
} Avoid muscle relaxants & PPV SV goal

<!-- PAGE=? -->
} Rescue

<!-- PAGE=? -->
 Rigid bronchoscopy

<!-- PAGE=? -->
 Lateral/prone positioning

<!-- PAGE=? -->
 Median sternotomy

<!-- PAGE=? -->
 CPB

<!-- PAGE=? -->
} Fem-Fem bypass

<!-- PAGE=? -->
 > 50% occlusion of PA or heart

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Metabolic Acidosis - Anion Gap

<!-- PAGE=? -->
Metabolic Acidosis - Non-Anion Gap

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Malignant Hyperthermia

<!-- PAGE=? -->
Avoid triggers

<!-- PAGE=? -->
MH prepared OR suite

<!-- PAGE=? -->
MH treatment cart

<!-- PAGE=? -->
Dantrolene

<!-- PAGE=? -->
NaHCO3

<!-- PAGE=? -->
Dextrose, insulin, Ca, lasix, ventolin

<!-- PAGE=? -->
Mannitol

<!-- PAGE=? -->
Monitors

<!-- PAGE=? -->
Arterial catheter

<!-- PAGE=? -->
Temp

<!-- PAGE=? -->
Urinary catheter

<!-- PAGE=? -->
Disposition - ICU

<!-- PAGE=? -->
Hypermetabolic disorder of skeletal muscle intracellular calcium control

<!-- PAGE=? -->
Intracellular hyperccalcemia results in ATP depletion, acidosis, membrane destruction and cell death

<!-- PAGE=? -->
Associated disorders

<!-- PAGE=? -->
o Muscular dystrophy

<!-- PAGE=? -->
o Central core disease

<!-- PAGE=? -->
o King-Denborough

<!-- PAGE=? -->
o Osteogenesis imperfecta

<!-- PAGE=? -->
o Myotonia

<!-- PAGE=? -->
Signs & Symptoms

<!-- PAGE=? -->
o Tachycardia/HTN

<!-- PAGE=? -->
o Tachypnea

<!-- PAGE=? -->
o Rigidity

<!-- PAGE=? -->
o Hyperthermia (1-2 o C / 5 min)

<!-- PAGE=? -->
o ↑ ETCO2

<!-- PAGE=? -->
o hypercarbic metabolic acidosis

<!-- PAGE=? -->
o ↑ K, Ca, lactate, myoglobin, CK (> 20,000)

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
o related to a mutation in the ryanodine receptor (calcium release channel)

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
o Halothane- Caffeine contracture test

<!-- PAGE=? -->
o NAMHG → +MH if either halothane or caffeine contracture is positive

<!-- PAGE=? -->
o Resting CK > 20,000 is a good screen for known family members and MMR patients

<!-- PAGE=? -->
Crisis Treatment

<!-- PAGE=? -->
o Discontinue inhalational agent

<!-- PAGE=? -->
o Hyperventilation with 100% oxygen

<!-- PAGE=? -->
o High flows (10 L/min) with new circuit/machine

<!-- PAGE=? -->
o Dantrolene 2.5 mg/kg

<!-- PAGE=? -->
o Acidosis → NaHCO3 1-2 mEq/kg

<!-- PAGE=? -->
o Hyperkalemia

<!-- PAGE=? -->
 Insulin / glucose (10 units / 50ml of 50%)

<!-- PAGE=? -->
 Hyperventilation / NaHCO3

<!-- PAGE=? -->
 CaCl (10-30 mg/kg) - arrythmias

<!-- PAGE=? -->
o Myglobinuria

<!-- PAGE=? -->
 U/O > 2 ml/kg/hr (mannitol/lasix)

<!-- PAGE=? -->
Post-crisis management

<!-- PAGE=? -->
o ICU 24-48 hours

<!-- PAGE=? -->
o Dantrolene 1 mg/kg IV/PO Q6H

<!-- PAGE=? -->
o Counsel regarding diagnosis and implications for family members

<!-- PAGE=? -->
Dantrolene

<!-- PAGE=? -->
o Muscle relaxant mixed with mannitol

<!-- PAGE=? -->
o Reduces intracellular calcium

<!-- PAGE=? -->
o Nausea/phlebitis/weakness

<!-- PAGE=? -->
Elective Management of MH susceptible patients

<!-- PAGE=? -->
o Flushed machined (> 10 L/min for 10 min)

<!-- PAGE=? -->
o Monitor temperature and ETCO2

<!-- PAGE=? -->
Complications of MH

<!-- PAGE=? -->
ATN Rhabdomyolysis DIC

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Mitral Stenosis

<!-- PAGE=? -->
Hemodynamic Goals

<!-- PAGE=? -->
Rate - Slow

<!-- PAGE=? -->
Rythym - Ideally sinus

<!-- PAGE=? -->
Contractility - maintain RV

<!-- PAGE=? -->
Preload - Normal (avoid ↑ volume)

<!-- PAGE=? -->
Afterload

<!-- PAGE=? -->
Decr PVR for RV

<!-- PAGE=? -->
No abrupt SVR change (fixed CO)

<!-- PAGE=? -->
Pulm HTN

<!-- PAGE=? -->
SBE prophylaxis

<!-- PAGE=? -->
Afib

<!-- PAGE=? -->
Regional: Cautious with SVR

<!-- PAGE=? -->
Medications

<!-- PAGE=? -->
General

<!-- PAGE=? -->
 Sequela of RHD

<!-- PAGE=? -->
 Majority are female

<!-- PAGE=? -->
 ↑ LA pressure / size ⇒ ↓ LV filling/SV during stress

<!-- PAGE=? -->
 CHF with N LV

<!-- PAGE=? -->
 May have Concominant valvular disease

<!-- PAGE=? -->
Signs & Symptoms

<!-- PAGE=? -->
 Dyspnea on exertion

<!-- PAGE=? -->
 Orthopnea/PND

<!-- PAGE=? -->
 Pulmonary Edema

<!-- PAGE=? -->
 Opening snap with diastolic rumble @ apex

<!-- PAGE=? -->
 Hoarsness - RLN compression

<!-- PAGE=? -->
 ECG

<!-- PAGE=? -->
o LAE: Large biphasic P (V1)

<!-- PAGE=? -->
o RAD

<!-- PAGE=? -->
o RVH

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
 Diuretics / Rate control

<!-- PAGE=? -->
 Anticoagulation (AF)

<!-- PAGE=? -->
 Balloon Valvuloplasty / Valvotomy

<!-- PAGE=? -->
OB:

<!-- PAGE=? -->
planned early delivery

<!-- PAGE=? -->
must avoid tachy, valsalva

<!-- PAGE=? -->
may not tolerate autotransfusion

<!-- PAGE=? -->
Milrinone/Norepi for RHF

<!-- PAGE=? -->
Lasix/Bipap for CHF

<!-- PAGE=? -->
VD

<!-- PAGE=? -->
o Aline, PAC

<!-- PAGE=? -->
o Slowly titrated, Strong Epid + Caudal

<!-- PAGE=? -->
o Instumental Delivery

<!-- PAGE=? -->
C/S

<!-- PAGE=? -->
o Main OR

<!-- PAGE=? -->
o TEE

<!-- PAGE=? -->
o Opioid induction + neonates with narcan

<!-- PAGE=? -->
o Post-op ICU

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Mitral Regurgitation

<!-- PAGE=? -->
Hemodynamic goals

<!-- PAGE=? -->
} Rate - 90-100

<!-- PAGE=? -->
} Rythym - Ideally sinus

<!-- PAGE=? -->
} Contractility - avoid depression

<!-- PAGE=? -->
} Preload - maintain adequate

<!-- PAGE=? -->
} Afterload - decrease

<!-- PAGE=? -->
Pulm HTN/CHF

<!-- PAGE=? -->
SBE prophylaxis

<!-- PAGE=? -->
Afib

<!-- PAGE=? -->
Medication concerns

<!-- PAGE=? -->
Diuretics - K +

<!-- PAGE=? -->
Digoxin - toxicity

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
} RHD

<!-- PAGE=? -->
} IHD

<!-- PAGE=? -->
} IE

<!-- PAGE=? -->
} Dilated

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
} ↑ LA volume → ↑ LA size / pressure

<!-- PAGE=? -->
 PHTN

<!-- PAGE=? -->
 Afib (30%)

<!-- PAGE=? -->
} Regurgitant Fraction (RF) > 60% = Severe

<!-- PAGE=? -->
Evaluation

<!-- PAGE=? -->
} Symptoms of CHF

<!-- PAGE=? -->
} Pansystolic murmur @ apex → axilla

<!-- PAGE=? -->
} ECG

<!-- PAGE=? -->
 LAE

<!-- PAGE=? -->
 LVH

<!-- PAGE=? -->
} CXR: Pulmonary edema

<!-- PAGE=? -->
} Echo

<!-- PAGE=? -->
 ↑ LA/LV

<!-- PAGE=? -->
 RF

<!-- PAGE=? -->
 Concomitant VHD

<!-- PAGE=? -->
} CVP / PAC

<!-- PAGE=? -->
 ↑ 'v' waves

<!-- PAGE=? -->
Surgical treatment prior to       RF > 60%

<!-- PAGE=? -->
Preop Dig, ACEI, Nitrates, Diuretics

<!-- PAGE=? -->
Consider 'Cardiac anesthesia'

<!-- PAGE=? -->
Mitral Valve Prolapse

<!-- PAGE=? -->
Avoid small heart/increased emptying:

<!-- PAGE=? -->
decr SNS & maintain afterload

<!-- PAGE=? -->
SBE

<!-- PAGE=? -->
If MVR or thickened leaflets

<!-- PAGE=? -->
Association with vWD

<!-- PAGE=? -->
Most common form of valvular heart disease

<!-- PAGE=? -->
} 5 - 10 %, familial pattern

<!-- PAGE=? -->
} female > male

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
} Anatomic

<!-- PAGE=? -->
 Marfans/Ehler's Danlos

<!-- PAGE=? -->
 vWD

<!-- PAGE=? -->
 muscular dystrophy

<!-- PAGE=? -->
 RHD

<!-- PAGE=? -->
} Functional

<!-- PAGE=? -->
Evaluation

<!-- PAGE=? -->
} Mid-systolic click ± late systolic murmur

<!-- PAGE=? -->
} ECG: Normal, PVC's, SVT

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Muscular Dystrophy

<!-- PAGE=? -->
'A group of progressive primary myopathies characterized by painless degeneration of (resp/cardiac) muscle.'

<!-- PAGE=? -->
Aspiration prophylaxis

<!-- PAGE=? -->
Post-operative respiratory insufficency

<!-- PAGE=? -->
Cardiac dysrythmia and dysfunction

<!-- PAGE=? -->
Altered Pharmacology:

<!-- PAGE=? -->
MH precautions

<!-- PAGE=? -->
Succinycholine contraindicated - rhabdo

<!-- PAGE=? -->
Sensitivity to NDMR's

<!-- PAGE=? -->
Sensitivity to Resp Depressants

<!-- PAGE=? -->
Preop:

<!-- PAGE=? -->
EKG, ECHO

<!-- PAGE=? -->
PFTs, ABG, CXR

<!-- PAGE=? -->
CK

<!-- PAGE=? -->
Intra-op:

<!-- PAGE=? -->
PNS

<!-- PAGE=? -->
TEE

<!-- PAGE=? -->
Classification

<!-- PAGE=? -->
o Pseudohypertrophic (Duchenne's)

<!-- PAGE=? -->
o Limb-girdle

<!-- PAGE=? -->
o Fascioscapulohumeral

<!-- PAGE=? -->
o Nemaline rod myopathy

<!-- PAGE=? -->
o Oculopharyngeal dystrophy

<!-- PAGE=? -->
Duchenne's Muscular Dystrophy

<!-- PAGE=? -->
X-linked recessive

<!-- PAGE=? -->
3:10,000

<!-- PAGE=? -->
Fatty infiltration (pseudohypertrophy)

<!-- PAGE=? -->
Delay in diagnosis - often at age 3-5

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Myotonic Dystrophy

<!-- PAGE=? -->
'A progressive primary myopathy characterized  by persistant contractures after voluntary contraction or electrical stimulation.'

<!-- PAGE=? -->
Aspiration prophylaxis

<!-- PAGE=? -->
Post-operative pulmonary dysfunction

<!-- PAGE=? -->
Cardiac dysrhythmias

<!-- PAGE=? -->
Altered Pharmacology:

<!-- PAGE=? -->
Succinycholine contraindicated (prolonged contraction)

<!-- PAGE=? -->
Avoid reversal of NDMR's

<!-- PAGE=? -->
Sensitivity to sedatives

<!-- PAGE=? -->
(OB - atony)

<!-- PAGE=? -->
General

<!-- PAGE=? -->
Cellular ATP system fails to return Ca to the SR

<!-- PAGE=? -->
Classification

<!-- PAGE=? -->
o Myotonic dystrophica

<!-- PAGE=? -->
o Myotonia congenital

<!-- PAGE=? -->
o Paramytonia congenital

<!-- PAGE=? -->
o Hyperkalemic periodic paralysis

<!-- PAGE=? -->
Myotonic Dystrophica

<!-- PAGE=? -->
Autosomal dominant, 0.3:10,000, Onset in 20s

<!-- PAGE=? -->
Classic triad - frontal baldness, mental retardation, cataract formation

<!-- PAGE=? -->
Pregnancy exacerbates myotonic dystrophy predisposed to uterine atony

<!-- PAGE=? -->
Anticholinesterases may trigger myoclonus

<!-- PAGE=? -->
Therapy - quinine, procainimide, phenytoin, melixetine, and tocainide

<!-- PAGE=? -->
Must avoid hypothermia

<!-- PAGE=? -->
Myotonic Crisis

<!-- PAGE=? -->
Ensure normal T/PaCO2/PaO2/pH

<!-- PAGE=? -->
Consider local infiltration of affected muscle

<!-- PAGE=? -->
Deepen anesthetic

<!-- PAGE=? -->
Procainamide

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Myasthenia Gravis

<!-- PAGE=? -->
Bulbar Weakness

<!-- PAGE=? -->
Aspiration risk

<!-- PAGE=? -->
Respiratory Weakness

<!-- PAGE=? -->
Pre-op pneumonia

<!-- PAGE=? -->
Post-op ventilatory failure

<!-- PAGE=? -->
Pharmacology

<!-- PAGE=? -->
Sensitivity to NDMR's

<!-- PAGE=? -->
Unpredictable to Succinylcholine

<!-- PAGE=? -->
Sensitivity to opioids/benzo

<!-- PAGE=? -->
Immunosuppression

<!-- PAGE=? -->
Potential Mediastinal mass

<!-- PAGE=? -->
General:

<!-- PAGE=? -->
Autoimmune disease of the NMJ with reduced number of Ach receptors

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Ach receptor antibodies in 85% of pts

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Hyperplastic thymus in 70%

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Other autoimmune disorders present in 10% of pts (hypothyroidism, hyperthyroidism, RA)

<!-- PAGE=? -->
Weakness and easy fatigability of skeletal muscle; weakness improves with rest and rapidly deteriorates with repeated efforts

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Ocular muscles affected most commonly (ptosis and diplopia)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Bulbar involvemnt with laryngeal & pharyngeal muscle weakness

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Respiratory muscle involvement in severe disease

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Exacerbations with pregnancy, surgery, stress, infection

<!-- PAGE=? -->
1:20,000 incidence

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Neonatal - 20% risk for infant of affected mother, transient, improves 2-4 weeks

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Congenital - rare

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Juvenile - 4% less than age 10, 24% less than age 20, F:M = 4:1

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Adult - F:M = 1:1 - age less than 50, F:M equal after age 50

<!-- PAGE=? -->
Diagnosis:

<!-- PAGE=? -->
EMGs

<!-- PAGE=? -->
Endrophonium (10 mg / ml - 1, 3 and 6 mg at 3 minute intervals

<!-- PAGE=? -->
Classification (Ossermann)

<!-- PAGE=? -->
I - ocular signs only

<!-- PAGE=? -->
IIB - generalized weakness + resp involvement +/- bulbar signs

<!-- PAGE=? -->
IIA - generalized mild muscle weakness +/- bulbar signs

<!-- PAGE=? -->
III - acute fulminating MG or respiratory dysfunction

<!-- PAGE=? -->
IV - late, sever, generalized disease

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Anticholinesterases (Pyridostigmine)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> ½ Ach at the NMJ

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Duration of 3-4hrs when given orally

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> 30 mg = 1 mg Neostigmine

<!-- PAGE=? -->
Immunosuppression

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Corticosteroids, Azathioprine, cyclophosphamide

<!-- PAGE=? -->
Plasmapheresis / IVIG

<!-- PAGE=? -->
Thymectomy

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> 85% show clinical improvement

<!-- PAGE=? -->
Levinthal's Criteria (Substernal thymectomy)

<!-- PAGE=? -->
Preop

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Avoid resp depressants (opioids and BDZ's)

<!-- PAGE=? -->
Intraop

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Minimize and avoid use of NMB's

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Sux - unpredictable effect (resistant before, sensitive if Tx)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> NDMRs - significantly prolonged effect

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Monitor NM blockade

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Consider inhalational induction

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Begin neostigmine IV 1h  before emergence at 1/30-1/60 daily pyridostigmine dose and infuse over 24hrs

<!-- PAGE=? -->
Postop

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> IMCU/ ICU

<!-- PAGE=? -->
Cholinergic Crisis

<!-- PAGE=? -->
Due to excessive administration of anticholinesterase

<!-- PAGE=? -->
↑ weakness

<!-- PAGE=? -->
↑ muscarinic effects (salivatn, diarrhea, miosis, brady)

<!-- PAGE=? -->
Myasthenia and Pregnancy

<!-- PAGE=? -->
↑ weakness in last trimester and early postpartum

<!-- PAGE=? -->
Epidural anesth preferred - PCEA

<!-- PAGE=? -->
Babies of myasthenic mothers show transient myasthenia for 1-3wks (requiring ventilation & anticholinesterases)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Aspiration risk

<!-- PAGE=? -->
Post-operative respiratory complications

<!-- PAGE=? -->
Pharmacology

<!-- PAGE=? -->
Sensitivity to NDMR's

<!-- PAGE=? -->
Sensitive to Succinylcholine

<!-- PAGE=? -->
Potential Cancer

<!-- PAGE=? -->
Associated with small cell carcinoma of the lung

<!-- PAGE=? -->
Antibody mediated destruction of presynaptic calcium channels -  Leads to deficient release of Ach

<!-- PAGE=? -->
Antiholinergics minimal help

<!-- PAGE=? -->
Give NMB in small increments

<!-- PAGE=? -->
Tx: guanidine, diaminopyridine, IVIG, plasmapheresis

<!-- PAGE=? -->
Anti-cholinesterase rarely effective

<!-- PAGE=? -->
Lambert-Eaton Syndrome (Myesthenic Syndrome)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
O2:

<!-- PAGE=? -->
PPV:

<!-- PAGE=? -->
 -40 to 60 bpm at whatever Pinsp to promptly achieve or maintain a heart rate >100 bpm. (initial inflation pressure of 20 to 25 cm H2O)

<!-- PAGE=? -->
 -exhaled CO2 detection is the recommended method of confirmation

<!-- PAGE=? -->
 -effectiveness of PPV is assessed by increasing HR, improved colour, RR, tone

<!-- PAGE=? -->
CPR:

<!-- PAGE=? -->
 3:1 ratio, 90 compressions and 30 breaths, 120 events per minute

<!-- PAGE=? -->
-DNR:

<!-- PAGE=? -->
 extreme prematurity (gestational age < 23 weeks or birth weight < 400 g)

<!-- PAGE=? -->
 chromosomal abnormalities incompatible with life (T13, anencephaly)

<!-- PAGE=? -->
 no VS after 10 minutes

<!-- PAGE=? -->
Neonatal Resucitation

<!-- PAGE=? -->
Term? Mec? Breathing? Tone? = Take My Baby Tony

<!-- PAGE=? -->
30s - dry, stimulate, warm

<!-- PAGE=? -->
Breathing? Pink? HR>100?  = BPH

<!-- PAGE=? -->
30s - O2, PPV

<!-- PAGE=? -->
HR<60

<!-- PAGE=? -->
30s - CPR

<!-- PAGE=? -->
HR< 60

<!-- PAGE=? -->
30s - Epi

<!-- PAGE=? -->
MEC:

<!-- PAGE=? -->
 no intrapartum suctioning

<!-- PAGE=? -->
 Endotracheal suctioning if not vigorous (one who has strong respiratory efforts, good muscle tone, and a heart rate > 100)

<!-- PAGE=? -->
 -Concerns about potential oxidant injury, especially in the premature infant.

<!-- PAGE=? -->
 -aim for SpO2 90-95%

<!-- PAGE=? -->
 -Supplementary oxygen is recommended when:

<!-- PAGE=? -->
 PPV

<!-- PAGE=? -->
 Central cyanosis is evident (face, trunk, MM)

<!-- PAGE=? -->
 no improvement in 90s

<!-- PAGE=? -->
DRUGS

<!-- PAGE=? -->
 Epinephrine 0.01-0.03 mg/kg = 0.1-0.3 mL/kg (1:10,000) OR 10x this for ETT

<!-- PAGE=? -->
 NaHCO3 2 meq/kg = 4 ml/kg (0.5 meq/mL - 4.2%)

<!-- PAGE=? -->
 Volume Expander (NS) - 10 mL/kg

<!-- PAGE=? -->
 Naloxone  0.1 mg/kg = 0.25 mL/kg  (0.4 mg/mL)

<!-- PAGE=? -->
 Glucose ( < 2.5) = 5 ml/kg D10W

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Approximate

<!-- PAGE=? -->
Routine Care

<!-- PAGE=? -->
Term gestation?

<!-- PAGE=? -->
Provide warmth

<!-- PAGE=? -->
Amniotic fluid clear?

<!-- PAGE=? -->
Clear airway if needed

<!-- PAGE=? -->
Breathing or crying?

<!-- PAGE=? -->
Dry

<!-- PAGE=? -->
Good muscle tone?

<!-- PAGE=? -->
Assess color

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Provide warmth

<!-- PAGE=? -->
Position; clear airway*

<!-- PAGE=? -->
(as necessary)

<!-- PAGE=? -->
Dry; stimulate; reposition

<!-- PAGE=? -->
Orealhinse

<!-- PAGE=? -->
Evaluate respirations;

<!-- PAGE=? -->
heart rate; and color

<!-- PAGE=? -->
Observational Care

<!-- PAGE=? -->
Brcathing,

<!-- PAGE=? -->
HR >100 bul

<!-- PAGE=? -->
Pink

<!-- PAGE=? -->
Cyanotic

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
supplementary

<!-- PAGE=? -->
30 sec

<!-- PAGE=? -->
oxygen

<!-- PAGE=? -->
Persislent

<!-- PAGE=? -->
EHeclivc

<!-- PAGE=? -->
Cyanosis

<!-- PAGE=? -->
100

<!-- PAGE=? -->
4 Pink

<!-- PAGE=? -->
Postresuscitation

<!-- PAGE=? -->
3

<!-- PAGE=? -->
Provide positive-pressure ventilation

<!-- PAGE=? -->
Care

<!-- PAGE=? -->
HR <60

<!-- PAGE=? -->
Provide positive-pressure ventilation*

<!-- PAGE=? -->
Administer chest compressions

<!-- PAGE=? -->
Administer epinephrine andlor volume*

<!-- PAGE=? -->
Endotracheal intubation may

<!-- PAGE=? -->
be considered at several steps

<!-- PAGE=? -->
Time

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
ICP/Decr Inctracranial compliance

<!-- PAGE=? -->
o A-Meticulous  A/W  -  no  hypoxia,  hypercarbia, straining

<!-- PAGE=? -->
o B-Ensuring good ventilation/oxygenation

<!-- PAGE=? -->
o C-Maintain CPP

<!-- PAGE=? -->
o D-Control ICP

<!-- PAGE=? -->
· ICP treatment: (blood - CSF)

<!-- PAGE=? -->
o Raise HOB 20 - 30 o

<!-- PAGE=? -->
o Neutral head position

<!-- PAGE=? -->
o Avoid straining

<!-- PAGE=? -->
o Mild hyperventilation ETCO2=30-35

<!-- PAGE=? -->
o Mannitol - 0.5 g/kg

<!-- PAGE=? -->
o Lasix - 0.5 mg/kg

<!-- PAGE=? -->
o Other:

<!-- PAGE=? -->
 CSF drainage/ICP monitor

<!-- PAGE=? -->
 Paralysis/decr Paw

<!-- PAGE=? -->
 High dose barbiturates 10mg/kg+ 1mg/kg/hr

<!-- PAGE=? -->
 Seizure prophylaxis

<!-- PAGE=? -->
 CPP> 70mmHg

<!-- PAGE=? -->
 Prevent hypoxia

<!-- PAGE=? -->
 Tight glycemic control

<!-- PAGE=? -->
 Passive cooling to 34

<!-- PAGE=? -->
 Isotonic solutions, minimize

<!-- PAGE=? -->
 Aggressive intravascular monitoring

<!-- PAGE=? -->
Assessment

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
difficulty to intubate, ?ability to protect

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
irregular breathing (resp rate and pattern)

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
dysrhythmias (tachy, brady, ½ QT), unstable BP( ½¾ )

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
GCS, headache, vomitting, stiff neck, focal neuro deficits, papilledema

<!-- PAGE=? -->
GU SIADH (oliguria) or DI (polyuria)

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
¾ ECG, ECHO

<!-- PAGE=? -->
¾ CT Head, MRI Head, Cerebral Angios

<!-- PAGE=? -->
¾ Serum and Urine Lytes and Osm

<!-- PAGE=? -->
Monitors

<!-- PAGE=? -->
CAS +  temp, Art Line, CVP - multioriface, ICP

<!-- PAGE=? -->
Foley

<!-- PAGE=? -->
Precordial doppler

<!-- PAGE=? -->
Intubation - Difficult

<!-- PAGE=? -->
-Awake with meticulous topical, simultaneous ICP treatment

<!-- PAGE=? -->
-Haldol (less hypercarbic than midaz/fent) vs. Ketamine after Midaz

<!-- PAGE=? -->
Bad Heart vs ICP

<!-- PAGE=? -->
-optmize Neuro (HOB, hypervent, no straining), but must maintain CPP

<!-- PAGE=? -->
-no mannitol/lasix (preload), HHH (demand), hypothermia (complication)

<!-- PAGE=? -->
Intra-op

<!-- PAGE=? -->
Moderate hyperventilation

<!-- PAGE=? -->
Remifentanyl (min post-op pain) + < 1MAC  (hyperventilation attenuates or abolishes effects of cerebral vasodilation)

<!-- PAGE=? -->
Maintain CPP > 60 mmHg

<!-- PAGE=? -->
Avoid PEEP

<!-- PAGE=? -->
Avoid N2O

<!-- PAGE=? -->
TIVA in patients with severe ICP

<!-- PAGE=? -->
Extubate promptly for early neuro evaluation

<!-- PAGE=? -->
Keep intubated if concerned about postop respiratory/neuro fxn

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Craniotomy

<!-- PAGE=? -->
Cerebral Protection

<!-- PAGE=? -->
Glu

<!-- PAGE=? -->
Temp

<!-- PAGE=? -->
CPP (BP and ICP)

<!-- PAGE=? -->
O2

<!-- PAGE=? -->
Limited Airway access

<!-- PAGE=? -->
Hidden Blood loss

<!-- PAGE=? -->
VAE

<!-- PAGE=? -->
Positioning

<!-- PAGE=? -->
Trans-sphenoidal:

<!-- PAGE=? -->
Small  pituitary  tumours  (large  extrasellar  tumours  must be removed via craniotomy)

<!-- PAGE=? -->
½ ICP issues with regards to anesthetic

<!-- PAGE=? -->
Throat pack

<!-- PAGE=? -->
Sitting or head elevated air embolus precautions

<!-- PAGE=? -->
Steroid coverage, antibx to cover nasal and oropharyngeal flora

<!-- PAGE=? -->
Cocaine infiltrated nasally (HTN, tachycardia, dysrhythmias)

<!-- PAGE=? -->
Complications:

<!-- PAGE=? -->
Blood loss (cavernous sinus and carotid artery)

<!-- PAGE=? -->
Potential for injury to CNs II - VI

<!-- PAGE=? -->
Pneumocephalus

<!-- PAGE=? -->
Endocrine - DI

<!-- PAGE=? -->
Meningitis

<!-- PAGE=? -->
CVA

<!-- PAGE=? -->
Brain Tumor:

<!-- PAGE=? -->
ICP (mass, edema)

<!-- PAGE=? -->
Hydrocephalus (obstructive)

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
Endrocrinopathies

<!-- PAGE=? -->
o DI/SIADH

<!-- PAGE=? -->
o Pituatory

<!-- PAGE=? -->
Pituatary Tumor

<!-- PAGE=? -->
Anterior pit: TSH, ACTH, GH, Prolactin, Gonadotropes (LH,FSH)

<!-- PAGE=? -->
Post pit: vasopressin, oxytocin

<!-- PAGE=? -->
Hormone secreting

<!-- PAGE=? -->
ACTH-Cushing's

<!-- PAGE=? -->
GH-Acromegaly

<!-- PAGE=? -->
TSH-Hyperthyroidism

<!-- PAGE=? -->
ADH: SIADH

<!-- PAGE=? -->
Non secreting  -  compression  which  impairs  secretion  of other pituitary hormones

<!-- PAGE=? -->
ACTH-Addison's

<!-- PAGE=? -->
GH-Short stature, poor stress response

<!-- PAGE=? -->
TSH-Hypothyroidism

<!-- PAGE=? -->
LH/FSH - impotence, amenorrhea, weakness

<!-- PAGE=? -->
ADH: DI

<!-- PAGE=? -->
Delay surgery for endocrine consult, eu-hormonal

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Autonomic dysfunction/instability

<!-- PAGE=? -->
Respiratory failure:

<!-- PAGE=? -->
pre/post op

<!-- PAGE=? -->
Aspiration and pneumonia

<!-- PAGE=? -->
NMB:

<!-- PAGE=? -->
Succinylcholine contraindicated

<!-- PAGE=? -->
NDMB unpredictable/sensitive

<!-- PAGE=? -->
} Decr muscle mass vs Inc Receptors

<!-- PAGE=? -->
Chronic disease

<!-- PAGE=? -->
Positioning/Spasticity/Ulcers

<!-- PAGE=? -->
Pain

<!-- PAGE=? -->
DVT

<!-- PAGE=? -->
Nutrition

<!-- PAGE=? -->
ALS:

<!-- PAGE=? -->
- degenerative upper and lower motor neuron disease, causing denervation, asymmetrical weakness, fasciculation and atrophy of muscle

<!-- PAGE=? -->
-vagal dysfunction - tachy

<!-- PAGE=? -->
-hyperglycemia

<!-- PAGE=? -->
Neuro Degenerative

<!-- PAGE=? -->
Orthostatic Vitals Neuro exam R/O pneumonia CXR, PFTs, ABG EKG

<!-- PAGE=? -->
Relative contraindication to regional

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Guillain-Barré Syndrome:

<!-- PAGE=? -->
-Acute, idiopathic, patchy polyneuritis of the peripheral and autonomic nervous system causing skeletal muscle weakness -emphasis on autonomic dysfunction:

<!-- PAGE=? -->
} Exaggerated response to stimuli and drugs

<!-- PAGE=? -->
} Arrythmia, BP swings

<!-- PAGE=? -->
} Avoid position changes

<!-- PAGE=? -->
} Bowel Obstruction

<!-- PAGE=? -->
} Pikilothermic

<!-- PAGE=? -->
Tx: - steroids, plasmapheresis

<!-- PAGE=? -->
Pregnancy:

<!-- PAGE=? -->
NO NA (Epidural or SAB) - may cause recurrence

<!-- PAGE=? -->
o -risk of exacerbation in 3 rd T

<!-- PAGE=? -->
o -labour: regional to avoid exaggerated hemodynamic response

<!-- PAGE=? -->
o -C-section: avoid regional because of resp failure with high block

<!-- PAGE=? -->
Multiple Sclerosis

<!-- PAGE=? -->
-Acquired, chronically relapsing, progressive autoimmune inflammatory demylination of the CNS that can be exacerbated during the postoperative period, due to surgical stress, emotional stress, infection and fever.  Pts can present with a variety of Motor, Sensory, Cerebellar or CN involvement.

<!-- PAGE=? -->
 Seizures

<!-- PAGE=? -->
 Chronic Pain

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Corticosteroids (methylprednisolone)

<!-- PAGE=? -->
o Cyclophosphamide / Azothiaprine / Methotrexate

<!-- PAGE=? -->
o Baclofen

<!-- PAGE=? -->
 Avoid Hyperthermia

<!-- PAGE=? -->
 Regional anesthesia

<!-- PAGE=? -->
o -Spinal anesthesia contraindicated

<!-- PAGE=? -->
o -Epidural - low concentration or opioid based

<!-- PAGE=? -->
 Avoid elective OR during relapse

<!-- PAGE=? -->
 Pregnancy: Increased exacerbation in first 3-6 months postpartum

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Neurofibromatosis

<!-- PAGE=? -->
'is a complicated multisystem disease with tumors that devlop in various organs causing potential:'

<!-- PAGE=? -->
Difficult airway, C-spine precautions

<!-- PAGE=? -->
Neuro:

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
↑ ICP

<!-- PAGE=? -->
Cord/Nerve compression

<!-- PAGE=? -->
Restrictive Lung Dz

<!-- PAGE=? -->
Kyphoscoliosis

<!-- PAGE=? -->
ILD

<!-- PAGE=? -->
HTN

<!-- PAGE=? -->
RAS

<!-- PAGE=? -->
Pheo

<!-- PAGE=? -->
Unpredictable response to NMBA

<!-- PAGE=? -->
Systems Review

<!-- PAGE=? -->
Airway Resp

<!-- PAGE=? -->
CVS Neuro

<!-- PAGE=? -->
airway obstruction, laryngeal stenosis, pharyngeal compression Kyphoscoliosis (RLD), pulmonary fibrosis, interstitial lung disease HTN (renal artery dysplasia, pheochromocytoma), dysrhythmias, RV outflow obstruction, cor pulmonale

<!-- PAGE=? -->
Intellectual impairment, intracranial tumours, pituitary involvemnent, ½ ICP, hydrocephalus, seizures, spinal cord and peripheral nerve compression, glaucoma

<!-- PAGE=? -->
 Common surgical procedures include nerve decompression, pheochromocytoma excision, repair of renal artery stenosis, obstructive uropathy, pathologic fractures or unrelated surgeries

<!-- PAGE=? -->
 autosomal dominant

<!-- PAGE=? -->
 Hallmark is café-au-lait spots (>6 that are > 1.5cm in diameter) and neurofibromas

<!-- PAGE=? -->
 Two forms are best delineated:

<!-- PAGE=? -->
NF1

<!-- PAGE=? -->
-1 in 3000; autos dominant neurocutaneous syndrome

<!-- PAGE=? -->
-manifestations range in severity and progress with time

<!-- PAGE=? -->
-usually identified under 6 yrs of age

<!-- PAGE=? -->
-50% have neurologic manifestations, also pheochromocytoma, meningioma, glioma, renal artery dysplasia with HTN and hypoglycemia, and 10% have diffuse interstitial pulmonary fibrosis

<!-- PAGE=? -->
NF2

<!-- PAGE=? -->
-1 in 50000

<!-- PAGE=? -->
-bilateral acoustic neuromas, meningiomas, schwannomas of the dorsal roots of the spinal cord, and gliomas

<!-- PAGE=? -->
-café-au-lait spots and neurofibromas much less common

<!-- PAGE=? -->
Anesthetic Implications

<!-- PAGE=? -->
 If emergency case:high index of suspicion for laryngeal obstructn, pheo, RV outflow obstructn, hydrocephalus

<!-- PAGE=? -->
 Consider awake F/O intubation

<!-- PAGE=? -->
 Consider potential for ½ ICP during induction

<!-- PAGE=? -->
 Some have shown prolonge response or resistance to sux and pancuronium

<!-- PAGE=? -->
 Regional blocks may be difficult due to spine deformities

<!-- PAGE=? -->
 Positioning problems second to spine abnormalities

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hyperthermia

<!-- PAGE=? -->
Rhabdomyalisis

<!-- PAGE=? -->
Metabolic Acidosis

<!-- PAGE=? -->
 Rare potentially fatal (20% mortality) complication of antipsychotic drug therapy

<!-- PAGE=? -->
 Presumed to reflect drug induced interference with dopamine's role in central thermoregulation

<!-- PAGE=? -->
 Typically manifests during the first few weeks of therapy or following an increase in drug dosage

<!-- PAGE=? -->
 Diagnostic Criteria

<!-- PAGE=? -->
o Treatment with neuroleptics within 7 days (2-4 weeks for depot preparations)

<!-- PAGE=? -->
o Hyperthermia - > 38C

<!-- PAGE=? -->
o Rigidity

<!-- PAGE=? -->
o Five of:

<!-- PAGE=? -->
 Mental status change

<!-- PAGE=? -->
 Tachycardia

<!-- PAGE=? -->
 Autonomic instability - hyper or hypotension

<!-- PAGE=? -->
 Tachypnea or hypoxia

<!-- PAGE=? -->
 Diaphoresis or sialorrhea

<!-- PAGE=? -->
 Tremor

<!-- PAGE=? -->
 Incontinence

<!-- PAGE=? -->
 CK elevation or myoglobinuria

<!-- PAGE=? -->
 Leukocytosis

<!-- PAGE=? -->
 Metabolic acidosis

<!-- PAGE=? -->
o Exclusion of other cause

<!-- PAGE=? -->
Neuroleptic Malignant Syndrome

<!-- PAGE=? -->
'a potentially fatal complication of antipsychotic drugs with complications including:'

<!-- PAGE=? -->
 DDx

<!-- PAGE=? -->
o Hyperthermia/Heat Stroke

<!-- PAGE=? -->
o Serotonin syndrome

<!-- PAGE=? -->
o MH

<!-- PAGE=? -->
o Thyrotoxicosis

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
o Anticholinergic excess

<!-- PAGE=? -->
o Drugs: ASA, dopaminergic agents, MAOI crisis, cocaine

<!-- PAGE=? -->
 Treatment

<!-- PAGE=? -->
o Oxygenation / ventilation

<!-- PAGE=? -->
o Active cooling

<!-- PAGE=? -->
o Prevent myoglobinuric renal failure

<!-- PAGE=? -->
o Bromocriptine - 5 mg PO Q6H

<!-- PAGE=? -->
o Dantrolene

<!-- PAGE=? -->
 1 mg/kg IV Q6H

<!-- PAGE=? -->
 max 6 mg/kg/day IV

<!-- PAGE=? -->
Acute Dystonia

<!-- PAGE=? -->
Signs & Symptoms

<!-- PAGE=? -->
} Oculogyric crisis

<!-- PAGE=? -->
} Trismus

<!-- PAGE=? -->
} Torticollis

<!-- PAGE=? -->
} Scoliosis

<!-- PAGE=? -->
} Normal mental status

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
} Benztropine (anticholinergic)

<!-- PAGE=? -->
 1 - 2 mg IV / PO BID

<!-- PAGE=? -->
} Diazepam

<!-- PAGE=? -->
 5 - 10 mg PO BID

<!-- PAGE=? -->
} Diphenhydramine

<!-- PAGE=? -->
 25 mg PO QID

<!-- PAGE=? -->
 Anticholinergic properties

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Amniotic Fluid Embolism

<!-- PAGE=? -->
AFE is an emergency, life threatening situation for mother and fetus characterized initially by pulmonary vasospasm resulting in hypoxia, RHF and CV collapse.  This is soon followed by DIC, hemorrhage, pulmonary edema and LV failure.

<!-- PAGE=? -->
Obsterical pt

<!-- PAGE=? -->
Emergency, life threatening

<!-- PAGE=? -->
Fetal and Maternal compromise:

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
RHF with CV Collapse

<!-- PAGE=? -->
DIC & Hemorrhage

<!-- PAGE=? -->
LV failure/Pulm Edema

<!-- PAGE=? -->
Emergency, ABCs

<!-- PAGE=? -->
Inform obstetrician and call for help

<!-- PAGE=? -->
Adequate Oxygenation and Ventilation

<!-- PAGE=? -->
100 % oxygen

<!-- PAGE=? -->
ETT

<!-- PAGE=? -->
Support circulation

<!-- PAGE=? -->
IV fluid, large bore, art line

<!-- PAGE=? -->
Vasopressors

<!-- PAGE=? -->
CPR (with C section), CPB

<!-- PAGE=? -->
Maintain LUD, stop oxytocin

<!-- PAGE=? -->
Blood samples

<!-- PAGE=? -->
Coagulation/factors

<!-- PAGE=? -->
X-match

<!-- PAGE=? -->
Consider corticosteroids

<!-- PAGE=? -->
Hydrocortisone 1-2 grams IV

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
4-5 / 100,000 live births

<!-- PAGE=? -->
12% maternal deaths

<!-- PAGE=? -->
60-85% mortality

<!-- PAGE=? -->
Risk factors

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Multiparity (only true RF)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Short or tumultuous L&D

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Macrosomia

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> CPD

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Uterine stimulation

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Advanced age, meconium, IUFD, titanic contraction, uterine rupture/laceration, chorioaminionitis

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Biphasic response to AFE

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Early transient pulmonary vasospasm → RV dysfunction

<!-- PAGE=? -->
 ↓ CO

<!-- PAGE=? -->
 hypoxia

<!-- PAGE=? -->
 hypotension

<!-- PAGE=? -->
 < 30 minutes

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Second phase of LV dysfunction and pulmonary edema

<!-- PAGE=? -->
 Etiology unclear

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Fetal squamous cells are NOT pathonagmonic

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Zinc coproporphyrin - component of meconium

<!-- PAGE=? -->
Clinical Presentation:

<!-- PAGE=? -->
DDx

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Obstetrical complications

<!-- PAGE=? -->
 AFE

<!-- PAGE=? -->
 Abruption

<!-- PAGE=? -->
 Eclampsia

<!-- PAGE=? -->
 Peripartum CM

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Non-obstetrical complications

<!-- PAGE=? -->
 SHOCKED

<!-- PAGE=? -->
PE / VAE

<!-- PAGE=? -->
Septic shock

<!-- PAGE=? -->
Anaphylaxis

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Anesthetic complications

<!-- PAGE=? -->
 Total spinal

<!-- PAGE=? -->
 Local anesthesia toxicity

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Difficult Airway, NRFHRT:

<!-- PAGE=? -->
No Epidural

<!-- PAGE=? -->
o Attempt SAB

<!-- PAGE=? -->
o Limited to 2 min

<!-- PAGE=? -->
o 22g Quincke

<!-- PAGE=? -->
o 3cc of 2% lidocaine

<!-- PAGE=? -->
Epidural Poorly Fx

<!-- PAGE=? -->
o Abandon epidural

<!-- PAGE=? -->
o No SAB since risk of high block

<!-- PAGE=? -->
o Topicalize A/W

<!-- PAGE=? -->
Epidural Functioning

<!-- PAGE=? -->
OB - Airway

<!-- PAGE=? -->
Failed

<!-- PAGE=? -->
intubation

<!-- PAGE=? -->
Attempt ONE

<!-- PAGE=? -->
more time

<!-- PAGE=? -->
Can

<!-- PAGE=? -->
ventilate

<!-- PAGE=? -->
Normal

<!-- PAGE=? -->
FHR

<!-- PAGE=? -->
Can't

<!-- PAGE=? -->
ventilate

<!-- PAGE=? -->
NRFHRT

<!-- PAGE=? -->
•

<!-- PAGE=? -->
Baby out

<!-- PAGE=? -->
•

<!-- PAGE=? -->
HELP

<!-- PAGE=? -->
•

<!-- PAGE=? -->
Alternate

<!-- PAGE=? -->
•

<!-- PAGE=? -->
Rescue:

<!-- PAGE=? -->
Fastrach

<!-- PAGE=? -->
•

<!-- PAGE=? -->
Surgical

<!-- PAGE=? -->
Wake up

<!-- PAGE=? -->
patient

<!-- PAGE=? -->
FOB

<!-- PAGE=? -->
Maintain

<!-- PAGE=? -->
ventilation +

<!-- PAGE=? -->
CP

<!-- PAGE=? -->
o Bolus Epidural WHILE topicalizing A/W

<!-- PAGE=? -->
Failed Inutbation:

<!-- PAGE=? -->
-Can I Ventilate?

<!-- PAGE=? -->
-What is the FHR?

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Peri-Partum Hemorrhage

<!-- PAGE=? -->
Pregnant pt

<!-- PAGE=? -->
ABC's

<!-- PAGE=? -->
CBC, INR / PTT, X-match, fibrinogen

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
Antepartum:

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
Previa - Placenta or Vasa

<!-- PAGE=? -->
Abruption

<!-- PAGE=? -->
Uterine Rupture

<!-- PAGE=? -->
Postpartum - 4Ts

<!-- PAGE=? -->
T one

<!-- PAGE=? -->
T rauma - vaginal / uterine lacerations

<!-- PAGE=? -->
T issue -  retained placenta, inversion

<!-- PAGE=? -->
T hrombin -  coagulopathy

<!-- PAGE=? -->
 PPH complicates 10% of deliveries

<!-- PAGE=? -->
 > 500 ml SVD, > 1000 ml C/S

<!-- PAGE=? -->
 > 10% decrease in pre-labor HCT

<!-- PAGE=? -->
 Primary - within 24 hours

<!-- PAGE=? -->
 Secondary - 24 hours → 6 weeks

<!-- PAGE=? -->
Antepartum

<!-- PAGE=? -->
Abruption

<!-- PAGE=? -->
¾ Risk factors:

<!-- PAGE=? -->
♦ ½ age, ½ parity

<!-- PAGE=? -->
♦ Prior abruption

<!-- PAGE=? -->
♦ cocaine, smoking

<!-- PAGE=? -->
♦ trauma

<!-- PAGE=? -->
♦ PROM

<!-- PAGE=? -->
♦ PIH

<!-- PAGE=? -->
¾ Anesthetic Considerations

<!-- PAGE=? -->
Hemorrhage, hypovolemia (concealed, refractory)

<!-- PAGE=? -->
Fetal Distress

<!-- PAGE=? -->
DIC

<!-- PAGE=? -->
Uterine Rupture

<!-- PAGE=? -->
¾ Anesth Considerations

<!-- PAGE=? -->
Maternal hemorrhage, hypovolemia, shock

<!-- PAGE=? -->
Fetal distress

<!-- PAGE=? -->
¾ Etiology

<!-- PAGE=? -->
scar: C-Sxn, myomectomy

<!-- PAGE=? -->
Prolonged labour, excess oxytocin stimulation

<!-- PAGE=? -->
CPD

<!-- PAGE=? -->
Multips, multigestation, polyhydramnios

<!-- PAGE=? -->
Traumatic/iatrogenic

<!-- PAGE=? -->
¾ Clinical Manifestations

<!-- PAGE=? -->
♦ Vaginal bleeding

<!-- PAGE=? -->
♦ Severe lower abdo pain

<!-- PAGE=? -->
♦ Absence of contractions

<!-- PAGE=? -->
♦ Shoulder pain

<!-- PAGE=? -->
♦ 'Floating' fetus

<!-- PAGE=? -->
♦ Fetal distress

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Post-Partum

<!-- PAGE=? -->
⋅ Uterine Atony (OPEN)

<!-- PAGE=? -->
 Risk factors:

<!-- PAGE=? -->
⋅ Multiparity

<!-- PAGE=? -->
⋅ Multiple births

<!-- PAGE=? -->
⋅ Polyhydramnios

<!-- PAGE=? -->
⋅ Large infants

<!-- PAGE=? -->
⋅ Retained placenta

<!-- PAGE=? -->
⋅ Operative intervention

<!-- PAGE=? -->
⋅ Chorioamnionitis

<!-- PAGE=? -->
 Bimanual compression / massage

<!-- PAGE=? -->
 O xytocin

<!-- PAGE=? -->
⋅ 0.1 U/kg IV (5-10 Units)

<!-- PAGE=? -->
⋅ 40 U/litre infusion (80 mU/min)

<!-- PAGE=? -->
⋅ peripheral vasodilation, ↓ MAP

<!-- PAGE=? -->
⋅ Carbetocin: 100ug IV bolus

<!-- PAGE=? -->
 P rostoglandins

<!-- PAGE=? -->
⋅

<!-- PAGE=? -->
↑ intracellular Ca ⇒ ↑ myosin light-chain kinase

<!-- PAGE=? -->
⋅ PGE2

<!-- PAGE=? -->
 20 mg PR

<!-- PAGE=? -->
 bronchodilation, ↓ SVR / MAP

<!-- PAGE=? -->
⋅ 15-methyl-PGF2alpha (hemabate)

<!-- PAGE=? -->
 250 mcg IM Q15min (max 2mg)

<!-- PAGE=? -->
 ↑ CO / PAP / SVR / PVR

<!-- PAGE=? -->
 Inc Paw

<!-- PAGE=? -->
⋅ PGE1 (misoprostol)

<!-- PAGE=? -->
 1000ug PR

<!-- PAGE=? -->
 Methylergonovine ( e rgot)

<!-- PAGE=? -->
⋅ 200 mcg IM (20 mcg IV - caution)

<!-- PAGE=? -->
⋅ uterotonic effect - ? alpha agonist (incBP)

<!-- PAGE=? -->
 Non-Rx

<!-- PAGE=? -->
⋅ B-Lynch suture

<!-- PAGE=? -->
⋅ Embolization

<!-- PAGE=? -->
⋅ Clamp Uterine Vessels

<!-- PAGE=? -->
⋅ Gravid Hysterectomy

<!-- PAGE=? -->
⋅

<!-- PAGE=? -->
Retained Placenta - anesthetic options

<!-- PAGE=? -->
 Neuroaxial - insitu

<!-- PAGE=? -->
 N2O

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
 GA

<!-- PAGE=? -->
 GERD prophylaxis

<!-- PAGE=? -->
 Uterine relaxation

<!-- PAGE=? -->
 NTG 50-500 mcg IV (800 mcg SL)

<!-- PAGE=? -->
 Volatile anesthetic

<!-- PAGE=? -->
⋅

<!-- PAGE=? -->
Genital lacerations - anesthetic options

<!-- PAGE=? -->
 Local infiltration

<!-- PAGE=? -->
 Neuroaxial - caution hypotension

<!-- PAGE=? -->
 N2O

<!-- PAGE=? -->
 Ketamine

<!-- PAGE=? -->
 GA

<!-- PAGE=? -->
 GERD prophylaxis

<!-- PAGE=? -->
⋅

<!-- PAGE=? -->
Uterine Inversion - anesthetic options

<!-- PAGE=? -->
 Must relax uterus

<!-- PAGE=? -->
 NTG (terbutaline, magnesium)

<!-- PAGE=? -->
 GA

<!-- PAGE=? -->
 GERD prophylaxis

<!-- PAGE=? -->
⋅

<!-- PAGE=? -->
Placenta Acreta

<!-- PAGE=? -->
 Acreta - adherent to myometrium

<!-- PAGE=? -->
 Increta - invades myometrium

<!-- PAGE=? -->
 Percreta - invades uterine serosa

<!-- PAGE=? -->
 ↑ risk with uterine trauma, placenta previa + prev C/S

<!-- PAGE=? -->
 0 C/S - 5% incidence

<!-- PAGE=? -->
 1 C/S - 25%

<!-- PAGE=? -->
 2 C/S - 50%

<!-- PAGE=? -->
 Anesthetic considerations

<!-- PAGE=? -->
 2 obstetricians

<!-- PAGE=? -->
 clamp uterine vessels

<!-- PAGE=? -->
 early hysterectomy

<!-- PAGE=? -->
 preoperative embolectomy catheter

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
ACLS - as per usual

<!-- PAGE=? -->
Place patient in left uterine displacement

<!-- PAGE=? -->
Perform chest compressions higher on the sternum

<!-- PAGE=? -->
Consult OB & neonatology STAT

<!-- PAGE=? -->
Perimortem C/S should begin within 4 minutes of cardiac arrest

<!-- PAGE=? -->
10.8 Pregnancy and ACLS

<!-- PAGE=? -->
-Airway: secure early. risk of regurgitation. Apply continuous cricoid pressure during positive pressure

<!-- PAGE=? -->
-Breathing: In late pregnancy the esophageal detector device is more likely to suggest esophageal placement

<!-- PAGE=? -->
-Circulation: - Perform chest compressions higher on the sternum, slightly above the center of the sternum. -Ltilt 15-30degr

<!-- PAGE=? -->
-is no evidence that shocks from a direct current defibrillator have adverse effects on the heart of the fetus.

<!-- PAGE=? -->
- If fetal or uterine monitors are in place, remove them before delivering shocks.

<!-- PAGE=? -->
-drugs decr uterine blood flow

<!-- PAGE=? -->
-fibrinolytics are relatively contraindicated in pregnancy, increased risk for spontaneous aortic dissection.

<!-- PAGE=? -->
-Life-threatening pulmonary embolism

<!-- PAGE=? -->
-Amniotic fluid embolism .

<!-- PAGE=? -->
-The best survival rate for infants >24 to 25 weeks in gestation occurs when the delivery of the infant occurs no more than 5 minutes after the mother's heart stops beating

<!-- PAGE=? -->
-Gestational age <20 weeks. Urgent cesarean delivery need not be considered because a gravid uterus of this size is unlikely to significantly compromise maternal cardiac output.

<!-- PAGE=? -->
Obstetric Cardiac Arrest

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Pregnancy

<!-- PAGE=? -->
Exagerated physiologic changes

<!-- PAGE=? -->
Materal complications

<!-- PAGE=? -->
PTL

<!-- PAGE=? -->
Uterine Atony

<!-- PAGE=? -->
Antepartum / PPH

<!-- PAGE=? -->
Abruption

<!-- PAGE=? -->
Fetal Complications

<!-- PAGE=? -->
Malpresentation

<!-- PAGE=? -->
IUGR

<!-- PAGE=? -->
Twin-twin transfusion

<!-- PAGE=? -->
Double Setup/Operative delivery

<!-- PAGE=? -->
Multiple Gestation

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Non-Obstetric Surgery

<!-- PAGE=? -->
Pregnant

<!-- PAGE=? -->
GOAL: Uteroplacental perfusion

<!-- PAGE=? -->
Risk of

<!-- PAGE=? -->
SA / PTL

<!-- PAGE=? -->
Teratogenicity

<!-- PAGE=? -->
Uterine Injury

<!-- PAGE=? -->
Team:

<!-- PAGE=? -->
Obstetric/Neonate/LD nurse

<!-- PAGE=? -->
FHR/Toco monitoring

<!-- PAGE=? -->
2% of pregnant pts undergo NOBS

<!-- PAGE=? -->
o Trauma

<!-- PAGE=? -->
o Rupture/torsion of ovarian cyst

<!-- PAGE=? -->
o Appendectomy

<!-- PAGE=? -->
o Breast tumors

<!-- PAGE=? -->
There is an increased risk of fetal death, especially in the first trimester, and with pelvic surgery or cervical cerclage.

<!-- PAGE=? -->
Indirect effects of anesthesia on embryo/fetus:

<!-- PAGE=? -->
o Placental perfusion is decreased by maternal hypotension, regional techniques, hemorrhage, and aortocaval compression.

<!-- PAGE=? -->
o Under anesthesia, several things influence placental perfusion:

<!-- PAGE=? -->
 Depth of GA

<!-- PAGE=? -->
 Sympathectomy with a high spinal/epi

<!-- PAGE=? -->
 Aortocaval compression

<!-- PAGE=? -->
 Hemorrhage/Hypovolemia

<!-- PAGE=? -->
 Hypo/hyper-ventilation

<!-- PAGE=? -->
 DRUGS:

<!-- PAGE=? -->
alpha-agonists and ketamine - increase uterine tone

<!-- PAGE=? -->
Epinephrine/norepinephrine - decr uterine BF

<!-- PAGE=? -->
General principles:

<!-- PAGE=? -->
o Delay until T2 if possible

<!-- PAGE=? -->
o zantac/maxeran/sodium citrate

<!-- PAGE=? -->
o LUD beginning at week 14

<!-- PAGE=? -->
o Regional > GA

<!-- PAGE=? -->
o Strick hemodynamic control

<!-- PAGE=? -->
o Choose drugs with a long history of safety - thiopental, morphine

<!-- PAGE=? -->
o Avoid Benzo, N2O - though no proven assoc.

<!-- PAGE=? -->
o Anesthetic requirements decreased in pregnancy

<!-- PAGE=? -->
o Avoid maternal hyperventilation, monitor ETCO2.

<!-- PAGE=? -->
o FHR monitoring if accessable - end organ measure

<!-- PAGE=? -->
o FHR + Toco monitor post-op

<!-- PAGE=? -->
o Avoid NSAIDs

<!-- PAGE=? -->
o PTL - ventolin/Ritodrine/MgSO4/Adalat (10mg)/consultation with OB

<!-- PAGE=? -->
Fetal effects of anesthesia

<!-- PAGE=? -->
o Oxygenation - Fetal PaO2 never increases beyond 60, even when maternal PaO2 is >600

<!-- PAGE=? -->
o Maternal CO2 and acid-base status - maternal hypercapnia can cause fetal acidosis and hypoperfusion.

<!-- PAGE=? -->
o Alkalosis can cause umbilical artery constriction and shifting the maternal oxygen-hemoglobin dissociation curve to the left

<!-- PAGE=? -->
o PPV decreases venous return

<!-- PAGE=? -->
Laparoscopy:

<!-- PAGE=? -->
o Can be safe, BUT - uterus injury, placental perf, incr CO2 in baby

<!-- PAGE=? -->
Intracranial OR:

<!-- PAGE=? -->
o No hyperventilation (decr uterine BF)

<!-- PAGE=? -->
o Avoid Mannitol - fetal dehydration

<!-- PAGE=? -->
o No SNP - accumulation of metabolites in fetus

<!-- PAGE=? -->
o Careful with hypothermia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
OB - Postpartum Headache

<!-- PAGE=? -->
'a relatively common complication of dural puncture secondary to decr CSF.  The most important anesthetic consideration is:'

<!-- PAGE=? -->
Establishing Correct Dx

<!-- PAGE=? -->
Relief of Symptoms:

<!-- PAGE=? -->
DDx

<!-- PAGE=? -->
Vascular:

<!-- PAGE=? -->
} SAH / SDH

<!-- PAGE=? -->
} Cortical vein thrombosis

<!-- PAGE=? -->
Neuro:

<!-- PAGE=? -->
} Migraine / cervicogenic

<!-- PAGE=? -->
} Pseudotumor cerebri

<!-- PAGE=? -->
Meningitis

<!-- PAGE=? -->
PDPH

<!-- PAGE=? -->
Frontal occipital headache

<!-- PAGE=? -->
Radiates to neck (nuchal rigidity)

<!-- PAGE=? -->
Worse in upright position

<!-- PAGE=? -->
CN VI (longest) palsy

<!-- PAGE=? -->
Generally improves with time

<!-- PAGE=? -->
Treament:

<!-- PAGE=? -->
Conservative:

<!-- PAGE=? -->
Psychological support

<!-- PAGE=? -->
Hydration → avoid dehydration

<!-- PAGE=? -->
Acetominophen / NSAID's / Codiene

<!-- PAGE=? -->
Caffeine 300 mg PO TID

<!-- PAGE=? -->
Invasive:

<!-- PAGE=? -->
Epidural blood patch (15-20 ml)

<!-- PAGE=? -->
} 80-90% success

<!-- PAGE=? -->
} warn: back pain, radiculopathy

<!-- PAGE=? -->
} Done at level below

<!-- PAGE=? -->
} Flat x 1hr, 45deg x 1hr, sitting x 1hr

<!-- PAGE=? -->
} Contraindication: c/i to epidural, sepsis/bacteremia

<!-- PAGE=? -->
Meningitis: ok if 3 days after antibiotics/antivirals and ∅ fever or ½ WBC

<!-- PAGE=? -->
HIV ∅ contraindication

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
1:4000 incidence

<!-- PAGE=? -->
Unknown etiology

<!-- PAGE=? -->
Diagnosis of exclusion

<!-- PAGE=? -->
Onset in final month of pregnancy or within 5 months of delivery

<!-- PAGE=? -->
Rapid decompensation

<!-- PAGE=? -->
} Biventricular failure

<!-- PAGE=? -->
} Low cardiac output

<!-- PAGE=? -->
} Elevated filling pressures

<!-- PAGE=? -->
} Ventricular ectopy

<!-- PAGE=? -->
Risk Factors

<!-- PAGE=? -->
} Multiple gestation

<!-- PAGE=? -->
} Preeclampsia

<!-- PAGE=? -->
} Obesity

<!-- PAGE=? -->
} Advanced maternal age

<!-- PAGE=? -->
} Breast-feeding

<!-- PAGE=? -->
} Previous PPCM (20% relapse)

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
} Supportive

<!-- PAGE=? -->
} Prompt delivery

<!-- PAGE=? -->
 Cesarean or instrumental vaginal

<!-- PAGE=? -->
 GA - 'cardiac'

<!-- PAGE=? -->
 Epidural - guided by PAC

<!-- PAGE=? -->
OB - Peripartum Cardiomyopathy

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
OB - Preeclampsia

<!-- PAGE=? -->
'is a complication of pregnancy that can vary in magnitude, at its worst leading to ICH or cardiac, respiratory, renal or hepatic failure'

<!-- PAGE=? -->
Airway Edema

<!-- PAGE=? -->
CVS:

<!-- PAGE=? -->
Increased SVR

<!-- PAGE=? -->
Unpredictable CI and volume status

<!-- PAGE=? -->
Potential for coagulopathy and seizure

<!-- PAGE=? -->
Fetal compromise

<!-- PAGE=? -->
IUGR

<!-- PAGE=? -->
PTL

<!-- PAGE=? -->
Systems Review

<!-- PAGE=? -->
Airway airway edema

<!-- PAGE=? -->
Resp pulmonary edema

<!-- PAGE=? -->
CVS ½ SVR, ¾ plasma volume, ¾ CO

<!-- PAGE=? -->
HTN, PHTN, CHF

<!-- PAGE=? -->
CNS CNS irritability : hyperreflexia, clonus, headaches, visual

<!-- PAGE=? -->
changes, somnolence,

<!-- PAGE=? -->
Cerebral Edema, seizures, ICH,

<!-- PAGE=? -->
GI hepatic dysfxn, hepatic subcapsular edema

<!-- PAGE=? -->
GU ½ proteinuria, ¾ RBF and GFR, oliguria, ARF

<!-- PAGE=? -->
Heme

<!-- PAGE=? -->
platelet dysfxn +/- thrombocytopenia

<!-- PAGE=? -->
Coag defects with ½ PTT, INR, FDP's

<!-- PAGE=? -->
Obst

<!-- PAGE=? -->
¾ UBF and placental perfusion

<!-- PAGE=? -->
½ uterine irritability, preterm labour, placental abruption IUGR, fetal distress

<!-- PAGE=? -->
History:

<!-- PAGE=? -->
 Headache, blurred vision, seizures

<!-- PAGE=? -->
 Epigastric pain

<!-- PAGE=? -->
 Easy bruising

<!-- PAGE=? -->
 Antepartum hemorrhage, preterm labour

<!-- PAGE=? -->
Exam:

<!-- PAGE=? -->
Vitals

<!-- PAGE=? -->
JVP, peripheral perfusion, generalized edema

<!-- PAGE=? -->
Airway for edema

<!-- PAGE=? -->
retinal edema, hyperreflexia, clonus

<!-- PAGE=? -->
enlarged liver edge

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
CXR, ECG +/- ECHO

<!-- PAGE=? -->
X-match (4 units)

<!-- PAGE=? -->
Urine Protein or dipstick

<!-- PAGE=? -->
LFT, CBC, Coags, FDP's, Lytes, Crea, Uric acid, Mg

<!-- PAGE=? -->
+/- CT head

<!-- PAGE=? -->
FH Monitor

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
-Assess for signs of severe disease

<!-- PAGE=? -->
-GOALS: Stablization and Delivery (dz process ends usu after 48hrs post delivery)

<!-- PAGE=? -->
-Monitors:  Routine, Foley, FH Monitor, Aline +/- CVP(PA cath)

<!-- PAGE=? -->
-Care:

<!-- PAGE=? -->
Highly monitored setting during L&D and postop

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Expand circulating blood volume carefully

<!-- PAGE=? -->
MgSO4 4-6g IV bolus over 15min's, then infusn of 1-3g/hr

<!-- PAGE=? -->
Tocolytic, vasodilator, anti-convusant, anti-SNS

<!-- PAGE=? -->
AntiHTN's to maintain dBP <110mmHg

<!-- PAGE=? -->
Monitor: levels (5-7mg/dl), DTR, NMBA

<!-- PAGE=? -->
-Labetolol or Hydralazine 5-10mg IV

<!-- PAGE=? -->
-NTG infusn 0.5-3.0 μ g/kg/min

<!-- PAGE=? -->
-SNP infusn 0.25-2 μ g/kg/min

<!-- PAGE=? -->
Analgesia (ideally epidural) ¾ catecholamine response to pain

<!-- PAGE=? -->
-Ensure adequate fluid loading

<!-- PAGE=? -->
-Check plt count and coags pre placement

<!-- PAGE=? -->
-Slow titration

<!-- PAGE=? -->
-NO epineph in test dose

<!-- PAGE=? -->
Oliguria: If no response to boluses insert CVP/PA cath

<!-- PAGE=? -->
 HELLP: hemolysis (smear/bili), AST> 70, Plts<100

<!-- PAGE=? -->
 CHF

<!-- PAGE=? -->
Consider lasix, digoxin, dopamine

<!-- PAGE=? -->
CVP/PA cath inserted to guide fluid resuscitation

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
Cricoid pressure and attempt to mask ventilate

<!-- PAGE=? -->
100% Oxygen by FM; maintain LUD

<!-- PAGE=? -->
Intubate if unable to mask ventilate; (consider small ETT and difficult airway)

<!-- PAGE=? -->
Drugs: STP 50-100mg Iv

<!-- PAGE=? -->
Midaz 1-2mg IV/ Diazpm 2.5-5mg IV

<!-- PAGE=? -->
MgSO4 2-4g IV bolus; continue infusn

<!-- PAGE=? -->
C-Sxn when stablized

<!-- PAGE=? -->
Consider mannitol if suspect cerebral edema

<!-- PAGE=? -->
GA for CSxn

<!-- PAGE=? -->
Consider art line placement pre-induction

<!-- PAGE=? -->
Aggressive BP control prior to inductn/emergence SNP infusn; NTG infusn; Labetolol boluses (esmolol bolus or infusn); Fenatanyl 50-150 μ g IV

<!-- PAGE=? -->
Difficult airway

<!-- PAGE=? -->
Criteria for the Diagnosis of Preeclampsia

<!-- PAGE=? -->
Hypertension

<!-- PAGE=? -->
A  sustained  SBP>  140  mmHg,  or  a  sustained  DBP>  90  mmHg,  that  occurs  after  20 weeks' gestation in a women with previously normal blood pressure

<!-- PAGE=? -->
Proteinuria

<!-- PAGE=? -->
> 300 mg protein in a 24 hour urine collection

<!-- PAGE=? -->
Features of Severe Preeclampsia

<!-- PAGE=? -->
Blood  preesure:    >  160  mmHg  systolic  or  >  110  mmHg  diastolic  on  two occasions at least 6 hours apart while the patient is on bed rest; diagnosis is not delayed if the diastolic blood pressure exceeds 110 mmHg

<!-- PAGE=? -->
Proteinuria:  > 5 g in a 24 hour urine specimen (or > 3+ on two random urine samples at least 4 hours apart

<!-- PAGE=? -->
Oliguria:  Urine output < 500 ml in 24 hours

<!-- PAGE=? -->
Cerebral or Visual  Disturbances:  Headache, blurred vision, or altered LOC

<!-- PAGE=? -->
Pulmonary edema or cyanosis

<!-- PAGE=? -->
Epigastric or RUQ pain

<!-- PAGE=? -->
Hepatic rupture

<!-- PAGE=? -->
Impaired liver function

<!-- PAGE=? -->
Thrombocytopenia

<!-- PAGE=? -->
Fetal growth restriction

<!-- PAGE=? -->
Differential Diagnosis of Hypertension During Pregnancy

<!-- PAGE=? -->
Drug abuse (Cocaine)

<!-- PAGE=? -->
Preeclampsia/eclampsia

<!-- PAGE=? -->
Chronic hypertension

<!-- PAGE=? -->
Pain/noxious stimulation

<!-- PAGE=? -->
Hypoxia/hypercarbia

<!-- PAGE=? -->
Pheochromocytoma

<!-- PAGE=? -->
MH

<!-- PAGE=? -->
Opioid/alcohol withdrawal

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Obstertical Pt

<!-- PAGE=? -->
Two patients

<!-- PAGE=? -->
Fetus is susceptible to compromise

<!-- PAGE=? -->
Mother-physiological and pharmacological changes:

<!-- PAGE=? -->
-aortocaval compression

<!-- PAGE=? -->
-full stomach

<!-- PAGE=? -->
-potentially difficult airway

<!-- PAGE=? -->
-Maintain LUD throughout management

<!-- PAGE=? -->
-consult obstetrics and neonates

<!-- PAGE=? -->
-request FHR

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
   Potentially difficult airway

<!-- PAGE=? -->
   Tissue edema, friable tissue, large breasts, increased obesity

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
decreased MAC changes epidural anatomy local anesthetic sensitivity

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
Increased alveolar ventilation

<!-- PAGE=? -->
Decreased FRC

<!-- PAGE=? -->
Increased oxygen consumption

<!-- PAGE=? -->
↑ 2.3 DPG, P50 O2 27-30

<!-- PAGE=? -->
Cardiovascular

<!-- PAGE=? -->
   increased CO, increased HR, increased SV

<!-- PAGE=? -->
   increased blood volume

<!-- PAGE=? -->
   decreased SVR

<!-- PAGE=? -->
   aortacaval compression starting 14wks

<!-- PAGE=? -->
Heme

<!-- PAGE=? -->
   increased HGB but relative anemia

<!-- PAGE=? -->
   hypercoagulable

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
   full stomach at 18wks (decreased LES tone, decreased emptying -post opioids)

<!-- PAGE=? -->
b.    relative pseudocholinesterase deficiency

<!-- PAGE=? -->
Endocrine

<!-- PAGE=? -->
   Insulin resistanvce/GDM

<!-- PAGE=? -->
   Obesity

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
FHR:

<!-- PAGE=? -->
DDx (any problem)

<!-- PAGE=? -->
OB

<!-- PAGE=? -->
AFE

<!-- PAGE=? -->
Eclampsia

<!-- PAGE=? -->
PIH

<!-- PAGE=? -->
Peri-partum CM

<!-- PAGE=? -->
Abruption

<!-- PAGE=? -->
Hemorrhage

<!-- PAGE=? -->
Aortocaval Compression

<!-- PAGE=? -->
Non-OB

<!-- PAGE=? -->
Cardiac - valve/rythym/muscle/sac

<!-- PAGE=? -->
Resp - ddx hypoxia, Paw

<!-- PAGE=? -->
Neuro - ddx loc

<!-- PAGE=? -->
Vascluar -  Dissection, ischemia

<!-- PAGE=? -->
e.

<!-- PAGE=? -->
Anesthesia

<!-- PAGE=? -->
High Block

<!-- PAGE=? -->
LA Toxiticty

<!-- PAGE=? -->
Analgesia

<!-- PAGE=? -->
Stage I: T10 - L1  Due to uterine contractions and cervical dilatation

<!-- PAGE=? -->
Stage II:

<!-- PAGE=? -->
T10 - S4 Perineum from pudendal nerve (S2 - S4)

<!-- PAGE=? -->
Non-pharm: TENS, Lamaze, Bath

<!-- PAGE=? -->
Parental - Fentanyl, Demerol, Ketamine, Nalbuphine

<!-- PAGE=? -->
Inhaled - N2O

<!-- PAGE=? -->
PNB

<!-- PAGE=? -->
Paracervical Block: for 1 st stage of labour

<!-- PAGE=? -->
Pudendal Block: Perineal analgesia for 2 nd stage; episiotomy; forceps or vacuum

<!-- PAGE=? -->
NA - SAB, CSE, Epidural

<!-- PAGE=? -->
C/S

<!-- PAGE=? -->
 CAS monitors, O2, free-flowing large-bore IV,

<!-- PAGE=? -->
 LUD, sniffing

<!-- PAGE=? -->
 NaCitrate 30cc, Bloodwork Sent

<!-- PAGE=? -->
 Call for OB - scrubbed, Neonates

<!-- PAGE=? -->
 RECHECK FHR

<!-- PAGE=? -->
 Topicalize A/W while Topping up epidural

<!-- PAGE=? -->
 SAB:

<!-- PAGE=? -->
o Urgent: 22g Quinke, 2% lido x 2.5cc + Fent 25ug

<!-- PAGE=? -->
o Elective: Bupiv 0.75% x 1.3cc = 10mg

<!-- PAGE=? -->
o Prepped/Draped

<!-- PAGE=? -->
o Maching Checked, Back-up A/Ws

<!-- PAGE=? -->
o Preoxygenate

<!-- PAGE=? -->
o STP 4mg/kg (Ketamine 2mg/kg), Sux 1.5mg/kg

<!-- PAGE=? -->
o Prior to Del: 100%O2 + Volatile

<!-- PAGE=? -->
o Maintenance: Opiod+N20+low Volatile

<!-- PAGE=? -->
 GA:

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Obesity

<!-- PAGE=? -->
'a disease with widespread systemic comorbidity and complications including potential'

<!-- PAGE=? -->
Difficult airway

<!-- PAGE=? -->
Difficult IV/Monitoring

<!-- PAGE=? -->
GERD

<!-- PAGE=? -->
Respiratory disease

<!-- PAGE=? -->
RLD

<!-- PAGE=? -->
OSA

<!-- PAGE=? -->
PHTN

<!-- PAGE=? -->
Other Concominant disease

<!-- PAGE=? -->
HTN

<!-- PAGE=? -->
CAD

<!-- PAGE=? -->
DM

<!-- PAGE=? -->
-BMI> 28M/27F, Morbid >35

<!-- PAGE=? -->
 -CNS -

<!-- PAGE=? -->
o neuropathy

<!-- PAGE=? -->
o central sleep apnea

<!-- PAGE=? -->
 -A/W -

<!-- PAGE=? -->
o

<!-- PAGE=? -->
diff BMV, diff DL

<!-- PAGE=? -->
 -Resp -

<!-- PAGE=? -->
o OSA

<!-- PAGE=? -->
o Pulm HTN

<!-- PAGE=? -->
o RLD

<!-- PAGE=? -->
o decr FRC (quick desat)

<!-- PAGE=? -->
o incr Paw

<!-- PAGE=? -->
 -CVS -

<!-- PAGE=? -->
o incr CO

<!-- PAGE=? -->
o decr. Function

<!-- PAGE=? -->
o HTN

<!-- PAGE=? -->
o Pulm HTN, Cor pulmonale

<!-- PAGE=? -->
o CAD

<!-- PAGE=? -->
o DVT

<!-- PAGE=? -->
 -GI -

<!-- PAGE=? -->
o GERD

<!-- PAGE=? -->
o Fatty Liver

<!-- PAGE=? -->
 -Metab:

<!-- PAGE=? -->
o DM

<!-- PAGE=? -->
o pharmacology/dynamics, (Vd, dosing, lipids)

<!-- PAGE=? -->
 -Other:

<!-- PAGE=? -->
o position, IV access, regional, monitoring, wound infection

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Akinesia

<!-- PAGE=? -->
Profound analgesia

<!-- PAGE=? -->
Obtundation of oculocardiac reflex

<!-- PAGE=? -->
Control of IOP

<!-- PAGE=? -->
Controlled emergence

<!-- PAGE=? -->
Avoid N2O

<!-- PAGE=? -->
Sulfar hexafluoride → 10 days

<!-- PAGE=? -->
Perfluoropropane → 30 days

<!-- PAGE=? -->
Open Globe:

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
Prevent Incr IOP

<!-- PAGE=? -->
No cough, straining

<!-- PAGE=? -->
Elevate HOB

<!-- PAGE=? -->
Mannitol, Lasix, Acetozolamide

<!-- PAGE=? -->
Hyperventilation

<!-- PAGE=? -->
Peds:

<!-- PAGE=? -->
FDT - no sux

<!-- PAGE=? -->
Ophthalmic Surgery

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Opioid Conversion

<!-- PAGE=? -->
IV :

<!-- PAGE=? -->
PO :

<!-- PAGE=? -->
Roughly : Codiene PO 200 = Morphine 30mg PO - 2 Tabs T#3 = 60mg codeine = 10mg morphine

<!-- PAGE=? -->
Duragesic

<!-- PAGE=? -->
not linear conversion!

<!-- PAGE=? -->
Roughly:  25ug/hr = Morphine 60mg PO/day   OR  3x the fentanyl dose

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Obstructive Sleep Apnea

<!-- PAGE=? -->
Difficult airway (BMV)

<!-- PAGE=? -->
CVS → HTN, LVH, PHTN

<!-- PAGE=? -->
Obesity

<!-- PAGE=? -->
Pain management (non-opioid)

<!-- PAGE=? -->
Postoperative monitoring / disposition

<!-- PAGE=? -->
SCORING OF INVASIVENESS OF SURGERY AND ANESIHESIA

<!-- PAGE=? -->
SCORING OF OPIOID REQUIREMENT

<!-- PAGE=? -->
DETERMINATION OF PERIOPERATIVE RISK OF OSA

<!-- PAGE=? -->
OSA SEVERITY (1-3)

<!-- PAGE=? -->
INVASIVENESS OF ANESTHESIA OR SURGERY (1-3)

<!-- PAGE=? -->
Whichever

<!-- PAGE=? -->
Either

<!-- PAGE=? -->
OR

<!-- PAGE=? -->
is

<!-- PAGE=? -->
POSTOP OPIOIDS (13)

<!-- PAGE=? -->
greater

<!-- PAGE=? -->
IF RISK SCORE = 4 = INCREASED PERIOP RISK IF RISK SCORE 2 5 = SIG INCREASED PERIOP RISK

<!-- PAGE=? -->
80 - 95 % undiagnosed

<!-- PAGE=? -->
Deep non-REM & REM sleep associated with loss of motor tone

<!-- PAGE=? -->
60 - 90 % of OSA pt's are obese

<!-- PAGE=? -->
Systemic Manifestations

<!-- PAGE=? -->
} HTN

<!-- PAGE=? -->
} Biventricular hypertrophy

<!-- PAGE=? -->
} Arrhythmias

<!-- PAGE=? -->
} PHTN

<!-- PAGE=? -->
} Polycythemia

<!-- PAGE=? -->
Apnea

<!-- PAGE=? -->
} Cessation of airflow > 10 sec associated with ↓ SpO2 of at least 4%

<!-- PAGE=? -->
Hyponea

<!-- PAGE=? -->
} 30% ↓ airflow > 10 sec associated with ↓ SpO2 of at least 4%

<!-- PAGE=? -->
Risk Factors

<!-- PAGE=? -->
} Obesity

<!-- PAGE=? -->
} Hypothyroidism

<!-- PAGE=? -->
} ↑ neck circumference (> 43 cm)

<!-- PAGE=? -->
 + 4 cm HTN

<!-- PAGE=? -->
 + 3 cm snoring

<!-- PAGE=? -->
 + 3 cm gasping

<!-- PAGE=? -->
} Craniofacial abnormalities

<!-- PAGE=? -->
} Acromegaly

<!-- PAGE=? -->
Apnea-Hyponea index (AHI)

<!-- PAGE=? -->
} 21-40 (peds 6-10) → moderate

<!-- PAGE=? -->
} 5-20 (peds 1-5) → mild

<!-- PAGE=? -->
} > 40 (peds 10) → severe

<!-- PAGE=? -->
} POOR correlation with symptoms and quality of life

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
} OSA/ASA = 4

<!-- PAGE=? -->
 PACU 3 hours longer - any signs of obstruction → 7 hours longer

<!-- PAGE=? -->
 Outpatient unless;

<!-- PAGE=? -->
Upper abdominal laparoscopy

<!-- PAGE=? -->
Tonsillectomy < 3 years

<!-- PAGE=? -->
UPPP

<!-- PAGE=? -->
} OSA/ASA > 4 → IMCU / ICU

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Anesthesia Out of the OR

<!-- PAGE=? -->
Poor access to the usual

<!-- PAGE=? -->
People - nurse, surgeon, RT

<!-- PAGE=? -->
Equipment - A/W, O2, Suction, Monitors, crash cart

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
-ensure that throughout management, you bring the each of those with you.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Elective surgery

<!-- PAGE=? -->
Identify:

<!-- PAGE=? -->
Determine type & function of pacer

<!-- PAGE=? -->
Indication & underlying rhythm

<!-- PAGE=? -->
Reprogram:

<!-- PAGE=? -->
VOO if pacer dependant

<!-- PAGE=? -->
Turn off antitachycardia or ICD function

<!-- PAGE=? -->
Electrocautery precautions

<!-- PAGE=? -->
Return plate distant from operative site

<!-- PAGE=? -->
Bipolar electrocautery

<!-- PAGE=? -->
Short burst

<!-- PAGE=? -->
Lowest possible energy

<!-- PAGE=? -->
Backup:

<!-- PAGE=? -->
Have external cardioversion-defibrillator available

<!-- PAGE=? -->
IV chronotropes ready :isopreteronol, dobutamine, atropine

<!-- PAGE=? -->
Emergent surgery

<!-- PAGE=? -->
Attempt identification of device (CXR) - number and continuity of leads

<!-- PAGE=? -->
Test magnet - should turn ICD to monitor only, pacer to VOO (not always)

<!-- PAGE=? -->
**follow up visit with pacemaker clinic**

<!-- PAGE=? -->
Pacemakers

<!-- PAGE=? -->
Indications

<!-- PAGE=? -->
Sick sinus syndrome

<!-- PAGE=? -->
2 nd degree Mobitz II block

<!-- PAGE=? -->
3 rd degree AV block

<!-- PAGE=? -->
sympotomatic bradycardia, SVT, VTach

<!-- PAGE=? -->
HCOM

<!-- PAGE=? -->
LQT

<!-- PAGE=? -->
Poor EF

<!-- PAGE=? -->
External Pacing pads - Management

<!-- PAGE=? -->
Use the lowest possible current

<!-- PAGE=? -->
Anterior - posterior placement (perpendicular to leads/generator)

<!-- PAGE=? -->
> 10 cm from pulse generator

<!-- PAGE=? -->
Situations probably requiring pacemaker reprogramming

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Pain - Blocks

<!-- PAGE=? -->
Stellate

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Head , neck, arm, and upper chest pain

<!-- PAGE=? -->
 CRPS, raynauds, scleroderma, refractory angina, frostbite, occlusive vascular dz, phantom limb

<!-- PAGE=? -->
 Usually blocks cervical ganglia and upper thoracic ganglia (down to T5)

<!-- PAGE=? -->
 Contraindication

<!-- PAGE=? -->
 Severe Lung Dz

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 Stellate ganglion (C7) is the largest of the four cervical ganglia (fusion of the lower cervical and T1 ganglia)

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Fluroscopic guided

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine, Arms at side

<!-- PAGE=? -->
 Head extended with roll under the shoulders to stretch esophagus away

<!-- PAGE=? -->
 Mouth open to relax neck muscles

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 transverse process of C6 (Chassaignac's tubercle)

<!-- PAGE=? -->
 Found at the medial edge of the SCM just below the level of the cricoid cartilage

<!-- PAGE=? -->
 Feel for the carotid pulse and retract the SCM with carotid sheath lateral with non-dominant hand, middle and index fingers

<!-- PAGE=? -->
 Push trachea medial

<!-- PAGE=? -->
 Needle : 2' 22g short bevel needle

<!-- PAGE=? -->
 LA to the skin with a 25 g 1.5' needle

<!-- PAGE=? -->
 Pierce the skin and advance the needle perpendicular to all plains between fingers until the transverse process of C6 is reached

<!-- PAGE=? -->
 withdraw the needle 1mm

<!-- PAGE=? -->
 Aspirate, Confirm location with ISOvue 200

<!-- PAGE=? -->
 Drug/Dose : 1cc test dose then 10 cc of marcaine 0.5% (no epi)

<!-- PAGE=? -->
 Sit pt up after so that drug settles to C7

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 SUCCESS: Ipsilateral Horner's Syndrome (ptosis, meiosis, enophthalmos, nasal congestion and anhydrosis), ½ skin temperature in ipsilateral arm

<!-- PAGE=? -->
 Intravascular Injection - seizure

<!-- PAGE=? -->
 Epidural anesthesia

<!-- PAGE=? -->
 Brachial Plexus block

<!-- PAGE=? -->
 RLN block (hoarseness)

<!-- PAGE=? -->


<!-- PAGE=? -->
Phrenic Nerve block (60%)

<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->


<!-- PAGE=? -->
Hematoma

<!-- PAGE=? -->
Pneumothorax

<!-- PAGE=? -->
Esophageal puncture

<!-- PAGE=? -->
Osteitis or mediastinitis

<!-- PAGE=? -->
Left: shorten QT

<!-- PAGE=? -->
Longus Colli Muscle

<!-- PAGE=? -->
2. Middle Cervical Ganglion

<!-- PAGE=? -->
3. Stellate Ganglion

<!-- PAGE=? -->
Scalenus Anterior Muscle

<!-- PAGE=? -->
5. Scalenus Medius Muscle

<!-- PAGE=? -->
Transverse Process of

<!-- PAGE=? -->
First Thoracic Vertebra

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Celiac Plexus

<!-- PAGE=? -->
 Indication

<!-- PAGE=? -->
 Pain arising from abdominal viscera (foregut)

<!-- PAGE=? -->
 Also blocks the lumbar sympathetic chain

<!-- PAGE=? -->
 Contraindication

<!-- PAGE=? -->
 Volume deplete

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 Clustered at the level of the body of L1

<!-- PAGE=? -->
 Posterior to the vena cava on the right

<!-- PAGE=? -->
 Just lateral to the aorta on the left

<!-- PAGE=? -->
 Posterior to the pancreas

<!-- PAGE=? -->
 Technique:

<!-- PAGE=? -->
 Fluroscopic/CT guided

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Prone pt with thoracic spine flexed using pillow under abdomen

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 spinous process of T12 and L1

<!-- PAGE=? -->
 12 th rib (marked 7cm from midline on each side at the lvel of the L1 spinous process)

<!-- PAGE=? -->
 Needle : 12.5cm 22G Chiba

<!-- PAGE=? -->


<!-- PAGE=? -->
 Advanced  45 degrees - aim medially, anteriorally and slightly cephlad

<!-- PAGE=? -->
 Once body of L1 contacted, needle is withdrawn, angle is steepened, walk off anterior border of the body of L1

<!-- PAGE=? -->
 Advance the needle 2-3cm beyond this point (stop when arterial pulsations are appreciated)

<!-- PAGE=? -->
 Aspirate x 4 , Confirm location with ISOvue 200

<!-- PAGE=? -->
 Drug/Dose : 20 cc of marcaine 0.25% + epi per side

<!-- PAGE=? -->
 Complication

<!-- PAGE=? -->
 SUCCESS: Pain relief, decrease N/V

<!-- PAGE=? -->
 Splanic dilation: hypotension

<!-- PAGE=? -->
 Parasympathetic predominance: diarrhea

<!-- PAGE=? -->
 Pt must remain supine for several hrs and must be adequately fluid resuscitated; gradual ambulation

<!-- PAGE=? -->
 Pneumothorax

<!-- PAGE=? -->
 Retroperitoneal hemorrhage

<!-- PAGE=? -->
 Injury to kidney or pancreas

<!-- PAGE=? -->
 Paraplegia (injury of artery of Adamkiewicz)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Lumbar Sympathetic

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 SNS block of the lower extremities without somatic nerve blockade

<!-- PAGE=? -->
 CRP, early herpes zoster, or diagnostically in severe PVD

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 SNS nerves all exit the cord above L2

<!-- PAGE=? -->
 All pass through a common gateway ganglia at the L2 level

<!-- PAGE=? -->
 lies much more anterior to the somatic nerves, (clean separation of SNS block from somatic block)

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Fluroscopic/CT guided

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Prone pt with lumbar spine flexed using pillow under abdomen

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 spinous process of L2 and L4

<!-- PAGE=? -->
 mark 10cm from midline on each side

<!-- PAGE=? -->
 Needle : 12.5cm 22G Chiba

<!-- PAGE=? -->
 Advanced  45 degrees - aim medially and  anteriorally between transverse proc.

<!-- PAGE=? -->
 Once body of L2 contacted (about 10cm), needle is withdrawn, angle is steepened, walk off anterior border of the body of L2

<!-- PAGE=? -->
 Advance the needle until through psoas fascia (LORTA)

<!-- PAGE=? -->
 Aspirate x 4 , Confirm location with ISOvue 200

<!-- PAGE=? -->
 Drug/Dose : 10 cc of marcaine 0.25% + epi at L2 and L4

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 SUCCESS:  vasodilation and ½ skin temperature within the leg in 5-10 minutes

<!-- PAGE=? -->
 L2 somatic nerve root block (anesthesia across the lateral and anterior thigh)

<!-- PAGE=? -->
 Lumbar plexus between psoas and quadratus - lumbar somatic block

<!-- PAGE=? -->
Aorta

<!-- PAGE=? -->
IVC.

<!-- PAGE=? -->
Sympathetic Ganglion

<!-- PAGE=? -->
Lumbar Plexus

<!-- PAGE=? -->
Quadratus

<!-- PAGE=? -->
Latissimus

<!-- PAGE=? -->
Lumborum M.

<!-- PAGE=? -->
Dorsi M.

<!-- PAGE=? -->
10 cm

<!-- PAGE=? -->
Psoas Major M.

<!-- PAGE=? -->
4 ins.

<!-- PAGE=? -->
Erector Spinae M.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hypogastric

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Painful pelvic condition

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 Superior hypogastric plexus is retroperitoneal at the sacral promontory (between the lower 1/3  of L5  and the upper 1/3 of S1 bodies)

<!-- PAGE=? -->
 In close proximity to the bifurcation of the common iliac vessels

<!-- PAGE=? -->
 Formed by lumbar sympathetic chains and aortic plexus (+ some PNS fibers by pelvic splanchinic)

<!-- PAGE=? -->
 Divides into L/R hypogastric nerves

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Fluroscopic/CT guided

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Prone pt with lumbar spine flexed using pillow under pelvis

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 L4/5 interspace

<!-- PAGE=? -->
 mark 7cm from midline on each side

<!-- PAGE=? -->
 Needle : 15cm 22G Chiba

<!-- PAGE=? -->
 Advanced  45 degrees medially and 30 degrees caudal towards lower L5 body (often hits iliac crest or L5 trans proc)

<!-- PAGE=? -->
 Once body of L5 contacted, walked off anterior and then advanced 1cm

<!-- PAGE=? -->
 Advance the needle until through psoas fascia (LORTA)

<!-- PAGE=? -->
 Aspirate x 4 , Confirm location with ISOvue 200

<!-- PAGE=? -->
 Drug/Dose : 6-8 cc of marcaine 0.25% + epi (somatics close by)

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 SUCCESS:  pain relief

<!-- PAGE=? -->
 Retroperitoneal hematoma

<!-- PAGE=? -->
 Somatic nerve block

<!-- PAGE=? -->
 Visceral/intraperitoneal puncture

<!-- PAGE=? -->
Plerus

<!-- PAGE=? -->
Anery

<!-- PAGE=? -->
A

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Chronic Pain Syndromes

<!-- PAGE=? -->
Cancer

<!-- PAGE=? -->
 Determine the type of cancer; site of origin; stage of the dz; presence of metastases; site of pain and mechanism of pain

<!-- PAGE=? -->
 Acute vs chronic

<!-- PAGE=? -->
 Related to tumour progression

<!-- PAGE=? -->
-compression or infiltration of peripheral nerves, nerve roots or spinal cord

<!-- PAGE=? -->
-infiltration of bone and soft tissue

<!-- PAGE=? -->
-obstruction or distension of visceral structures

<!-- PAGE=? -->
-vascular occlusion/ischemia

<!-- PAGE=? -->
 Related to therapeutic intervention

<!-- PAGE=? -->
-Surgical related scar pain; neuroma formation; sympathetic dystrophy; venous or lymphatic obstruction

<!-- PAGE=? -->
-Chemotherapy related peripheral neuropathies

<!-- PAGE=? -->
-Radiotherapy related esophagitis; plexopathy; myopathy; bone necrosis

<!-- PAGE=? -->
-Herpes zoster due to immune suppression

<!-- PAGE=? -->
-Steroid related aseptic bony necrosis or rheumatoid-like sx's

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
Non-neurolytic Nerve Blocks

<!-- PAGE=? -->
 Useful in pts with tumour compression of nerve roots, brachial and femoral plexuses, and peripheral nerves

<!-- PAGE=? -->
 Perineural or epidural steroid injections can provide pain relief for up to 1 month

<!-- PAGE=? -->
Neuroltyic Nerve Blocks

<!-- PAGE=? -->
 Useful in pts with refractory cancer pain who are terminal usually within months

<!-- PAGE=? -->
 Extent and duration of analgesia limited by regrowth of axons and development of central pain mechanisms

<!-- PAGE=? -->
 Drawback is the inability to precisely control spread of agents

<!-- PAGE=? -->
 Alcohol (pain on injection, prompt neurolysis)

<!-- PAGE=? -->
 Phenol (no pain on injectioninitial anesthetic effect, takes 15 minutes to produce neurolysis)

<!-- PAGE=? -->
 Neurolytic celiac plexus blocks effective for intraabdo cancers especially of the pancreas

<!-- PAGE=? -->
 Lumbar sympathetic, hypogastric plexus, trans-sacral neurolytic blocks useful for malignancies of the pelvis

<!-- PAGE=? -->
 Neurolytic saddle block in pts with refractory pelvic pain; although significant bowel and bladder dysfxn

<!-- PAGE=? -->
 Neurolytic intercostal blocks helpful in pts with rib metastases

<!-- PAGE=? -->
Radiation

<!-- PAGE=? -->
Chemotherapy

<!-- PAGE=? -->
Hormonal Therapy

<!-- PAGE=? -->
Surgery: Can be used for tumour debulking; alleviation of compression and fixation of fracture

<!-- PAGE=? -->
Psychological Intervention

<!-- PAGE=? -->
Post-Herptic

<!-- PAGE=? -->
Acute Tx:

<!-- PAGE=? -->
Acyclovir

<!-- PAGE=? -->
Epid Steroid

<!-- PAGE=? -->
Prevention

<!-- PAGE=? -->
Famcyclovir 500mg TID x 7d

<!-- PAGE=? -->
Sympathetic Block

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
TCA

<!-- PAGE=? -->
Anticonvulsant

<!-- PAGE=? -->
Capsacin

<!-- PAGE=? -->
TENS

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Back Pain

<!-- PAGE=? -->
DDx:

<!-- PAGE=? -->
DDD, Stenosis, Failed Back Surg

<!-- PAGE=? -->
Radicular, (L4, L5, S1), radiation to buttocks

<!-- PAGE=? -->
Worse with activity, flexion

<!-- PAGE=? -->
Mechanical (Facet, SI)

<!-- PAGE=? -->
Mainly back, spasm

<!-- PAGE=? -->
Worse with extension, lateral flexion

<!-- PAGE=? -->
SI: Faber

<!-- PAGE=? -->
Myofacial

<!-- PAGE=? -->
Other

<!-- PAGE=? -->
Cancer, Hematoma, Abcess, Pancreatitis, Ank Spon, Renal Colic, #

<!-- PAGE=? -->
O/E:

<!-- PAGE=? -->
-Flex, Ext, Rotate, Lat Flex

<!-- PAGE=? -->
-Posture, Guarding, Gait

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
-Epidural Steroid

<!-- PAGE=? -->
-Facet block

<!-- PAGE=? -->
-Surgery

<!-- PAGE=? -->
Phantom Limb:

<!-- PAGE=? -->
DDx:

<!-- PAGE=? -->
prosthogenic (poor prosthetic fit)

<!-- PAGE=? -->
neurogenic (can be from neuroma formation)

<!-- PAGE=? -->
arthrogenic

<!-- PAGE=? -->
sympathogenic

<!-- PAGE=? -->
referred

<!-- PAGE=? -->
abnormal stump tissue

<!-- PAGE=? -->
Tx: Preemptive Block, Nerve infiltration, Neuropathich Rx.

<!-- PAGE=? -->
CRPS

<!-- PAGE=? -->
burning pain, allodynia, autonomic and dystrophic changes

<!-- PAGE=? -->
Type 1: neuropath pain with minor inj: crush, laceration, sprain, fractures

<!-- PAGE=? -->
Type 2: neuropath pain with major nerve trunk injury

<!-- PAGE=? -->
Pathophysiology - sensitization of WDR neurons by C-nociceptors, becoming more sensitive to all subsequent input

<!-- PAGE=? -->
-Delay surgery x 1yr

<!-- PAGE=? -->
-Early treatment: WHO, neuropathic agents, sympathetic blocks

<!-- PAGE=? -->
-Physio

<!-- PAGE=? -->
-Avoid ketamine, pressors

<!-- PAGE=? -->
Stages:

<!-- PAGE=? -->
Acute Phase - lack of sympathetic

<!-- PAGE=? -->
Burning/aching quality

<!-- PAGE=? -->
Alodynia/hyperesthesia

<!-- PAGE=? -->
+/- temperature changes & edema

<!-- PAGE=? -->
↑ periarticular uptake on three-phase technetium bone scan

<!-- PAGE=? -->
accelerated hair and nail growth

<!-- PAGE=? -->
Dystrophic Phase - excess sympathetic

<!-- PAGE=? -->
cool, mottled

<!-- PAGE=? -->
cyanosis

<!-- PAGE=? -->
hairless

<!-- PAGE=? -->
diffuse osteoporosis

<!-- PAGE=? -->
Atrophic Phase2 nd to prolonged vasoconstriction

<!-- PAGE=? -->
thin shiny skin

<!-- PAGE=? -->
thickened fascia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Chronic Pain

<!-- PAGE=? -->
- 'This constellation of symptoms is consistent with a chronic pain syndrome such as ….., which has psychological (depression, sleep alteration), pharmacologic (opiod tolerance, s/e, post-op pain) and physiologic (decrease function, ADLs) considerations.  I will begin by completing a history, physical exam to establish a differential diagnosis'

<!-- PAGE=? -->
History ( CPAP)

<!-- PAGE=? -->
Characterize Pain

<!-- PAGE=? -->
 SOLDERR

<!-- PAGE=? -->
 Burning, Electrical, Allodynia, Hyperalgesia

<!-- PAGE=? -->
 Dermatomal vs PN distribution

<!-- PAGE=? -->
Psychological Effects

<!-- PAGE=? -->
 Sleep

<!-- PAGE=? -->
 Mood

<!-- PAGE=? -->
 Effects on Daily Living/Loss of Function

<!-- PAGE=? -->
Associated Manifestations

<!-- PAGE=? -->
 Co-morbidities

<!-- PAGE=? -->
 Neurologic (Semsory, Motor, Bowel & Bladder)

<!-- PAGE=? -->
 Autonomic

<!-- PAGE=? -->
 Temperature/palor

<!-- PAGE=? -->
 Sweating/Dryness

<!-- PAGE=? -->
Prior Interventions

<!-- PAGE=? -->
 Pharmacologic

<!-- PAGE=? -->
 Nerve Blocks

<!-- PAGE=? -->
 Surgical

<!-- PAGE=? -->
 Physio

<!-- PAGE=? -->
Physical Examination

<!-- PAGE=? -->
 Vitals

<!-- PAGE=? -->
 Regional landmarks

<!-- PAGE=? -->
 Site of  Pain

<!-- PAGE=? -->
 Neuro Exam - Motor, Sens, Reflex

<!-- PAGE=? -->
 Vascular Exam

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
 CBC, ESR (CT disease, infection), Vit B12, Folate, TSH, HgA1C

<!-- PAGE=? -->
 Radiologic

<!-- PAGE=? -->
 X-rays/CT/MRI

<!-- PAGE=? -->
 Bone Scan

<!-- PAGE=? -->
 EMG

<!-- PAGE=? -->
 Consultants: Neuro, Rehab, PT/OT, psych

<!-- PAGE=? -->
Differential Diagnosis

<!-- PAGE=? -->
¿ Acute vs Chronic, CRPS

<!-- PAGE=? -->
 Neuropathic

<!-- PAGE=? -->
 Neuroaxial - stenosis, tumor

<!-- PAGE=? -->
 Lumbosacral Radiculopathy

<!-- PAGE=? -->
 Plexopathy

<!-- PAGE=? -->
 Peripheral Neuropathy (Neurodegen, DM, Vitamin)

<!-- PAGE=? -->
 Sympathetic

<!-- PAGE=? -->
 Vascular

<!-- PAGE=? -->
 Ischemia

<!-- PAGE=? -->
 Clot

<!-- PAGE=? -->
 Infection

<!-- PAGE=? -->
 Inflammatory - cellulitis, trauma, lymphedema

<!-- PAGE=? -->
 Connective Tissue Dz (scleroderma, raynauds)

<!-- PAGE=? -->
 MS

<!-- PAGE=? -->
 Diabetic Neuropathy

<!-- PAGE=? -->
 Cancer Pain

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Management 'Multimodal and multidisciplinary approach where the goal is establishing

<!-- PAGE=? -->
the diagnosis and regain function'

<!-- PAGE=? -->
Non-Invasive:

<!-- PAGE=? -->
psychology - living and functioning with pain

<!-- PAGE=? -->
physio

<!-- PAGE=? -->
TENS/acupuncture

<!-- PAGE=? -->
Phamacology: (Anti-nociceptive vs Neuropathic vs other)

<!-- PAGE=? -->
NSAIDS

<!-- PAGE=? -->
Acetaminophen 325 - 600 mg Q4H PO (Max 4g/day)

<!-- PAGE=? -->
Ibuprofen (Advil) 200 - 400 mg Q8-12H PO

<!-- PAGE=? -->
Naproxen (Naprocin) 500 mg initially followed by 250 mg Q6-8H PO

<!-- PAGE=? -->
Celecoxib (Celebrex) 100mg PO Q12H

<!-- PAGE=? -->
Opioids

<!-- PAGE=? -->
 PO

<!-- PAGE=? -->
 IV (CADD)

<!-- PAGE=? -->
TCA

<!-- PAGE=? -->
 Effects due to blockade of presynaptic reuptake of seritonin and/or NE; drugs that have significant seritonin blocking activity are more effective as analgesics (amitriptyline, imipramine, prozac)

<!-- PAGE=? -->
 Drugs:

<!-- PAGE=? -->
a)

<!-- PAGE=? -->
Amitriptyline (Elavil)

<!-- PAGE=? -->
-25 mg PO OD

<!-- PAGE=? -->
-high sedating (antihistamine) effect ∴ best given at HS

<!-- PAGE=? -->
-high anticholinergic effect (dry mouth, impaired visual accomodation, urinary retention, constipation)

<!-- PAGE=? -->
-orthostatic hypotension (moderate antiNE effect)

<!-- PAGE=? -->
Nortriptyline (Desipramine)

<!-- PAGE=? -->
-10 mg PO OD

<!-- PAGE=? -->
-less sedation

<!-- PAGE=? -->
Anticonvulsants

<!-- PAGE=? -->
 Suppress spontaneous neural discharges

<!-- PAGE=? -->
 Indicated in pts with neuropathic pain, especially trigeminal neuralgia

<!-- PAGE=? -->
 Drugs:

<!-- PAGE=? -->
Gabapentin (Neurontin) 100mg TID,  max 3600mg/day

<!-- PAGE=? -->
Carbamazepine (Tegretol) 200 - 1200 mg daily

<!-- PAGE=? -->
Pregabalin (lyrica) 75mg Q12H

<!-- PAGE=? -->
Steroids

<!-- PAGE=? -->
Phentolamine 0.5mg/kg, clonidine

<!-- PAGE=? -->
Lidocaine

<!-- PAGE=? -->
 1.5 mg/kg bolus, 1.5mg/kg over 1hr

<!-- PAGE=? -->
Tramacet (37.5 mg + Tylenol) 2tabs Q4-6H PO, max 8tabs

<!-- PAGE=? -->
 weak mu agaonist, SNRI

<!-- PAGE=? -->
 not in seizures, renal failure

<!-- PAGE=? -->
Cesamet (nabilone) 1mg QHS PO

<!-- PAGE=? -->
Invasive:

<!-- PAGE=? -->
-IVRA: Bretlium 1.5mg/kg or Guanethidine 10mg + Lidocaine

<!-- PAGE=? -->
Peripheral Nerve Blocks - Nerve Sheath Cath 100mg + Toradol + Dex

<!-- PAGE=? -->
Sympathetic Blocks

<!-- PAGE=? -->
Epidural/SAB (bilat, symp+somatic)

<!-- PAGE=? -->
Epidural Steroid (solumedrol 80mg in 5cc NS) x 3

<!-- PAGE=? -->
Adrenal suppression, glucose, AVN of femoral head, risk of infection, arachnoiditis

<!-- PAGE=? -->
Facet : Radio Freq Ablation or depomedrol 10mg+ 4ccNS each level)

<!-- PAGE=? -->
Dorsal Column Stimulation (refer)

<!-- PAGE=? -->
Neurolysis: (refer) 1 to 2 ml of 6% aqueous phenol or 10% phenol with local, dye

<!-- PAGE=? -->
Surgical Sympathectomy

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Adenosine

<!-- PAGE=? -->
100 mcg/kg IV (2 nd dose 200 mcg)

<!-- PAGE=? -->
Amiodarone

<!-- PAGE=? -->
5 mg/kg IV (upto 15mg/kg)

<!-- PAGE=? -->
Atropine

<!-- PAGE=? -->
20 mcg/kg

<!-- PAGE=? -->
Min dose=0.1 mg

<!-- PAGE=? -->
Max single dose=0.5 mg child, 1.0 mg adolescent

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
10 ug/kg IV (1:10,000 0.1 mL/kg)

<!-- PAGE=? -->
ETT 10x that amount, dilute with 3-5cc NS

<!-- PAGE=? -->
Glucose

<!-- PAGE=? -->
0.5-1 g/kg (i.e. 5 - 10 ml/kg D10W)

<!-- PAGE=? -->
Lidocaine

<!-- PAGE=? -->
1 mg/kg  IV / ETT

<!-- PAGE=? -->
CaCl2(10%)

<!-- PAGE=? -->
20 mg/kg IV (0.2ml/kg)

<!-- PAGE=? -->
Ca gluconate

<!-- PAGE=? -->
50 mg/kg IV

<!-- PAGE=? -->
MgSO4

<!-- PAGE=? -->
25-50 mg/kg IV (over 10min)

<!-- PAGE=? -->
Max=2g/dose

<!-- PAGE=? -->
Naloxone

<!-- PAGE=? -->
≤ 5 yrs or ≤ 20 kg 0.1 mg/kg

<!-- PAGE=? -->
>5 yrs or >20 kg 2.0 mg

<!-- PAGE=? -->
1-15ug/kg for resp depression

<!-- PAGE=? -->
Procainamide

<!-- PAGE=? -->
15 mg/kg over 30-60 min

<!-- PAGE=? -->
NaHCO3

<!-- PAGE=? -->
1 - 2 mEq / kg

<!-- PAGE=? -->
8.4% = 1 mEq/mL (1-2 ml/kg)

<!-- PAGE=? -->
Pediatric ACLS

<!-- PAGE=? -->
BLS:

<!-- PAGE=? -->
-if pulse< 60 with signs of poor perfusion: compressions

<!-- PAGE=? -->
-30:2 for single rescue, 15:2 for 2 rescuer

<!-- PAGE=? -->
-with airway 8-10bpm, rescue breaths only 12-20bpm

<!-- PAGE=? -->
-The 2 thumb-encircling hands, compress about 1/3 AP depth

<!-- PAGE=? -->
-most pedsarrests are asphyxial, should give one cycle of CPR then get EMS

<!-- PAGE=? -->
FBO:

<!-- PAGE=? -->
-child: perform subdiaphragmatic abdominal thrusts (Heimlich maneuver)

<!-- PAGE=? -->
-infant: 5 back blows, followed by 5 chest thrusts (relatively large liver)

<!-- PAGE=? -->
Hypotension:

<!-- PAGE=? -->
< 60 mm Hg in term neonates (0 to 28 days)

<!-- PAGE=? -->
< 70 mm Hg in infants (1 month to 12 months)

<!-- PAGE=? -->
< 70 mm Hg + (2 x age in years) in children 1 to 10 years

<!-- PAGE=? -->
< 90 mm Hg in children > 10 years of age

<!-- PAGE=? -->
Interosseous Access:

<!-- PAGE=? -->
Needle - marrow or 18 G

<!-- PAGE=? -->
Position - 1 cm below tibial tuberosity

<!-- PAGE=? -->
A/W:

<!-- PAGE=? -->
-EDD can be used if >20kg

<!-- PAGE=? -->
-max suction: 80-120 mm Hg for the airway via an endotracheal tube

<!-- PAGE=? -->
Electrical:

<!-- PAGE=? -->
-largest paddles that will fit on the chest wall  with 3 cm between the paddles

<!-- PAGE=? -->
-Defib:  (monophasic or biphasic) 2 J/kg for the first attempt,  4 J/kg after

<!-- PAGE=? -->
-AED used safely for age> 1yr, should use dose-attenuating system

<!-- PAGE=? -->
-Cardioversion: 0.5 to 1 J/kg

<!-- PAGE=? -->
Tachy:

<!-- PAGE=? -->
-QRS duration is for Narrow comples: < 0.08 second

<!-- PAGE=? -->
-Vagal: ice to face, Valsalva (blow through an obstructed straw_

<!-- PAGE=? -->
-NO verapamil in infants(refractory hypotension and cardiac arrest)

<!-- PAGE=? -->
Trauma:

<!-- PAGE=? -->
-recess the occiput or elevate the torso (avoid cervical flexion)

<!-- PAGE=? -->
-bolus of 20 mL/kg. If signs of shock persist 3 boluses of isotonic crystalloid, give 10 to 15 mL/kg of blood

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
9 +

<!-- PAGE=? -->
{

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
14

<!-- PAGE=? -->
81

<!-- PAGE=? -->
1

<!-- PAGE=? -->
i

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
84

<!-- PAGE=? -->
g

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
3

<!-- PAGE=? -->
g

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
8

<!-- PAGE=? -->
5

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
g

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
7

<!-- PAGE=? -->
ë

<!-- PAGE=? -->
8

<!-- PAGE=? -->
8

<!-- PAGE=? -->
8

<!-- PAGE=? -->
;

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
1

<!-- PAGE=? -->
9

<!-- PAGE=? -->
1

<!-- PAGE=? -->
|

<!-- PAGE=? -->
8

<!-- PAGE=? -->
5

<!-- PAGE=? -->
9

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
5

<!-- PAGE=? -->
I

<!-- PAGE=? -->
1

<!-- PAGE=? -->
H

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
W

<!-- PAGE=? -->
8

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
:

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
2

<!-- PAGE=? -->
1

<!-- PAGE=? -->
2

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
8

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1i

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
8

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
81

<!-- PAGE=? -->
1

<!-- PAGE=? -->
5

<!-- PAGE=? -->
==

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
JI

<!-- PAGE=? -->
2

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
1

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Peds  BLS

<!-- PAGE=? -->
No movement or response

<!-- PAGE=? -->
Send someone to phone 911,

<!-- PAGE=? -->
AED

<!-- PAGE=? -->
Lone Hescuer: For SUDDEN COLLAPSE,

<!-- PAGE=? -->
PHONE 911, Get AED

<!-- PAGE=? -->
Open AIRWAY; check BREATHING

<!-- PAGE=? -->
It not breathing give 2 BREATHS that make chest rise

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
brealh every

<!-- PAGE=? -->
DEFINITE

<!-- PAGE=? -->
3 seconds

<!-- PAGE=? -->
within 10 seconds?

<!-- PAGE=? -->
Recheck pulse every

<!-- PAGE=? -->
2 minutes

<!-- PAGE=? -->
One Rescuer: Give cycles of 30 COMPRESSIONS and 2 BREATHS

<!-- PAGE=? -->
Push hard and fast (1OOmin) and release completely

<!-- PAGE=? -->
Minimize interruptions in compressions

<!-- PAGE=? -->
Two Rescuers: Give cycles of 15 COMPRESSIONS and 2 BREATHS

<!-- PAGE=? -->
If not already done; PHONE 911, for chlld get AED/defibrillator

<!-- PAGE=? -->
Infant (<1 year): Continue CPR until ALS responders take over or

<!-- PAGE=? -->
Child (21 year): Continue CPR; use AEDIdelibrillator after 5 cycles of CPR

<!-- PAGE=? -->
(Use AED as soon as it is available tor sudden; witnessed collapse)

<!-- PAGE=? -->
Child >1 year;

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
get

<!-- PAGE=? -->
pulse

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Peds

<!-- PAGE=? -->
Arrest

<!-- PAGE=? -->
PULSELESS ARREST

<!-- PAGE=? -->
BLS Algorithm: Continue CPR

<!-- PAGE=? -->
Give oxygen when available

<!-- PAGE=? -->
Attach monitorldefibrillator when available

<!-- PAGE=? -->
Shockable

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
VFNT

<!-- PAGE=? -->
Asystole/PEA

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Resume CPR immediately

<!-- PAGE=? -->
AED: >1 year of age

<!-- PAGE=? -->
Give epinephrine

<!-- PAGE=? -->
Use pediatric system if available

<!-- PAGE=? -->
IVIIO: 0.01 mg/kg

<!-- PAGE=? -->
for

<!-- PAGE=? -->
to 8 years of age

<!-- PAGE=? -->
Resume CPR immediately

<!-- PAGE=? -->
Endotracheal tube: 0.1 mg/kg

<!-- PAGE=? -->
(1:1000: 0.1 mUkg)

<!-- PAGE=? -->
Repeat every 3 to 5 min

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
Continue CPR while defibrillator

<!-- PAGE=? -->
12

<!-- PAGE=? -->
charging

<!-- PAGE=? -->
If asystole, g0 to Box 10

<!-- PAGE=? -->
13

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
If electrical activity; check

<!-- PAGE=? -->
Manual:

<!-- PAGE=? -->
Jlkg

<!-- PAGE=? -->
pulse. If no pulse, go to

<!-- PAGE=? -->
shockable

<!-- PAGE=? -->
Go to

<!-- PAGE=? -->
AED: >1 year of age

<!-- PAGE=? -->
Box 10

<!-- PAGE=? -->
Box

<!-- PAGE=? -->
Resume CPR immediately

<!-- PAGE=? -->
If pulse present, begin

<!-- PAGE=? -->
Give epinephrine

<!-- PAGE=? -->
postresuscitation care

<!-- PAGE=? -->
IVIIO: 0.01 mg/kg

<!-- PAGE=? -->
Endotracheal tube: 0.1 mg/kg

<!-- PAGE=? -->
Repeat every 3 to 5 minutes

<!-- PAGE=? -->
Check rhythm

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Shockable rhythm?

<!-- PAGE=? -->
During CPR

<!-- PAGE=? -->
Push hard and fast (1OO/min)

<!-- PAGE=? -->
Rotate compressors every 2 minutes

<!-- PAGE=? -->
Ensure full chest recoil

<!-- PAGE=? -->
with rhythm checks

<!-- PAGE=? -->
Continue CPR while defibrillator

<!-- PAGE=? -->
Minimize interruptions in chest

<!-- PAGE=? -->
Search for and treat possible

<!-- PAGE=? -->
is charging

<!-- PAGE=? -->
compressions

<!-- PAGE=? -->
contributing factors:

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
shock

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
One cycle of CPR: 15 compressions

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
Manual: 4 Jlkg

<!-- PAGE=? -->
then 2 breaths; 5 cycles =1 to 2 min

<!-- PAGE=? -->
Hydrogen ion (acidosis)

<!-- PAGE=? -->
AED: >1 year of age

<!-- PAGE=? -->
Hvpo-Ihvperkalemia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Peds

<!-- PAGE=? -->
Brady

<!-- PAGE=? -->
BRADYCARDIA

<!-- PAGE=? -->
With a Pulse

<!-- PAGE=? -->
Causing

<!-- PAGE=? -->
cardiorespiratory compromise

<!-- PAGE=? -->
Support ABCs as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Attach monitorldefibrillator

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Bradycardia still causing

<!-- PAGE=? -->
cardiorespiratory compromise?

<!-- PAGE=? -->
Perform CPR if despite

<!-- PAGE=? -->
oxygenation and ventilation

<!-- PAGE=? -->
HR <6O/min with poor perfusion

<!-- PAGE=? -->
5A

<!-- PAGE=? -->
Support ABCs; give oxygen

<!-- PAGE=? -->
No

<!-- PAGE=? -->
if needed

<!-- PAGE=? -->
Persistent symptomatic bradycardia?

<!-- PAGE=? -->
Observe

<!-- PAGE=? -->
Consider expert consultation

<!-- PAGE=? -->
Give epinephrine

<!-- PAGE=? -->
IVIIO: 0.01 mg/kg

<!-- PAGE=? -->
Endotracheal tube:

<!-- PAGE=? -->
0.1 mg/kg

<!-- PAGE=? -->
(1:1000: 0.1 mLkg)

<!-- PAGE=? -->
Repeat every 3 to

<!-- PAGE=? -->
5 minutes

<!-- PAGE=? -->
If increased vagal tone

<!-- PAGE=? -->
or primary AV block:

<!-- PAGE=? -->
Give atropine, first dose:

<!-- PAGE=? -->
Reminders

<!-- PAGE=? -->
0.02 mg/kg, may repeat.

<!-- PAGE=? -->
During CPR, push hard and fast

<!-- PAGE=? -->
Search for and treat possible

<!-- PAGE=? -->
(Minimum dose: 0.1

<!-- PAGE=? -->
mg;

<!-- PAGE=? -->
(1oO/min)

<!-- PAGE=? -->
contributing factors:

<!-- PAGE=? -->
maximum total dose for

<!-- PAGE=? -->
Ensure full chest recoil

<!-- PAGE=? -->
Hypovolemia

<!-- PAGE=? -->
child:

<!-- PAGE=? -->
Minimize interruptions in chest

<!-- PAGE=? -->
Hypoxia or ventilation problems

<!-- PAGE=? -->
compressions

<!-- PAGE=? -->
Hydrogen ion (acidosis)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Peds

<!-- PAGE=? -->
Tachy

<!-- PAGE=? -->
TACHYCARDIA

<!-- PAGE=? -->
With Pulses and Poor Perfusion

<!-- PAGE=? -->
Assess and support ABCs as needed

<!-- PAGE=? -->
Give oxygen

<!-- PAGE=? -->
Attach monitor/defibrillator

<!-- PAGE=? -->
Symptons

<!-- PAGE=? -->
Evaluate rhythm

<!-- PAGE=? -->
Possible

<!-- PAGE=? -->
with 12-lead

<!-- PAGE=? -->
Ventricular

<!-- PAGE=? -->
ECG or monitor

<!-- PAGE=? -->
Tachycardia

<!-- PAGE=? -->
10

<!-- PAGE=? -->
Probable Sinus Tachycardia

<!-- PAGE=? -->
Probable Supraventricular Tachycardia

<!-- PAGE=? -->
Synchronized cardioversion:

<!-- PAGE=? -->
Compatible history consistent

<!-- PAGE=? -->
Compatible history (vague; nonspecific)

<!-- PAGE=? -->
0.5 to 1 J/kg; if not effective;

<!-- PAGE=? -->
with known cause

<!-- PAGE=? -->
P waves absentabnormal

<!-- PAGE=? -->
increase to 2 J/kg

<!-- PAGE=? -->
P waves present/normal

<!-- PAGE=? -->
HR not variable

<!-- PAGE=? -->
Sedate if possible but don't

<!-- PAGE=? -->
Variable R-R; constant P-R

<!-- PAGE=? -->
History of abrupt rate changes

<!-- PAGE=? -->
delay cardioversion

<!-- PAGE=? -->
Infants: rate usually <220 bpm

<!-- PAGE=? -->
Infants: rate usually 2220 bpm

<!-- PAGE=? -->
attempt adenosine if it

<!-- PAGE=? -->
Children: rate usually <180 bpm

<!-- PAGE=? -->
Children: rate usually 2180 bpm

<!-- PAGE=? -->
does not delay electrical

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
Search for and treat cause

<!-- PAGE=? -->
Consider vagal

<!-- PAGE=? -->
maneuvers

<!-- PAGE=? -->
(No delays)

<!-- PAGE=? -->
If IV access readily available:

<!-- PAGE=? -->
Expert consultation advised

<!-- PAGE=? -->
Give adenosine 0.1 mg/kg (maximum

<!-- PAGE=? -->
Amiodarone 5 mg/kg IV

<!-- PAGE=? -->
first dose 6 mg) by rapid bolus

<!-- PAGE=? -->
over 20 to 60 minutes

<!-- PAGE=? -->
May double first dose and give once

<!-- PAGE=? -->
or

<!-- PAGE=? -->
(maximum second dose 12 mg)

<!-- PAGE=? -->
Procainamide 15 mg/kg IV

<!-- PAGE=? -->
or

<!-- PAGE=? -->
over 30 to 60 minutes

<!-- PAGE=? -->
Synchronized cardioversion: 0.5 to

<!-- PAGE=? -->
Do not routinely administer

<!-- PAGE=? -->
Jlkg; if not effective; increase to 2

<!-- PAGE=? -->
amiodarone and procainamide

<!-- PAGE=? -->
Sedate if possible but don't delay

<!-- PAGE=? -->
together

<!-- PAGE=? -->
cardioversion

<!-- PAGE=? -->
May

<!-- PAGE=? -->
Jlkg

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
NRP

<!-- PAGE=? -->
Approximate

<!-- PAGE=? -->
Time

<!-- PAGE=? -->
Routine Care

<!-- PAGE=? -->
Term gestation?

<!-- PAGE=? -->
Provide warmth

<!-- PAGE=? -->
Amniotic fluid clear?

<!-- PAGE=? -->
Yes

<!-- PAGE=? -->
Clear airway if needed

<!-- PAGE=? -->
Breathing or crying?

<!-- PAGE=? -->
Dry

<!-- PAGE=? -->
Good muscle tone?

<!-- PAGE=? -->
Assess color

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Provide warmth

<!-- PAGE=? -->
Position; clear airway*

<!-- PAGE=? -->
A

<!-- PAGE=? -->
(as necessary)

<!-- PAGE=? -->
Dry; stimulate; reposition

<!-- PAGE=? -->
Brealhing,

<!-- PAGE=? -->
Hr >100

<!-- PAGE=? -->
Evaluate respirations;

<!-- PAGE=? -->
heart rate, and color

<!-- PAGE=? -->
Observational Care

<!-- PAGE=? -->
Broathing,

<!-- PAGE=? -->
HR >100 bul

<!-- PAGE=? -->
Pink

<!-- PAGE=? -->
Cyanotic

<!-- PAGE=? -->
Give

<!-- PAGE=? -->
Apnelc or

<!-- PAGE=? -->
30 sec

<!-- PAGE=? -->
Hr <100

<!-- PAGE=? -->
supplementary

<!-- PAGE=? -->
oxygen

<!-- PAGE=? -->
Persistent

<!-- PAGE=? -->
EHectivc

<!-- PAGE=? -->
Cyanosis

<!-- PAGE=? -->
Ventllation,

<!-- PAGE=? -->
Pink

<!-- PAGE=? -->
Postresuscitation

<!-- PAGE=? -->
3

<!-- PAGE=? -->
Provide positive-pressure ventilation

<!-- PAGE=? -->
Care

<!-- PAGE=? -->
Hr >60

<!-- PAGE=? -->
Provide positive-pressure ventilation*

<!-- PAGE=? -->
Administer chest compressions

<!-- PAGE=? -->
Hr <60

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Parkinsons

<!-- PAGE=? -->
'progressive degenerative disease of the extrapyramidal system characterized by tremor, rigidity, and bradykinesia.'

<!-- PAGE=? -->
Dementia

<!-- PAGE=? -->
Autonomic dysfunction

<!-- PAGE=? -->
Orthostatic hypotension

<!-- PAGE=? -->
Gastropareiss

<!-- PAGE=? -->
Bulbar symptoms

<!-- PAGE=? -->
GERD / dysphagia

<!-- PAGE=? -->
Aspiration

<!-- PAGE=? -->
Central apnea

<!-- PAGE=? -->
Labile Blood Pressure

<!-- PAGE=? -->
Pharmacology

<!-- PAGE=? -->
On Dopamine agaonists, Anti-cholinergics, Anti-histamine

<!-- PAGE=? -->
Avoid anti-dopamine, meperidine, ketamine

<!-- PAGE=? -->
-sensitive to anesthetic agents - delayed emergence

<!-- PAGE=? -->
-post-op delirium

<!-- PAGE=? -->
-laryngospasm

<!-- PAGE=? -->
-Medication:continue throughout perioperative period (NG)

<!-- PAGE=? -->
-Levodopa (L-dopa) + Sinemet (carbidopa)

<!-- PAGE=? -->
arrythmogenic

<!-- PAGE=? -->
delpletion of NE stores - hypotension

<!-- PAGE=? -->
-Bromocriptine - direct Dop agonist

<!-- PAGE=? -->
-Amantadine - anti-cholinergic

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Pediatric Patient

<!-- PAGE=? -->
Neonate/Infant: (phys/pharm changes including):

<!-- PAGE=? -->
Rapid Desaturation

<!-- PAGE=? -->
(Potential Reversion to Persistant Fetal Circulation)

<!-- PAGE=? -->
Difficult A/W, IV and temperature maintenance

<!-- PAGE=? -->
Autonomic system imbalance - ATROPINE

<!-- PAGE=? -->
Laryngospasm

<!-- PAGE=? -->
Child:

<!-- PAGE=? -->
Psychologic: Separation Anxiety and poor Cooperation

<!-- PAGE=? -->
Pharmocologic: higher anesthetic requirements

<!-- PAGE=? -->
Physiological differences:

<!-- PAGE=? -->
Potential for laryngospasm

<!-- PAGE=? -->
Temperature instability

<!-- PAGE=? -->
Premature:

<!-- PAGE=? -->
Neonate

<!-- PAGE=? -->
Multiple Complications and Comorbidites of prematurity:

<!-- PAGE=? -->
RDS/BPD

<!-- PAGE=? -->
Apnea

<!-- PAGE=? -->
Potential ROP and IVH

<!-- PAGE=? -->
Potential for Shunt and Pradoxical Emboli

<!-- PAGE=? -->
Vitals: - preductal sat

<!-- PAGE=? -->
Wt: (2 x age in yrs) + 9

<!-- PAGE=? -->
LMA: 1<5kg, 1.5<10kg,  2<20,  2.5<30

<!-- PAGE=? -->
ETT Depth: (3 x ID) + 3for NTT  or 12 + Age/2

<!-- PAGE=? -->
ETT: (age + 4)/4

<!-- PAGE=? -->
Epidural:

<!-- PAGE=? -->
19g Touhy, 23g catheter

<!-- PAGE=? -->
-1mm/kg, LOTS

<!-- PAGE=? -->
-Bupiv 0.25%+Fent 5ug/kg: 0.4ml/kg/hr (0.2 for neonate)

<!-- PAGE=? -->
-Epimorph: 50ug/kg, Fent 2ug/kg

<!-- PAGE=? -->
SAB:

<!-- PAGE=? -->
22G, 1.5'

<!-- PAGE=? -->
-<1yo: Cord L3, Sac S3

<!-- PAGE=? -->
-0.1ml/kg 0.5% Bupiv + epi rinse

<!-- PAGE=? -->
-Epimorph: 1ug/kg

<!-- PAGE=? -->
Caudal:

<!-- PAGE=? -->
24G Jelco

<!-- PAGE=? -->
0.25% Bupivicaine + epi 1:400k

<!-- PAGE=? -->
0.5cc/kg: L1

<!-- PAGE=? -->
1cc/kg: T10

<!-- PAGE=? -->
1.5cc/kg : T8

<!-- PAGE=? -->
Fem/Axillary

<!-- PAGE=? -->
: Ropiv 0.2% - 0.5cc/kg

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Airway

<!-- PAGE=? -->
Large head and tongue

<!-- PAGE=? -->
Anterior and cephalad larynx (C4 level vs C6 in adults)

<!-- PAGE=? -->
Long epiglottis

<!-- PAGE=? -->
Cricoid is the narrowest point of the airway

<!-- PAGE=? -->
Infants are obligate nasal breathers

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
Rapid Desat: ½ VO2, ½ Ve, ¾ O2 reserve

<!-- PAGE=? -->
¾ FRC; ½ Closing Volume, ½ likelihood of atelectasis

<!-- PAGE=? -->
VT and VD per kg is constant

<!-- PAGE=? -->
Alveolar maturation incomplete until late childhood

<!-- PAGE=? -->
¾ lung compliance and ½ chest wall compliance ∴ chest wall collapse during inspiration

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
CO dependent on HR, ½ basal HR

<!-- PAGE=? -->
Prone to profound bradycardia  (hypoxia, PNS activatn, anesth OD)

<!-- PAGE=? -->
Noncompliant LV

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
PNS > SNS activity, immature SNS and baroreceptor reflexes GI

<!-- PAGE=? -->
NPO - Clear fluids 2H, Breast milk 4H, Solids 6H

<!-- PAGE=? -->
Endo

<!-- PAGE=? -->
Neonates prone to hypoglycemia (frequent assessment)

<!-- PAGE=? -->
Fluids

<!-- PAGE=? -->
Skin turgur, frontanelle, U/O, color, MM, Post Tib, activity

<!-- PAGE=? -->
Maintenance using 4-2-1:  D51/2NS + 20 mEq KCl

<!-- PAGE=? -->
Replace preexisting deficits in aliquots of 50% for 1 st hr; 25% for 2 nd hr; 25% for 3 rd hr

<!-- PAGE=? -->
EBV (replaced with crystalloids and colloids)

<!-- PAGE=? -->
o Premature neonate 100 cc/kg

<!-- PAGE=? -->
o Neonate

<!-- PAGE=? -->
90 cc/kg

<!-- PAGE=? -->
o Infant

<!-- PAGE=? -->
80 cc/kg

<!-- PAGE=? -->
o Child

<!-- PAGE=? -->
70 cc/kg

<!-- PAGE=? -->
Heme

<!-- PAGE=? -->
Hct varies with age: Neonate 55%, 3 mo 30%, 6 mo 35%

<!-- PAGE=? -->
Hb type changes form 75% HbF at birth to almost 100% HbA by 6 mo's

<!-- PAGE=? -->
Transufsion: 80, (100 if ill, 140 if cyanotic HD)

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
½ ratio of body surface area to body weight

<!-- PAGE=? -->
½ heat loss to the environment (b/c of ½ s.a.)

<!-- PAGE=? -->
Laryngospasm: CPAP, deepen, NMB, remove trigger Croup: Racemic Epi, O2, Decadron, observe

<!-- PAGE=? -->
Drugs:

<!-- PAGE=? -->
Defib 2J/kg

<!-- PAGE=? -->
Epi 10ug/kg, (racemic 0.5cc of 2.25% in 2cc NS)

<!-- PAGE=? -->
Amio 5mg/kg

<!-- PAGE=? -->
Mg 25mg/kg

<!-- PAGE=? -->
CaCl2 10mg/kg

<!-- PAGE=? -->
Flumazenil 0.1mg/kg

<!-- PAGE=? -->
Nalaxone 10ug/kg

<!-- PAGE=? -->
Ketamine PO 5mg/lg, IM 3mg/kg - sedate, 6mg/kg - induction

<!-- PAGE=? -->
Ketorolac 0.5mg/kg,

<!-- PAGE=? -->
Tylenol 20mg/kg PO, max 90mg/kg/day

<!-- PAGE=? -->
Dilaudid 15ug/kg

<!-- PAGE=? -->
Morphine: 50ug/kg

<!-- PAGE=? -->
Codiene 1mg/kg PO

<!-- PAGE=? -->
Ranitidine 0.5mg/kg, Maxeran 0.15mg/kg

<!-- PAGE=? -->
Zofran: 0.1mg/kg

<!-- PAGE=? -->
Hydrocortisone 1mg/kg

<!-- PAGE=? -->
Ventolin 0.15mg/kg in 2cc NS neb

<!-- PAGE=? -->
Dilantin 25mg/kg IV

<!-- PAGE=? -->
Phenylephrine 1ug/kg

<!-- PAGE=? -->
Ephedrine 0.1mg/kg

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Apnea of Prematurity

<!-- PAGE=? -->
Ddx:

<!-- PAGE=? -->
-CNS:

<!-- PAGE=? -->
o seizure

<!-- PAGE=? -->
o bleed

<!-- PAGE=? -->
o structural change

<!-- PAGE=? -->
-Systemic

<!-- PAGE=? -->
o hypoglycemia

<!-- PAGE=? -->
o sepsis

<!-- PAGE=? -->
o GERD

<!-- PAGE=? -->
o anemia

<!-- PAGE=? -->
Risk Factors

<!-- PAGE=? -->
CGA <60wks

<!-- PAGE=? -->
sepsis

<!-- PAGE=? -->
BPD

<!-- PAGE=? -->
anemia Hct <30

<!-- PAGE=? -->
GERD

<!-- PAGE=? -->
hypoglycemia

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
Delay until >60wks, symptom free

<!-- PAGE=? -->
PRBC

<!-- PAGE=? -->
Caffeine 10mg/kg

<!-- PAGE=? -->
-post-op monitoring until 60wks PCA if premature or 48wks in term

<!-- PAGE=? -->
-regional with no sedation

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Post-op Stridor/Croup

<!-- PAGE=? -->
Cool O2 / Heliox

<!-- PAGE=? -->
Racaemic epinephrine

<!-- PAGE=? -->
0.5 ml (2.25%) + 4 ml NS

<!-- PAGE=? -->
Epinephrine

<!-- PAGE=? -->
0.3 mg IM (0.15 mg if < 3 years old)

<!-- PAGE=? -->
Dexamethasone

<!-- PAGE=? -->
0.5 mg/kg (max 20 mg) IV

<!-- PAGE=? -->
CPAP

<!-- PAGE=? -->
ETT

<!-- PAGE=? -->
Cleft Palate:

<!-- PAGE=? -->
Occasionally part of a syndrome (eg. Pierre Robin)

<!-- PAGE=? -->
 CHD (SBE prophylaxis, cyanosis, CHF)

<!-- PAGE=? -->
 Micrognathia (difficult intubation)

<!-- PAGE=? -->
 Retroglossia (difficult mask ventilatn)

<!-- PAGE=? -->
Post-op A/W obstruction

<!-- PAGE=? -->
 Tylenol preop, local for post-op pain,

<!-- PAGE=? -->
 Extubate awake - no OPA

<!-- PAGE=? -->
 tongue stay suture, apnea monitoring

<!-- PAGE=? -->
 Repaired to separate oral and nasal cavities; improve feeding and speech; prevent middle ear infxns and hearing loss

<!-- PAGE=? -->
 (careful if obstructive apnea hx)

<!-- PAGE=? -->
 Palate is infiltrated with epinephrine for hemostasis pre-incision

<!-- PAGE=? -->
 EBL is variable

<!-- PAGE=? -->
 Intubate orally with RAE tube

<!-- PAGE=? -->
 Check for endobronchial intubation with head at different positions

<!-- PAGE=? -->
Peds - A/W

<!-- PAGE=? -->
Acute Epiglottitis

<!-- PAGE=? -->
 Bacterial infxn caused by B-hemo strep, H.flu  - Cefuroxime

<!-- PAGE=? -->
 Mostly affecting children 2-6yrs

<!-- PAGE=? -->
 Rapid progression, sore throat, toxic, drooling, dysphagia

<!-- PAGE=? -->
 Risk of NP- pulm edema

<!-- PAGE=? -->
 Sepsis, dehydration

<!-- PAGE=? -->
Infxious Croup (laryngotracheobronchitis)

<!-- PAGE=? -->
 Viral infxn usu following URTI

<!-- PAGE=? -->
 Usu affects children 3mo's - 3yrs

<!-- PAGE=? -->
 Slow progression which rarely requires intubatn

<!-- PAGE=? -->
'impending a/w collapse, potentially worsened by a/w manipulation'

<!-- PAGE=? -->
 Lat Neck X-ray occasionally useful but unnecessary and timeconsuming

<!-- PAGE=? -->
 MAINTAIN SPONTANEOUS VENTILATION (until pt intubated)

<!-- PAGE=? -->
 ENT surgeon - rigid bronchoscopy, trach

<!-- PAGE=? -->
 Caregiver present

<!-- PAGE=? -->
 Inhalation induction with 100% oxygen

<!-- PAGE=? -->
 Ensure adequate depth of anesthesia prior to laryngoscopy (to avoid laryngospasm)

<!-- PAGE=? -->
 Oral intubation with ETT 0.5 - 1.0 sizes smaller than usual

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Tonsillectomy & Adenoidectomy

<!-- PAGE=? -->
OSA

<!-- PAGE=? -->
Recurrent Infection

<!-- PAGE=? -->
Post-op N/V + Bleeding risk

<!-- PAGE=? -->
Assessment

<!-- PAGE=? -->
 Question indication for procedure: OSA, infection, peritonsillar abscess

<!-- PAGE=? -->
 Evidence of chronic nasal obstruction (nasal speech, adenoid facies, mouth breathing - ask to breathe with mouth closed)

<!-- PAGE=? -->
 Look for symptoms of OSA (disturbed sleep, daytime sleepiness, poor feeding, snoring)

<!-- PAGE=? -->
 Look for symptoms of PTA/RPA (torticolis, trismus)

<!-- PAGE=? -->
 Look for evidence of PHTN/Cor pulmonale

<!-- PAGE=? -->
 Pre-existing bleeding disorders (family hx)

<!-- PAGE=? -->
Anesthetic Considerations

<!-- PAGE=? -->
 Avoid preop sedatives if hx of sleep apnea or very large tonsils

<!-- PAGE=? -->
 IV preinduction if hx of significant airway obstruction, avoid paralysis until able to ventilate

<!-- PAGE=? -->
 Oral intubation with a reinforced ETT or a RAE tube

<!-- PAGE=? -->
 Meticulous but gentle inspection and sxning of pharynx before extubation

<!-- PAGE=? -->
Pain Control vs OSA/Bleeding

<!-- PAGE=? -->
 Tylenol

<!-- PAGE=? -->
 Tonsilar bed local infiltration

<!-- PAGE=? -->
 Apnea monitoring

<!-- PAGE=? -->
 D/C home if stable, no evidence of bleeding, pain-free, no vomitting

<!-- PAGE=? -->
Reoperation to Control Bleeding

<!-- PAGE=? -->
 Postop Bleeding - Most common 7d posto

<!-- PAGE=? -->
 Volume resuscitation

<!-- PAGE=? -->
 RSI vs. Ketamine (difficult to do Inhaled Induction with bleeding)

<!-- PAGE=? -->
 NG to sxn blood from stomach

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Bronchopulmonary Dysplasia

<!-- PAGE=? -->
-'BPD is a chronic lung disease in premature infants treated for respiratory distress with mechanical ventilation and supplemental O2'

<!-- PAGE=? -->
Prematurity

<!-- PAGE=? -->
Respiratory:

<!-- PAGE=? -->
Airway reactivity

<!-- PAGE=? -->
Tracheo and bronchomalcia

<!-- PAGE=? -->
V/Q mismatch - hypercarbia, hypoxia

<!-- PAGE=? -->
Pulmonary Htn, Cor pulmonale

<!-- PAGE=? -->
Poor wt gain, feeding

<!-- PAGE=? -->
SIDS

<!-- PAGE=? -->
Etiology:

<!-- PAGE=? -->
-O2 Toxicity

<!-- PAGE=? -->
-Barotrauma

<!-- PAGE=? -->
-Inflammation

<!-- PAGE=? -->
Resp effects:

<!-- PAGE=? -->
-air trapping: incr FRC

<!-- PAGE=? -->
-decr compliance

<!-- PAGE=? -->
-maldistribution of ventilation - V/Q mismatch

<!-- PAGE=? -->
-incr WOB

<!-- PAGE=? -->
-frequent URTI

<!-- PAGE=? -->
Labs:

<!-- PAGE=? -->
-ABG: CO2 rention, varying degree of hypoxia

<!-- PAGE=? -->
-CXR: hyperinflation, fibrosis, cystic, atelactasis

<!-- PAGE=? -->
-PFTs: improve with age

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
Bronchodilators: B agonists, theophylline

<!-- PAGE=? -->
Diuretics

<!-- PAGE=? -->
Fluid restriction

<!-- PAGE=? -->
Steroids -incr risk of htn/infection

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
-avoid elective surgery during URTI

<!-- PAGE=? -->
-deep anesthesia

<!-- PAGE=? -->
-bronchospasm precautions

<!-- PAGE=? -->
-alternative to GA/ETT

<!-- PAGE=? -->
-post-op apnea monitoring

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Neonatal Patient

<!-- PAGE=? -->
CDH

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
Acidosis

<!-- PAGE=? -->
Hypoxia

<!-- PAGE=? -->
hypercarbia

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
pulmonary hypoplasia

<!-- PAGE=? -->
tension pneumothorax

<!-- PAGE=? -->
Cardiovascular

<!-- PAGE=? -->
pulmonary hypertension,

<!-- PAGE=? -->
cardiac anomalies (ASD, VSD, coarctation, TOF)

<!-- PAGE=? -->
1:5,000 live births

<!-- PAGE=? -->
Mortality of 30-60% of live births

<!-- PAGE=? -->
12-25% have associated anomalies (CV, CNS, GI, GU)

<!-- PAGE=? -->
Presents with respiratory failure within first 6 hours

<!-- PAGE=? -->
Majority are posterolateral (Bochdalek's, 90%) and left-sided (80%)

<!-- PAGE=? -->
Polyhydramnios on U/S

<!-- PAGE=? -->
Dyspnea, cyanosis, heart displaced to right, scaphoid abdomen, barrel chest, mediastinal shift, absence of air in bowel

<!-- PAGE=? -->
Associated anomalies (12-25%):

<!-- PAGE=? -->
 CHD incl ASD, VSD, Coarctatn, TOF

<!-- PAGE=? -->
 Spina bifida, hydrocephalus, anencephaly

<!-- PAGE=? -->
 Malrotation, duodenal atresia

<!-- PAGE=? -->
 Hypospadias

<!-- PAGE=? -->
Diaphragmatic Hernia (Congenital)

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
Early ETT, minimize BMV

<!-- PAGE=? -->
NG tube

<!-- PAGE=? -->
Medical stabilization before surgery

<!-- PAGE=? -->
Minimize PIP (< 30 cm H2O), increase rate

<!-- PAGE=? -->
HFV, ECMO support if necessary

<!-- PAGE=? -->
PaO2=80, PaCO2=25-30, pH mild alkalosis

<!-- PAGE=? -->
Preductal arterial catheter, CVP

<!-- PAGE=? -->
Precordial stethoscope in contralateral axilla

<!-- PAGE=? -->
Opioid technique

<!-- PAGE=? -->
Avoid volatile agents and N2O

<!-- PAGE=? -->
Treat pulmonary hypertension with vasodilators, NaHCO3, NO

<!-- PAGE=? -->
Anesth Considerations

<!-- PAGE=? -->
¿ Avoid triggers for PHTN

<!-- PAGE=? -->
¿ Goals:

<!-- PAGE=? -->
 PaO2 > 80

<!-- PAGE=? -->
 PaCO2 25-30

<!-- PAGE=? -->
 normal or ½ pH

<!-- PAGE=? -->
 normothermia

<!-- PAGE=? -->
¿ Watch for pneumothorax (signalled by sudden ¾ lung comliance, hypotensn, ¾ oxygenation)

<!-- PAGE=? -->
Conflict: permissive hypercapnia/htn vs pulm HTN

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Anesthetic Concerns

<!-- PAGE=? -->
Neonate

<!-- PAGE=? -->
Full Stomach

<!-- PAGE=? -->
Effect of Closure

<!-- PAGE=? -->
Ventilation

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
Intra-op

<!-- PAGE=? -->
Heat loss

<!-- PAGE=? -->
Fluid loss/shift

<!-- PAGE=? -->
Infection

<!-- PAGE=? -->
Post op Nutrition

<!-- PAGE=? -->
(Anomalies/Syndromes)

<!-- PAGE=? -->
Anesthetic Plan

<!-- PAGE=? -->
IV access

<!-- PAGE=? -->
Arterial & CVP monitoring if large defect

<!-- PAGE=? -->
Volume resuscitation

<!-- PAGE=? -->
Sat probe above and below diaphragm

<!-- PAGE=? -->
Gastric decompression

<!-- PAGE=? -->
Temperature monitor

<!-- PAGE=? -->
RSI with cricoid pressure

<!-- PAGE=? -->
Muscle relaxation

<!-- PAGE=? -->
Avoid nitrous

<!-- PAGE=? -->
CVP rise > 4 mm Hg, intragstric pressure > 20 mm Hg consider staged closure - silastic silo

<!-- PAGE=? -->
Gastroschisis/Ophalocele

<!-- PAGE=? -->
Gastroschisis

<!-- PAGE=? -->
rare (1/20,000)

<!-- PAGE=? -->
Due to occlusion of artery

<!-- PAGE=? -->
Abdominal wall defect to right of umbilical cord

<!-- PAGE=? -->
Contents not covered by sac

<!-- PAGE=? -->
60% premature

<!-- PAGE=? -->
Other anomalies rare (except GI)

<!-- PAGE=? -->
Ophalocele:

<!-- PAGE=? -->
1/3000-1/10,000

<!-- PAGE=? -->
Vary in size

<!-- PAGE=? -->
Abdominal wall defect via base of umbilical cord

<!-- PAGE=? -->
30-50% other anomalies- GI, CV, GU, CNS

<!-- PAGE=? -->
Syndromes - trisomies 13 & 18, Beckwith-Wiedmann (microcephaly, macroglossia)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Myelomeningocele

<!-- PAGE=? -->
Urgent - Infection Risk

<!-- PAGE=? -->
Neonate

<!-- PAGE=? -->
Positioning

<!-- PAGE=? -->
Positioning for intubation

<!-- PAGE=? -->
Prone for surgery

<!-- PAGE=? -->
Arnold Chiari Malformation

<!-- PAGE=? -->
Hydrocephalus

<!-- PAGE=? -->
Cardiac/GI anomalies

<!-- PAGE=? -->
Latex precaution

<!-- PAGE=? -->
 Arnold Chiari Malformation

<!-- PAGE=? -->
o Caudal displacement of the brainstem and cerebellar tonsil into the cervical spinal canal with compression

<!-- PAGE=? -->
o CN palsy - poor gag, aspiration

<!-- PAGE=? -->
o Apnea

<!-- PAGE=? -->
o Post - fossa

<!-- PAGE=? -->
 Hydrocephalus

<!-- PAGE=? -->
o Arnold-Chiari causes obliteration of the normal exit of the foramen of the 4 th ventricle, in 90% will cause obstructive hydrocephalus (after repair)

<!-- PAGE=? -->
 Succinylcholine OK

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Medical, NOT surgical emergency

<!-- PAGE=? -->
Neonate

<!-- PAGE=? -->
Aspiration risk

<!-- PAGE=? -->
Volume status

<!-- PAGE=? -->
Acid/Base & Electrolyte abnormalities

<!-- PAGE=? -->
Post-operative apnea

<!-- PAGE=? -->
General

<!-- PAGE=? -->
Benign hypertrophy of the pyloric smooth muscle

<!-- PAGE=? -->
4:1 male:female

<!-- PAGE=? -->
2-3 / 1000 births

<!-- PAGE=? -->
Projectile non-bilious vomiting between 2-5 weeks

<!-- PAGE=? -->
Hypochloremic, hypokalemic metabolic alkalosis

<!-- PAGE=? -->
Pyloric Stenosis

<!-- PAGE=? -->
Anesthetic Plan

<!-- PAGE=? -->
Consult Pediatrics

<!-- PAGE=? -->
Maintenance Fluid - D5 1/2NS @ 4 ml/kg/hr

<!-- PAGE=? -->
Fluid resuscitation - 20 ml/kg NS

<!-- PAGE=? -->
Potassium replacement once urine output established

<!-- PAGE=? -->
Goals prior to OR

<!-- PAGE=? -->
o Stable vital signs

<!-- PAGE=? -->
o U/O > 1 ml/kg/hr

<!-- PAGE=? -->
o Cap Gas:

<!-- PAGE=? -->
 pH 7.3-7.5

<!-- PAGE=? -->
 Na > 132

<!-- PAGE=? -->
 Cl > 100

<!-- PAGE=? -->
 HCO3 < 32

<!-- PAGE=? -->
 K > 3.2

<!-- PAGE=? -->
OR:

<!-- PAGE=? -->
NG suction, 3 positions

<!-- PAGE=? -->
RSI

<!-- PAGE=? -->
Atropine

<!-- PAGE=? -->
Avoid opiods: Local infiltration, Tylenol, NSAIDS

<!-- PAGE=? -->
Post-op apnea monitoring

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
-Cobb >50: likely RLD

<!-- PAGE=? -->
Scoliosis Surgery

<!-- PAGE=? -->
Respiratory

<!-- PAGE=? -->
Pre-op RLD

<!-- PAGE=? -->
Post-op Ventilation

<!-- PAGE=? -->
Cardiac

<!-- PAGE=? -->
Pulm HTN

<!-- PAGE=? -->
Cor pulmonale

<!-- PAGE=? -->
Blood conservation

<!-- PAGE=? -->
Spinal cord monitoring

<!-- PAGE=? -->
'wake-up' test

<!-- PAGE=? -->
SSEP

<!-- PAGE=? -->
MEP

<!-- PAGE=? -->
Prone

<!-- PAGE=? -->
VAE

<!-- PAGE=? -->
-Cobb >50: likely RLD

<!-- PAGE=? -->
Cardiorespiratory effects of scoliosis

<!-- PAGE=? -->
Ventilationlperfusion abnormality fAlveolar-arterial oxygen gradient (A-aDO2) fDead space (Vo/Vr)

<!-- PAGE=? -->
Total lung volume (TLV) Wvital capacity (VC) LFunctional residual capacity (FRC)

<!-- PAGE=? -->
JPaoz normal Pacoz (may increase with advanced disease)

<!-- PAGE=? -->
Pulmonary hypertension, cor pulmonale (secondary to chronic hypoxia and low volumes)

<!-- PAGE=? -->
Right ventricular enlargement

<!-- PAGE=? -->
Right atrial enlargement

<!-- PAGE=? -->
Pulmonic insufficiency

<!-- PAGE=? -->
Tracheal shortening or distortion, pulmonary artery kinking

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
TracheoEsophageal Fistula

<!-- PAGE=? -->
Neonate

<!-- PAGE=? -->
R Thoracotomy

<!-- PAGE=? -->
VATER

<!-- PAGE=? -->
Difficult

<!-- PAGE=? -->
oxygenation/ventilation

<!-- PAGE=? -->
ETT placement

<!-- PAGE=? -->
Aspiration

<!-- PAGE=? -->
Secretions

<!-- PAGE=? -->
Reactivity

<!-- PAGE=? -->
Pneumonia

<!-- PAGE=? -->
Post-op tracheomalacia

<!-- PAGE=? -->
 Type IIIB is most common (upper esophagus ending in blind pouch and a lower esophagus fistula which connects to trachea)

<!-- PAGE=? -->
 Gastric distension with breathing; choking and coughing with feeding

<!-- PAGE=? -->
 Copious pharyngeal secretions and require frequent sxning

<!-- PAGE=? -->
 Often dehydrated and malnourished

<!-- PAGE=? -->
 Dx by failure to pass NG into stomach and visualization of coiled NG in upper esophagus

<!-- PAGE=? -->
 Often premature

<!-- PAGE=? -->
 Associated anomalies:

<!-- PAGE=? -->
 VATER syndrome (vertebral defects, anal atresia, TEF with esoph atresia, radial dysplasia)

<!-- PAGE=? -->
 CHD (25%) incl ASD, VSD, PDA, TOF

<!-- PAGE=? -->
 Subglottic stenosis

<!-- PAGE=? -->
 Renal abnormalities

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
 Elevate HOB

<!-- PAGE=? -->
 Preop gastrostomy tube under local:

<!-- PAGE=? -->
 Reduce aspiration

<!-- PAGE=? -->
 pass Fogerty catheter via G-tube to occlude esophagus/fistula to aid ventilation

<!-- PAGE=? -->
 intermittent venting

<!-- PAGE=? -->
 G-tube into water - early sign of PPV leak

<!-- PAGE=? -->
 SV until intubated (prevents gastric distension)

<!-- PAGE=? -->
 'Awake' intubation

<!-- PAGE=? -->
 Ideal ETT placement b/n fistula and carina (to encourage ventilatn of lungs and not stomach)

<!-- PAGE=? -->
 OLV difficult in Neonate

<!-- PAGE=? -->
 100% Oxygen despite risks of ROP

<!-- PAGE=? -->
 Frequent sxning of G-tube and upper esophageal pouch to ¾ aspiratn

<!-- PAGE=? -->
 Blood available for transfusion

<!-- PAGE=? -->
 Precordial stethoscope; arterial line

<!-- PAGE=? -->
 Traction of lung, heart, great vessels, and vagus may lead to hypoxia, hypotn

<!-- PAGE=? -->
Postop

<!-- PAGE=? -->
 Continued intubation and PPV

<!-- PAGE=? -->
 Vigorous infants may be extubated immediately postop (preferred for maintenance of repair)

<!-- PAGE=? -->
 Avoid neck extension and instrumentation (sxning)

<!-- PAGE=? -->
 Complications include aspiratn, GER, tracheal compression (tracheomalacia) and anastamotic leak

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Pheochromocytoma

<!-- PAGE=? -->
'catecholamine secreting tumor resulting in Malignant HTN'

<!-- PAGE=? -->
End-organ dysfunction

<!-- PAGE=? -->
Cardiomyopathy

<!-- PAGE=? -->
CVA

<!-- PAGE=? -->
Renal failure

<!-- PAGE=? -->
Hemodynamic Instability

<!-- PAGE=? -->
Risk Malignant hypertension

<!-- PAGE=? -->
Post vein clamping - hypotension

<!-- PAGE=? -->
Associated disease (NF, MEN II, vHL)

<!-- PAGE=? -->
Preoperative optimization

<!-- PAGE=? -->
Alpha blockade

<!-- PAGE=? -->
Beta blockade

<!-- PAGE=? -->
Rare catecholamine secreting tumor (90% norepi, 10% epi)

<!-- PAGE=? -->
10% bilateral (25% pediatric), 10% malignant, 10% extra-adrenal

<!-- PAGE=? -->
associated with

<!-- PAGE=? -->
o neurofibromatosis

<!-- PAGE=? -->
o von Hippel-Lindau disease

<!-- PAGE=? -->
o carotid body tumours

<!-- PAGE=? -->
o MEN IIA - thyroid medullary Ca, parathyroid hyperplasia, and pheochromocytoma

<!-- PAGE=? -->
o MEN IIB - thyroid medullary Ca, pheochromocytoma, and oral mucosal neuromas

<!-- PAGE=? -->
Presentation: headache, diaphoresis, palpitations, tremulousness, and weight loss

<!-- PAGE=? -->
Diagnosis : 24 hr urine for norepinephrine, VMA, metanephrines, and norepi>epi ratio, CT/MRI (>1cm), MIBG, renal artery sampling

<!-- PAGE=? -->
Preop preparation:

<!-- PAGE=? -->
o Alpha blockade traditionally 10-14 days

<!-- PAGE=? -->
 Phenoxybenzamine (start10 mg bid, increase to 80-200 mg

<!-- PAGE=? -->
 Prazosin 1mg QHS (6-10 mg/day)

<!-- PAGE=? -->
 Clonidine 0.2mg PO OD

<!-- PAGE=? -->
o If tachycardia: add beta blocker (propranolol 40-80 mg od)

<!-- PAGE=? -->
o Criteria for adequate alpha blockade (Roizen's Criteria)

<!-- PAGE=? -->
 Control of blood pressure (<160/80 X 48hrs)

<!-- PAGE=? -->
 Symptomatic postural hypotension of 20% or SBP<90

<!-- PAGE=? -->
 No more than 5 PVCs/hr

<!-- PAGE=? -->
 0.05% decrease in Hematocrit

<!-- PAGE=? -->
 2 weeks free of ST and T wave changes

<!-- PAGE=? -->
 signs of alpha blockade (nasal stuffiness)

<!-- PAGE=? -->
o artline, CVP, +/- PAC, +/- TEE

<!-- PAGE=? -->
o Epidural (to block sympathetic)

<!-- PAGE=? -->
o MgSO4 (50mg/kg bolus then 2g/hr)

<!-- PAGE=? -->
Intraop problems:

<!-- PAGE=? -->
o Severe hypertension:  cerebral hemorrhage, encephalopathy, pulmonary edema, MI, V. fib, renal failure

<!-- PAGE=? -->
o Severe hypotension / hypoglycemia: following removal of tumour

<!-- PAGE=? -->
o Catecholamine surge with tracheal intubation, pneumoperitoneum, handling of the tumour, and certain drugs

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
o Hypertension - phentolamine(1-5 mg), nitroprusside (1-2ug/kg bolus, 0.2-10 ug/kg/min)

<!-- PAGE=? -->
o Tachycardia - B blockers (propranolol 1-2 mgIV), amiodarone if heart failure

<!-- PAGE=? -->
Disposition

<!-- PAGE=? -->
o ICU

<!-- PAGE=? -->
OR:

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Porphyria

<!-- PAGE=? -->
'is an inborn error of metabolism that results in overproduction of heme by ALA synthetase.

<!-- PAGE=? -->
Autonomic instability

<!-- PAGE=? -->
Avoid Triggers

<!-- PAGE=? -->
Medications

<!-- PAGE=? -->
Fasting/Dehydration

<!-- PAGE=? -->
Avoid Confusion with Dx

<!-- PAGE=? -->
Ketamine: delerium

<!-- PAGE=? -->
Regional anesthesia: neuropathy

<!-- PAGE=? -->
Prevention:

<!-- PAGE=? -->
glucose infusion

<!-- PAGE=? -->
Hematin

<!-- PAGE=? -->
Heme is a component of hemoglobin and cytochromes

<!-- PAGE=? -->
Heme production is controlled by ALA synthetase

<!-- PAGE=? -->
ALA synthetase is inducible by increased heme requirements such as the administration of drugs that require cytochromes for their metabolism

<!-- PAGE=? -->
Autosomal inheiritance with variable penetrance

<!-- PAGE=? -->
Triggers include medications, infections, starvation, dehydration, menstration

<!-- PAGE=? -->
Inducible forms

<!-- PAGE=? -->
o Acute intermittent porphyria

<!-- PAGE=? -->
o Variegate porphyria

<!-- PAGE=? -->
o Hereditary coproporphyria

<!-- PAGE=? -->
o plumboporphyria

<!-- PAGE=? -->
Potential triggers

<!-- PAGE=? -->
o Barbiturates / Etomidate

<!-- PAGE=? -->
o Steroids

<!-- PAGE=? -->
o Benzodiazepines (diazepam)

<!-- PAGE=? -->
o Lidocaine / Bupivicaine

<!-- PAGE=? -->
o Phenoxybenzamine

<!-- PAGE=? -->
o Phenytoin

<!-- PAGE=? -->
o Estrogens

<!-- PAGE=? -->
o Ethanol

<!-- PAGE=? -->
o Ergot methyldopa

<!-- PAGE=? -->
o Talwin

<!-- PAGE=? -->
Signs and symptoms - abdominal pain, autonomic instability, neuropsych, peripheral neuropathy, muscle weakness, ↓ K, ↓ Na (SIADH), ↓ Mg

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
o Glucose infusion - decr ALA synthetase activity

<!-- PAGE=? -->
o Cimetidine - 300 mg

<!-- PAGE=? -->
o Propranolol

<!-- PAGE=? -->
o Somatostatin

<!-- PAGE=? -->
o Hematin (3 mg/kg IV over 20 min)

<!-- PAGE=? -->
 ARF

<!-- PAGE=? -->
 Thromboprophlebitis

<!-- PAGE=? -->
 Coagulopathy

<!-- PAGE=? -->
o Plasmapharesis

<!-- PAGE=? -->
Regional anesthesia - not contraindictated but postoperative neurologic signs may be confused

<!-- PAGE=? -->
o Ensure preoperative neuro exam

<!-- PAGE=? -->
Post-op monitoring for porphyria crisis x 5 days

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Brainstem Compression

<!-- PAGE=? -->
CN palsy (a/w reflexes

<!-- PAGE=? -->
Arrythmia/BP/Breathing

<!-- PAGE=? -->
Hydrocephalus

<!-- PAGE=? -->
Sitting Position:

<!-- PAGE=? -->
Poor airway access

<!-- PAGE=? -->
VAE

<!-- PAGE=? -->
Hidden Blood Loss

<!-- PAGE=? -->
Incr ICP/decr compliance

<!-- PAGE=? -->
Post-op monitoring

<!-- PAGE=? -->
Monitoring VAE: TEE> Doppler>PAC/incr PAP> capnograph> N2 mass spec

<!-- PAGE=? -->
Post Fossa

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Differential Diagnosis

<!-- PAGE=? -->
Posterior Ischemic Optic Neuropathy (PION)

<!-- PAGE=? -->
Anterior Ischemic Optic Neuropathy (AION)

<!-- PAGE=? -->
Cortical blindness

<!-- PAGE=? -->
Retinal artery occlusion (RAO)

<!-- PAGE=? -->
Ophthalmic venous obstruction

<!-- PAGE=? -->
Anterior Ischemic Optic Neuropathy

<!-- PAGE=? -->
Infarction of the watershed areas in the choriocapillaris

<!-- PAGE=? -->
Lower hemifield defect with central sparing

<!-- PAGE=? -->
Most commonly non-arteritic decrease in oxygen delivery

<!-- PAGE=? -->
No consistent successful treatment - 30% have partial recovery

<!-- PAGE=? -->
Optic disc edema

<!-- PAGE=? -->
Posterior Ischemic Optic Neuropathy

<!-- PAGE=? -->
Due to decreased oxygen delivery to the posterior portion of the optic nerve

<!-- PAGE=? -->
Most commonly at the point of entry of the central retinal artery

<!-- PAGE=? -->
Post-operative Blindness

<!-- PAGE=? -->
Similar field defects as AION

<!-- PAGE=? -->
Delayed optic disc edema

<!-- PAGE=? -->
Risk Factors

<!-- PAGE=? -->
Carotid artery atherosclerosis

<!-- PAGE=? -->
Smoking

<!-- PAGE=? -->
HTN

<!-- PAGE=? -->
RA

<!-- PAGE=? -->
SCC

<!-- PAGE=? -->
Polycythemia

<!-- PAGE=? -->
Anemia

<!-- PAGE=? -->
Glaucoma

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
Review anesthetic record for position, procedure, hypotension, and fluid balance

<!-- PAGE=? -->
Assess for risk factors

<!-- PAGE=? -->
Address hypotension & anemia

<!-- PAGE=? -->
Consult ophthalmology +/- high dose steroids

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Pseudohyperkalemia

<!-- PAGE=? -->
} Thrombocytosis

<!-- PAGE=? -->
} Leukocytosis

<!-- PAGE=? -->
} Venipuncture technique

<!-- PAGE=? -->
Redistribution

<!-- PAGE=? -->
} Acidosis

<!-- PAGE=? -->
} Insulin deficiency

<!-- PAGE=? -->
} Beta-blocker drugs

<!-- PAGE=? -->
} Digoxin toxicity

<!-- PAGE=? -->
} Succinylcholine

<!-- PAGE=? -->
} Arginine hydrochloride

<!-- PAGE=? -->
} Hyperkalemic familial periodic paralysis

<!-- PAGE=? -->
Excessive endogenous potassium load

<!-- PAGE=? -->
} Rhabdomyolysis

<!-- PAGE=? -->
} Tumor Lysis

<!-- PAGE=? -->
} Hemolysis

<!-- PAGE=? -->
Excessive exogenous potassium load

<!-- PAGE=? -->
} Parenteral administration

<!-- PAGE=? -->
} Excess in diet

<!-- PAGE=? -->
} Potassium supplements

<!-- PAGE=? -->
} Salt substitutes

<!-- PAGE=? -->
} PRBCs

<!-- PAGE=? -->
Diminished potassium excretion

<!-- PAGE=? -->
} Addison's

<!-- PAGE=? -->
} CRF

<!-- PAGE=? -->
} RTA II and IV

<!-- PAGE=? -->
} Drugs (eg, NSAIDs, ACE-I, cyclosporine, K-sparing diuretics)

<!-- PAGE=? -->
Hyperkalemia

<!-- PAGE=? -->
Signs:

<!-- PAGE=? -->
-weakness

<!-- PAGE=? -->
peaked T waves, flattened P waves, prolonged PR interval (firstdegree heart block), widened QRS complex, deepened S waves, and merging of S and T waves, a sine-wave pattern, idioventricular rhythms, and asystolic

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hypokalemia

<!-- PAGE=? -->
Insufficient Oral Intake

<!-- PAGE=? -->
GI losses

<!-- PAGE=? -->
Vomiting/Diarrhea

<!-- PAGE=? -->
NG suction

<!-- PAGE=? -->
Villous adenoma of colon

<!-- PAGE=? -->
Renal losses

<!-- PAGE=? -->
Osmotic diuretics

<!-- PAGE=? -->
Tubular/Loop diuretics

<!-- PAGE=? -->
Hyperglycemia

<!-- PAGE=? -->
Cushings

<!-- PAGE=? -->
Hyperaldosteronism

<!-- PAGE=? -->
Surgical trauma

<!-- PAGE=? -->
Penicillins/AmphoB

<!-- PAGE=? -->
4. Redistribution

<!-- PAGE=? -->
Alkalosis-respiratory or metabolic

<!-- PAGE=? -->
Insulin

<!-- PAGE=? -->
Beta-2 agonist (Ventolin)

<!-- PAGE=? -->
Familial periodic paralysis

<!-- PAGE=? -->
Hypomagnesemia

<!-- PAGE=? -->
Hypercalcemia

<!-- PAGE=? -->
Signs:

<!-- PAGE=? -->
-weakness, fatigue, paralysis, respiratory difficulty, constipation, paralytic ileus, and leg cramps

<!-- PAGE=? -->
-ECG changes such as U waves, T-wave flattening, and ventricular arrhythmias (especially if the patient is taking digoxin)

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
maximum amount of IV potassium replacement should be 10 to 20 mEq/h (10meq/100cc)

<!-- PAGE=? -->
-if arrest imminent Give an initial infusion of 10 mEq IV over 5 minutes; repeat once if needed.

<!-- PAGE=? -->
-Oral: Slow-release pills typically contain 8, 10 or 20 meq tablet. Thus, it will take several days to replete the potassium depletion. Replacement doses should be 40-120 meq qd in divided doses. More than 20 meq in one dose can cause GI upset.

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
A/W

<!-- PAGE=? -->
ETT migration

<!-- PAGE=? -->
Extubation

<!-- PAGE=? -->
Secretions

<!-- PAGE=? -->
Edema

<!-- PAGE=? -->
Resp Atelechtasis

<!-- PAGE=? -->
Paw - lung, circuit, abdo

<!-- PAGE=? -->
CNS Blindness

<!-- PAGE=? -->
nerve injury - optic, brachial

<!-- PAGE=? -->
CVS VAE Line Access Decr Preload (pooling) Difficult ACLS - bed in room Monitor Blackout

<!-- PAGE=? -->
Prone

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Underlying etiology/Dz

<!-- PAGE=? -->
PVR management:

<!-- PAGE=? -->
Resp - avoid hypoxia/hypercarbia

<!-- PAGE=? -->
Metabolim - avoid acidosis, hypothermia

<!-- PAGE=? -->
Ventilation - minimize Paw, avoid N20

<!-- PAGE=? -->
Vessels - vasodilators, avoid hypervolemia

<!-- PAGE=? -->
Right heart failure

<!-- PAGE=? -->
Vasodilators

<!-- PAGE=? -->
Inotropic support - Dobutamine/Milrinone

<!-- PAGE=? -->
Anticoagulation

<!-- PAGE=? -->
+RV, -PH

<!-- PAGE=? -->
#vasoconstfictor

<!-- PAGE=? -->
+RW. +PH

<!-- PAGE=? -->
Pulmonary Hypertension

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
MPAP > 25 mmHg ( > 30 mmHg during exercise)

<!-- PAGE=? -->
o Severe >45

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
Primary

<!-- PAGE=? -->
Secondary:

<!-- PAGE=? -->
Volume O/L: ASD, L → R Shunt

<!-- PAGE=? -->
Pressure O/L: MS, MR, LVF

<!-- PAGE=? -->
HPV: COPD, OSA, CF

<!-- PAGE=? -->
Decr Vascular bed: PE, Vasculitis, Connective Tissue Dz (RA, SLE, scleroderma)

<!-- PAGE=? -->
Signs & symptoms

<!-- PAGE=? -->
o Dyspnea angina, syncope, edema

<!-- PAGE=? -->
o ↑ JVP (v wave), hepatomegaly, peripheral edema, RV heave, TR/PR murmur, ↑ P2 , S3

<!-- PAGE=? -->
Preoperative workup

<!-- PAGE=? -->
o ECG: P pulmonale(>2.5mA lead II), RVH → ↑ R in V1 and T -1 anteriorly, RBBB, RAD

<!-- PAGE=? -->
o Echo (RVH, TR, LVf n , PFO, PAP, septal interdependence)

<!-- PAGE=? -->
o CXR/CT-chest

<!-- PAGE=? -->
o ABG (metabolic acidosis - ominous sign)

<!-- PAGE=? -->
o Cardio/Resp Consult

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
o Optimize reversible:

<!-- PAGE=? -->
 O2, anticoagulants, Antibiotics, Diuretics, Bronchodilator

<!-- PAGE=? -->
 Pulm Toilet, PT

<!-- PAGE=? -->
o CCB's (some non-responders)

<!-- PAGE=? -->
o PDE-I: Sildenafil (po)

<!-- PAGE=? -->
 Hypotension, anemia

<!-- PAGE=? -->
o Endothelin Antagonist: Bosentan (po)

<!-- PAGE=? -->
 Hepatotoxicity, anemia, CP450 inducer

<!-- PAGE=? -->
o Prostacyclin Analogues: Epoprostenol (inh)

<!-- PAGE=? -->
 Inhibit platelet aggregation

<!-- PAGE=? -->
 Hypotension

<!-- PAGE=? -->
 Rebound PHTN

<!-- PAGE=? -->
o Lung Transplant

<!-- PAGE=? -->
Intraoperative management

<!-- PAGE=? -->
o TEE - ? decr BP 2 nd to CO vs SVR

<!-- PAGE=? -->
o NO (20 - 40 ppm)

<!-- PAGE=? -->
o Vasodilators

<!-- PAGE=? -->
 NG , SNP

<!-- PAGE=? -->
 PGE1 (IV) , PGI2 (Inh)

<!-- PAGE=? -->
o Inotropic support

<!-- PAGE=? -->
 Milrinone

<!-- PAGE=? -->
 Dobutamine

<!-- PAGE=? -->
 Norepinephrine (For RV perfusion)

<!-- PAGE=? -->
 Epi

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Lumbar Plexus/Femoral/3in 1

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 surgery on the anterior thigh, knee, quadriceps tendon repair

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
o Large inguinal tumor/lymph nodes

<!-- PAGE=? -->
o Prior ilioinguinal surgery eg. Femoral grafts

<!-- PAGE=? -->
o Concern re: compartment syndrome

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 blocks 3 of the leg's 4 nerves: femoral, obturator, lateral femoral cutaneous

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 PNS

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Line drawn from the ASIS to the pubic tubercle

<!-- PAGE=? -->
 Identify femoral artery below this line; enter lateral to the artery

<!-- PAGE=? -->
 Needle : 5cm 22G B-bevel Stimulating

<!-- PAGE=? -->
 Advanced 45 degrees cephalad until patellar twich found <0.5mA

<!-- PAGE=? -->
 If sartorius muscle twitch is obtained, redirect laterally and a few mm deeper

<!-- PAGE=? -->
 Drug/Dose : 30-40 cc of Ropivicaine 0.5% + epi 1:200k

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 falls

<!-- PAGE=? -->
Fascia Iliaca

<!-- PAGE=? -->
Landmark

<!-- PAGE=? -->
o 1 cm caudal  of intersection of the medial and lateral 3 rd of inguinal ligament

<!-- PAGE=? -->
Block

<!-- PAGE=? -->
17 touhy, perpendicular to skin

<!-- PAGE=? -->
'pop' # 1 - fascia lata

<!-- PAGE=? -->
'pop' # 2 - fascia iliaca

<!-- PAGE=? -->
Drug/dose

<!-- PAGE=? -->
30 cc 0.5% marcaine or ropivacaine +/- epi

<!-- PAGE=? -->
10

<!-- PAGE=? -->
FN

<!-- PAGE=? -->
FA

<!-- PAGE=? -->
20

<!-- PAGE=? -->
ASIS

<!-- PAGE=? -->
Right

<!-- PAGE=? -->
30

<!-- PAGE=? -->
Ico

<!-- PAGE=? -->
40

<!-- PAGE=? -->
50

<!-- PAGE=? -->
60

<!-- PAGE=? -->
PT

<!-- PAGE=? -->
SM

<!-- PAGE=? -->
wwW.nysora.com

<!-- PAGE=? -->
Legend

<!-- PAGE=? -->
anlerior component of the femoral nerve

<!-- PAGE=? -->
Latcral

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Sciatic 

<!-- PAGE=? -->
Indications

<!-- PAGE=? -->
 surgery on the posterior thigh, knee, calf, ankle or  foot

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 Sacral Plexus L4-S3

<!-- PAGE=? -->
 Technique (Classic)

<!-- PAGE=? -->
 PNS

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Lat Decub, surgical side up

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Line drawn from the PSIS to the GT

<!-- PAGE=? -->
 Mark 4 cm distal to the midpoint

<!-- PAGE=? -->
 Should lie on line from GT to SH

<!-- PAGE=? -->
 Needle : 4' 22G B-bevel Stimulating

<!-- PAGE=? -->
 Advanced perpendicular to all planes, deep to gluteus twitches (usuall 5-8cm) until sciatic twitch found <0.5mA

<!-- PAGE=? -->
 Drug/Dose : 25 cc of Ropivicaine 0.5% + epi 1:200k

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Loss of hamstrings

<!-- PAGE=? -->
OTHER:

<!-- PAGE=? -->
 Technique (Lateral)

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Line drawn from posterior border GT parallel to femur

<!-- PAGE=? -->
 Mark 3 cm distal to GT

<!-- PAGE=? -->
 Advanced perpendicular to all planes, walking off posterior border of femur

<!-- PAGE=? -->
 Technique (Lithotomy)

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Lithotomy

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Line drawn from GT to IT, enter at midpoint

<!-- PAGE=? -->
 Advanced perpendicular to all planes

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Popiteal Fossa

<!-- PAGE=? -->
Indications 

<!-- PAGE=? -->
 surgery below knee, catheter

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 Sciatic splits into the post tibial and common peroneal 5-12 cm proximal to crease

<!-- PAGE=? -->
 Lateral and superficial to vessels

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 PNS

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Prone, with tibia resting on pillow so that foot is free

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Apex of fossa, where medial Semi-tendon/membrane meet lateral bicep femoris

<!-- PAGE=? -->
 10cm proximal to crease

<!-- PAGE=? -->
 Needle : 2'  22G B-bevel Stimulating

<!-- PAGE=? -->
 Advanced 45 degrees cephalad until inversion ankle twich found <0.5mA

<!-- PAGE=? -->
 Superficial Peroneal - Eversion

<!-- PAGE=? -->
 Posterior tibial - Plantarflexion

<!-- PAGE=? -->
 Deep Peroneal - Dorsiflexion

<!-- PAGE=? -->
 Deep peroneal + tibial - inversion

<!-- PAGE=? -->
 Drug/Dose : 40 cc of Ropivicaine 0.5% + epi 1:200k

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Toxicity/vascular injection rare since no NV sheath

<!-- PAGE=? -->
OTHER

<!-- PAGE=? -->
 Technique (Lateral)

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine, foot 90 degrees to bed

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
Popliteal Fossa Cross-Sectional View

<!-- PAGE=? -->
ANTERIOR

<!-- PAGE=? -->
Vastus medialis m

<!-- PAGE=? -->
Vastus lateralis m.

<!-- PAGE=? -->
Distal femur

<!-- PAGE=? -->
MEDIAL

<!-- PAGE=? -->
Saphenous n

<!-- PAGE=? -->
LATERAL

<!-- PAGE=? -->
Sartorius M

<!-- PAGE=? -->
temoris m

<!-- PAGE=? -->
Common

<!-- PAGE=? -->
peroneal n

<!-- PAGE=? -->
Semimembranous m

<!-- PAGE=? -->
Posterior

<!-- PAGE=? -->
Semitendinous m & t

<!-- PAGE=? -->
emoral

<!-- PAGE=? -->
culancous n.

<!-- PAGE=? -->
POSTERIOR

<!-- PAGE=? -->
Biceps

<!-- PAGE=? -->
 10cm proximal to pop fossa crease, in groove between bicep femoris and vastus lateralis

<!-- PAGE=? -->
 Advanced horizontal until contact with femur

<!-- PAGE=? -->
 Then redirected 30 degrees posterior, within 2 cm after local BF twich stops

<!-- PAGE=? -->
 Needle : 4'  22G B-bevel Stimulating

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Ankle

<!-- PAGE=? -->
 Indication

<!-- PAGE=? -->
 Surgery on the foot and toes

<!-- PAGE=? -->
 Good for anesthesia but popliteal gives better postop pain control

<!-- PAGE=? -->
 Quicker onset than pop-fossa

<!-- PAGE=? -->
 Technique:

<!-- PAGE=? -->
 Parasthesia

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine with foot on rest

<!-- PAGE=? -->
 Needle : 25g 1.5'

<!-- PAGE=? -->
 Drug/Dose : 30 cc of bupivicaine 0.5% NO EPI

<!-- PAGE=? -->
Deep Peroneal Nerve

<!-- PAGE=? -->
 Major nerve of the dorsum of the foot

<!-- PAGE=? -->
 Inject 5cc of LA below the fascia just lateral to the dorsalis pedis artery (or extend big toe and inject just deep to the extensor hallucus longus tendon)

<!-- PAGE=? -->
Posterior Tibial Nerve

<!-- PAGE=? -->
 Major nerve to the sole of the foot

<!-- PAGE=? -->
 Posterior and Distal to medial maleolus, posterior tibial artery

<!-- PAGE=? -->
 A needle is introduce behind the PT artery and directed 45 ° anteriorly (seeking paresthesia in sole)

<!-- PAGE=? -->
 Inject 5cc of LA

<!-- PAGE=? -->
3. Sural Nerve

<!-- PAGE=? -->
 SQ injection of 5cc of LA behind the lateral maleolus filling the groove b/n it and the calcaneous

<!-- PAGE=? -->
4. Saphenous Nerve

<!-- PAGE=? -->
 Inject 5cc of LA around the saphenous vein at the level where this vein passes anterior to the medial maleolus)

<!-- PAGE=? -->
5. Superficial Peroneal Nerve

<!-- PAGE=? -->
 SQ ridge of LA (5-10cc) is injected along the foot skin crease b/n the DP artery and the lateral malleolus (above the fascia)

<!-- PAGE=? -->
Achilles Tandon

<!-- PAGE=? -->
Sural Nervc

<!-- PAGE=? -->
Sural Norvo

<!-- PAGE=? -->
Posterior Tibial Artery

<!-- PAGE=? -->
Tibial Nerve

<!-- PAGE=? -->
Saphenous Nerve

<!-- PAGE=? -->
Peroneal Nerve

<!-- PAGE=? -->
Oeep Peroneal Nerve

<!-- PAGE=? -->
Tendon of Extensor

<!-- PAGE=? -->
Hallucis Longus Muscle

<!-- PAGE=? -->
Plantar n.

<!-- PAGE=? -->
PT

<!-- PAGE=? -->
Sural n

<!-- PAGE=? -->
Calcaneal n.

<!-- PAGE=? -->
(PT)

<!-- PAGE=? -->
WWW.nysora.com

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Sural

<!-- PAGE=? -->
Saphenous n.

<!-- PAGE=? -->
Superficial peroneal

<!-- PAGE=? -->
Sural n.

<!-- PAGE=? -->
Deep peroneal nerve

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Epidural & Spinal Anesthesia

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
 Absolute:

<!-- PAGE=? -->
 ½ ICP (risk of herniation, can ½ ICP with injection)

<!-- PAGE=? -->
 Coagulopathy/Thrombocytopenia

<!-- PAGE=? -->
 Sepsis or bacteremia

<!-- PAGE=? -->
 Relative:

<!-- PAGE=? -->
 Hypovolemia/Shock

<!-- PAGE=? -->
 Critical AS or Obstructive cardiac lesions

<!-- PAGE=? -->
 Pre-existing CNS dz (eg. MS)

<!-- PAGE=? -->
 Chronic back pain or prior spine surgery

<!-- PAGE=? -->
Complications

<!-- PAGE=? -->
LA Toxicity (Epidural)

<!-- PAGE=? -->
Dural Puncture Headache

<!-- PAGE=? -->
 Manifestations

<!-- PAGE=? -->
 mild or absent when supine

<!-- PAGE=? -->
 fronto-occipital

<!-- PAGE=? -->
 cranial nerve (diplopia, tinnitis) and N+V present

<!-- PAGE=? -->
 Management

<!-- PAGE=? -->
 Spontaneous resolution in several days to a week

<!-- PAGE=? -->
 Conservative initially: Bedrest, Analgesia, Caffeine

<!-- PAGE=? -->
 Epidural Blood Patch

<!-- PAGE=? -->
-Aseptic injection of 10-20cc of autologous blood below

<!-- PAGE=? -->
-relief in 1-24 hrs in 85-90%;  90% of those who fail respond to second patch

<!-- PAGE=? -->
-SE's: backache and radicular pain

<!-- PAGE=? -->
-Complications: infection, abscess, hematoma

<!-- PAGE=? -->
Epidural Abscess

<!-- PAGE=? -->
 Neuro deficit below lesion

<!-- PAGE=? -->
 Back pain, tenderness; fever

<!-- PAGE=? -->
 Urgent decompressive laminectomy within 6H

<!-- PAGE=? -->
 Meningitis

<!-- PAGE=? -->
Epidural Hematoma

<!-- PAGE=? -->
Back or radicular pain

<!-- PAGE=? -->
Sensory or motor deficits that outlast drug, bowel/bladder

<!-- PAGE=? -->
Neurologic Injury

<!-- PAGE=? -->
TRI:

<!-- PAGE=? -->
 Back/buttock aching and cramping

<!-- PAGE=? -->
 Normal neuro exam

<!-- PAGE=? -->
 Lasts for several days, resolves spontaneously

<!-- PAGE=? -->
 Improves with ambulation + NSAIDS +/- opioid

<!-- PAGE=? -->
 Assoc with obese, outpt, 5% lidocaine, lithotomy and knee arthroscopy

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Post NA neuro deficit

<!-- PAGE=? -->
Risk Factors:

<!-- PAGE=? -->
Pt:

<!-- PAGE=? -->
Old, Obese, Male

<!-- PAGE=? -->
DM

<!-- PAGE=? -->
ETOH/Smoker

<!-- PAGE=? -->
Malnutrition/B12/Folate

<!-- PAGE=? -->
Preexisting Neuro deficit

<!-- PAGE=? -->
Meds: Steroids, Anticoagulant, Chemo

<!-- PAGE=? -->
Surgery:

<!-- PAGE=? -->
Vascular/Ischemia

<!-- PAGE=? -->
Instuments/Retractors near nerves

<!-- PAGE=? -->
Position

<!-- PAGE=? -->
Prolonged

<!-- PAGE=? -->
OB

<!-- PAGE=? -->
Anesthesia:

<!-- PAGE=? -->
Traumatic Insertion

<!-- PAGE=? -->
Hypotension

<!-- PAGE=? -->
Anemia

<!-- PAGE=? -->
Fluids/edema

<!-- PAGE=? -->
Drug Toxicity

<!-- PAGE=? -->
Differential:

<!-- PAGE=? -->
Residual LA

<!-- PAGE=? -->
Intrathecal Rx

<!-- PAGE=? -->
Cord ischemia/infarct

<!-- PAGE=? -->
Hematoma

<!-- PAGE=? -->
Abcess

<!-- PAGE=? -->
Plexopathy

<!-- PAGE=? -->
Peripheral neuropathy

<!-- PAGE=? -->
Management:

<!-- PAGE=? -->
Stop epidural (take LA out)

<!-- PAGE=? -->
Review Chart - PMHx, insertion, position, length, fluids

<!-- PAGE=? -->
Vitals including Temp

<!-- PAGE=? -->
Entry Site

<!-- PAGE=? -->
Neuro exam

<!-- PAGE=? -->
Motor

<!-- PAGE=? -->
Sens

<!-- PAGE=? -->
Reflexes

<!-- PAGE=? -->
Anal sphincter

<!-- PAGE=? -->
Vascular Exam

<!-- PAGE=? -->
Pulses

<!-- PAGE=? -->
Cap Refill

<!-- PAGE=? -->
Imaging, EMG/NCS

<!-- PAGE=? -->
Consult Neuro

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Deep Cervical Plexus

<!-- PAGE=? -->
Indications 

<!-- PAGE=? -->
 CEA,  neck surgery

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
o Sever Resp dz, contralat phrenic palsy

<!-- PAGE=? -->
o Contralateral SLN/RLN palsy

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 formed from the anterior divisions of C1 to C4

<!-- PAGE=? -->
 roots exit the vertebral column through a gutter in its respective transverse process

<!-- PAGE=? -->
 lie immediately posterior to the vertebral artery

<!-- PAGE=? -->
o Ansa cervicalis complex (Infrahyoid, geniohyoid)

<!-- PAGE=? -->
o Phrenic nerve (Diaphragm)

<!-- PAGE=? -->
o Contributions to accessory nerve (Sternocleidomastoid, trapezius)

<!-- PAGE=? -->
o Direct muscular branches (Prevertebral muscles)

<!-- PAGE=? -->
o Cutaneous branches

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Position: Supine, head slightly turned, neck extended

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 A line is drawn from the mastoid process to the C6 transverse process (Chassaignac's tubercle)

<!-- PAGE=? -->
 A second line is drawn 0.5-1 cm posterior and parallel to first line

<!-- PAGE=? -->
 A line at mandible is C4, then C2/3 are marked as thirds to mastoid

<!-- PAGE=? -->
 Needle : 2' 22G B-bevel, attached to control syringe

<!-- PAGE=? -->
 EMLA applied pre-op

<!-- PAGE=? -->
 Advanced perpendicular to all planes, slightly caudal

<!-- PAGE=? -->
 Prior to injection of local, needle withdrawn 1-2mm off transverse process

<!-- PAGE=? -->
 Drug/Dose : 5-8 cc of Bupivicaine 0.375% + epi 1:200k (or 1.5% Lido/Mepiv)

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Vertebral artery - seizure

<!-- PAGE=? -->
 Epidural/SAB

<!-- PAGE=? -->
 BPB

<!-- PAGE=? -->
 Phrenic 60%

<!-- PAGE=? -->
 Horner's

<!-- PAGE=? -->
 SLN

<!-- PAGE=? -->
17

<!-- PAGE=? -->
Cricoid

<!-- PAGE=? -->
(Chassaignac'$ Iubercle)

<!-- PAGE=? -->
cartilage

<!-- PAGE=? -->
MASTOID

<!-- PAGE=? -->
Sternocleicomastola m

<!-- PAGE=? -->
CLAVICLE

<!-- PAGE=? -->
Figure 19

<!-- PAGE=? -->
C2

<!-- PAGE=? -->
C4

<!-- PAGE=? -->
Cricoid

<!-- PAGE=? -->
Cartilage

<!-- PAGE=? -->
C6

<!-- PAGE=? -->
Figure

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Superficial Cervical Plexus

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 CEA, trach,  neck, supraclavicular surgery

<!-- PAGE=? -->
 (Contraindications)

<!-- PAGE=? -->
o Sever Resp dz, contralat phrenic palsy

<!-- PAGE=? -->
o Contralateral SLN/RLN palsy

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 formed from the anterior divisions of C1 to C4

<!-- PAGE=? -->
 blocks the cutaneous branches including:

<!-- PAGE=? -->
o Lesser occipital nerve (C2,3)

<!-- PAGE=? -->
o Greater auricular nerve (C2,3)

<!-- PAGE=? -->
o Transverse cervical nerve (C2,3)

<!-- PAGE=? -->
o Supraclavicular nerve (C3,4)

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine, head slightly turned

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Midpoint of SCM, posterior border (approx C4), near EJ

<!-- PAGE=? -->
 Infiltrate along post border sup and inf

<!-- PAGE=? -->
 Needle : 2' 22G B-bevel, bent

<!-- PAGE=? -->
 Drug/Dose : 5 cc of LA at each site

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Can track through planes to Deep Cervical Plexus

<!-- PAGE=? -->
Tronsverse

<!-- PAGE=? -->
Lelela

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Paravertebral

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Breast (T2-T6), rib #, PHN

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
o Kyphoscoliosis

<!-- PAGE=? -->
o Previous Thoracotomy

<!-- PAGE=? -->
o Empyema

<!-- PAGE=? -->
o Hypotension (do get sympathetic block)

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
Posterior boundary: Superior costotransverse ligament  (from TP to rib one level below)

<!-- PAGE=? -->
Medial boundary: Vertebral body, disk , foramen and its contents

<!-- PAGE=? -->
Anterolateral boundary: Parietal pleura

<!-- PAGE=? -->
Continuous sup/inf, and with the intercostal space laterally, epidural space medially

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Tactile

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Sitting, spine and neck flexed

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Spinous process of vertebrae (same level as TP level below)

<!-- PAGE=? -->
 Enter 2.5 cm lateral

<!-- PAGE=? -->
 Advance perpedndicular to all planes to hit TP

<!-- PAGE=? -->
 Withdraw to skin and redirect 25% caudal 1cm deeper

<!-- PAGE=? -->
 Needle : 10cm 22G Touhy, attached to control syringe (closed system)

<!-- PAGE=? -->
 Drug/Dose : 6 cc of Ropiv + epi at each site

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Incomplete block

<!-- PAGE=? -->
 Pneumo

<!-- PAGE=? -->
 Epidural/SAB

<!-- PAGE=? -->
Figure 2

<!-- PAGE=? -->
foramen

<!-- PAGE=? -->
Paraverlebral spoce

<!-- PAGE=? -->
Cephalad and caudoa

<!-- PAGE=? -->
spreod in porovertebrol

<!-- PAGE=? -->
spoce

<!-- PAGE=? -->
Posterior

<!-- PAGE=? -->
intercostal

<!-- PAGE=? -->
spoce

<!-- PAGE=? -->
Dorsal

<!-- PAGE=? -->
Intercostal

<!-- PAGE=? -->
romus

<!-- PAGE=? -->
Epidural spoce

<!-- PAGE=? -->
Epidural

<!-- PAGE=? -->
needle

<!-- PAGE=? -->
Skin

<!-- PAGE=? -->
Pleura

<!-- PAGE=? -->
Neck

<!-- PAGE=? -->
rib

<!-- PAGE=? -->
Nerve

<!-- PAGE=? -->
Superior

<!-- PAGE=? -->
cosi0-Iransverse

<!-- PAGE=? -->
ligomeni

<!-- PAGE=? -->
Inferior

<!-- PAGE=? -->
costo

<!-- PAGE=? -->
transverse

<!-- PAGE=? -->
ligoment

<!-- PAGE=? -->
Tip

<!-- PAGE=? -->
transverse

<!-- PAGE=? -->
process

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
A) Indication

<!-- PAGE=? -->
Eye surgery - akinesis

<!-- PAGE=? -->
mydrasis

<!-- PAGE=? -->
Block Ocular-Cardiac reflec

<!-- PAGE=? -->
B) Procedure:

<!-- PAGE=? -->
Position

<!-- PAGE=? -->
Supine

<!-- PAGE=? -->
Forward neutral gaze or infero-medial

<!-- PAGE=? -->
b) Block

<!-- PAGE=? -->
Palpate the inferolateral margin of the orbit

<!-- PAGE=? -->
Procedure:  Retrobulbar Block

<!-- PAGE=? -->
The injection is at the junction of the lateral and middle thirds  of the inferior orbital rim

<!-- PAGE=? -->
The needle is directed upward and medially to approach the midsagittal plane of the globe.

<!-- PAGE=? -->
1.25 inch (31 mm) needle parallel to the plane of the orbit until the tip of the needle passes the equator of the globe

<!-- PAGE=? -->
Advance slowly. The needle should only penetrate retrobulbar fat and intermuscular septum.

<!-- PAGE=? -->
c) Drug/dose

<!-- PAGE=? -->
8-10 ml local anesthetic + 5 mcg/ml epi (1% xylocaine & 0.5% bupivacaine mixture)

<!-- PAGE=? -->
C) Complications

<!-- PAGE=? -->
Brainstem anesthesia

<!-- PAGE=? -->
Oculocardic reflex

<!-- PAGE=? -->
Siezure

<!-- PAGE=? -->
Retrobulbar hemorrhage

<!-- PAGE=? -->
Globe penetration

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
Uncontrolled tremor

<!-- PAGE=? -->
Coagulopathy

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
IVRA

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Distal extremity surgery < 60min

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
o Severe Seizure Disorder

<!-- PAGE=? -->
o Severe PVD

<!-- PAGE=? -->
o Sickle Cell

<!-- PAGE=? -->
o Raynaud's

<!-- PAGE=? -->
o AV fistula

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Secure IV as distal as possible

<!-- PAGE=? -->
 Double Tourniquet (blue-bottom, distal)

<!-- PAGE=? -->
 Test tourniquet - 100mmHg above SBP or 250 (whichever is higher)

<!-- PAGE=? -->
 Elevate limb and exsanguinate with Esmarch, inflate distal then proximal

<!-- PAGE=? -->
 Confirm loss of pulse and inject slowly over 2 minutes

<!-- PAGE=? -->
 Min 20 minutes, between 20 and 40 staged release

<!-- PAGE=? -->
 Drug/Dose

<!-- PAGE=? -->
:

<!-- PAGE=? -->
 50cc of 0.5% Lido (or take 3mg/kg divided into 50cc)

<!-- PAGE=? -->
 Ketorolac 20mg

<!-- PAGE=? -->
 Preservative Free

<!-- PAGE=? -->
 No Epi

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Tourniquet Pain

<!-- PAGE=? -->
 Neuropathy (related to ischemia)

<!-- PAGE=? -->
 Tourniquet failure

<!-- PAGE=? -->
 Local anesthetic toxicity

<!-- PAGE=? -->
 Bupiv: (keep tourniquet up at least 2 hours (risk of ischemia), crash cart, transfer CPB, breytlium, Intralipid, staged tourniquet release)

<!-- PAGE=? -->
 Anaphylaxis

<!-- PAGE=? -->
 Failed block

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Interscalene

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Shoulder and upper arm surgery

<!-- PAGE=? -->
 Catheter

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
o Sever Resp dz (100% blockade of phrenic, 25% decr FEV1)

<!-- PAGE=? -->
o Contralateral phrenic or RLN palsy

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 blocks at the level of Roots as they line-up between ant and middle scalenes

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 PNS

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine, head slightly turned, arm exposed

<!-- PAGE=? -->
 Standing on ipsilateral side

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 At level of C6, index and 3 rd finger of nondominant hand under SCM

<!-- PAGE=? -->
 Ask pt to sniff, follow groove as it widens postero-laterally, pulse at base

<!-- PAGE=? -->
 Needle : 1' 24G B-bevel Stimulating

<!-- PAGE=? -->
 Advanced perpendicular to all planes (Backward Inward Downward)

<!-- PAGE=? -->
 Any upper extremity twich <0.5mA

<!-- PAGE=? -->
 Trapezius too low, Diaphragm too high (lies on ant scalene)

<!-- PAGE=? -->
 Drug/Dose : 30-40 cc of Ropivicaine 0.5% + epi 1:200k (or 1.5% Lido/Mepiv)

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Must block intercostobrachial

<!-- PAGE=? -->
 Often spares C8/T1

<!-- PAGE=? -->
 Horner's 90%

<!-- PAGE=? -->
 Pneumothorax

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Infraclavicular (Coracoid)

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Mid-humerus and distal

<!-- PAGE=? -->
 Catheter

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 blocks at the level of Cords (Medial, Lateral and Post) around Axillary Artery

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 PNS

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine, head slightly turned, arm exposed

<!-- PAGE=? -->
 Standing on ipsilateral side

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 2cm medial and 2cm inferior to most prominent part of coracoid

<!-- PAGE=? -->
 3cm inferior to coracoid

<!-- PAGE=? -->
 Needle : 5cm, 22G B-bevel Stimulating

<!-- PAGE=? -->
 Advanced perpendicular to pt (plumb-bob), Deep to pec major, usually 4.5 cm

<!-- PAGE=? -->
 Musculocutaneous - may have already branched, therefore aim inferior

<!-- PAGE=? -->
 Deltoid - too caudal

<!-- PAGE=? -->
 Drug/Dose : 30-40 cc of Ropivicaine 0.5% + epi 1:200k (or 1.5% Lido/Mepiv)

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Must block intercostobrachial

<!-- PAGE=? -->
 Pneumothorax if too medial

<!-- PAGE=? -->
Brachial

<!-- PAGE=? -->
plexus

<!-- PAGE=? -->
Pectoralis

<!-- PAGE=? -->
minor m.

<!-- PAGE=? -->
OMayo

<!-- PAGE=? -->
De

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Axillary

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Distal Arm, Hand

<!-- PAGE=? -->
 Good for fracture (limited motion)

<!-- PAGE=? -->
 Minimal pneumo risk

<!-- PAGE=? -->
 Contraindications

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 blocks at the level of Branches around axillary artery

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 PNS, Transarterial

<!-- PAGE=? -->
 Position

<!-- PAGE=? -->
 Supine, arm abducted 90 degrees, elbow flexed

<!-- PAGE=? -->
 Landmarks

<!-- PAGE=? -->
 Palpate artery high in axilla  with index and 3 rd finger, non-dominant hand

<!-- PAGE=? -->
 Needle : 5cm 22G B-bevel Stimulating

<!-- PAGE=? -->
 Advanced perpendicular to all planes, with constant aspiration

<!-- PAGE=? -->
 Any twich <0.5mA (corresponding to site of surgery)

<!-- PAGE=? -->
 Firm distal pressure

<!-- PAGE=? -->
 Immediately adduct arm to relieve pressure from humeral head

<!-- PAGE=? -->
 Drug/Dose : 40 cc of Ropivicaine 0.5% + epi 1:200k (20 each side of artery)

<!-- PAGE=? -->
 Complications

<!-- PAGE=? -->
 Must block intercostobrachial

<!-- PAGE=? -->
 Must block musculocutaneous

<!-- PAGE=? -->
 Patchy

<!-- PAGE=? -->
LATERAL

<!-- PAGE=? -->
POSTERIOR

<!-- PAGE=? -->
ANTERIOR

<!-- PAGE=? -->
MEDIAL

<!-- PAGE=? -->
Axillary Block

<!-- PAGE=? -->
10-12. Cross-section of arm at elbow. (1) Median nerve (2) Radial nerve block. (3) Lateral cutaneous nerve of rm block. (Note nerve under deep fascia and close to bitendon )

<!-- PAGE=? -->
Medial

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Musculocutaneous

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Axillary block

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 Exits around the infraclavicular block

<!-- PAGE=? -->
 Lies in belly of coracobrachialis which is above/lateral to axillary artery

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Needle : 1.5' 25G

<!-- PAGE=? -->
 Drug/Dose : Fan 5 cc of LA into muscle belly or lateral to bicep tendon at elbow

<!-- PAGE=? -->
Intercostobrachial & Medial Brachial Cutaneous

<!-- PAGE=? -->
 Indications

<!-- PAGE=? -->
 Upper Arm tourniquet

<!-- PAGE=? -->
 Anatomy

<!-- PAGE=? -->
 ICB (T2) and the MBC nerves are cutaneous nerves that originate in neck and upper thorax

<!-- PAGE=? -->
 Technique

<!-- PAGE=? -->
 Needle : 1.5' 25G

<!-- PAGE=? -->
 Drug/Dose : Fan 5-10 cc of LA sub-cutaneous medial (below) axillary artery

<!-- PAGE=? -->
Block at the Elbow

<!-- PAGE=? -->
 Ulnar

<!-- PAGE=? -->
 Nerve is found in groove b/n medial condyle of  the humerus and the olecranon

<!-- PAGE=? -->
 Elbow joint flexed at 30 ° , Inject 1-4cc of LA deep to the fascia (+/paresthesia)

<!-- PAGE=? -->
 Median

<!-- PAGE=? -->
 At the level of the condyles, medial to artery (TAN)

<!-- PAGE=? -->
 Inject 5cc of LA

<!-- PAGE=? -->
 Radial

<!-- PAGE=? -->
 Along same intracondylar line 2cm lateral to the biceps tendon

<!-- PAGE=? -->
 Inject 5cc of LA

<!-- PAGE=? -->
 Subcutaneous

<!-- PAGE=? -->
 LCNF

<!-- PAGE=? -->
 MCNF

<!-- PAGE=? -->
Block at the Wrist

<!-- PAGE=? -->
 Ulnar

<!-- PAGE=? -->
 Nerve lies b/n FCU tendon and ulnar artery

<!-- PAGE=? -->
 Raise skin wheal at the level of the styloid process

<!-- PAGE=? -->
 Inject 3cc of LA

<!-- PAGE=? -->
 Median

<!-- PAGE=? -->
 Nerve lies b/n tendons of PL and FCR at the same level

<!-- PAGE=? -->
 Raise a skin wheal; pierce the deep fascia

<!-- PAGE=? -->
 Inject 3cc of LA

<!-- PAGE=? -->
 Radial

<!-- PAGE=? -->
 The nerve has already started to ramify as it crosses the wrist

<!-- PAGE=? -->
 Inject 3cc of LA in the anatomic snuffbox + a SQ wheal extending over the dorsum of the wrist for 3-4cm

<!-- PAGE=? -->
Digital Nerve Block

<!-- PAGE=? -->
 terminal nerve branches which enter the fingers near the periosteum of the bone at four corners (of a rectangle)

<!-- PAGE=? -->
 2-3cc of LA (NO EPI) in the digital web space near the periosteum while withdrawing using a 25g needle

<!-- PAGE=? -->
 Inject in both the radial and ulnar side of the digit of interest

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Regional:

<!-- PAGE=? -->
-After reviewing any contraindications to the __ block, I will obtain informed consent and discuss the major potential complications including …… .  I will place an IV and the standard CAS monitors with oxygen, then position the patient and check my landmarks.  I will use judicious sedation to maintain a co-operative, alert patient. -I will prepare the area using sterile technique and infiltrate my insertion point with subcutaneous lidocaine using a 27g needle.

<!-- PAGE=? -->
-I will ask my trained assistant to aspirate, then inject 1cc test dose.  After ruling out (SA, Epid or) intravascular injection, I will then continue incremental dosing with aspiration every 5cc to total of 0.5cc/kg 0.5% (or 1cc/kg 0.25%)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
↑ K +

<!-- PAGE=? -->
metabolic acidosis

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
HTN, labile

<!-- PAGE=? -->
Unpredictable Volume status

<!-- PAGE=? -->
Heme

<!-- PAGE=? -->
Uremic bleeding

<!-- PAGE=? -->
Anemia

<!-- PAGE=? -->
GERD

<!-- PAGE=? -->
Pharmacokinetic changes

<!-- PAGE=? -->
Concominant disease

<!-- PAGE=? -->
HTN

<!-- PAGE=? -->
DM

<!-- PAGE=? -->
CAD

<!-- PAGE=? -->
Emergency

<!-- PAGE=? -->
DDAVP 0.3 μ g/kg

<!-- PAGE=? -->
No Succinylcholine

<!-- PAGE=? -->
NaHCO3

<!-- PAGE=? -->
Hyperkalemia tx with CaCl, insulin/glucose, bicarb, hyperventilatn, ventolin, kayexalate, dialysis

<!-- PAGE=? -->
Renal Failure

<!-- PAGE=? -->
Etiology (FeNa, SG, Osm)

<!-- PAGE=? -->
 ARF

<!-- PAGE=? -->
 Pre-renal (renal hypoperfusion)

<!-- PAGE=? -->
-Hypotension, hypovolemia

<!-- PAGE=? -->
-CHF, sepsis, anaphylaxis, liver failure

<!-- PAGE=? -->
-Embolic, ischemic

<!-- PAGE=? -->
-ACEI + NSAID

<!-- PAGE=? -->
 Renal

<!-- PAGE=? -->
-ATN (nephrotoxicity, ischemia)

<!-- PAGE=? -->
-Interstitial nephritis, glomerulonephritis

<!-- PAGE=? -->
-Hburia, Mburia, multiple myeloma, crystals

<!-- PAGE=? -->
 Post-renal

<!-- PAGE=? -->
-Ureteral calculi, urethral obstruction

<!-- PAGE=? -->
 CRF

<!-- PAGE=? -->
 HTN, DM

<!-- PAGE=? -->
 SLE, polycystic kidneys,

<!-- PAGE=? -->
 Chronic GN, reflux nephropathy, pyelonephritis

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hx:

<!-- PAGE=? -->
Dialysis Hx:

<!-- PAGE=? -->
type, when last, problems

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
Pulmonary edema, pleural effusions

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
CHF, pericardial effusions, HTN

<!-- PAGE=? -->
Neuro

<!-- PAGE=? -->
Peripheral neuropathy, encephalopathy (uremia),

<!-- PAGE=? -->
ANS dysfxn

<!-- PAGE=? -->
GI

<!-- PAGE=? -->
impaired GI motility, N+V, anorexia, malnutrition

<!-- PAGE=? -->
Heme

<!-- PAGE=? -->
Platelet dysfxn, anemia

<!-- PAGE=? -->
O/E:

<!-- PAGE=? -->
 Orthostatic Vitals (incl SPO2)

<!-- PAGE=? -->
 Airway edema

<!-- PAGE=? -->
 AVF sites

<!-- PAGE=? -->
 Volume Status: ½ JVP and pulmonary edema

<!-- PAGE=? -->
 LVH, pulsus paradox

<!-- PAGE=? -->
Anesthetic Implications

<!-- PAGE=? -->
 Preop

<!-- PAGE=? -->
 Dialysis preferred at 24hrs preop

<!-- PAGE=? -->
 Ensure euvolemic status

<!-- PAGE=? -->
 Reflux prophylaxis

<!-- PAGE=? -->
 DDAVP (0.3 μ g/kg) to enhance plt fxn

<!-- PAGE=? -->
 Intraop

<!-- PAGE=? -->
 Treat as for full stomach

<!-- PAGE=? -->
 Exaggerated BDZ response

<!-- PAGE=? -->
 Use cis-atracurium

<!-- PAGE=? -->
 Avoid morphine and meperidine: M-6-G accum

<!-- PAGE=? -->
 Avoid sevo

<!-- PAGE=? -->
 Exaggerated BP swings with induction/intubation

<!-- PAGE=? -->
 Minimize fluids in anuric; use CVP to titrate fluids and avoid hypovolemia insult

<!-- PAGE=? -->
 Regional:  reduce LA dose if metab acidosis

<!-- PAGE=? -->
 Postop

<!-- PAGE=? -->
 Ensure adequate NMB reversal prior to extubation

<!-- PAGE=? -->
 May require postop dialysis

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Rheumatoid Arthritis

<!-- PAGE=? -->
'an autoimmune polyarthropathy with multisystem involvement'

<!-- PAGE=? -->
Difficult airway

<!-- PAGE=? -->
Cricoarytenoid arthritis

<!-- PAGE=? -->
TMJ dysfunction

<!-- PAGE=? -->
Unstable C-spine/RCJD

<!-- PAGE=? -->
AA instability, decr ROM

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
Pulmonary fibrosis

<!-- PAGE=? -->
Pleural effusions

<!-- PAGE=? -->
CV

<!-- PAGE=? -->
Pericardial thickening

<!-- PAGE=? -->
arrythmia

<!-- PAGE=? -->
Complications of medical treatment

<!-- PAGE=? -->
Steroids

<!-- PAGE=? -->
MTX

<!-- PAGE=? -->
Opiod Tolerant

<!-- PAGE=? -->
NSAID's

<!-- PAGE=? -->
3:1 female

<!-- PAGE=? -->
90% RF +

<!-- PAGE=? -->
Airway - TMJ synovitis, cricoarytenoid arthritis, rheumatoid cervical joint disease

<!-- PAGE=? -->
Cardiovascular - pericarditis, myocarditis, conduction delay, arteritis, aortitis, AI

<!-- PAGE=? -->
Respiratory - RLD: pleural effusions, rheumatoid nodules, pulmonary fibrosis

<!-- PAGE=? -->
Hemematology - anemia

<!-- PAGE=? -->
Treatment - ASA, NSAID, MTX (heme/liver), corticosteroid

<!-- PAGE=? -->
Rheumatoid cervical joint disease (RCJD) - 15% incidence in RA

<!-- PAGE=? -->
o Increased prevalence: +RF, disease severity, steroid use, rheumatoid nodules

<!-- PAGE=? -->
o headache, dysphonia, diploplia, & dysarthria

<!-- PAGE=? -->
o cervical pain & radiculopathy

<!-- PAGE=? -->
o cord impingment with neck flexion

<!-- PAGE=? -->
Preop:

<!-- PAGE=? -->
o Flex/Ext Xray - if on steroid/MTX (<3mm)

<!-- PAGE=? -->
Intra-op:

<!-- PAGE=? -->
o Smaller tube sizes

<!-- PAGE=? -->
o Difficult positioning

<!-- PAGE=? -->
o Difficult NA/Regional

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Sarcoidosis

<!-- PAGE=? -->
'a systemic granulomatous disorder with significant cardiac and respiratory effects'

<!-- PAGE=? -->
Airway granulomas

<!-- PAGE=? -->
RLD

<!-- PAGE=? -->
Myocardial sarcoid

<!-- PAGE=? -->
Conduction delay

<!-- PAGE=? -->
Hypercalcemia

<!-- PAGE=? -->
Steroid therapy

<!-- PAGE=? -->
General

<!-- PAGE=? -->
 Predilection for thoracic lymph nodes and lungs

<!-- PAGE=? -->
 Laryngeal sarcoid (1 - 5 %)

<!-- PAGE=? -->
Systems Review

<!-- PAGE=? -->
Assessment

<!-- PAGE=? -->
A hoarseness, stridor

<!-- PAGE=? -->
B dyspnea, exercise tolerance, wheezes

<!-- PAGE=? -->
C palpitations, arrhythmias, orthopnea, PND, rales, S3

<!-- PAGE=? -->
D focal nerve deficits

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
 CXR, PFTs, ABGs

<!-- PAGE=? -->
 ECG, (ECHO)

<!-- PAGE=? -->
 BUN, Crea, Urine Lytes & Osmolality

<!-- PAGE=? -->
 LFTs( ½ ), Alk Phos ( ½ )

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
High Risk Patients (PVC x 3)

<!-- PAGE=? -->
-P revious bacterial endocarditis

<!-- PAGE=? -->
-Prosthetic cardiac v alves

<!-- PAGE=? -->
-Complex c yanotic c ongenital heart disease

<!-- PAGE=? -->
-Constructed systemic pulmonary shunts or c onduits

<!-- PAGE=? -->
Moderate-risk category (MACH)

<!-- PAGE=? -->
-M itral valve prolapse with MR and/or thickened leaflets

<!-- PAGE=? -->
-A cquired valvar dysfunction

<!-- PAGE=? -->
-Other c ongenital cardiac malformations

<!-- PAGE=? -->
-H ypertrophic cardiomyopathy

<!-- PAGE=? -->
NOT at risk

<!-- PAGE=? -->
-Isolated secundum ASD

<!-- PAGE=? -->
-Surgical repair of atrial septal defect, ventricular septal defect, or patent ductus arteriosus (without residua beyond 6 mo)

<!-- PAGE=? -->
Any infected surgery

<!-- PAGE=? -->
Biliary

<!-- PAGE=? -->
Mucus membrance (other than vagina)

<!-- PAGE=? -->
-Dental Procedures

<!-- PAGE=? -->
-Respiratory tract

<!-- PAGE=? -->
-Gastrointestinal tract (moderate is optional)

<!-- PAGE=? -->
-Genitourinary tract

<!-- PAGE=? -->
SBE Prophylaxis

<!-- PAGE=? -->
Optional for High-risk patients (BEVT)

<!-- PAGE=? -->
-Bronchoscopy

<!-- PAGE=? -->
-Endoscopy

<!-- PAGE=? -->
-Vaginal hysterectomy

<!-- PAGE=? -->
-Vaginal delivery

<!-- PAGE=? -->
-TEE

<!-- PAGE=? -->
Antibiotic Regimens

<!-- PAGE=? -->
Above Diagphram - 1 agent

<!-- PAGE=? -->
Amoxil/Ampicillin 50 mg/kg (2 gm)

<!-- PAGE=? -->
Allergic: Clindamycin 20 mg/kg (600 mg)

<!-- PAGE=? -->
Below Diagphram

<!-- PAGE=? -->
High-risk - 2 agents

<!-- PAGE=? -->
o Ampicillin + gentamicin 1.5 mg/kg (120 mg)

<!-- PAGE=? -->
o Allergic: Vanco 20 mg/kg (1g) + gent

<!-- PAGE=? -->
Moderate-risk

<!-- PAGE=? -->
o Ampicillin

<!-- PAGE=? -->
o Allergic: Vanco

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Scleroderma

<!-- PAGE=? -->
'A connective tissue disease characterized by microvascular inflammation and fibrosis'

<!-- PAGE=? -->
Difficult airway

<!-- PAGE=? -->
Limited mouth opening

<!-- PAGE=? -->
bleeding

<!-- PAGE=? -->
Restrictive lung disease

<!-- PAGE=? -->
Cardiac disease

<!-- PAGE=? -->
Myocardial fibrosis and effusion

<!-- PAGE=? -->
Arrhythmias

<!-- PAGE=? -->
Pulm HTN

<!-- PAGE=? -->
Gastroparesis / esophageal dysmotility

<!-- PAGE=? -->
Aspiration risk / RSI

<!-- PAGE=? -->
CREST

<!-- PAGE=? -->
Difficult venous access

<!-- PAGE=? -->
associated with CREST syndrome

<!-- PAGE=? -->
Ö C alcinosis

<!-- PAGE=? -->
Ö R aynauds

<!-- PAGE=? -->
Ö E sophageal dysmotility

<!-- PAGE=? -->
Ö S clerodactyly

<!-- PAGE=? -->
Ö T elangectasia

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
Ö immunosuppression

<!-- PAGE=? -->
steroids

<!-- PAGE=? -->
penicillamine - decr collagen formation

<!-- PAGE=? -->
cyclophosphomide

<!-- PAGE=? -->
ROS

<!-- PAGE=? -->
Ö Airway

<!-- PAGE=? -->
 Limited mouth opening

<!-- PAGE=? -->
 Oral/nasal telangectasia

<!-- PAGE=? -->
Ö CVS

<!-- PAGE=? -->
 Myocardial fibrosis

<!-- PAGE=? -->
 Conduction abnormalities

<!-- PAGE=? -->
 Pericardial effusion

<!-- PAGE=? -->
 Accelerated atherosclerosis

<!-- PAGE=? -->
 PHTN

<!-- PAGE=? -->
 Raynauds

<!-- PAGE=? -->
Ö Resp

<!-- PAGE=? -->
 RLD / pulmonary fibrosis

<!-- PAGE=? -->
 Recurrant aspiration

<!-- PAGE=? -->
 Chronic hypoxia / PHTN

<!-- PAGE=? -->
Ö GI

<!-- PAGE=? -->
 Esophageal dysmotility

<!-- PAGE=? -->
 GERD

<!-- PAGE=? -->
Ö GU

<!-- PAGE=? -->
 Renal artery obstruction

<!-- PAGE=? -->
 Arteriolar intimal proliferation

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Etiology/Syndrome

<!-- PAGE=? -->
Anti-convulsant

<!-- PAGE=? -->
o S/E - liver, blood

<!-- PAGE=? -->
o Interaction - NMBA

<!-- PAGE=? -->
o Levels

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
o CBC, lytes, BUN, Cr

<!-- PAGE=? -->
o Ca, Mg, glucose

<!-- PAGE=? -->
o LFT's

<!-- PAGE=? -->
o Urinalysis

<!-- PAGE=? -->
o +/- LP

<!-- PAGE=? -->
o CT - head

<!-- PAGE=? -->
Management

<!-- PAGE=? -->
o ABCs

<!-- PAGE=? -->
o IV access & monitors

<!-- PAGE=? -->
o Glucometer & dextrose

<!-- PAGE=? -->
o Midazolam - 0.5 mg IV Q2min

<!-- PAGE=? -->
o STP 0.5-1mg/kg IV incrementally

<!-- PAGE=? -->
o Phenytoin 10 mg/kg IV over 30 min

<!-- PAGE=? -->
o Consider ↑ ICP treatment

<!-- PAGE=? -->
o Pregnancy - MgSO4

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
Etiology: CHILD

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
o Structural

<!-- PAGE=? -->
 Tumor, trauma, bleeding, ischemia

<!-- PAGE=? -->
o Intrinsic

<!-- PAGE=? -->
 Epilepsy

<!-- PAGE=? -->
Hypoxemia

<!-- PAGE=? -->
Infection

<!-- PAGE=? -->
o Meningitis

<!-- PAGE=? -->
o Encephalitis

<!-- PAGE=? -->
o Abscess

<!-- PAGE=? -->
Lytes/Metabolic

<!-- PAGE=? -->
o Electrolytes

<!-- PAGE=? -->
 ↑ / ↓ Na, ↑ Ca, ↓ Mg

<!-- PAGE=? -->
o hypoglycemia

<!-- PAGE=? -->
o hepatic encephalopathy

<!-- PAGE=? -->
Drugs

<!-- PAGE=? -->
o Local anesthetic

<!-- PAGE=? -->
o Cocaine

<!-- PAGE=? -->
o Amphetamines

<!-- PAGE=? -->
o Theopylline

<!-- PAGE=? -->
o INH

<!-- PAGE=? -->
o Withdrawl

<!-- PAGE=? -->
 EtOH

<!-- PAGE=? -->
 Opioid

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Triad

<!-- PAGE=? -->
M ental agitation

<!-- PAGE=? -->
N eurologic disorders

<!-- PAGE=? -->
A utonomic instability - hyperthermia

<!-- PAGE=? -->
Myoclonus

<!-- PAGE=? -->
Muscle rigidity

<!-- PAGE=? -->
Results from overstimulation of 5-HT1A receptors by SSRISs, TCAs, MAOI, triptans, metoclopramide, demerol

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
D/C serotonergic agent

<!-- PAGE=? -->
Avoid myoglobinuria - mannitol, HCO3, diuresis

<!-- PAGE=? -->
IV access & BUN/Cr, lytes, Mg, Ca

<!-- PAGE=? -->
Anxiolytic: Midazolam

<!-- PAGE=? -->
Anticonvulsants

<!-- PAGE=? -->
Active cooling

<!-- PAGE=? -->
Antihypertensive agents in severe cases

<!-- PAGE=? -->
Serotonin Syndrome

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Sickle Cell Disease

<!-- PAGE=? -->
'a hereditary disease causing sickling of RBC which lead to microvascular occlusion that can cause:'

<!-- PAGE=? -->
Acute/Chronic Pain

<!-- PAGE=? -->
Vaso-occlusive disease - head to toe

<!-- PAGE=? -->
Anemia

<!-- PAGE=? -->
Prevention:

<!-- PAGE=? -->
Hypoxia/Hypercarbia

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Acidosis

<!-- PAGE=? -->
Dehydration

<!-- PAGE=? -->
Stasis (tourniquet relative contra)

<!-- PAGE=? -->
Hgb SS - valine for glutamic acid substitution at position 6 of β chain

<!-- PAGE=? -->
Polymerization of Hgb SS leads to 'sickling' of RBC's

<!-- PAGE=? -->
Clinical Features

<!-- PAGE=? -->
CNS - pain, cerebral infarction, retinopathy, peripheral neuropathy

<!-- PAGE=? -->
CVS - cor pulmonale, pulmonary HTN

<!-- PAGE=? -->
Resp - Acute chest syndrome, airway hyperreactivity, RLD

<!-- PAGE=? -->
GU - CRF, priaprism,

<!-- PAGE=? -->
GI - cholelithiasis, cirrhosis, dyspepsia

<!-- PAGE=? -->
Heme - hemolytic anemia (normal Hgb 60-90), functional hyposplenism

<!-- PAGE=? -->
MSK - osteonecrosis, osteomyelitis ( salmonella/S. aureus ), dactylitis

<!-- PAGE=? -->
Acute Chest Syndrome (10% mortality)

<!-- PAGE=? -->
new pulmonary infiltrate involving at least one complete lung segment on chest radiograph consistent with alveolar consolidation

<!-- PAGE=? -->
pleuritic chest pain, T>38.5 o C, tachypnea, wheezing, cough

<!-- PAGE=? -->
precipitated by infection, fat embolism, pulmonary infarction, surgical procedures

<!-- PAGE=? -->
Tx: oxygen, bronchodilators, incentive spirometry, good analgesia, antibiotics, transfusion (Hgb S < 30%), mechanical ventilation, possibly steroids and nitric oxide

<!-- PAGE=? -->
Predictors of Postop Complications

<!-- PAGE=? -->
Type of  procedure - low (ing. Hernia/extremity sx), moderate (intraabdominal), high (intra-thoracic/neuro)

<!-- PAGE=? -->
Increased age (assoc. with disease progression)

<!-- PAGE=? -->
Frequency of recent complications (current activity of disease state)

<!-- PAGE=? -->
Hospitalization (marker of disease severity)

<!-- PAGE=? -->
Temporal clustering of ACS (progression of lung disease)

<!-- PAGE=? -->
Abn. Lung fields on CXR (evidence of sickle chronic lung disease

<!-- PAGE=? -->
Pregnancy (increased risk of maternal complications)

<!-- PAGE=? -->
Pre-existing infection (triggering agent for ACS)

<!-- PAGE=? -->
Haplotype (African haplotypes have more severe disease)

<!-- PAGE=? -->
Preop Investigations

<!-- PAGE=? -->
Hct, BUN/Cr, crossmatch (extended for E,C, K groups), CXR, EKG, +/PFTS

<!-- PAGE=? -->
Preop Transfusion Goals

<!-- PAGE=? -->
Minor procedures - no transfusion required

<!-- PAGE=? -->
Intermdiate/Severe - transfuse to Hgb > 100 (Hct  > 30%)

<!-- PAGE=? -->
Hgb S < 30%

<!-- PAGE=? -->
Only the most severe cases require 'exchange' transfusions in conjunction with a Hematologist

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
Seizures, peripheral neuropathy

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
Pericarditis, myocarditis, conduction defects

<!-- PAGE=? -->
Resp

<!-- PAGE=? -->
Fibrosis, RLD, effusions

<!-- PAGE=? -->
Heme

<!-- PAGE=? -->
Thrombosis, anemia

<!-- PAGE=? -->
GU

<!-- PAGE=? -->
Renal Failure, nephrotic syndrome

<!-- PAGE=? -->
Medications

<!-- PAGE=? -->
Steroids/Immunesupressants

<!-- PAGE=? -->
NSAID's

<!-- PAGE=? -->
Systemic Lupus Erythematous

<!-- PAGE=? -->
'a multisystem autoimmune disease causing fibrinoid deposits and inflammation in multiple tissues'

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
 CXR, PFTs, ABGs

<!-- PAGE=? -->
 ECG, ECHO

<!-- PAGE=? -->
 CBC, BUN/Cr, lytes, Coags

<!-- PAGE=? -->
Anesthetic Implications

<!-- PAGE=? -->
 Steroid coverage

<!-- PAGE=? -->
 Assess for contraindications of regional given neuropathies, abnormal coags, and ½ infxns

<!-- PAGE=? -->
 Goal is to minimize surgical stress

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gains in sodium

<!-- PAGE=? -->
o hyperaldosteronism (excess mineralocorticoid)

<!-- PAGE=? -->
o Cushing's syndrome (excess glucocorticoid)

<!-- PAGE=? -->
o excessive hypertonic saline or sodium bicarbonate administration

<!-- PAGE=? -->
Loss of free water

<!-- PAGE=? -->
o gastrointestinal losses

<!-- PAGE=? -->
o renal excretion (eg, osmotic diuresis or diabetes insipidus).

<!-- PAGE=? -->
S/S: altered mental status, weakness, irritability, focal neurologic deficits, and coma or seizures.

<!-- PAGE=? -->
Tx: underlying cause, correction of the water deficit

<!-- PAGE=? -->
-administer fluid to lower serum sodium at a rate of 0.5 to 1 mEq/h with a decrease of no more than approximately 12 mEq/L in the first 24 hours and the remainder over the next 48 to 72 hours.

<!-- PAGE=? -->
Hypernatremia

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Clinical Manifestations

<!-- PAGE=? -->
Headache

<!-- PAGE=? -->
Nausea

<!-- PAGE=? -->
Vomiting

<!-- PAGE=? -->
Muscle cramps

<!-- PAGE=? -->
Useful Facts / Formulae

<!-- PAGE=? -->
Total body sodium deficit = TBW x (140 - [Na])

<!-- PAGE=? -->
3% saline = 513 mmol/L sodium

<!-- PAGE=? -->
Volume of 3% required = deficit/ (513)

<!-- PAGE=? -->
Acute symptoms:

<!-- PAGE=? -->
correct at 1mEq/L/hr to 125 mEq/L

<!-- PAGE=? -->
then 0.5 mEq/L/hr

<!-- PAGE=? -->
Max 12 mEq/L/day - CPD

<!-- PAGE=? -->
SIADH:

<!-- PAGE=? -->
Causes

<!-- PAGE=? -->
Tumors: brain, lung, pancreas, bladder, uterus

<!-- PAGE=? -->
Pulmonary infections

<!-- PAGE=? -->
Drugs: nicotine, narcotics, chlorpropamide, cyclophosphamide

<!-- PAGE=? -->
Hypothyroidism

<!-- PAGE=? -->
Adrenal insufficiency

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
Serum Na < 130 mEq/L

<!-- PAGE=? -->
Serum Osm < 270

<!-- PAGE=? -->
Urine Na > 20mEq/L

<!-- PAGE=? -->
Urine Osm > 300

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Fluid restrict (< 1 litre / day), Diuretic, Hypertonic saline

<!-- PAGE=? -->
Lethargy

<!-- PAGE=? -->
Disorientation

<!-- PAGE=? -->
Seizures

<!-- PAGE=? -->
Coma

<!-- PAGE=? -->
Hyponatremia

<!-- PAGE=? -->
Hyponatremla: Evaluallon

<!-- PAGE=? -->
Measure Serum Osmclality

<!-- PAGE=? -->
Normal

<!-- PAGE=? -->
Low

<!-- PAGE=? -->
Hich

<!-- PAGE=? -->
280

<!-- PAGE=? -->
290

<!-- PAGE=? -->
<280

<!-- PAGE=? -->
3290

<!-- PAGE=? -->
mOsm-Ke '

<!-- PAGE=? -->
Glurose

<!-- PAGE=? -->
Eharol

<!-- PAGE=? -->
Mannitol

<!-- PAGE=? -->
Gucose

<!-- PAGE=? -->
Renal {a lure

<!-- PAGE=? -->
Low Total Body Sodlum

<!-- PAGE=? -->
Normal Total Body Sodlum

<!-- PAGE=? -->
Nonrenal Na Icssos

<!-- PAGE=? -->
<10-15

<!-- PAGE=? -->
anc

<!-- PAGE=? -->
(Uxa >30

<!-- PAGE=? -->
ara

<!-- PAGE=? -->
Svalosses

<!-- PAGE=? -->
Nephrosis

<!-- PAGE=? -->
waterintakc

<!-- PAGE=? -->
use

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Considerations:

<!-- PAGE=? -->
Spinal Cord Injury Pt:

<!-- PAGE=? -->
Prevention, Monitoring and Treatment for AD

<!-- PAGE=? -->
Respiratory and Cardiac Insufficiency

<!-- PAGE=? -->
Sux contraindication

<!-- PAGE=? -->
C-spine injury/fusion, previous trach

<!-- PAGE=? -->
GI atony/Full stomach

<!-- PAGE=? -->
resp insufficiency - FRC, weak cough

<!-- PAGE=? -->
cardiac deconditioning, Brady (T1-T4)

<!-- PAGE=? -->
temperature instability

<!-- PAGE=? -->
Latex precautions

<!-- PAGE=? -->
DVT

<!-- PAGE=? -->
sepsis

<!-- PAGE=? -->
decubitus ulcer

<!-- PAGE=? -->
UTI

<!-- PAGE=? -->
pneumonia

<!-- PAGE=? -->
Sux contraindication >48H

<!-- PAGE=? -->
Difficult Assessment of Regional

<!-- PAGE=? -->
Autonomic Dysfunction

<!-- PAGE=? -->
Orthostatic Hypotension

<!-- PAGE=? -->
Dysreflexia

<!-- PAGE=? -->
Spinal Cord Injury

<!-- PAGE=? -->
Acute Spinal Cord Transection

<!-- PAGE=? -->
Methylprednisolone 30 mg/kg IV within 8 hours

<!-- PAGE=? -->
Then 5.4 mg/kg/hr x 24 - 48 hours

<!-- PAGE=? -->
Profound SNS discharge, Pulm Edema

<!-- PAGE=? -->
Optimize perfusion:

<!-- PAGE=? -->
} ↑ MAP

<!-- PAGE=? -->
} Consider lumbar drain (10 ml/hr)

<!-- PAGE=? -->
Spinal Cord Syndromes

<!-- PAGE=? -->
Central cord syndrome

<!-- PAGE=? -->
Disproportionately greater motor power in upper extremities than in lower extremities with varying degrees of sensory loss

<!-- PAGE=? -->
Recovery lower extremities>bladder function>proximal upper extremities and hands last

<!-- PAGE=? -->
Due to vascular compromise of anterior spinal artery

<!-- PAGE=? -->
Anterior Cord Syndrome

<!-- PAGE=? -->
Paraplegia and dissociated sensory loss with loss of pain and temperature sensation

<!-- PAGE=? -->
Posterior column function (position, vibration, and deep pressure sense) is preserved

<!-- PAGE=? -->
Due to infarction of cord in territory supplied by anterior spinal artery

<!-- PAGE=? -->
Poorest prognosis of incomplete injuries

<!-- PAGE=? -->
Brown-Sequard's Syndrome

<!-- PAGE=? -->
Hemisection of cord

<!-- PAGE=? -->
Consists of ipsilateral motor loss (corticospinal tract) and loss of position sense (posterior column) associated with contralateral loss of pain and temperature sensation beginning 1 to 2 levels below the level of injury (STT)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
AUTONOMIC HYPERREFLEXIA (DYSREFLEXIA)

<!-- PAGE=? -->
'AD is characterized by a massive unopposed sympathetic discharge in response to any noxious stimulus or distention of a viscus below the lesion, and a patient with an established (2-3wo) spinal cord transection above T5/6.'

<!-- PAGE=? -->
Signs/Symptoms

<!-- PAGE=? -->
 Paroxysmal HTN

<!-- PAGE=? -->
 Reflex bradycardia

<!-- PAGE=? -->
 Arrhythmias

<!-- PAGE=? -->
 H/A

<!-- PAGE=? -->
 Vasodilation, flushing and sweating above

<!-- PAGE=? -->
 Vasoconstriction, palor and piloerection below

<!-- PAGE=? -->
Anesthetic Management

<!-- PAGE=? -->
Prevention:

<!-- PAGE=? -->
o Spinal anesthesia

<!-- PAGE=? -->
o Epidural anesthesia (but limited by sacral sparing)

<!-- PAGE=? -->
o Deep GA

<!-- PAGE=? -->
o Clonidine 0.2mg PO

<!-- PAGE=? -->
Monitoring:

<!-- PAGE=? -->
o Aline

<!-- PAGE=? -->
o CVP for drugs

<!-- PAGE=? -->
Treat paroxysmal HTN:

<!-- PAGE=? -->
o Stop stimulus

<!-- PAGE=? -->
o Deepen anesthetic

<!-- PAGE=? -->
o direct vasodilators:

<!-- PAGE=? -->
 SNP 0.5 mcg/kg/min

<!-- PAGE=? -->
 NTG 0.5 mcg/kg/min

<!-- PAGE=? -->
 Phentolamine 1-5 mg IV, 0.1 mg/min

<!-- PAGE=? -->
 Trimethaphan 0.1-1mg/min

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Corticosteroids

<!-- PAGE=? -->
-also: IVIG, plasmapheresis

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Sux

<!-- PAGE=? -->
Contraindications

<!-- PAGE=? -->
Allergy

<!-- PAGE=? -->
MH hx or family hx

<!-- PAGE=? -->
½ IOP/open globe

<!-- PAGE=? -->
Hyperkalemia (will get rise of 1mmol/L normally)

<!-- PAGE=? -->
Burn > 48hrs

<!-- PAGE=? -->
Spinal cord injury > 48hrs

<!-- PAGE=? -->
Massive traumas, Crush injuries, prolonged immobilization

<!-- PAGE=? -->
CVA, ruptured cerebral aneurysm

<!-- PAGE=? -->
UMN disease, any dz leading to paralysis/weakness

<!-- PAGE=? -->
MS, Guillain-Barre syndrome

<!-- PAGE=? -->
DMD, Myotonic dystrophy

<!-- PAGE=? -->
Pseudocholinesterase Deficiency:

<!-- PAGE=? -->
-does not affect plasma/non-specific/tissue esterase (RAE) - remi, atra, esmolol

<!-- PAGE=? -->
-inherited, pregnancy, liver failure, plasmaphereisis, drug-induced - must drop 75% to see effect

<!-- PAGE=? -->
-Dibucaine:

<!-- PAGE=? -->
 amide LA that has 20x the affinity for N enzyme than abnormal

<!-- PAGE=? -->
 # = % inhibition of the Normal enzyme

<!-- PAGE=? -->
Relative

<!-- PAGE=? -->
½ ICP (can give defasciculating dose and lidocaine) Myasthenia Gravis (unpredictable effect )

<!-- PAGE=? -->
OK: CMPA

<!-- PAGE=? -->
CP

<!-- PAGE=? -->
Myelomenigocele

<!-- PAGE=? -->
Parkinson's

<!-- PAGE=? -->
Acute injury (<24H)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Syncope

<!-- PAGE=? -->
cardiac

<!-- PAGE=? -->
valves - AS

<!-- PAGE=? -->
muscle - failure, ischemia

<!-- PAGE=? -->
Electrical - tachy/brady, vagal

<!-- PAGE=? -->
Pericadium - tamponade, constrictive

<!-- PAGE=? -->
neuro

<!-- PAGE=? -->
seizures

<!-- PAGE=? -->
stroke

<!-- PAGE=? -->
bleed

<!-- PAGE=? -->
ischemia - embolic, thrombotic, global

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
o Seizure

<!-- PAGE=? -->
o Pain/Tourniquet

<!-- PAGE=? -->
o ↑ ICP

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
o Hypovolemia

<!-- PAGE=? -->
o Arrhythmias

<!-- PAGE=? -->
o Ischemia

<!-- PAGE=? -->
o Obstruction (PE, tamponade)

<!-- PAGE=? -->
Endocrine

<!-- PAGE=? -->
o MH

<!-- PAGE=? -->
o Pheochromocytoma

<!-- PAGE=? -->
o Carcinoid

<!-- PAGE=? -->
o Thyrotoxicosis

<!-- PAGE=? -->
Drug (In/Out)

<!-- PAGE=? -->
o Beta agonist

<!-- PAGE=? -->
o Cocaine

<!-- PAGE=? -->
o Dig

<!-- PAGE=? -->
o Withdrawl (EtOH, narcotics)

<!-- PAGE=? -->
Tachycardia (NSR)

<!-- PAGE=? -->
Metabolic

<!-- PAGE=? -->
o Electrolytes

<!-- PAGE=? -->
o Hypoxia

<!-- PAGE=? -->
o Hypercarbia

<!-- PAGE=? -->
o Hyperthermia

<!-- PAGE=? -->
Unstable Tachy with Diff A/W

<!-- PAGE=? -->
-if time: topicalize

<!-- PAGE=? -->
-if too unstable: midaz + shock, LMA ready

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Cardiac tamponade

<!-- PAGE=? -->
Hemodynamic goals

<!-- PAGE=? -->
↑ HR (>90)

<!-- PAGE=? -->
↑ preload

<!-- PAGE=? -->
↑ afterload

<!-- PAGE=? -->
normal / ↑ contractility

<!-- PAGE=? -->
 Avoid PPV / maintain SV

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
Infectious

<!-- PAGE=? -->
} TB

<!-- PAGE=? -->
} Bacterial

<!-- PAGE=? -->
} Viral

<!-- PAGE=? -->
Non-infectious

<!-- PAGE=? -->
} Uremia

<!-- PAGE=? -->
} Neoplastic

<!-- PAGE=? -->
} Radiation

<!-- PAGE=? -->
} CTD (RA, SLE)

<!-- PAGE=? -->
Drug-induced

<!-- PAGE=? -->
} Procainamide

<!-- PAGE=? -->
} Hydralazine

<!-- PAGE=? -->
Trauma

<!-- PAGE=? -->
} Blunt / penetrating trauma

<!-- PAGE=? -->
} Post-MI

<!-- PAGE=? -->
} Dissecting aneurysm

<!-- PAGE=? -->
Manifestations

<!-- PAGE=? -->
Beck: muffled HS, elevated JVP, Hypotension

<!-- PAGE=? -->
Dyspnea

<!-- PAGE=? -->
Tachycardia

<!-- PAGE=? -->
¾ pulse pressure

<!-- PAGE=? -->
½ CVP

<!-- PAGE=? -->
Pulsus paradoxus ( > 10 mmHg ↓ of SBP with inspiration)

<!-- PAGE=? -->
Electrical alternans

<!-- PAGE=? -->
} PTX

<!-- PAGE=? -->
} Bullous emphysema

<!-- PAGE=? -->
} Tamponade

<!-- PAGE=? -->
Diagnosis

<!-- PAGE=? -->
Echo (compression of RV and right atrium during diastole)

<!-- PAGE=? -->
CVP/PAC

<!-- PAGE=? -->
} increased mean pressure (16 mm Hg)

<!-- PAGE=? -->
} equalization of diastolic P

<!-- PAGE=? -->
} attenuation of the y descent.

<!-- PAGE=? -->
 ++ Fluid, SV, Dopamine/Epi infusion

<!-- PAGE=? -->
Pericardiocentesis:

<!-- PAGE=? -->
 Large bore 16g, 3' catheter over needle attached to a 50cc syringe

<!-- PAGE=? -->
 Subxyphoid approach

<!-- PAGE=? -->
 inserted b/n the xyphoid and the left costal margin at 30-45 ° angle to skin and directed towards the left scapula

<!-- PAGE=? -->
 ECG changes, arrhythmias suggestive of contact with myocardium therefore withdraw

<!-- PAGE=? -->
 If time, ideally like to attach V lead of ECG via a sterile alligator clip and monitor ECG during needle insertion

<!-- PAGE=? -->
-½ ST suggests ventricular contact

<!-- PAGE=? -->
-½ PR suggest atrial contact

<!-- PAGE=? -->
-Blood withdrawn from the pericardium should not clot

<!-- PAGE=? -->
OR:

<!-- PAGE=? -->
Tx

<!-- PAGE=? -->
o surgeon scrubbed, prepped ready to go

<!-- PAGE=? -->
o Ketamine for induction

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Thrombocytopenia

<!-- PAGE=? -->
↓ platelet production

<!-- PAGE=? -->
Gestational

<!-- PAGE=? -->
Congenital thrombocytopenia

<!-- PAGE=? -->
Aplastic anemia

<!-- PAGE=? -->
MDS

<!-- PAGE=? -->
Leukemia

<!-- PAGE=? -->
↑ platelet consumption

<!-- PAGE=? -->
PIH / HELLP

<!-- PAGE=? -->
TTP

<!-- PAGE=? -->
Antiphospholipid syndrome

<!-- PAGE=? -->
HUS

<!-- PAGE=? -->
DIC

<!-- PAGE=? -->
Plt Sequestration/destruction

<!-- PAGE=? -->
Drug inuduced thrombocytopenia

<!-- PAGE=? -->
ITP

<!-- PAGE=? -->
HSM

<!-- PAGE=? -->
-< 20 - spontaneous ICH,  >50 for surgery, > 75 for NA block -treat immune disorders with steroids, IVIG, plasmapheresis -potential airway bleeding

<!-- PAGE=? -->
-splenectomy: pneumococcal, meningococcal, Hemophilus vaccine

<!-- PAGE=? -->
Gestational Thrombocytopenia

<!-- PAGE=? -->
Most common cause of thrombocytopenia during pregnancy

<!-- PAGE=? -->
Related to dilution/accelerated turnover/ ↑ destruction of platelets

<!-- PAGE=? -->
Typically < 70

<!-- PAGE=? -->
Returns to normal within 12 weeks

<!-- PAGE=? -->
Asymptomatic, third trimester thrombocytopenia

<!-- PAGE=? -->
HELLP

<!-- PAGE=? -->
circulating platelets adhere to damaged endothelium

<!-- PAGE=? -->
occurs in 50% of pre-eclamptic patients

<!-- PAGE=? -->
rare fetal thrombocytopenia

<!-- PAGE=? -->
Plt count < 100

<!-- PAGE=? -->
Immune Thrombocytopenic Purpura (ITP)

<!-- PAGE=? -->
Immunologically mediated platelet destruction

<!-- PAGE=? -->
IgG antibodies to platelet membrane glycoproteins

<!-- PAGE=? -->
5% of pregnancy induced thrombocytopenia

<!-- PAGE=? -->
12% neonates have severe thrombocytopenia

<!-- PAGE=? -->
Plt count < 100

<!-- PAGE=? -->
Peripheral megathrombocytes

<!-- PAGE=? -->
Easy bruising and petechiae

<!-- PAGE=? -->
Treatment: steroid, IVIG, splenectomy

<!-- PAGE=? -->
Thrombotic Thrombocytopenic Purpura (TTP)

<!-- PAGE=? -->
Deficiency of vWF-cleaving protease - plt aggregation

<!-- PAGE=? -->
Microangiopathic hemolytic anemia

<!-- PAGE=? -->
Microthrmbi - CNS, renal dysfunction

<!-- PAGE=? -->
Severe purpura

<!-- PAGE=? -->
Treatment: plasmapheresis, ASA, steroids, splenectomy

<!-- PAGE=? -->
Avoid Plt transfusion

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hyperthyroidism

<!-- PAGE=? -->
Potential difficult airway/obstruction

<!-- PAGE=? -->
Potential Hypermetabolic state

<!-- PAGE=? -->
CNS

<!-- PAGE=? -->
CVS

<!-- PAGE=? -->
GI / Heme

<!-- PAGE=? -->
Post-operative complications

<!-- PAGE=? -->
RLN injury

<!-- PAGE=? -->
Hematoma

<!-- PAGE=? -->
Hypoparathyroidism ( ↓ Ca)

<!-- PAGE=? -->
Avoid Sympathetic stimulation

<!-- PAGE=? -->
Deep anesthesia

<!-- PAGE=? -->
Avoid ketamine

<!-- PAGE=? -->
↑ MAC

<!-- PAGE=? -->
Eye protection

<!-- PAGE=? -->
Airway - goiter, displaced trachea, tracheal compression

<!-- PAGE=? -->
CVS - tachycardia, Afib, MVP, cardiomyopathy, volume depletion

<!-- PAGE=? -->
Neuro anxiety, tremours, heat intolerance, opthalmopathy

<!-- PAGE=? -->
GI -weight loss, diarrhea

<!-- PAGE=? -->
Heme - mild anemia, thrombocytopenia

<!-- PAGE=? -->
Metabolic - hypercalcemia (bone resorption)

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Grave's Disease (IgG that stimulates TSH receptor)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Iatrogenic

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Toxic nodular goiter

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Thyroiditis

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Pregnancy (ectopic TSH-like substance)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Adenoma: Pituatary, Thyroid

<!-- PAGE=? -->
Treatment (KI May Prevent B-Blocker S/E - FRC - 21212)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Propylthiouracil and methimazole

<!-- PAGE=? -->
 inhibit thyroid hormone synthesis

<!-- PAGE=? -->
 Propylthiouracil also ¾ peripheral conversion of T4 to T3

<!-- PAGE=? -->
 Tx for at least 2-6 months before pt is rendered euthyroid (stores of thyroid hormone in the gland last several months)

<!-- PAGE=? -->
 Toxic reactions include skin rash, nausea, fever, agranulocytosis, hepatitis, lupus-like syndrome

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Inorganic Iodide

<!-- PAGE=? -->
 Inhibits thyroid hormone formation and release

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Radioactive Iodine ( Avoid in pregnant pts)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> β antagonists

<!-- PAGE=? -->
 attenuate manifestations of excess SNS activity ( ¾ tachycardia, heat intolerance, tremour, anxiety)

<!-- PAGE=? -->
 Also ¾ peripheral conversion of T4 to T3 over 1-2 wks

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Corticosteroids

<!-- PAGE=? -->
 Decadron 8-12mg/day used in severe thyrotoxicosis to ¾ peripheral conversion of T4 to T3

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Thyroidectomy

<!-- PAGE=? -->
Continue all antithyroid meds until the morning of surgery

<!-- PAGE=? -->
Render euthyroid over 1-2 wks using Propranolol (10-40mg PO Q4-6H) and Potassium Iodide (2-5dropsQ8H)

<!-- PAGE=? -->
Emergency surgery: β block with esmolol bolus or infusion to ¾ HR < 90

<!-- PAGE=? -->
Management of thyroid storm (Medical Emergency)

<!-- PAGE=? -->
 DDx - light anesthesia, pheo, MH, NMS

<!-- PAGE=? -->
Ö IV fluids

<!-- PAGE=? -->
Ö K + iodide (250 mg PO/IV Q6H, 10% soln=5 drops)

<!-- PAGE=? -->
Ö Propylthiouracil (200 mg PO/NG Q6H)

<!-- PAGE=? -->
Ö Methimazole (25 mg PO Q6H)

<!-- PAGE=? -->
Ö Hydrocortisone (100 mg IV Q6H)

<!-- PAGE=? -->
Ö Propranolol (1-10 mg IV, 10-40 mg PO Q6H)

<!-- PAGE=? -->
Ö Active cooling

<!-- PAGE=? -->
Ö Acetominophen (650-975 mg PO/PR)

<!-- PAGE=? -->
Ö Meperidine (25-50 mg IV Q6H)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Hypothyroidism

<!-- PAGE=? -->
Potential Difficult A/W

<!-- PAGE=? -->
Potential Myxedema coma

<!-- PAGE=? -->
End-organ systemic effects

<!-- PAGE=? -->
Operative risks

<!-- PAGE=? -->
Hypothermia

<!-- PAGE=? -->
Hypotension

<!-- PAGE=? -->
Delayed emergence

<!-- PAGE=? -->
Difficult wean

<!-- PAGE=? -->
Concominant endocrinopathy

<!-- PAGE=? -->
Adrenal insufficiency

<!-- PAGE=? -->
Hypoglycemia

<!-- PAGE=? -->
Myesthenia Gravis

<!-- PAGE=? -->
TSH ( μ U/ml)

<!-- PAGE=? -->
4-11 → subclinical → OR

<!-- PAGE=? -->
11-18 → mild → asymptomatic & treated (2-4 weeks) → OR

<!-- PAGE=? -->
19-89 → moderate → endocribe/echo/CT → 2 months → OR

<!-- PAGE=? -->
> 90

<!-- PAGE=? -->
→

<!-- PAGE=? -->
severe

<!-- PAGE=? -->
→

<!-- PAGE=? -->
endocrine/echo/CT

<!-- PAGE=? -->
→

<!-- PAGE=? -->
4-6 months

<!-- PAGE=? -->
→

<!-- PAGE=? -->
OR

<!-- PAGE=? -->
Etiology

<!-- PAGE=? -->
· Primary (1 ° )

<!-- PAGE=? -->
o most common (95%)

<!-- PAGE=? -->
o autoimmunte thyroiditis, 131 I tx for hyperthyroidism, thyroidectomy

<!-- PAGE=? -->
o ½ TSH  but ¾ T3 and T4

<!-- PAGE=? -->
· Secondary (2 ° )

<!-- PAGE=? -->
o Pituitary cysts, tumours, necrosis, infarction, surgery, radiation

<!-- PAGE=? -->
o Normal TSH, ¾ T3 and T4

<!-- PAGE=? -->
· Tertiary (3 ° )

<!-- PAGE=? -->
o Congenital defects, hypothyroid infxns, tumours, cysts, radiation

<!-- PAGE=? -->
o TRH, ¾ TSH, ¾ T3, ¾ T4

<!-- PAGE=? -->
Clinical Findings

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Levothyroxine (T4),  halflife 6-7 days

<!-- PAGE=? -->
Effect - 4 weeks

<!-- PAGE=? -->
IV levothyroxine available (half the oral dose)

<!-- PAGE=? -->
Surgery and Hypothyroidism

<!-- PAGE=? -->
If urgent surgery then 200 IV levothyroxine + hydrocortisone 100 mg IV Myxedema Coma

<!-- PAGE=? -->
Uncommon but mortality up to 60%

<!-- PAGE=? -->
precipitated by hypothermia, trauma, infections, CVA, anesthetics, sedatives and analgesics, amiodarone, and lithium

<!-- PAGE=? -->
manifestation -↓ mental status, delirium, coma, hypothermia, bradycardia, hypopnea, pericardial effusion +/- tamponade, hanging reflexes hyponatremia, hypoglycemia

<!-- PAGE=? -->
Hypotension - tamponade, decreased cardiac output

<!-- PAGE=? -->
Treatment:

<!-- PAGE=? -->
o IV levothyroxine 200 mcg IV, then 50 mcg IV OD

<!-- PAGE=? -->
o Alternative - IV T3 0.2 mcg/kg Q6H (watch for myocardial ischemia)

<!-- PAGE=? -->
o Hydrocortisone 100 mg IV then 25 mg IV Q6H

<!-- PAGE=? -->
o Cover patient (no warming blanket)

<!-- PAGE=? -->
o Fluid, electrolyte and glucose therapy as needed

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
'Trauma'

<!-- PAGE=? -->
ABCD

<!-- PAGE=? -->
Full Stomach

<!-- PAGE=? -->
Unknown PMHx, co-injestion

<!-- PAGE=? -->
Decontamination

<!-- PAGE=? -->
Protect Staff

<!-- PAGE=? -->
Remove clothing

<!-- PAGE=? -->
Gastric Lavage (large/life-threatening, within 1hr) c. Gastric Lavage (large/life-threatening, within 1hr)

<!-- PAGE=? -->
Activated Charcoal (1 g/kg PO initially)

<!-- PAGE=? -->
Consult Toxicologist

<!-- PAGE=? -->
Potential Dialysis

<!-- PAGE=? -->
Identify Toxidromes

<!-- PAGE=? -->
toxicity screen, CBC, LFTs, ABG, Glu, Cr, Osm, Lactate - CXR, AXR, EKG, NG, Foley

<!-- PAGE=? -->
Treatments:

<!-- PAGE=? -->
-A prolonged CPR and resuscitation may be warranted

<!-- PAGE=? -->
-DON'T

<!-- PAGE=? -->
-Naloxone 1ug/kg (10ug/kg in neonates)

<!-- PAGE=? -->
-Flumazenil 10ug/kg

<!-- PAGE=? -->
VT

<!-- PAGE=? -->
Lidocaine is the antiarrhythmic of choice in most cases of drug-induced monomorphic VT.  Types IA and IC and other antiarrhythmics that block the fast sodium channel (eg, sotalol) are contraindicated in cases of poisoning with tricyclic antidepressants or other fast sodium channel blockers because of the risk of synergistic toxicity.

<!-- PAGE=? -->
Toxicology

<!-- PAGE=? -->
Contraindicated Interventions

<!-- PAGE=? -->
Therapies to Considert

<!-- PAGE=? -->
(or Use With Caution)

<!-- PAGE=? -->
Bradycardia

<!-- PAGE=? -->
Pacemaker (transcutaneous or transvenous)

<!-- PAGE=? -->
Toxic drug

<!-- PAGE=? -->
caldum channe blocker:

<!-- PAGE=? -->
inhibitorpoisonings)

<!-- PAGE=? -->
eplnephrine , calcium salt? glucose Insulln?

<!-- PAGE=? -->
Isoproterenol If Irypotensive

<!-- PAGE=? -->
glucagon? NS (If hypotenslve)

<!-- PAGE=? -->
Prophylactic transvenous pacing

<!-- PAGE=? -->
Toxic drug

<!-- PAGE=? -->
B-bbcker: NS, epinephrine

<!-- PAGE=? -->
calcium

<!-- PAGE=? -->
salt? alucose'insulin? glucagon?

<!-- PAGE=? -->
Tachycardia

<!-- PAGE=? -->
Toxic drug

<!-- PAGE=? -->
sympathomimetics: benzodiazepines,

<!-- PAGE=? -->
B-Blockers (not generally useful in drug-induced

<!-- PAGE=? -->
lidocaine , sodlum bicarbonate , nitroglycerin,

<!-- PAGE=? -->
tachycardla)

<!-- PAGE=? -->
nitroprusside , labetalol

<!-- PAGE=? -->
Do not use propranolol for cocalne intoxication

<!-- PAGE=? -->
Toxic drug

<!-- PAGE=? -->
Cardioversion (rarely indicated)

<!-- PAGE=? -->
bicarbonate

<!-- PAGE=? -->
hyperventilation , NS , magnesium

<!-- PAGE=? -->
Adenosine (rarely indicated)

<!-- PAGE=? -->
Calcium channel blockers (rarely indicated)

<!-- PAGE=? -->
Toxic drug

<!-- PAGE=? -->
anticholinergics: physostigmine

<!-- PAGE=? -->
Sodium blcarbonate

<!-- PAGE=? -->
It TCA overdose: amiodarone or type kw

<!-- PAGE=? -->
Lidocaine

<!-- PAGE=? -->
antiarrhythmics (eg, procainamide)

<!-- PAGE=? -->
Toxic

<!-- PAGE=? -->
sympathomimeics: benzodiazepines,

<!-- PAGE=? -->
B-Blockers

<!-- PAGE=? -->
lidocaine , sodium bicarbonate , nitroglycerin,

<!-- PAGE=? -->
nitroprusside , phentolamine

<!-- PAGE=? -->
Benzodiazepines

<!-- PAGE=? -->
B-Blockers

<!-- PAGE=? -->
Lidocalne

<!-- PAGE=? -->
sodium bicarbonate

<!-- PAGE=? -->
Mitroglycerin

<!-- PAGE=? -->
Aspirin , heparin

<!-- PAGE=? -->
Base reperfusion strategy on cardiac

<!-- PAGE=? -->
catheterizationdata

<!-- PAGE=? -->
Shock

<!-- PAGE=? -->
Toxic drug

<!-- PAGE=? -->
caldum channe blocker: NS

<!-- PAGE=? -->
Isoproterenol

<!-- PAGE=? -->
Avold calcium salts

<!-- PAGE=? -->
digoxin toxicity Is suspected

<!-- PAGE=? -->
salt? glucosefinsulin? glucagon?

<!-- PAGE=? -->
Toxic

<!-- PAGE=? -->
B-bbcker: NS, epinephrine

<!-- PAGE=? -->
norepinephrine

<!-- PAGE=? -->
circulatory assist devices

<!-- PAGE=? -->
Atropine

<!-- PAGE=? -->
Succinylcholine

<!-- PAGE=? -->
Pralidoximelobidoxime

<!-- PAGE=? -->
Benzodiazepine

<!-- PAGE=? -->
Antipsychotics

<!-- PAGE=? -->
Physostigmine (not for TCA overdose)

<!-- PAGE=? -->
Other anticholinergic agents

<!-- PAGE=? -->
Assisted ventilation

<!-- PAGE=? -->
Do not use naloxone for meperidine-induced

<!-- PAGE=? -->
Maloxone

<!-- PAGE=? -->
selzures

<!-- PAGE=? -->
Tracheal Intubation

<!-- PAGE=? -->
druo

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Beta Blockers

<!-- PAGE=? -->
 IVF

<!-- PAGE=? -->
 Glucagon - 5mg bolus + 5 mg/hr IV

<!-- PAGE=? -->
 high dose epi

<!-- PAGE=? -->
 Calcium if glucagon and catecholamine are ineffective

<!-- PAGE=? -->
 Glucose / Insulin:

<!-- PAGE=? -->
 Bolus → 0.1 U/kg (I) + 0.1 g/kg (D50)

<!-- PAGE=? -->
 Infusion → 0.1 U/kg/hr (I) + 0.1 g/kg/hr (D50)

<!-- PAGE=? -->
 Pacing

<!-- PAGE=? -->
 Dialysis (Atenolol, Sotolol, Nadolol)

<!-- PAGE=? -->
 CPB

<!-- PAGE=? -->
CCB

<!-- PAGE=? -->
 IVF (careful because of myocardial depression)

<!-- PAGE=? -->
 CaCl → 20mg/kg + 20-50 mg/kg/hr, CaGluc → 50 mg/kg

<!-- PAGE=? -->
 Glucagon 50 mcg/kg

<!-- PAGE=? -->
 Epi/Norepinephrine

<!-- PAGE=? -->
 GIK: 500 ml D5W + 10 U humulin R + 40 mEq KCl @ 100 ml/hr

<!-- PAGE=? -->
 Pacing

<!-- PAGE=? -->
 CPB

<!-- PAGE=? -->
Digoxin

<!-- PAGE=? -->
 worse with hypoK, causes hyperK

<!-- PAGE=? -->
 IV Fluid

<!-- PAGE=? -->
 Glucose / Insulin

<!-- PAGE=? -->
 Digibind

<!-- PAGE=? -->
o Indications

<!-- PAGE=? -->
 Dysrhythmia with hemodynamic instability

<!-- PAGE=? -->
 Altered mental status with dig toxicity

<!-- PAGE=? -->
 ↑ K > 5.0

<!-- PAGE=? -->
 Dig level > 10 ng/ml

<!-- PAGE=? -->
 Ingestion > 0.3 mg/kg

<!-- PAGE=? -->
o Dose

<!-- PAGE=? -->
 # Vials = Dig level (ng/ml) x wt (kg) / 100

<!-- PAGE=? -->
 Dopamine / Norepinephrine

<!-- PAGE=? -->
 Lidocaine 1 mg/kg

<!-- PAGE=? -->
 NaHCO3

<!-- PAGE=? -->
 Magnesium: 2 gram bolus and 2 g/hr

<!-- PAGE=? -->
 Cardioversion relatively contraindicated

<!-- PAGE=? -->
Opiod:

<!-- PAGE=? -->
-Heroin: frequently causes pulmonary edema.

<!-- PAGE=? -->
Naloxone: lasts 45 to 70min, (tachy, HTN, acute pulm edema, arrhythmias, seizures)

<!-- PAGE=? -->
Organophosphate (are dumb)

<!-- PAGE=? -->
Pesticides and nerve gases (i.e. Sarin, tabun, soman), also anticholinergics: physostigmine

<!-- PAGE=? -->
Irreversible inhibitors of acetycholinesterases/plasma cholinesterase → accumulation of acetylcholine

<!-- PAGE=? -->
o Diaphoresis/Diarrhea

<!-- PAGE=? -->
o Urination

<!-- PAGE=? -->
o Miosis

<!-- PAGE=? -->
o Bronchospasm/Bradycardia

<!-- PAGE=? -->
o Emesis/Excitation of muscle

<!-- PAGE=? -->
o Lacrimation

<!-- PAGE=? -->
o Salivation/Sweat

<!-- PAGE=? -->
Atropine 2 mg IV initially, then titrate to effect (mydriasis, dry mouth, increased HR)

<!-- PAGE=? -->
o 35-70 mcg/kg IV Q5MIN, May require > 200 mg

<!-- PAGE=? -->
Pralidoxime

<!-- PAGE=? -->
o reactivats phosphorylated cholinesterase and protecting it from further inhibition

<!-- PAGE=? -->
o Administer within 6 hrs of poisoning

<!-- PAGE=? -->
o 15-30 mg/kg (1-2 g) over 10-20 min Q4H

<!-- PAGE=? -->
may take 3 months for cholinesterase to normalize: avoid drugs requiring the enzyme for metabolism (ester LA, emolol, sux, miv, remi)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Aspirin Toxicity

<!-- PAGE=? -->
Acute toxic dose is >150 mg/kg/day, chronic toxic dose is 100 mg/kg/day

<!-- PAGE=? -->
CNS - Tinnitus, deafness, hallucinations, coma, seizures (b/c of hypoglycemia)

<!-- PAGE=? -->
Resp - Hyperpnea, then hypoventilation

<!-- PAGE=? -->
CVS Noncardiogenic pulmonary edema, hypotension

<!-- PAGE=? -->
GURenal failure - nephritis

<!-- PAGE=? -->
Metabolic respiratory alkalosis & anion gap metabolic acidosis, ↓ K + , ↓ Na +

<!-- PAGE=? -->
Heme - Platelet dysfunction

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
IVF

<!-- PAGE=? -->
Urinary Alkalinization:  goal urine pH > 7.5 and 1-3cc/kg/hr

<!-- PAGE=? -->
Hemodialysis

<!-- PAGE=? -->
TCA Overdose ('hot as a hare, dry as a bone, red as a beet, mad as a hatter')

<!-- PAGE=? -->
Anticholinergic - mydriasis, blurred vision, fever, dry skin and mucous membranes, lethargy, delirium, coma, tachycardia, ileus, myoclonus, and urinary retention

<!-- PAGE=? -->
α & Na channel blockade Sinus tachycardia, Hypotension, Prolonged QRS, QTc, and PR intervals, BBB

<!-- PAGE=? -->
Limb lead QRS >0.1 s predicts seizures and QRS >0.16 s is associated with ventricular arrhythmias

<!-- PAGE=? -->
Quantitative levels less predictive

<!-- PAGE=? -->
Tx:

<!-- PAGE=? -->
NaHCO3: Goal → QRS < 0.1 or pH > 7.50

<!-- PAGE=? -->
Tylenol Overdose

<!-- PAGE=? -->
Rapidly absorbed, peak levels in <1hr, half life 2-4 hrs

<!-- PAGE=? -->
5% metabolized to n-acetyl-p-benzoquinonimine (NAPQI) which is hepatotoxic - normally detoxified by glutathione but in overdose this mechanism is overwhelmed

<!-- PAGE=? -->
Toxic dose is 150 mg/kg in adults and 200 mg/kg in children Acetominophen toxicity

<!-- PAGE=? -->
Phase 1

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Phase 2

<!-- PAGE=? -->
o

<!-- PAGE=? -->
Phase 3

<!-- PAGE=? -->
o 48 to 96 h - symptoms of severe hepatotoxicity → encephalopathy, coagulopathy, and hypoglycemia

<!-- PAGE=? -->
o Liver function abnormalities peak (extreme elevations in ALT/AST ( ≥ 10,000 IU/L), total bilirubin, and PT

<!-- PAGE=? -->
o Rarely hemorrhagic pancreatitis, myocardial necrosis, and ARF

<!-- PAGE=? -->
Phase 4

<!-- PAGE=? -->
o >4days - patient may die, fully recover (without chronic liver disease), or undergo emergent liver transplantation

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
N-acetylcysteine

<!-- PAGE=? -->
o if Tylenol level falls within hepatic toxicity range

<!-- PAGE=? -->
o if unknown time since ingestion and blood level >5ug/ml

<!-- PAGE=? -->
o if evidence of hepatotoxicity and blood level not available

<!-- PAGE=? -->
NAC repletes glutathione, 100% effective if started within 8-10 hrs but probably useful within 1 st 24hrs

<!-- PAGE=? -->
IV/PO loading dose of 140 mg/kg of NAC is followed by a maintenance dose of 70 mg/kg q4h for 17 doses

<!-- PAGE=? -->
Urticaria, angioedema, and respiratory symptoms - treat with IV diphenhydramine and β 2 -agonist bronchodilators

<!-- PAGE=? -->
Liver transplant for fulminant liver failure

<!-- PAGE=? -->
Anaphylactoid reactions to the IV drug have been reported

<!-- PAGE=? -->
anorexia, malaise, pallor, diaphoresis, nausea, and vomiting

<!-- PAGE=? -->
24 to 48 h after untreated overdose - RUQ  pain and abnormalities of LFTs (signs and symptoms of phase 1 improve)

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Toxicology

<!-- PAGE=? -->
High Anion/Osm Gap Metabolic Acidosis

<!-- PAGE=? -->
Incr ICP

<!-- PAGE=? -->
Pulm Edema

<!-- PAGE=? -->
ARF

<!-- PAGE=? -->
Hypo-Calcemia

<!-- PAGE=? -->
Found in solvents, de-icers, radiator antifreeze (95%) and air conditioning units

<!-- PAGE=? -->
Oxidized by alcohol dehydrogenase to glycoaldehyde → glycolic acid and glyoxalic acid

<!-- PAGE=? -->
Glyoxalic acid → oxalic acid

<!-- PAGE=? -->
Toxic dose 0.1ml/kg (fatal dose is 1.4 ml/kg)

<!-- PAGE=? -->
Osmolal gap - >10 supports dx (calculated osmolal = 2Na +glu + BUN)

<!-- PAGE=? -->
Ethylene glycol levels  >20 mg/dl considered toxic

<!-- PAGE=? -->
Clinical Manifestations

<!-- PAGE=? -->
Onset 4-12 hr

<!-- PAGE=? -->
CNS - intoxication, stupor, coma, seizures, cerebral edema, ½ ICP

<!-- PAGE=? -->
CV hype rtension, tachycardia, pulm edema (cardiogenic and noncardiogenic)

<!-- PAGE=? -->
Renal -ARF , Ca oxalate crystalluria

<!-- PAGE=? -->
Acid-base -Anion gap metabolic acidosis

<!-- PAGE=? -->
GI - Nausea, vomiting

<!-- PAGE=? -->
Other - Hypocalcemia, myoclonic jerks, tetany, myositis

<!-- PAGE=? -->
Ethylene Glycol Toxicity

<!-- PAGE=? -->
Investigations

<!-- PAGE=? -->
ABG, lytes, BUN, Cr, glucose, lactate, ethylene glycol level

<!-- PAGE=? -->
Increased anion gap correlates directly with glycolate levels

<!-- PAGE=? -->
↓ Ca (complexes with oxalic acid)

<!-- PAGE=? -->
ECG → LQTc , nonspecific ST-T

<!-- PAGE=? -->
Urinalysis - calcium oxalate crystals

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
Supportive care

<!-- PAGE=? -->
o Airway management

<!-- PAGE=? -->
o GI decontamination

<!-- PAGE=? -->
o Na HCO3 if pH < 7.10

<!-- PAGE=? -->
o Ca → CaCl 10 mg/kg

<!-- PAGE=? -->
o Seizures management

<!-- PAGE=? -->
Alcohol Dehydrogenase Inhibitor

<!-- PAGE=? -->
o Fomepizole

<!-- PAGE=? -->
 15 mg/kg (in 250 NS) over 30 min then 10 mg/kg Q12H

<!-- PAGE=? -->
o ETOH

<!-- PAGE=? -->
 1 ml/kg (100% EtOH) diluted in 1 litre D5W then 130 mg/kg/hr

<!-- PAGE=? -->
Cofactors

<!-- PAGE=? -->
 goal → serum ethanol level 100-150 mg/dL

<!-- PAGE=? -->
o Thiamine 100 mg/day

<!-- PAGE=? -->
o Mg/Folate

<!-- PAGE=? -->
o Pyridoxine 100 mg/day

<!-- PAGE=? -->
Dialysis

<!-- PAGE=? -->
o ethylene glycol level > 50 mg/dL

<!-- PAGE=? -->
o ongoing metabolic acidosis or evidence of end organ damage

<!-- PAGE=? -->
o unexplained metabolic acidosis with anion or osmol gap when suspicion of exposure is high

<!-- PAGE=? -->
o may require dialysis for weeks or months but full renal recovery expected

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Elderly

<!-- PAGE=? -->
TURP syndrome

<!-- PAGE=? -->
Lithotomy

<!-- PAGE=? -->
Risk of bleeding, bladder perforation

<!-- PAGE=? -->
Absorbtion affected by:

<!-- PAGE=? -->
 Size of gland

<!-- PAGE=? -->
 Resection time >60min

<!-- PAGE=? -->
 Irrigation > 60cm above pt

<!-- PAGE=? -->
20ml fluid absorbed/min of surgery

<!-- PAGE=? -->
Syndrome (2%)

<!-- PAGE=? -->
HypoNa H/A Confusion Vision change CHF/MI

<!-- PAGE=? -->
Tx : Lasix, Hypertonic NS

<!-- PAGE=? -->
Glycine, mannitol, urea, sorbitol Sorbitol: metabolized to fructose, lactate - hyperglycemia, acidosis Glycine: metabolized to ammonia - confusion, temporary blindness

<!-- PAGE=? -->
TURP

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Emergency (OHSHIT)

<!-- PAGE=? -->
100% oxygen, avoid nitrous oxide

<!-- PAGE=? -->
Fluid bolus

<!-- PAGE=? -->
Prevent further

<!-- PAGE=? -->
Flood surgical field

<!-- PAGE=? -->
Bone wax

<!-- PAGE=? -->
PPV and PEEP (?paradox emboli)

<!-- PAGE=? -->
Position

<!-- PAGE=? -->
Lower surgical field

<!-- PAGE=? -->
LLD / Trendelenburg

<!-- PAGE=? -->
Support circulation

<!-- PAGE=? -->
Inotrope > vasopressor

<!-- PAGE=? -->
Aspirate air from central catheter

<!-- PAGE=? -->
Hyperbaric

<!-- PAGE=? -->
Venous Air or Gas Embolism

<!-- PAGE=? -->
Classically occurs when the operative site is above the heart (> 5 cm)

<!-- PAGE=? -->
Pathophysiology

<!-- PAGE=? -->
Highest prevalence (50%) during posterior fossa craniotomy in the sitting position

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> RV outflow obstruction

<!-- PAGE=? -->
 ↑ PVR secondary to mechanical obstruction and the release of endogenous vasoactive agents

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> RV Failure

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> CV collapse

<!-- PAGE=? -->
Detection

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Paradoxical embolism (intracardiac defect vs direct)

<!-- PAGE=? -->
No

<!-- PAGE=? -->
Modest

<!-- PAGE=? -->
Chnically

<!-- PAGE=? -->
Cardio-

<!-- PAGE=? -->
physiol

<!-- PAGE=? -->
physiol

<!-- PAGE=? -->
appareni

<!-- PAGE=? -->
vascuar

<!-- PAGE=? -->
changes

<!-- PAGE=? -->
changos

<!-- PAGE=? -->
Changes

<!-- PAGE=? -->
collapse

<!-- PAGE=? -->
1

<!-- PAGE=? -->
BP

<!-- PAGE=? -->
Pap

<!-- PAGE=? -->
ECG

<!-- PAGE=? -->
Techo

<!-- PAGE=? -->
Dopoler

<!-- PAGE=? -->
Stetho

<!-- PAGE=? -->
Decreasing sensitivity

<!-- PAGE=? -->
Procedures with risk for VAE

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Sitting posterior fossa craniotomy (50%)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Horizontal posterior fossa surgery (10%)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Craniosyntosis (85%)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> C/S (10-45%)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Hip arthroplasty (67%)

<!-- PAGE=? -->
GLYPH<c=0,font=/LONEAJ+SymbolMT> Laparoscopy

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Review laboratory measurements

<!-- PAGE=? -->
Optimization

<!-- PAGE=? -->
Nasal ETT contraindicated

<!-- PAGE=? -->
Most common inherited coagulation disorder

<!-- PAGE=? -->
Initial step in platelet aggregation/adhesion

<!-- PAGE=? -->
Protects VIII from protein C

<!-- PAGE=? -->
Incidence 1%,  female=male

<!-- PAGE=? -->
Type 1

<!-- PAGE=? -->
o Most common - 80%

<!-- PAGE=? -->
o Mildest form

<!-- PAGE=? -->
o Mild quantitative abnormality

<!-- PAGE=? -->
o 20-30% vWF activity

<!-- PAGE=? -->
Type 2 (four subtypes) - 15%

<!-- PAGE=? -->
o Qualitative disorder

<!-- PAGE=? -->
o 2B: always active - clearance of vWB/Plt complexes

<!-- PAGE=? -->
 low plts

<!-- PAGE=? -->
 no DDAVP

<!-- PAGE=? -->
Type 3 - 5%

<!-- PAGE=? -->
o Rare, most severe form

<!-- PAGE=? -->
o Almost no detectable vWF and FVIII deficiency

<!-- PAGE=? -->
o Prolonged PTT

<!-- PAGE=? -->
Associated disorders

<!-- PAGE=? -->
o AS

<!-- PAGE=? -->
o SLE

<!-- PAGE=? -->
o RA

<!-- PAGE=? -->
o MVP

<!-- PAGE=? -->
Von Willebrands Disease

<!-- PAGE=? -->
Symptoms (primary hemostasis)

<!-- PAGE=? -->
o Menorrhagia

<!-- PAGE=? -->
o Epistaxis

<!-- PAGE=? -->
o Gingival bleeding

<!-- PAGE=? -->
Treatment

<!-- PAGE=? -->
o DDAVP

<!-- PAGE=? -->
 0.3 mcg/kg IV/SC (max 20 mcg)

<!-- PAGE=? -->
 contraindicated in type 2B (thrombocytopenia)

<!-- PAGE=? -->
 onset 30 min, peak 60 min

<!-- PAGE=? -->
 2-3 x ↑ vWF activity

<!-- PAGE=? -->
 don't give unless you know they respond to DDAVP

<!-- PAGE=? -->
o Humate-P

<!-- PAGE=? -->
 Pooled from FFP

<!-- PAGE=? -->
 75 IU/kg Q8H (2 nd dose 50 IU/kg)

<!-- PAGE=? -->
 1.5 IU/kg elevation of vWF:RCo activity per 1 IU/kg HumateP

<!-- PAGE=? -->
 goal = nadir vWF:RCo > 50%

<!-- PAGE=? -->
o TXA

<!-- PAGE=? -->
 IV 10 mg/kg

<!-- PAGE=? -->
 PO 25 mg/kg

<!-- PAGE=? -->
 Oral rinse (10%) - 10ml

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
Weaning Criteria

<!-- PAGE=? -->
Resolution of pathology

<!-- PAGE=? -->
Hemodynamically stable

<!-- PAGE=? -->
Reversal of neuromuscular block

<!-- PAGE=? -->
Appropriate LOC

<!-- PAGE=? -->
Adequate cough/gag

<!-- PAGE=? -->
Oxygenation/Ventilation parameters

<!-- PAGE=? -->
o Intubation Criteria reversed

<!-- PAGE=? -->
o RSBI < 100 breaths/min/L

<!-- PAGE=? -->
DDx - Failure to Wean

<!-- PAGE=? -->
o CNS

<!-- PAGE=? -->
Critical illness polyneuropathy

<!-- PAGE=? -->
Steroid myopathy/miositis

<!-- PAGE=? -->
Disuse atrophy

<!-- PAGE=? -->
CVA

<!-- PAGE=? -->
o CVS

<!-- PAGE=? -->
IHD

<!-- PAGE=? -->
CHF

<!-- PAGE=? -->
Pulmonary HTN

<!-- PAGE=? -->
o Resp

<!-- PAGE=? -->
Pneumonia

<!-- PAGE=? -->
PTX

<!-- PAGE=? -->
Pleural effusions

<!-- PAGE=? -->
o Metabolic

<!-- PAGE=? -->
Hypothyroidism

<!-- PAGE=? -->
↓ Mg / PO4 / K / Ca

<!-- PAGE=? -->
Excessive hyperalimentation ( ↑ CO2)

<!-- PAGE=? -->
o Sepsis

<!-- PAGE=? -->
Acalculous cholecystitis

<!-- PAGE=? -->
Sinusitis

<!-- PAGE=? -->
Pancreatitis

<!-- PAGE=? -->
Intubation Criteria

<!-- PAGE=? -->
Objective

<!-- PAGE=? -->
Impaired oxygenation

<!-- PAGE=? -->
PaO2 < 60 with FiO2 70%

<!-- PAGE=? -->
Aa gradient >350

<!-- PAGE=? -->
Impaired Ventilation

<!-- PAGE=? -->
RR> 35

<!-- PAGE=? -->
PaCO2 > 60  (45 in asthma)

<!-- PAGE=? -->
Mechanics

<!-- PAGE=? -->
NIF < -25

<!-- PAGE=? -->
Vt < 5 ml/kg

<!-- PAGE=? -->
FVC < 15 ml/kg

<!-- PAGE=? -->
Subjective:

<!-- PAGE=? -->
Patency - impending airway obstruction

<!-- PAGE=? -->
Protection - from aspiration

<!-- PAGE=? -->
PPV

<!-- PAGE=? -->
Pulmonary Toilet

<!-- PAGE=? -->
Provide 100% O2

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? -->
A spiration

<!-- PAGE=? -->
A naphylaxis

<!-- PAGE=? -->
A sthma

<!-- PAGE=? -->
T ube - obstructed

<!-- PAGE=? -->
P ulmonary edema

<!-- PAGE=? -->
P ulmonary embolism

<!-- PAGE=? -->
P neumothorax

<!-- PAGE=? -->
Wheezing DDx

<!-- PAGE=? -->
Gavin Gracias 2007

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| repeat ID | Emergent/Urgent/Elective | Anesthetic considerations | Pt | Surg | Anesthesia | monitoring | numb | post-op pain/disposition | options | ga, reg, pnb | position | Anesthetic Hx/ROS/AMPLE | HPI | PE: | ht/wt/orthostatic vitals, R/A Spo2 | A/W, regional landmarks | JVP | 'base investigations on above' | Labs with endpoints | Consults with question | add considerations summarize issues/conflicts | state how optimize each issue/conflict | CAR: | cancel, alternate, refer | GAASSS: gastric, anxiolysis, ABx, Sialogogue, SBE, steroid | LMNOP: lines, monitors, numb, options, position | Intra-op: (plan ABC) | or setup | induction, maintenance, emergence | post-op plan | post-op |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE 3 Cardiac Risk' Stratification for Noncardiac Surgical Procedures**

| System       | Conditions                                                                                     |
|--------------|-----------------------------------------------------------------------------------------------|
| Airway       | macroglossia, prognathism, TMJ arthritis, hoarseness (vocal cord thickening), subglottic stenosis, RLN dysfunction |
| CVS          | HTN, cardiomyopathy (LV dysfunction, CHF, dysrhythmias, cardiomegaly)                        |
| Respiratory  | OSA, kyphoscoliosis                                                                          |
| Neuro        | Pituitary mass effect (visual defects, hypersomnolence), carpal tunnel syndrome (paresthesias, weakness) |
| Endo         | Hyperthryroidism, glucose intolerance, ↑ BMR, hyperprolactinemia                             |
| GU           | ↑ Ca absorption (urolithiasis), ↑ intravascular volume ( ↑ total body Na & plasma volume)   |
| MSK          | Arthralgias/arthritis (knees, hips, shoulder, LS spine), myalgias (muscle weakness)         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
| Laser   | Wavelength | Scope    | Penetration/Absorption                                      | Protective  |
|---------|------------|----------|------------------------------------------------------------|-------------|
| CO 2    | 10,600 nm  | Rigid    | 90% absorbed in the first 0.03 mm (i.e. corneal abrasions) | Clear       |
| Nd-YAG  | 1064 nm    | Flexible | Deep penetration, coagulation                               | Green       |
| Argon   | 488 nm     | Flexible | Selectively absorbed by hemoglobin and melanin             | Orange      |
| KTP     | 532 nm     | Flexible | Frequency-doubled Nd-YAG, less deep, better cutting        | Orange/Red  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Group     | Pathological Condition                                               | Principal Pathologic Clinical Features Pertaining to Airway                                                                                     |
|-----------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| CONGENITAL| Pierre Robin syndrome                                               | Micrognathia, macroglossia, glossoptosis, cleft soft palate                                                                                     |
|           | Treacher Collins syndrome (mandibulofacial dysostosis)            | Auricular and ocular defects; malar and mandibular hypoplasia, microstomia choanal atresia                                                      |
|           | Goldenhar's syndrome (oculo- auriculo-vertebral syndrome)         | Auricular and ocular defects; malar and mandibular hypoplasia; occipitalization of atlas                                                         |
|           | Down's syndrome (mongolism)                                       | Poorly developed or absent bridge of the nose; macroglossia, microcephaly, cervical spine abnormalities (AA instability)                         |
|           | Klippel-Feil syndrome                                              | Congenital fusion of a variable number of cervical vertebrae; restriction of neck movement                                                       |
|           | Alpert's syndrome (acrocephalosyndactyly)                         | Maxillary hypoplasia, prognathism, cleft soft palate, tracheobronchial cartilaginous anomalies                                                  |
|           | Beckwith's syndrome (infantile gigantism)                          | Macroglossia                                                                                                                                     |
|           | Cherubism                                                          | Tumorous lesion of mandibles and maxillae with intraoral masses                                                                                 |
|           | Cretinism (congenital hypo- thyroidism)                           | Absent thyroid tissue or defective synthesis of thyroxine; macroglossia, goiter, compression of trachea, deviation of larynx/trachea            |
|           | Cri du chat syndrome                                                | Chromosome 5-P abnormal; microcephaly, micrognathia, laryngomalacia, stridor                                                                    |
|           | Meckel's syndrome                                                  | Microcephaly, micrognathia, cleft epiglottis                                                                                                    |
|           | von Recklinghausen disease (neurofibromatosis)                    | Increased incidence of phaeochromocytoma; tumors may occur in the larynx and right ventricle outflow tract                                     |
|           | Hurler's syndrome (mucopolysaccharidosis I)                       | Stiff joints, upper airway obstruction due to infiltration of lymphoid tissue; abnormal tracheobronchial cartilages; frequent upper respiratory infections |
|           | Hunter's syndrome (mucopolysaccharidosis II)                      | Same as in Hurler's syndrome, but less severe; pneumonias (odontoid hypoplasia)                                                                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Condition                                                                 | Associated Issues                                                                                      |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Supraglottitis/Epiglottitis                                              | Laryngeal edema                                                                                      |
| Croup                                                                     | Laryngeal edema                                                                                      |
| Abscess (intraoral, retropharyngeal)                                    | Distortion and stenosis of the airway and trismus                                                    |
| Ludwig's angina                                                          | Distortion and stenosis of the airway and trismus                                                    |
| Arthritis                                                                 | Deviation of larynx, restricted mobility of cervical spine                                           |
| Rheumatoid arthritis, Temporomandibular joint ankylosis, cricoarytenoid arthritis |                                                                                                       |
| Ankylosing spondylitis                                                   | Ankylosis of cervical spine; less commonly ankylosis of temporomandibular joints; lack of mobility of cervical spine |
| Benign tumors                                                             | Stenosis or distortion of the airway                                                                  |
| Cystic, hygroma, lipoma, adenoma, goiter                                 |                                                                                                       |
| Malignant tumors                                                          | Stenosis or distortion of the airway; fixation of larynx or adjacent tissues secondary to infiltration or fibrosis from irradiation |
| Carcinoma of tongue, larynx, thyroid                                     |                                                                                                       |
| Trauma                                                                    | Cerebrospinal rhinorrhea, edema of the airway; hemorrhage; unstable fracture(s) of the maxillae and mandible; intralaryngeal damage; dislocation of cervical vertebrae |
| Head injury, facial injury, cervical spine injury                         |                                                                                                       |
| Miscellaneous conditions                                                  |                                                                                                       |
| Morbid Obesity                                                           | Short, thick neck and large tongue are likely to be present                                            |
| Acromegaly                                                                | Macroglossia; prognathism                                                                             |
| Acute burns                                                               | Edema of airway                                                                                      |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| LMASIZE | ETT (ID, mm) | FOB SIZE (mm) |
|---------|---------------|----------------|
| 1       | 3.5           | 2.7            |
| 2       | 4.5           | 3.5            |
| 2.5     | 5.0           | 4.0            |
| 3       | 6.0 cuffed    | 5.0            |
| 4       | 6.0 cuffed    | 5.0            |
| 5       | 7.0 cuffed    | 6.0            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
****

| Treatment/Medication | Dosage/Administration |
|----------------------|-----------------------|
| Adrenalin            | titrate from 1ug/kg IV q2min. (IM 0.3 to 0.5 mg Q15min, SC absorption maybe low) |
| Benadryl             | 0.5-1 mg/kg -1       |
| Bronchodilator       | Aminophylline (5 mg/kg -1 over 20 min) |
| Cimetidine           | 300 mg orally, IM, or IV |
| Crystalloid          | Volume Deficit = 60 ml/kg |
| Steroids             | Solumedrol 100mg + 25mg/hr |

**DDx:**
- Scombroid (fish) poisoning
- Hereditary angioedema
- Acquired angioedema
- asthma
- panic
- vasovagal
- carcinoid
- Anaphylaxis: antigen and IgE antibodies from prev. exposure
- Anaphylactoid: Histamine, occurs on first exposure
- Glucagon. If unresponsive to epinephrine, (B-blockers) give 1 to 2 mg every 5 minutes IM or IV
- Biphasic responses have been reported to occur up to 36 hours after the initial reaction.
- Indication for prolonged CPR
- Triptase in anaphylaxis not anaphylactoid (red top) peaks 30mins, t½: 2 hours
- RAST test post op, refer to allergist
- Most common: Nmba 60% - (roc43%, sux 23%), Latex 16%, Antibx 16%
- X reactivity is very high for nmba (86%)
- Latex - 36% crossreactivity with avocado, kiwi, bananas
- myelomenigecele, bladder, chronic catheter, health care
- Protamine: fish allergy, NPH insulin
- Penicillin: Only 1% true allergy but 10% report it. Only 30% will have allergy after 10y avoiding. X reactive with ceph 2%

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Category   | Area (cm 2) | Mean Grad (mmHg) | Peak Grad (mmHg) |
|------------|--------------|-------------------|-------------------|
| Normal     | 2.5 - 3.5   | 0 - 10            |                   |
| Mild       | 1.2 - 2.4   | 10 - 25           | 16 - 35           |
| Moderate   | 0.8 - 1.2   | 25 - 50           | 35 - 70           |
| Severe     | < 0.8       | > 50              | > 70              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Regurg%   | Symptoms | LVEDP |
|-----------|----------|-------|
| Mild      | <40      | None  | N     |
| Moderate  | 40-60    | CHF    | incr  |
| Severe    | >60      | Angina | incr  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Medication        | Timing/Notes                                                                                          |
|-------------------|-------------------------------------------------------------------------------------------------------|
| UFH               | SC minidose IV • OK, check plts, prefer to give after block • Dose → Cath out/(Needle) = 2-4 hours • Needle → Dose = 1 hour |
| LMWH              | Pre-op • Prophylaxis: Dose → Needle = 10-12 hours • Treatment: Dose → Needle = 24 hours o Enoxaparin 1mg/kg Q12H or 1.5mg/kg Q24H o Dalteparin 120U/Kg Q12H or 200U/kg Q24H |
|                   | Post-op -Blood in needle - wait 24H UID (8-12-2) • Initiate 6-8 hours post needle placement, then 24H from first • Remove catheter 10-12 hours after last dose • Begin therapy 2 hours post removal of catheter BID (24-0-2) • Not Recommended • Initiate 24 hours post needle placement • Remove catheter prior to initiation of prophylaxis • Begin therapy 2 hours post removal of catheter |
| Warfarin          | • Discontinue 4-5 days, Measure INR / PTT • Remove catheter if INR < 1.5 (= >40% factor activity) • One dose <24H prior is ok |
| Ticlid            | • 2 weeks                                                                                             |
| Clopidogrel       | • 1 week                                                                                              |
| GP IIb / IIIa    | • held for 48H prior, 4 weeks after                                                                    |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Treatment Type                                         | Recommendations                                                        |
|-------------------------------------------------------|----------------------------------------------------------------------|
| Thrombolytics                                         | • Avoid lytics for 10 days after puncturing noncompressible vessels   |
|                                                       | • After lytics, measure fibrinogen levels as marker of recovery      |
| Herbal (Garlic, Ginko, Ginseng)                      | • OK                                                                 |
| Thrombin Inhibitors ('rudin, argatroban) &Xa Inhibit (Fondaparinux) | • Atruamatic single shot, single pass                                 |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Antiplatelet Medications | Unfractionated Heparin | Low Molecular Weight Heparin | Warfarin |
|--------------------------|------------------------|------------------------------|----------|
| Subcutaneous             | Intravenous            | Thrombolytics                | Herbal Therapy |
| Amelican Society of Aegional Anesthesia and Pain Medicine | No contraindication with NSAIDs; discontinue ticlopidine 14 d, clopidogrel 7 d, GP difficulty anticipated Ilbllla inhibitors 8-48 h in advance | No contraindication; Heparinize consider delaying heparin until after block # technical | after neuraxial technique, remove catheter heparin dose; no mandatory if traumatic delay |
| Twice daily dosing: LMWH 24 h after surgery, regardless of technique; remove neuraxial catheter 2 h before first LMWH dose. Single daily dosing: according to European statements | Document normal No data on INR after discontinuation (prior to neuraxial performance technique); remove catheter when INR = 1.5 (initiation of therapy) | safety interval mandatory for of neuraxial technique or catheter removal; follow fibrinogen level | No evidence for discontinuation prior to neuraxial technique; be aware of potential drug interactions |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Severity  | PEFR        | FEV 1     | %of N    | SpO 2     |
|-----------|-------------|-----------|----------|-----------|
| Mild      | >300L/min   | > 2.1 L   | > 70%    | > 95%     |
| Moderate  | <300L/min   | < 2.1 L   | 50 - 70% | 92 - 95%  |
| Severe    | <200L/min   | < 1.6 L   | < 50%    | < 92%     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Class I                       | Class II                     | Class III                   | Class IV                   |
|-------------------------------|------------------------------|-----------------------------|----------------------------|
| Blood loss (ml) (70kgM)      | ≤ 750                        | 750-1500                    | 1500-2000                  | >2000                      |
| Blood loss (% blood volume)   | ≤ 15                         | 15-30                       | 30-40                      | >40                        |
| Pulse rate (per min)         | <100                         | >100                        | >120                       | >140                       |
| Blood pressure                | Normal                       | Normal                      | Decreased                  | Decreased                  |
| Pulse pressure                | Normal or increased          | Decreased (incr DBP)       | Decreased (decr SBP)      | Decreased                  |
| Respiratory rate (breaths•min-1) | 14-20                     | 20-30                       | 30-40                      | >35                        |
| Urine output (ml•hr-1)       | >30                          | 20-30                       | 5-15                       | Negligible                 |
| CNS mental status             | Slightly anxious             | Mildly anxious              | Anxious and confused       | Confused, lethargic       |
| Fluid replacement (3:1 rule)  | Crystalloid                  | Crystalloid                 | Crystalloid + blood        | Crystalloid + blood        |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| System  | <25% blood Volume         | 25-45                     | >45                      |
|---------|---------------------------|---------------------------|--------------------------|
| Cardiac | -incr HR                  | -weak thready pulse       | -decr BP, possible brady |
| CNS     | -lethargic, irritable     | -dulled response to pain   | -coma                    |
| Skin    | -cool, clammy             | -cyanotic, decr cap refill | -pale, cold              |
| Kidneys |                           | -min urine output         | -no output               |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**TABLE. Suggested Indications for Resuscitative Thoracotomy: Patients With Traumatic Cardiac Arrest**

| Type of Injury                        | Assessment                                                                                                                                                                                                                     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Blunt trauma                          | Patient arrives at ED or trauma center with pulse, blood pressure, and spontaneous respirations, and then experiences witnessed cardiac arrest                                                                                 |
| Penetrating cardiac trauma            | Patient experiences a witnessed cardiac arrest in ED or trauma center. Patient arrives in ED or trauma center after <5 minutes of out-of-hospital CPR and with positive secondary signs of life (eg, pupillary reflexes; spontaneous movement; organized ECG activity) |
| Penetrating thoracic (noncardiac) trauma | Patient experiences a witnessed cardiac arrest in ED or trauma center. Patient arrives in ED or trauma center after <15 minutes of out-of-hospital CPR and with positive secondary signs of life (eg, pupillary reflexes, spontaneous movement; organized ECG activity) |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

|          | IHD                | AS                     | AI                | HOCM              | MS                | MR                | DCM               | TR                | Tampon.         |
|----------|--------------------|-----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------------------|
| Preload  | Low/N              | M/Inc                 | M/Inc             | Inc               | M                 | M/Inc             | M                 | Inc               | Incr             |
| Afterload| Decr               | M/Inc                 | Dec               | Inc               | M                 | Dec               | Dec               | Dec               | M                |
| Contract | Low/N              | M                     | M                 | Dec               | MRight            | M                 | M                 | Incr             |                  |
| Rate     | 50-70              | 50-70                 | 80-100            | 60-80             | 60-80             | 80-100            | No Decr           | 80-90            | Fast             |
| Rythym   |                    | NSR!                  |                   | NSR!              | No afib           |                   |                   |                   |                  |
| OTHER    | - also treat supply -keep warm | -full, tight -risk for ischemia | -full, fast, forward | -not tropes -ischemia | -RV               | -RV               | -no sudden changes |                   | -Spont Vent      |
| Good Drugs| -MONA -BBlock -NTG -ACEI -Milrinone | -phenyl | -milrinone -ephedrine | -phenyl -Bblock -pressors |                   | -milrinone -ephedrine -ketamine |                   |                   |                  |
| Bad Drugs | -Ketamine         | -Ketamine -vasodilat | -phenyl           | -Ketamine -iontrope -Nitrates |                   | -phenyl           |                   |                   |                  |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

|                | R to L                                           | L to R                                           |
|----------------|--------------------------------------------------|--------------------------------------------------|
| SVR goal       | Incr                                             | Dec                                              |
| PVR goal       | Dec                                              | Incr                                             |
| Eg:            | ToF, TGA                                        | ASD, VSD, PDA                                   |
| Result         | -cyanosis -TGA unique - need the shunt -polycythemia | - RV overload -Pulm edema -Pulm hypertension -Essenmenger |
| Tx:            | Inc SVR: -ketamine -alpha agonist -position (squat, valsalva) | Dec SVR: -alpha antagonist -neuroaxial -avoid pain, regional - deepen anesthesia |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Site                   | Pressure (mm Hg)   | Oxygen Saturation (%) (mean ± SD) |
|------------------------|---------------------|------------------------------------|
| Inferior vena cava     | 0-8                 | 80 ± 5                             |
| Superior vena cava     | 0-8                 | 70 ± 5                             |
| Right atrium           | 0-8                 | 75 ± 5                             |
| Right ventricle        | 15-30/0-8           | 75 ± 5                             |
| Pulmonary artery        | 15-30/4-12          | 75 ± 5                             |
| Pulmonary wedge        | 5-12                | 75 ± 5                             |
| Left atrium            | 12 (mean)           | 95 ± 1                             |
| Left ventricle         | 100-140/4-12        | 95 ± 1                             |
| Aorta                  | 100-140/60-90       | 95 ± 1                             |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Category       | Conditions                                                                                     |
|----------------|-----------------------------------------------------------------------------------------------|
| CNS            | Autonomic neuropathy (gastroparesis, orthostatic hypotension, LQT, asymptomatic hypoglycemia) |
|                | Peripheral neuropathy (stocking glove distribution)                                            |
|                | Vasculopathy disease                                                                           |
|                | Silent CVS (CAD, CVA, renovascular ischemia)                                                 |
| Resp / Airway  | Stiff joint syndrome (glycosylation) Potential difficult airway                               |
|                | DKA                                                                                           |
|                | HONK                                                                                          |
| Endo           |                                                                                               |
| GU             | Nephropathy                                                                                   |
|                | Altered wound healing,                                                                        |
|                | Incr wound infections                                                                          |
|                | Delayed emergence                                                                              |
| Misc.          |                                                                                               |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Criteria                                   | Details                                                                                     |
|--------------------------------------------|---------------------------------------------------------------------------------------------|
| Definition                                 | DEF N - irreversible loss of all brain function demonstrated by coma, apnea, and absence of brainstem reflexes |
| Examinations                               | Single physician (2 if transplant candidate), two examinations                             |
| Known cause of death                       | All reversible causes fixed - lytes, glucose, drugs (relaxants, sedatives)                |
| Temperature                                | ≥ 34                                                                                       |
| Absence of brainstem reflexes              | - pupillary<br>- oculocephalic (doll's eye)<br>- oculovestibular (cold calorics)<br>- corneal<br>- gag<br>- cough<br>- respirations<br>- Note: seizures or decorticate positioning rule out brain death |
| Apnea Test                                 | - Hyperventilate on 100% O2<br>- Apnea until pH<7.28 or pCO2 > 60 (pCO2 increased by 20 from baseline) |
| Ancillary Testing                          | - Cerebral angiography (4-vessels) to r/o intracranial flow<br>- Radionuclide angiography (perfusion scintography) |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| System | Condition                          |
|--------|------------------------------------|
| CNS    | ICP Poikilotherm                  |
| CVS    | Labile, Arrythmia Pressors Cardiomyopathy |
| Resp   | Ventilator ARDS                    |
| GI     | Liver Failure                      |
| Heme   | Coagulopathy/DIC                  |
| Endo   | Panhypopit                        |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Hormone-Replacement Therapy

| Hormone                | Bolus               | Infusion                                   |
|-----------------------|---------------------|--------------------------------------------|
| Triiodothyronine      |                     | 3.0 'vglhr                                 |
| Thyroxine and         | 20 pg               | 10                                         |
| Methylprednisolone    | 15 mg/kg            | Repeat in 24 hr                            |
| Vasopressin           |                     | 0.54.0 Ufhr                                |
| Insulin               | 10 U (50% dextrose) | Maintain glucose between 80 and 150 mg/dl (minimum insulin rate, 1 Ujhr) mgldl |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Drug                          | Dose                                           | Notes                                      |
|-------------------------------|------------------------------------------------|--------------------------------------------|
| Amiodarone                    | 150 mg IV bolus 1 mg/min x 6 hours 0.5 mg/min x 18 hours | Bolus given over 15 minutes                |
| Atropine                      | 20 mcg/kg                                     | Max = 0.4 mg/kg                           |
| Diltiazem                     | 0.25-0.35 mg/kg bolus 5 - 15 mg/hr           |                                            |
| Dobutamine                    | 2 - 20 mcg/kg/min                            | 1600 mcg/ml                               |
| Dopamine                      | 2 - 20 mcg/kg/min                            | 1600 mcg/ml                               |
| Ergot (methylergonovine)      | 200 mcg IM                                   | 20 mcg IV (caution)                       |
| Epinephrine                   | 0.05 - 1 mcg/kg/min                          | 1 mg / 250 ml @15ml/hr ~ 0.01            |
| Epinephrine                   | 10 mcg/kg IV 100 mcg/kg ETT                  | 1:10,000 = 0.1 ml/kg 1:1000 = 0.1 ml/kg  |
| Esmolol                       | 50 - 200 mcg/kg/min                          |                                            |
| Hemabate (PGF 2-alpha )      | 250 mcg IM                                   |                                            |
| Hematin                       | 3-4 mg/kg IV                                 | Given over 20 minutes                      |
| Labetolol                     | 0.5 - 2 mg/min                               |                                            |
| Milrinone                     | 0.25 - 1 mcg/kg/min                          | 10 mg / 250 ml @50 ml/hr ~ 0.5 optional bolus = 50 mcg/kg |
| Nitroglycerine                | 0.5 - 10 mcg/kg/min                          | 50 mg / 250 ml D5W or NS                  |
| Nitroprusside                 | 0.5 - 10 mcg/kg/min                          | 50 mg / 250 ml D5W Photosensitive         |
| Norepinephrine                 | 0.05 - 0.5 mcg/kg/min                        | 4mg / 250 ml @15ml/hr ~ 0.05              |
| Octreotide                    | 50 - 100 mcg/hour                            | 500 mcg / 250 ml (2 mcg/ml)               |
| Phenylephrine                 | 0.5 - 10 mcg/kg/min                          |                                            |
| Vasopressin                   | 0.02 - 0.1 U/min                             | 40 U / 250 ml @15ml/hr = 0.04 U/min      |
| Verapamil                     | 75 - 150 mcg/kg (5 - 10 mg)                  |                                            |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| System                                         | Response |
|------------------------------------------------|----------|
| Tonic-clonic seizure ↑ CBF - ↑ ICP            | CNS      |
| Bradycardia, Tachycardia Hypertension Myocardial Ischemia | CVS      |
| Hypoventilation                                | Resp     |
| Fracture-dislocations, Myalgias               | MSK      |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Systemic Effects of Hypothermia

| System      | Effects                                                                                     |
|-------------|---------------------------------------------------------------------------------------------|
| CVS         | ↑ HR/BP, ↑ SVR ↓ O 2 consumption / CO 2 production ECG: ↑ PR, QRS, QT, J-waves <33 o C - irritable <28 o C - spontaneous VF <25 o C - asystole |
| CNS         | ↓ CBF ↑ Sypathetic NS ↓ MAC(5-7% / o)                                                     |
| Heme        | ↓ platelet function ↑ fibrinolysis ↑ blood viscosity (2% / o C)                           |
| Metabolic   | Metabolic acidosis Hyperglycemia Altered K &Ca homestasis                                 |
| Misc.       | Delayed PACU ↑ wound infections ↓ drug metabolism                                          |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Definition                                           | Criteria                                                                                          |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Infection                                           | Inflammatory response microorganisms or invasion of normally sterile tissues                      |
| SIRS (systemic inflammatory response syndrome)      | Clinical response to infection manifested by 22 of the following Temperature 238PC or =36C HR 290 bpm Respirations 220 breaths / min |
| Sepsis Severe sepsis Septic shock                   | Confirmed or suspected infection plus 22 SIRS criteria Sepsis and 21 organ dysfunction Sepsis plus hypotension <90 mm Hg) despite fluid resuscitation |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Points              | 1       | 2        | 3        |
|---------------------|---------|----------|----------|
| Alb U min           | >35     | 28-35    | <28      |
| I NR                | <1.7    | 1.7-2.3  | >2.3     |
| Bilirubin Y         | <34     | 34-51    | >51      |
| A scites            | None    | Mod      | Tense     |
| E ncephalopathy     | None    | Grade 1-2| Grade 3-4|

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| AGENT          | pKa | MDmg/kg (epi) |
|----------------|-----|----------------|
| Bupivacaine    | 8.1 | 2.5 / (3)      |
| Ropivacaine    | 8.1 | 3              |
| Lidocaine      | 7.9 | 5 / (7)        |
| Mepivicaine    | 7.8 | 5 / (7)        |
| Tetracaine     | 8.5 | 1.5            |
| Chloroprocaine |     | 11 / (14)      |
| Cocaine        |     | 3              |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| PFT                                   | Units and Designation                     | Normal         | Pneumonectomy   | Lobectomy       | Segmental Res   |
|---------------------------------------|-------------------------------------------|----------------|------------------|------------------|------------------|
| FEV 1                                 | Liters (measured preop)                  | >4.0           | >2.1 -1.7        | >1.2-1.0         | >0.6-0.9         |
|                                       | %(measured preop)                        | >80% FVC       | >50% FVC         | >40% FVC         | >40% FVC         |
|                                       | Liters (predicted postop)                | N/A            | >0.9- 0.8       | >1               | >0.6-0.9         |
| FEV 25-75%                            | Liters (measured preop)                  | >2             | >1.6             | 0.6-1.6          | >0.6            |
| FVC                                   | Liters                                   | >5.0           | >2.0             | -                | -                |
| MVV                                   | Liters/min (measured for 1 min preop)   | 100            | >50              | >40              | >25              |
|                                       | %predicted (measured preop)             | 100%           | >50%             | >40%             | 25%              |
| DLCO                                  | %predicted (measured preop)              | 100            | >60%             | -                | -                |
|                                       | %(predicted postop)                      | NA             | >40%             | -                | -                |
| Exercise testing                      | Stair climbing (measured preop)          | >10 flights    | >5 flights       | >3 flights       | >2 flights       |
|                                       | 6 min walk test                          |                | >2000'           |                  |                  |
|                                       | VO 2 max (L/min)                        | 2.8            | >1= 15ml/kg/min  | >1               | >1               |
|                                       | Oxy-Hb saturation drop with exercise      | None           | <3%              | <5%              | <5%              |
| PaO 2                                 | mmHg (whole lung measured preop)        | >90            | >80              | >70              | >60              |
| PaCO 2                                | mmHg (whole lung measured preop)        | 40             | <45              | <50              | <55              |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Complications                                                                                     | Treatment                                                                                                           |
|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| 1. Atelectasis                                                                                   | 1. Emergency - Surgeon stat                                                                                        |
| 2. Hemorrhage                                                                                    | 2. Check vent - Paw, exp volumes (BPF vs Torsion/Herniation)                                                     |
| 3. BPF                                                                                           | 3. Examine pt - heart sounds, apex, JVP, lung sounds                                                              |
| 4. Post-pneumonectomy Pulm Edema                                                                 | a. Surgical Side Up                                                                                                |
| 5. RHF                                                                                           | b. lower Paw                                                                                                      |
| 6. Nerve Injury: Phrenic, Vagus, RLN, Spinal Cord                                                | c. Clamp CT Suction, instill 1-2L Air                                                                            |
| 7. Torsion - expanding mass, chest pain, hemoptysis (DLT)                                       | d. Support BP                                                                                                     |
| 8. Cardiac Herniation - obstructive shock, pulm edema, arrythmia                                 |                                                                                                                    |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Observed condition                          | Meq/L  |
|---------------------------------------------|--------|
| Normal plasma level                         | 1.5-2  |
| Therapeutic range                           | 4-6    |
| ECG Δ (prolonged PQ, widened QRS)          | 5-10   |
| Loss DTR                                   | 10     |
| SA & AV Block                               | 15     |
| Respiratory paralysis                        | 15     |
| Cardiac arrest                              | 25     |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Abbreviation | Condition                                      |
|--------------|------------------------------------------------|
| A            | Alcoholic ketoacidosis                         |
| H            | Hyperalimentation                              |
| M            | Methanol                                       |
| A            | Acetazolomide (CAI's)                         |
| U            | Uremia                                        |
| R            | RTA                                            |
| D            | DKA                                            |
| D            | Diarrhea / Diuretics (K sparing)              |
| P I          | Paraldehyde & Metformin - Iron & INH          |
| U            | Ureteral Diversions                            |
| L E          | Lactate - Ethylene glycol                      |
| P            | Pancreatic fistula                             |
| C            | Carbamazepine - ASA                           |
| &            | Normal Saline                                  |
| A T          | (salicylates) - Toluene                       |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Severity   | Area         | Pressure   |
|------------|--------------|------------|
| Normal     | 4-6 cm²     | < 2 mmHg  |
| Mild       | 1.5-2 cm²   | 2-6 mmHg  |
| Moderate   | 1-1.5 cm²   | 6-12 mmHg |
| Severe     | < 1.0 cm²   | > 12 mmHg |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Review of Systems          | Conditions                             |
|----------------------------|---------------------------------------|
| CVS                        | MVP, MR, DCM, conduction defects      |
| Resp                       | RLD, recurrent pneumonia, OSA         |
| Intellectual impairment     | Neuro                                 |
| MSK                        | Calf hypertrophy, kypho scoliosis     |
| GI                         | Dysmotility, Ileus                    |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| System | Findings                                                                                     |
|--------|----------------------------------------------------------------------------------------------|
| CVS    | MVP, DCM , conduction defects                                                                |
| Resp   | RLD, central sleep apnea, impaired response to hypoxia and hypercarbia, resp muscle weakness  |
| Endo   | DM, hypothyroidism, adrenal insufficiency                                                    |
| Neuro  | Mental retardation, visual impairment                                                         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Clinical Criteria                          | Points |
|--------------------------------------------|--------|
| Duration of MG > 6 years                   | 2      |
| Concominant pulm dz                        | 2      |
| Pyrido > 750 mg/day 48 hours pre-op       | 2      |
| VC < 2.9 L (40 ml/kg)                      | 4      |
| ** > 9 predicts post-op ventilation > 3 hours ** |        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Manifestations                                   | Myasthenic Syndrome                             | Myasthenia Gravis                               |
|--------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Proximal limb weakness (arms > legs)             | Extraocular, bulbar, and facial muscle weakness |                                                |
| Exercise improves with strength                   | Fatigue with exercise                           |                                                |
| Muscle pain common                                | Muscle pain uncommon                           |                                                |
| Reflexes absent or decreased                      | Reflexes normal                                 |                                                |
| Gender                                           | Male > female                                   | Female > male                                   |
| Response to muscle relaxants                      | Sensitive to succinylcholine and nondepolarizing muscle relaxants | Resistant to succinylcholine                   |
|                                                  | Sensitive to nondepolarizing muscle relaxants   |                                                |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Sign or Symptom                  | %Patients |
|----------------------------------|-----------|
| Hypotension                      | 100       |
| Fetal distress                   | 100       |
| Pulmonary edema / ARDS           | 93        |
| Cardiopulmonary arrest           | 87        |
| Cyanosis                         | 83        |
| Coagulopathy                     | 83        |
| Dyspnea                          | 49        |
| Seizure                          | 48        |
| Atony                            | 23        |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Criteria for the Diagnosis of Preeclampsia                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------|
| Hypertension                                                                                                                  |
| A sustained SBP> 140 mmHg, or a sustained DBP> 90 mmHg, that occurs after 20 weeks' gestation in a women with previously normal blood pressure |
| Proteinuria                                                                                                                  |
| > 300 mg protein in a 24 hour urine collection                                                                                |

| Features of Severe Preeclampsia                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------|
| Fetal growth restriction                                                                                                      |

| Differential Diagnosis of Hypertension During Pregnancy                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------|
| Drug abuse (Cocaine)                                                                                                         |
| Preeclampsia/eclampsia                                                                                                       |
| Chronic hypertension                                                                                                          |
| Pain/noxious stimulation                                                                                                      |
| Hypoxia/hypercarbia                                                                                                          |
| Pheochromocytoma                                                                                                             |
| MH                                                                                                                            |
| Opioid/alcohol withdrawal                                                                                                     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Variable                  | Change | Amount          |
|---------------------------|--------|------------------|
| RBC volume                | ↑      | 20%              |
| Plasma volume             | ↑      | 50%              |
| Fibrinogen                | ↑      | 50%              |
| Cholinesterase activity    | ↓      | 30%              |
| CO                        | ↑      | 50%              |
| HR                        | ↑      | 20%              |
| SV                        | ↑      | 30%              |
| TLC                       | -      | -                |
| MV                        | ↑      | 50%              |
| Alveolar ventilation      | ↑      | 70%              |
| FRC                       | ↓      | 20%              |
| V t                       | ↑      | 40%              |
| Dead Space                | -      | -                |
| RR                        | ↑      | 10%              |
| P a O 2                  | ↑      | 10 %(10mmHg)     |
| P a CO 2                 | ↓      | 15 %(10mmHg)     |
| V o2                      | ↑      | 20%              |
| MAC                       | ↓      | 30%              |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| ↑ FHR                                      | ↓ FHR                                      | ↓ Variability                          |
|--------------------------------------------|-------------------------------------------|---------------------------------------|
| 1. Anemia                                  | 1. Uterine hypercontractility             | 1. Hypoxia                            |
| 2. Arrythmia                               | 2. Congenital heart block                 | 2. Narcotics                          |
| 3. Hypoxia                                 | 3. Hypotension                            | 3. MgSO 4                             |
| 4. Chorioamnitis                           | 4. Beta-blockers                          | 4. CNS anomalies                      |
| 5. Fever                                   |                                           | 5. Sleep                              |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Drug        | Drug     | IV potency | IV :PO ratio |
|-------------|----------|------------|---------------|
| Demerol     | Demerol  | 0.1        | 4x            |
| Makes       | Morphine | 1          | 3x            |
| My          | Methadone| 1          | 2x            |
| Desert&     | Dilaudid | 5          | 4x            |
| All         | Alfent   | 10         |               |
| Food        | Fentanyl | 100        |               |
| Rich&       | Remi     | 100        |               |
| Sweet       | Sufenta  | 1          |               |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Drug      | Drug        | PO Potency | PO equivalent Dose |
|-----------|-------------|------------|---------------------|
| Half      | Hydromoph   | 4x         | 8                   |
| My        | Methadone   | 1.33x      | 20                  |
| Oral      | Oxycodone   | 1.33x      | 20                  |
| Morphine  | Morphine    | 1          | 30                  |
| Chronic   | Codiene     | 1/6x       | 200                 |
| Dose      | Demerol     | 1/10x      | 300                 |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| SURGERY              | SCORF                |
|----------------------|----------------------|
| Pcriphcral           | Mokrate Sohtion      |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| OPIOID REQUIRMENT        | SCORE |
|--------------------------|-------|
| NONE                     |       |
| LOW DOSE ORAL           |       |
| HIGH DOSEORAL           |       |
| PARENTAL OR NEUROAXIAL  |       |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Paced | Sensed | Response         | Programability     | Antitachycardia Function |
|-------|--------|------------------|---------------------|---------------------------|
| A,V,D | A,V,D,O| I, T, D, O       | P, M, O, R          | O, P, S                   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
**** 

| Procedure                                   | Notes                                               |
|---------------------------------------------|-----------------------------------------------------|
| Lithotripsy                                | triggers on the R, if A paced may trigger          |
| Transurethral resection                    | monopolar                                          |
| Hysteroscopy                               | monopolar                                          |
| Electroconvulsive therapy                   | muscle fasiculations can cause oversensing          |
| Succinylcholine use                        | muscle fasiculations can cause oversensing          |
| MRI                                        |                                                     |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| L4                | Knee, Medial foot | Patellar | Tib Ant/Dorsi |
|-------------------|-------------------|----------|----------------|
| L5                | Dorsum Foot       | Tib Post | Toe Extension   |
| S1                | Lateral foot      | Plantar/Achilles | Plantar Flex |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Age     | Resp Rate | Heart Rate | Blood Pressure |
|---------|-----------|------------|----------------|
| Neonate | 40        | 140        | 65/40          |
| 1 yo    | 30        | 120        | 95/65          |
| 3 yo    | 25        | 100        | 100/70         |
| 12 yo   | 20        | 80         | 110/60         |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Tube size     | Depth | Weight     | Gestational Age |
|---------------|-------|------------|------------------|
| 2.5           | 7 cm  | < 1 000 g  | < 28            |
| 3.0           | 8 cm  | 2 000 g    | 28-34           |
| 3.5           | 9 cm  | 3 000 g    | 34-38           |
| 3.5 - 4.0     | 10cm  | > 3000 g   | > 38            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
```
| Treatment                                                                 | Mechanism of Action | Onset        | Duration      |
|---------------------------------------------------------------------------|---------------------|--------------|---------------|
| Calcium Chloride                                                          | Direct antagonism    | Immediate     | Brief         |
| NaHCO3 50 mEq IV                                                         | Redistribution       | Prompt        | Short         |
| Glucose (50ml of D50) & Insulin (10 U IV)                               | Redistribution       | Prompt        | 4-6 hours     |
| Ion exchange resin Kayexalate 15 to 30 g in 50 to 100 mL of 20% sorbitol PO/PR | Removes potassium    | 1-2 hours     |               |
| Dialysis                                                                  | Removes potassium     | prompt        |               |
| Diuretic (lasix)                                                         | Removes potassium     |                |               |
| Nebulized albuterol: 10 to 20 mg                                         | Redistribution       | prompt        |               |
```

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Contraindications | Absolute                                                                 | Relative                                   |
|-------------------|--------------------------------------------------------------------------|--------------------------------------------|
|                   | o Patient refusal                                                        | o Preexisting Neuropathy                  |
|                   | o Umfamiliarity with technique                                            | o Systemic infection                       |
|                   | o Lack of emergency and resuscitative equipment                          | o Infection at Site                        |
|                   | o Allergy to agent                                                       | o Anticoagulation                          |
|                   |                                                                          | o Distorted Anatomy                        |
|                   |                                                                          | o (Severe Lung Disease)                   |
| Complications      | - LA toxicity                                                            | - allergic reaction                        |
|                   | - intravascular                                                          |                                            |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| System | Conditions                                                                                     |
|--------|-----------------------------------------------------------------------------------------------|
| Airway Resp | granulomas of larynx, epiglottis and arytenoids, pulmonary granulomas, airway obstruction, pulmonary fibrosis, interstitial dz, bilateral hilar lymphadenopathy |
| CVS    | heart block, arrhythmias, cor pulmonale, CHF                                                  |
| Neuro  | focal nerve deficits, space-occupying lesions                                                 |
| Endo   | DI                                                                                            |
| GI     | hepatic involvement                                                                            |
| GU     | ½ Ca reabsorption                                                                             |
| Pharm  | Steroids                                                                                      |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Classification of Hemorrhagic Shock

| Classification       | I            | II            | III           | IV            |
|----------------------|--------------|---------------|---------------|---------------|
| %Blood               | < 15%       | 15 - 30%      | 30 - 40%      | > 40%         |
| Volume Blood Volume   | < 750 ml    | 750 - 1500 ml | 1500 - 2000ml | > 2000 ml     |
| Heart Rate           | < 100       | > 100         | > 120         | > 140         |
| Blood Pressure       | Normal       | Normal        | ¾             | ¾¾            |
| Pulse Pressure       | Normal       | ¾             | ¾             | ¾¾            |
| Respiration          | Normal       | Normal / ½    | ½             | ½½            |
| Urinary output       | > 30 ml/h   | 20 - 30 ml/h  | 5 - 20 ml/h   | < 5 ml/h      |
| Mental Status        | Normal       | Agitated       | Confused       | Lethargic     |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** Systems Review

| Systems | Review                                                      |
|---------|------------------------------------------------------------|
| Neuro   | seizures, peripheral neuropathy, psychosis                 |
| Resp    | restrictive disease, atelectasis, effusions                |
| CVS     | pericarditis, myocarditis, CHF, conduction blocks          |
| GI      | pancreatitis, hepatitis, ileus                              |
| GU      | glomerulitis, nephrotic syndrome, renal failure            |
| Heme    | thrombosis, hemmorhage (lupus anticoag), anemia            |
| MSK     | arthritis, aseptic necrosis, vasculitis                    |
| Pharm   | NSAID, Steroids, Antimalarials -chloroquine (c'myopathy and periph neuropathy), azathioprine (cytotoxic), Cyclosporin (renal dysfxn) |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Drug               | Equivalent dose | Antiinflam potency | HPA axis suppression | Duration of action (hrs) |
|--------------------|------------------|---------------------|----------------------|---------------------------|
| Cortisone          | 25               | 1                   | 25                   | 8 - 12                    |
| Hydrocortisone     | 20               | 0.8                 | 20                   | 8 - 36                    |
| Methylprednisolone | 4                | 5                   | 7.5                  | 12 - 36                   |
| Prednisone         | 5                | 4                   | 7.5                  | 12 - 36                   |
| Dexamethasone      | 0.75             | 25                  | 1                    | 36 - 54                   |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Genotype | Incidence  | Dibucaine | Duration  |
|----------|------------|-----------|-----------|
| N        | 96%        | 80        | 6-10min   |
| Hetero   | 1 in 25    | 60        | 20min     |
| Homo     | 1 in 2000  | 20        | 180min    |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| System   | Findings                                                                                     |
|----------|----------------------------------------------------------------------------------------------|
| Airway   | enlarged tongue, goiter                                                                     |
| Resp     | hypoventilation, OSA, ↓ response to ↑ CO2 and ↓ O2                                          |
| CVS      | bradycardia, ↓ CO, ↑ SVR, volume deplete, hypotension, pericardial effusions, arrhythmias, CHF |
| Neuro GI | lethargy, weakness, mental slowness, obtundation, gastroparesis                             |
| Heme     | qualitative plt dysfunction, FVIII deficiency                                                |
| GU       | ¾ free water clearance with fluid retention and edema ( ↓ Na, ↑ TBW but ↓ plasma volume)    |
| Endo     | adrenal insufficiency, myasthenia gravis, hypoglycemia, amyloidosis                        |

<!-- PAGE=? CONFIDENCE=? BBOX=? -->
**** 

| Therapies to Consider | Contraindicated Interventions (or Use With Caution) |
|-----------------------|------------------------------------------------------|
| Bradycardia           | Pacemaker (transcutaneous or transvenous) Toxic drug caldum channe blocker: eplnephrine , calcium salt? glucose Insulln? glucagon? NS (If hypotenslve) Toxic drug B-bbcker: NS, epinephrine calcium salt? alucose'insulin? glucagon? inhibitorpoisonings) Isoproterenol If Irypotensive Prophylactic transvenous pacing |
| Tachycardia           | Toxic drug sympathomimetics: benzodiazepines, lidocaine , sodlum bicarbonate , nitroglycerin, nitroprusside , labetalol Toxic drug bicarbonate hyperventilation , NS , magnesium Toxic drug anticholinergics: physostigmine B-Blockers (not generally useful in drug-induced tachycardla) Do not use propranolol for cocalne intoxication Cardioversion (rarely indicated) Adenosine (rarely indicated) Calcium channel blockers (rarely indicated) |
|                       | Sodium blcarbonate Lidocaine It TCA overdose: amiodarone or type kw antiarrhythmics (eg, procainamide) |
|                       | Toxic sympathomimeics: benzodiazepines, lidocaine , sodium bicarbonate , nitroglycerin, nitroprusside , phentolamine B-Blockers |
|                       | Benzodiazepines Lidocalne sodium bicarbonate Mitroglycerin Aspirin , heparin Base reperfusion strategy on cardiac catheterizationdata B-Blockers |
| Shock                 | Toxic drug caldum channe blocker: NS salt? glucosefinsulin? glucagon? Toxic B-bbcker: NS, epinephrine norepinephrine circulatory assist devices druo Isoproterenol Avold calcium salts digoxin toxicity Is suspected |
|                       | Atropine Pralidoximelobidoxime Succinylcholine |
|                       | Benzodiazepine Physostigmine (not for TCA overdose) Antipsychotics Other anticholinergic agents |
|                       | Assisted ventilation Maloxone Tracheal Intubation Do not use naloxone for meperidine-induced selzures |